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Ionizing radiation (IR) induces various DNA lesions, with the double strand breaks (DSB) 
be the most threatening to the cell survival. The two main mechanisms that detect and 
repair DSBs are the non-homologous end joining (NHEJ) and the homologous 
recombination (HR), that are driven by the DNA repair protein kinases Ataxia 
telangiectasia mutated (ATM), ATM and Rad3 related (ATR), and  the catalytic subunit 
of DNA-dependent protein kinase (DNA-PKcs). Specific inhibitors suppressing these 
proteins, restricting the DNA repair process are studied for numerous cancer types. The 
aim of the work described in this thesis was to investigate and understand the effect of 
inhibition of ATM, ATR and DNA-PKcs protein kinases on head and neck squamous cell 
carcinoma (HNSCC) cell lines in combination with either X – rays or Proton beams (PB). 
A large proportion of HNSCC is driven by human papilloma virus (HPV). Interestingly, 
clinical data suggest that HPV-positive patients have a better prognosis compared to 
HPV-negative ones. This was reflected in in vitro studies, where HPV-positive HNSCC cell 
lines were more sensitive to IR compared to the HPV-negative ones. Three inhibitors 
were used, KU-55933, VE-821 and NU7441, inhibiting ATM, ATR and DNA-PKcs 
respectively, to investigate the impact of inhibition alone or in combination with IR, in 
HPV-positive and HPV-negative HNSCC cell lines (UMSCC74A, UMSCC6, UMSCC47, UPCI-
SCC090, FaDu, and A253). Cell survival and growth was analysed using 2D clonogenic 
and 3D spheroid growth assays. Also, the impact of the inhibitors on the respective 
enzyme target was analysed by immunoblotting, and on DSB signalling by 
Immunofluorescence (IF) staining and DSB repair foci analysis of histone γH2AX, 53BP1, 
and Rad51. My results exhibited reduced phosphorylation levels on the inhibited 
proteins up to 24 h following exposure to IR, thus demonstrating the effectiveness of 
the inhibitors at the protein level. Moreover, inhibitor and IR treatment altered all three 
DSB repair foci formation, where decreased levels but also persistent foci were 
observed. Finally, inhibition of ATM, ATR, and particularly DNA-PKcs, caused a significant 
reduction in HNSCC cell proliferation in 2D as well as in 3D, post IR, with less of an impact 
on the most radiosensitive HPV-positive cell lines. Cumulatively, my results 
demonstrated that targeting DNA DSB repair via NHEJ or HR can exacerbate the impact 
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of x – rays and PB in radiosensitising HNSCC cell models, constituting a promising 
combination treatment for HNSCC. 
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Chapter 1: Introduction 
 
1.1 Ionising Radiation and Radiotherapy 
The physics of Radiobiology constitutes the basis for the understanding and 
development of modern medical applications in the widely expanding areas of 
diagnostic radiology, radiotherapy and nuclear medicine. It involves using radiation for 
numerous techniques, from imaging to therapy, and studies the radiation effects on 
biological tissue. 
Radiation in physics describes the distinct units of energy, waves or particles, that 
transmit or emit through space and matter. There are several types of radiation, 
including electromagnetic, such as visual light, infrared and ultraviolet, acoustic 
radiation, such as the sound and the seismic waves, and particle radiation, such as alpha 
and beta radiation.  
1.1.1 Electromagnetic Radiation 
In electromagnetic radiation, the energy has the properties of both waves and particles, 
these small particles (quantum of energy) are called photons, and they have no mass 
and no electric charge. The energy of photons can vary widely resulting in a range of 
physical characteristics. High energy photons have a high frequency and a very small 
wavelength, as frequency and wavelength are inversely proportional according to the 
Planck–Einstein relation (equation 1.1). In contrast, lower energy photons, have a 
smaller frequency and a bigger wavelength. 
𝐸 = ℎ ∙ 𝑣      (1.1)        𝑣 =
𝑐
𝜆
   (1.2) 
𝛦 =  
ℎ∙𝑐
𝜆
     (1.3) 
E, is the photon energy and is measured in electron volt (eV) where 1 eV describes the 
energy gained by an electron as it is accelerated through a potential difference of 1 volt; 
h= 6.63 ٠10-34 J s,  is the Planck’s constant; v, is the frequency quantified in Hertz (Hz); 
c, is the speed of light counted in meters per second (m/s); and λ, is the wavelength 




As photons transmit through matter, they interact with atoms along their track loosing 
energy and eventually stop, therefore the bigger energy and smaller wavelength allows 
photons to penetrate deeper into matter.  
The amount of energy carried by photons is defined by the frequency of the radiation. 
The wide range of the electromagnetic frequencies is called electromagnetic spectrum. 
On the one side of the spectrum are the lower frequencies, such as radio waves (107 - 
109 Hz) and microwaves (109 - 1011 Hz), and on the other side are higher frequency 
radiations including x-rays (1017 – 1018 Hz) and gamma rays (1018 – 1019 Hz). Within that 
range also lies the visible spectrum (~1013 Hz), from red at a wavelength of 700 nm to 
violet at 400 nm. There is no distinct line between the different areas of the spectrum, 
on the contrary the frequency windows rather overlap with each other. The quantum 
nature of radiation is more important in the smaller wavelengths and higher 
frequencies, it is dominant in the high energy x – rays and γ – rays, but not as significant 
in the lower energies in radio waves and microwaves (2).  
Radiation that carries enough energy, higher than that of the electrons binding energy, 
can temporarily or permanently remove orbital electrons from the atoms it interacts 
with, when travelling through matter. These atoms get excited, their electrical status 
changes, and they are then called ions. There are positive ions, known as cations, and 
negative ions, known as anions. This type of radiation is called Ionising Radiation (IR), as 
it can ionise the matter. Photons at very high frequencies of x-rays and γ – rays have 
enough energy to ionise atoms and molecules along their track into matter. As shown in 
Figure 1.1, in electromagnetic radiation an ionisation occurs when fast-moving photons 
with sufficient energy excite electrons mostly via the photoelectric, Compton and pair 
production effects (3).  
The photoelectric effect is the most important in the lower ionising energies, between 
50 and 100 keV, where the photon energy is equivalent to the binding energy of the 
planetary electrons in the atoms of the matter (absorber). Specifically, in that 
interaction, an electron in the inner orbit absorbs all of an incoming photon’s energy 
and gets ejected, leaving a vacancy. This is filled by another electron from the outer orbit 
that while it drops, releases the excess energy (characteristic energy), in the form of 
photons. Electrons ejected from K-shell, release characteristic K x – rays and so on, and 
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these are characteristic of the absorber’s material. Production of characteristic x – rays 
dominate for high atomic number materials, however for low atomic number materials 
such as water or tissue, auger electrons are typically emitted instead of characteristic x-
rays. Either way, the atom then becomes a positively charged ion, as it has lost an 
electron. The photoelectric effect is used in diagnostic radiology, to produce low energy 
x – rays (4). 
 
Figure 1. 1. Electromagnetic radiation interaction with matter. Electromagnetic 
radiation is ionising matter through 3 main mechanisms. The photoelectric effect which 
occurs in the lower energies, the Compton effect which is the most important effect in 
the median energies and the pair production which is only relevant at higher energies 
and above a threshold.     
 
The Compton effect is the most important interaction in biological tissue in the middle 
ionising energies, between 100 keV and 10 MeV, where the photons have plenty of 
energy to excite an outer orbit electron, and thus ionise the atom. In this phenomenon, 
photons loose only part of their energy to the ejected electron, they get scattered and 
continue their transmission and further interactions through the absorber (5).  
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Finally, pair production occurs at higher energies and above a threshold of 1.02 MeV, 
that equals the sum of the mass (energies) of the produced particles. The higher the 
photons energy the most possible is an event of pair production. During this process, a 
fast moving photon in close proximity to a nucleus is absorbed by nucleus directly and 
provides all its energy to the production of a pair of an electron and positron, any 
remaining energy is distributed between the pair as kinetic energy. The presence of the 
nucleus satisfies the conservation of momentum. Spontaneous ejection of neutrons may 
occur simultaneously. This effect arises in radiotherapy units, where x – rays of at least 
10 MV are used, raising the shielding requirements to protect not only from the high 
penetrate x – rays but also from the produced neutrons (3). 
 
1.1.2. Particle Radiation  
In particle radiation, the energy is transmitted and emitted in particles. In this radiation 
type, particles are the equivalent of photons of the electromagnetic radiation. There are 
numerous types of particle radiations, named usually after the main particle carrying the 
energy. The particles can be positively or negatively charged, such as protons and 
electron respectively, as well as electrically uncharged, including neutrons. Moreover, 
particle radiation can consist of heavier particles, atoms or ions, an example being the 
carbon ion radiation. Here are discussed some well-studied particle radiations. 
Similarly to photons, as particles transmit through matter they interact with atoms along 
their track in many small steps, losing energy. Thus, generally the higher the particle’s 
energy, the further it can penetrate into matter. Particles with energy greater than the 
binding energy of the planetary electrons (ionising energy) can produce multiple 
ionisations along their track. Following a few interactions and possible change of 
direction, the particles eventually stop. The depth that they can penetrate into matter 
is called the particle range, that is defined by the Bethe – Bloch formula as the mean 
energy loss per distance travelled and is dependent on the atomic number and density 
of the absorber, as well as the mass and the energy of the particles (6, 7).   
Charged particles interact directly with the absorber’s atoms, mainly with Coulomb 
forces. These interactions occur between the electric field of the charged particle and 
the electric field of the absorber’s electrons or nuclei. There are three categories of 
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particle interactions; the hard collisions where there is close encounter, equivalent to 
the atomic radius, between the charged particle and the orbital electron; the soft 
collisions, where there is distant encounter, greater than the atomic radius, between 
the charged particle and the orbital electron; and the radiative collisions, where there is 
a very close encounter between the charged particle and the nucleus.  
In all three collision types, the momentum conservation law dictates that the particles 
velocity and therefore its energy, is inversely proportional to the energy transfer, as 
indicated in equation 1.8. In other words, high energy particles transfer only a small 
amount of energy to the atomic electrons, as they have a large velocity and only stay in 
the proximity of the electrons a short amount of time.  Moreover, the energy transfer is 
inversely proportional to the encounter distance, hence the closer the proximity 
between the interacting parts, the larger the energy transfer. This is particularly 
important in high density materials, where the atoms are closely packed, and the 
interaction probability increases for particles of a given velocity. Therefore, the incoming 
particles lose energy quicker and cannot penetrate deep into high density materials. 
Such high-density materials are used as shielding in radiology and radiotherapy units, 
due to their ability to block radiation penetrance. 




  (1.6) 













    (1.8) 
 E, is the particle’s energy; m, the particle’s mass; and v, is velocity; p, is the particle’s 
momentum (1.5). ΔE and Δp refer to the alteration in the energy and the momentum of 
the particle during the collision and describe the occurring energy transfer; and mo, is the 
rest mass of the particle (1.6). F, is the force applied in the particle by the electric field of 
the nucleus and electrons; dt, is the time alteration and refers to how much time the 
interaction lasted; α, is a variable defined by a number of factors including, the radius of 
the atom, the electric charge and the rest mass of the particle; b, is a variable describing 




Finally, the particles mass is proportional to the energy transfer, so heavier particles are 
more likely to have less interactions with bigger energy losses as they travel through 
matter (8, 9).  
In hard collision, the ejected electron absorbs a large amount of energy and is 
transmitted through the absorber, having its own interactions and ionisations along its 
track, the amount of hard collisions however is small. In soft collisions, the ejected 
electron absorbs a part of energy that is inversely proportional to the original energy, 
and proportional to the mass of the incident particle, and thus is most important in 
heavier particles of lower energies. Finally, in the radiative collision, a fast-moving 
charged particle approaching the nucleus, gets trapped in the electrostatic field. The 
particle then accelerates and diverts from its path as it momentarily orbits around the 
nucleus, before it is released with simultaneous emission of electromagnetic radiation 
(x – rays). The particle then gets decelerated and follows the diverted track. The emitted 
x – rays interact with the absorber, ionizing atoms along their track via the 
electromagnetic radiation effects. The energy loss in this effect is inversely proportional 
to the mass of the particle, therefore is most important in lighter particles. In fact, the 
energy from the deceleration of electrons is around 4 million times higher that of 
equivalent kinetic energy protons. The x – ray production through this deceleration 
effect is known as bremsstrahlung, which means braking radiation in German. 
Bremsstrahlung will be further discussed below.    
It is worth noting that hard collisions between free electrons (incoming particle 
radiation) and atomic electrons may also result in large energy loss and diverted 
trajectories, not observed in the rest of the charged particles radiations. This is partly 
because the two interacting parts have the same mass, but also due to the small mass 
of the electrons, which makes the relativistic effects important even from low energies, 
and large energy loss and change in the direction is more often (8, 9).   
In general, as illustrated in a schematic representation in Figure 1.2, charged particles 
lose energy gradually in multiple collisions with mostly small energy transfers. As the 
mass and energy of the particles increases, there are less interactions, but they carry 
bigger energy depositions and there is less diversion from the original track. Whereas 
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light particles of lower energies (electrons and positrons) lose energy in multiple 
ionisations, get scattered and decelerate, soon after they enter matter. 
 
Figure 1. 2. Schematic representation of charged particles tracks in water. The energy 
transfer is inversely proportional to the particles energy and proportional to the particles 
mass. Lighter particles, such as electrons, of low energies are more likely to have plenty 
of interactions with small energy transfers and they are not expected to penetrate deep 
into matter. As their energy increases, so does their velocity, and the number of 
interactions decreases since they only stay in the proximity of the atomic electrons a 
short amount of time; they get less scattered and penetrate deeper into matter. For 
similar energy, heavier particles like protons, produce a few interactions yet with big 
energy losses and the particles stop before they travel deep in to matter. As the heavy 
particles energy increase, they can reach further into matter without interacting before 
they give all their energy in very few collisions and eventually stop.   
 
Uncharged particles (neutrons), interact with matter in a different way compared to the 
charged particles, as they have mass but no electric charge. The energy loss is defined 
by the neutrons energy and the density of the absorber, and occurs in multiple steps 
through the elastic scattering, inelastic scattering, radioactive integration and nuclear 
reactions.  Elastic scatter is the most important mechanism of energy transfer in 
biological tissues. Approximately 85% of the energy loss of neutrons occurs following 
the elastic scattering of the fast neutrons by the hydrogen atoms (H2) of the tissue. In 
inelastic scattering, electromagnetic energy (γ – ray) is released and is more important 
in heavier absorbers (with higher atomic and mass number). In radioactive integration, 
a fast neutron is captured by a nucleus, the produced nucleus is then unstable and 
decays with the ejection of electrons and γ – rays. Finally, during nuclear reactions, a 
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mother nucleus captures the fast neutron to produce a daughter nucleus and other 
particles, like protons, neutrons or other smaller nuclei (10).  
 
1.1.3 Clinically used Radiation types  
Radiation has multiple uses in medicine, both in diagnosis and in treatment. In this 
section, the most used radiation types are discussed in more detail.  
1.1.3.1. Alpha particle radiation 
The α particle radiation, is produced through the α disintegration. In this nuclear process 
α particles, which are in fact Helium atoms ( 𝐻𝑒2
4 ) consisting of 2 protons and 2 neutrons, 
are emitted when an unstable heavy nucleus decays spontaneously into an α particle 
and another heavy nucleus, in order to become more physically stable. The α particles 
absorb a part of the released nuclear energy as their own kinetic energy. They have a 
positive charge and produce intense ionisations by stripping the electrons from the 
atoms along their track. They usually have a high energy, but very small range, and are 
stopped within μm of biological tissue (11, 12). α particle emitters are often used in 
brachytherapy, a type of radiation therapy where a radioactive source is inserted into 
or next to the area of interest. This is achieved either as an open source treatment, 
where the high energy and small range of α particles is ensuring significant targeted 
tumour damage; or as sealed sources, where the tumour damage is achieved by 
secondary γ-rays or other emissions associated with the decay of α particles (13).    
1.1.3.2 Beta particle radiation 
β particle radiation occurs through the β decay via three different types. The β- radiation, 
is produced when an unstable heavy nucleus spontaneously decays by emitting β- -
particles, which in fact are electrons, and energy. Similarly, the β+ -radiation is released 
when an unstable heavy nucleus spontaneously decays by emitting β+ -particles, also 
known as positrons (positive electrons), and energy.  Finally, the Electron Capture (EC) 
process occurs when an unstable heavy nucleus absorbs an atomic electron, usually 
from the K-shell, realising energy. The K-shell vacancy is then filled by an electron of the 
outer orbit with the simultaneous release of x-rays. This process is antagonistic to the β+ 
decay. In all cases, the nucleus decays to produce a more stable daughter nucleus, and 
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the nuclear energy released is distributed between the products of the decay (11, 14). β 
particles carry enough energy to produce multiple ionisations, but also offer a relatively 
narrow range between μm to mm, depending on the isotope producing them, and are 
profoundly used in brachytherapy (13). 
1.1.3.3 Gamma radiation (γ – rays) 
γ radiation is electromagnetic radiation, travelling through space and matter in the form 
of waves and photons. The γ rays are emitted following nuclear reactions and are usually 
the by-product of an α or β decay, as in most cases the daughter nucleus is created in 
an already excited state. These short living nuclei are de-excited mainly through y decay, 
releasing γ – rays with a discrete spectra characteristic of the parent-daughter nuclei. 
The γ – rays are highly penetrating as they often carry a large proportion of the nuclear 
excitation energy (15). γ – rays were used in radiotherapy (i.e. cobalt units), but these 
have now been replaced by modern x – ray units, and are currently used in Gamma Knife 
for stereotactic radiosurgery (16). They are currently used in Positron emission 
tomography (PET) scan for diagnostic purposes, where annihilation of the a positron 
with an electron emit two back-to-back 0.511MeV γ – ray photons, as a result of mass 
being converted to energy, imaging the metabolic activity of tumours (17). 
1.1.3.4 X – rays  
 As electromagnetic radiation, x – rays consist of photons. They have a similar spectrum 
range to γ – rays, the only difference being the origin of the radiation, γ – rays are the 
product of radio nuclear reaction, whereas x – rays are produced through the 
photoelectric effect, where there is distinct characteristic spectrum, and through the 
deceleration effect, known as bremsstrahlung. As demonstrated in Figure 1.3, 
bremsstrahlung occurs when a fast charged particle (e.g. electron) travelling in close 
proximity to a nucleus, is temporarily trapped in the electrostatic field and accelerates 
while it orbits around the nucleus, then decelerates producing x – rays before it breaks 
free to continue travelling in a diverted track. The energy of the newly produced x – rays 
depends on the energy lost, hence of the acceleration – deceleration process of the 
electron while it deflects trapped in the nucleus field. The longer it stays in orbit, the 
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more it accelerates and the more energy is released when it decelerates, resulting in 
higher energy x – rays (Figure 1.3) (15, 18). 
 
Figure 1. 3. Bremsstrahlung – Deceleration effect. Bremsstrahlung occurs when a 
charged particle and the nucleus are in close proximity. The particle gets trapped in the 
electrostatic field and accelerates while orbits around the nucleus, then decelerates 
producing x – rays before it breaks free to continue travelling in a diverted track. The 
longer it stays in orbit, the more it accelerates, and the more energy is released when it 
decelerates, resulting in higher energy x – rays, of higher frequency and smaller 
wavelength. This phenomenon is much more important in electrons than in any other 
charged particle, due to its small mass.       
 
X – rays transmitting through biological tissue, lead to several ionisations due to the 
photon interaction with atoms, but moreover due to the subsequent production of quite 
a few electrons. When each of these electrons slows down, they too interact with the 
tissue producing further ionisations. Therefore, the biological effect of x – rays depends 
not only on the initial radiation, but also on the secondary electrons produced. 
X – rays are widely used in medicine, lower energies for imaging in radiology and 
dentistry and higher energies for therapy, particularly in cancer patients. The most 
commonly used x – ray generators are the x – ray tubes, which consist of an evacuated 
glass cylinder that contains a tungsten filament cathode and an anode, usually made 
also of tungsten, illustrate in Figure 1.4. When the filament is heated there is a significant 
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number of electrons that escape its surface, the electrons travel then through the 
vacuum to the positively charged anode forming a current, and they get accelerated. 
Once the electrons reach the anode, they hit the high-density material and slow down, 
producing x – rays. The x – rays produced are emitted to all directions, and only a small 
amount of them, that head to the exit window, will be used, while the rest are absorbed 
by the anode. The tube current depends on the voltage applied, the target material  and 
the filament excitation but also on other tube characteristics such as the distance 
between the cathode – anode and the filament temperature (8).  
Diagnostic and therapeutic tubes produce quite a different x – ray spectrum. Lower 
voltage (≤ 100 kV) applied in diagnostic tubes result in only about 1% production of x – 
rays through bremsstrahlung and about 30% production of characteristic x – rays, since 
most of the electrons will be either absorbed by the anode producing heat or produce 
secondary ionisation through soft collisions. Whereas, the higher voltage (~ few MV) 
applied in therapeutic tubes leads to almost 95% bremsstrahlung x – rays and only 1-2% 
characteristic x – rays, as the majority of electrons will interact with radiative collision 
(8, 18). The x – ray units used in cancer radiotherapy are mostly linear accelerators 
(LINAC) that use high voltage electric field and accelerate electrons through a long tube 
to produce high energy photon beams.  LINACS usually offer two modes, the photon and 
the electron mode. The former is the produced photon beam, the latter is an electron 
beam, consisting of the accelerated electrons that exit the tube without hitting the 
target (19).  
Once the beam exits the LINACS tube, it is processed through a series of components, 
used in both modes. The photon or electron beam is shaped through a series of high-
density collimators, to produce the required field of radiation and gets flattened to 
become evenly distributed across the field. Low energy electrons that can contaminate 
the beam, and increase the skin (surface) radiation dose, without contributing into 
image quality or radiotherapeutic result, are removed using appropriate filters. The 
radiation dose is monitored through a pair of ion chambers and finally a light localizer is 
used to confirm right positioning of the patient before any radiation is applied. The head 
of the LINAC, called a gantry, is designed to turn 360o around its axis, allowing to 
irradiate without any change in patient position. Accuracy and reproducibility of the 
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positioning and proper delivery of radiation is highly important, to achieve tumour 
control while protecting the surrounding healthy tissue, particularly the organs at risk 
(OARs). Many modern LINACs are now combined with imaging guidance units such as 
MRI (Magnetic Resonance Imaging) or cone beam CT (computed tomography) to 
optimise the therapeutic potential while ensuring safe and accurate treatment delivery 
(20-23).   
 
Figure 1. 4. X – ray tube. Schematic representation of an x – ray tube. The x – rays are 
generated in a vacuum cylinder that contains a negatively charged cathode and a 
positively charged anode. The cathode’s tungsten filament is heated, and a number of 
electrons escape its surface, and travel through the vacuum getting accelerated. The fast 
electrons hit the high-density material and slow down, producing x -rays. The x – ray 
energy depends on the tube characteristics like the voltage applied, the target’s material 
and any subsequent filtration. 
 
1.1.3.5 Proton radiation 
Proton radiation is positively charged particle radiation. High energy protons can travel 
through matter with minimal interactions, releasing small energy units, before they 
eventually stop depositing all their remaining energy in a small and finite region.  This is 
due to only few ionisations occurring along their track and multiple hard collisions in 
depth of the biological tissue. As shown in Figure 1.5, these physical characteristics, 
present protons with a great advantage over conventional x – ray radiotherapy, as they 
produce a low entrance dose that peaks in depth at a narrow and well-defined range, 
called the Bragg peak, sparring the surrounding tissue and OARs in close proximity to 
the tumour – target, which is particularly important for children and younger patients.  
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A combination of beams with different initial energies can produce a wider peak, the so-
called spread-out Bragg peak (SOBP), allowing to irradiate larger target volumes (24).  
Proton beams are typically accelerated in circular accelerators called cyclotrons. A 
cyclotron consists of two poles of a large circular magnet over two D-shaped conductors, 
(electrodes) with a narrow gap in between, connected to an oscillator of high frequency 
(radio waves) and high alternating voltage (~ 20 keV) (Figure 1.6). The magnet produces 
a strong magnetic field while the oscillator produces a high frequency electric field. The 
two hollow conductors have opposite polarity, and they switch potential constantly 
oscillating between positive and negative charge. The electromagnetic field can be 
variable to achieve the desired particle accelerations by shifting the frequency of the 
applied electric field. The cyclotron frequency is not dependent on the particle’s energy 
and radius, but rather on their charge to mass ratio (e/m). The cyclotron unit is placed 
within a vacuum cylinder. Modern cyclotrons now include superconducting magnets 
that are particle and energy variable and can reach relativistic energies for most ions.   
In proton cyclotrons, protons are released between the two electrodes, when hydrogen 
atoms are bombarded by electrons escaping a tungsten filament, similar to the one used 
in x – ray tubes (Figure 1.4).  The electric forces push the positive protons on to the 
negative electrode. Once there, the magnetic forces shove protons to move along the 
electrode in circular or spiral trajectories gaining speed and energy. When the polarity 
changes, protons move towards the new negative conductor, due to the electric forces 
and as soon as they reach it, they again move in the arc of the electrode, gaining speed 
and energy. As they move faster, they orbit in a larger circle. That process continues and 
the particles get accelerated until they reach the required energy before they exit the 
cyclotron. Cyclotrons produce very high and very stable energy particle beams, but they 
have high requirements for power consumption and its relatively difficult to achieve 





Figure 1. 5. Relative radiation dose in depth. Qualitative representation of energy 
deposition in water (biological tissue equivalent). Photons deposit their maximum energy 
after a short build-up region, and they continue to interact with mater releasing energy 
along their track. Electrons energy deposition peaks very close to the surface but quickly 
lose all their energy and eventually stop. Monoenergetic protons travel through matter 
with minimal interactions, before they completely stop depositing all their energy in a 
small and finite region, the Bragg Peak. Similarly, modified energy protons have a low 
entrance dose and give multiple neighbouring peaks that produce a wider peak, the so-
called spread-out Bragg peak. 
        
Extraction of the proton beam is achieved by placing an electrostatic deflector at the 
extraction radius of the cyclotron. The deflector consists of a complex of two electrodes, 
one with ground potential and one with high negative voltage, that greatly attracts the 
positively charged particles. The strong electric field guides the thin monoenergetic 
proton beam outside of the cyclotron’s magnetic field. A series of bending magnets, that 
can both deflect and focus the beam (dipole magnets and quadruple magnets 
respectively), drive the beam through the vacuum to the patient either as a fixed beam 
line or through a gantry. A proton gantry, similar to an electron or x – ray gantry, can 
turn 360o around its isocentre, to access the tumour from any angle (28-30).  The energy 
can be modulated, through a range shifter, and it can break into multiple energy beams 
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that will deposit their peak energy over multiple depths, covering a bigger volume of the 
tumour. In order to broaden the radiation field laterally, a set of scatter foils is used, 
equivalent to a photon flattening filter. The first one, is a uniform foil that creates a 
Gaussian distribution of protons, while the second one is a non-uniform foil through 
which the central protons of the beam are scattered to a greater degree compared to 
the outer protons, resulting in a uniform radiation filed. The beam is then shaped, 
though a series of high-density collimators, and the radiation dose is monitored, using a 
pair of ionisations chamber. This is called a passive scattered system. A newer system, 
called a spot scanning system, uses magnets to shift the proton beam across the tumour, 
allowing for better shaping of the distal and proximal ends of the proton beam. 
Moreover, it provides the advantage of precise 3D dose distribution, also called dose 
painting (31, 32). 
Cyclotrons are also used for the acceleration of heavier particles in medicine, including 
carbon ions, but they are not suitable for the acceleration of uncharged particles, since 
the electric field is not able to set them into movement. Equally, the cyclotron is not 
suitable for the acceleration of electrons, because the relativistic effects are important, 
and their mass will significantly increase with velocity even in low energies (8).  The 
relativistic effects in protons are important for energies higher than some tens of MeV. 
To overcome this limitation and achieve higher energy proton beams, two alternate 
cyclotrons are available. The first is a synchrocyclotron, where a stable magnetic field is 
applied along with an accelerating radio frequency (RF) field, following the mass 
acceleration, to provide particle synchronism. The second is an isochronous-cyclotron, 
where a stable RF field and a variable magnetic field is applied causing particles to 





Figure 1. 6. Schematic representation of a cyclotron. A cyclotron consists of the two poles 
of a large circular magnet over two D – shaped conductors, with a narrow gap in 
between, placed within a vacuum cylinder. The magnet produces a strong magnetic field 
while the conductors are connected to an oscillator, that produces a high frequency (RF) 
alternating electric field.  The two hollow conductors have opposite polarity, and they 
switch potential constantly. The electric forces push the positive protons on to the 
negative electrode, once there, the magnetic forces force the protons to move along the 
electrode gaining speed and energy. A deflector extracts the beam with a strong 
negatively charged electric field.   
 
Proton beams accelerated in medical cyclotrons have many more applications in 
medicine apart from directly been used in cancer radiotherapy. For example they are 
used in Boron Neutron capture therapy (BNCT), where the accelerated protons produce 
neutron beams, that are directed on to the Boron injected tumour. The Boron – Neutron 
interaction releases high energy α particles, that due to their small range (few mm), 
selectively and severely damage the tumour (34). Another use of proton beams outside 
proton radiotherapy is for the production of radioisotopes for positron emission 







1.2 DNA damage and repair 
Induction of DNA damage occurs naturally and spontaneously during the lifespan of 
mammalian cells. It has been estimated that each cell suffers tens of thousands DNA 
lesions per day that may be through endogenous sources, including via metabolism and 
errors during DNA replication, or externally induced by stressing factors, such as heat 
fluctuation, ultraviolet and ionising radiation (IR), environmental chemicals and more 
(36). As discussed previously, IR produces multiple ionisations in the atoms, inducing 
DNA damage which could potentially kill the cells. This property of IR is used 
therapeutically in radiation oncology, where tumour are exposed to high doses of IR, 
eventually promoting tumour cell death. External photon beam radiotherapy, a well – 
established treatment used worldwide includes different techniques, such as 
conventional radiotherapy (RT), 3D RT, intensity modulated RT (IMRT), and image 
guided RT (IGRT), where this utilises high voltage x – ray irradiation (photons) (37, 38). 
Proton beam therapy (PBT), uses protons instead of photons, it is a fairly new and 
promising radiation treatment, including a variety of delivery methods, such as image 
guided proton therapy (IGPT) and dose painting PBT, that is gaining ground in radiation 
oncology thanks to its radiobiological and physical advantages over photon radiotherapy 
(39-41). Both radiation modalities have a common target, to introduce severe physical 
damage, that lead to chemical and biological damage within the DNA of the cells, 
threatening the genome stability and proliferation of the tumour cells.    
 
1.2.1 The DNA 
Damage into the cellular DNA can affect the integrity of the molecule, which is required 
for cell survival. DNA, deoxyribonucleic acid, is a macromolecule that carries all the 
genetic information required for cell proliferation, stored in the cell’s nucleus. In 
eukaryotes small amounts of DNA is also stored in mitochondria. The structure of the 
DNA was discovered in 1953 to be a double helix, similar to a twirling ladder, using x – 
ray diffraction analysis (42). The two long polymer strands are composed by 4 types of 
nucleotides. The chemical structure of the nucleotides is that of a five – carbon sugar, in 
the case of DNA the sugar is deoxyribose, a phosphate group (PO4H3), and a nitrogen – 
containing base, which can be either adenine (A), thymine (T), guanine (G) or cytosine 
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(C) (Figure 1.7). Phosphodiester bonds between sugar – phosphate backbone, strongly 
connects the nucleotides producing the basis of the two chains, while hydrogen bonds 
between the bases hold the two chains together. The bases face inside the double helix 
and are complementary to each other, two-ring bases, called purines, pair with single-
ring bases, called pyrimidines. In fact, A always pairs with T, and G with C, to hold an 
equal distance between the two chains and secure the most stable structure (Figure 
1.8). 
After every ten base pairs the helix completes a full turn, to maximize its stability. The 
chain structure provides a chemical polarity, as along the chain there are several 
nucleotides with the same orientation, but at the end of the chain can be either a 
phosphate group  at the 5’ end, or a sugar (containing a terminal hydroxyl group) at the 
3’ end. The double helix is formed by antiparallel chains with opposite polarities, this 
means that in the one end of the double helix there is a 5’ end on strand A and a 3’ end 
on strand B, on the other end of the helix there is a 3’ end on strand A and a 5’ end on 
strand B (Figure 1.8).   
The DNA sequence is encoded using the 4 nucleotides. Human cells contain DNA that 
consists of approximately 3.2 x 109 nucleotides and is about 2 m long if stretched in a 
straight line, yet is securely packed to fit within the 6 μm in diameter nucleus of the cell. 
To achieve that, the genetic information is stored in compact structures called 
chromosomes. Each chromosome consists of a very long but tightly and orderly packed 
DNA molecule, along with proteins, histones and non-histone chromosomal proteins. 
The complex of DNA and proteins is also known as chromatin. 
The long DNA molecule is folded, around histone octamers, a combination of eight 
histone proteins, two of each of H2A, H2B, H3, and H4, forming core particles called 
nucleosomes. The DNA helix is wrapped in two tight turns around each octamer. 
Nucleosomes contain 146 nucleotide pairs and are connected with linker DNA of up to 
80 nucleotide pairs, but the spacing between the nucleosomes varies. Human cells have 






Figure 1. 7. DNA Components. A nucleotide consists of a five-carbon sugar, a phosphate 
group and a nitrogen containing base.  A) Pentose Deoxyribose is the five-carbon sugar 
found in the DNA nucleotides. B) Phosphate group, PO4H3, and pentose are linked with 
phosphodiester bonds in the 3’ and 5’ carbon of the sugar to form the core of the DNA 
strand.  C)Purines, are the two ring Nitrogen containing bases, Adenine and Guanine. 







Cellular genome is composed of genes, DNA segments encoding the sequence to 
produce a specific protein or a set of related proteins, and RNA molecules, responsible 
for the structural and catalytic function of the cells. There are about 30,000 genes 
included in the human DNA, the average size of a human gene is 27,000 nucleotide pairs, 
yet only about 1,300 nucleotide pairs are required to encode an average size protein 
(approximately 430 amino acids). The remaining parts are either sequences that 
regulate proper gene expression, or large noncoding DNA sequences, called introns, in 
between the coding parts of the sequence, called exons. Interestingly, there are plenty 
of noncoding DNA segments, also called junk DNA, that contain non-essential 
information, and that its role and importance has not yet been identified.  
 
 Figure 1. 8. DNA structure and base formation. The DNA helix is composed of a series of 
nucleotides, with the sugar-phosphate backbone forming the strong core of the two 
antiparallel strands, and the inside facing bases holding the two strands together, 
forming base pairs. A is always paired with T, G is always paired with C, to hold an equal 
distance between the two chains and secure the most stable structure. The bases are 




Generally, the more complex species tend to have more genes, nevertheless due to the 
large amounts of excess DNA there is no direct connection between species complexity 
and chromosomal number or genome size, and there are big differences observed even 
in closely related species (43). 
 
1.2.2 Cell cycle  
The genetic information, encoded in the DNA of the cell is passing from a parent cell to 
its daughter cells, through repetitive cell divisions. A cell is essentially created by a 
parental cell, that grows and duplicates its contents before it divides into two new 
genetically identical daughter cells. Cell life, known as cell cycle, is divided in four phases 
and is controlled and coordinated by a complex network of regulatory proteins, that 
promote progression from one phase to the next one or can temporarily hold it and even 
lead cell to programmed cell death (apoptosis) if necessary.  
1.2.2.1 Cell cycle phases 
The two major cell cycle phases are synthesis (S) and mitosis (M), separated by two 
interfering phases the gap 1 (G1) and the gap 2 (G2) phases. In addition to these, there 
is an extra phase, the gap 0 (G0), which includes cells at a resting stage that can last from 
days to years before cells resume proliferation or be led to apoptosis.  
The cell cycle begins at G1, allowing time for cell growth but also ensuring extracellular 
environmental conditions are suitable before progressing into the next phases. Next is 
S, a long-lasting phase (10 – 12 hours for mammalian cells) during which the DNA is 
carefully replicated. The chromosomes get untangled, and the two DNA strands are 
separated, each to be used as a template for the creation of a complementary strand to 
produce two full DNA double helices. G2 follows, allowing time for further cell growth 
as well as replication of other cell components such as proteins and organelles. Finally, 
when all the components are ready the cell is divided in M phase, a process that is 
completed within 1 h. During M phase, the duplicated DNA is concentrated into 
chromosomes, which are aligned on the assembled mitotic spindle in the central region 
of the cell. The sister chromatids are separated and head in opposite directions of the 
dividing cell, forming two intact nuclei while the cytoplasm is torn into two (43, 44).   
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1.2.2.2 Cell cycle control 
The cell cycle control system is driven by a family of cyclin-dependent protein kinases 
(Cdks). Their activation is regulated by cyclins, cyclically activated subunits, and results 
in phosphorylation of intracellular proteins that initiate cell cycle progression to the next 
phase and prevents any of the completed phases to be repeated. The main cyclin 
complexes in eukaryotic cells are G1-Cdk, where extracellular signals initiate the cell 
cycle, G1/S-Cdk, which drive the cell to enter S phase, S-Cdk, which lead to cell 
replication, and M-Cdk that trigger mitosis.  
In addition the Cdk protein complexes can arrest the cell cycle at specific checkpoints. A 
negative signal can block progression into the next phase until the one undergoing is 
fully completed. This is particularly important in case of DNA damage, where the 
checkpoints allow for DNA repair. For example DNA damage in cells in G1 phase results 
in phosphorylation of p53, a regulatory protein that stimulates transcription of several 
genes including p21, a protein that binds in G1-Cdk and G1/S-Cdk complexes, prohibiting 
their activation and progression in S phase. DNA damage in cells in G2 initiates a series 
of protein kinases that block activation of M-Cdk complexes and thus progression to M 
phase (43, 44). 
1.2.2.3 Programmed cell death – apoptosis  
To secure genomic integrity, cells that are no longer needed or with irreparable DNA 
damage can undergo programmed cell death, also known as apoptosis. Apoptosis is a 
neat process, during which the cell collapses from within, the biological components get 
recycled, and there is no damage caused to the neighboring cells. The process is driven 
by the proteolytic enzymes caspases that can cleave specific proteins initiating cell 
death. Multiple caspases exist within the cells in the inactive form of procaspases and 
can be activated by either extracellular or intracellular signals. Once activated caspase 
cleaves and activates more procaspases, within the cell, leading to an irreversible 




1.2.3 Induction of DNA lesions  
DNA damage, as well as being continuously formed endogenously, is also exogenously 
induced by several damaging agents, with IR being one of the most critical ones. IR 
interacts with matter on multiple levels, there are numerous events triggered instantly 
post-exposure and effects that can be seen from weeks to even years later. The events 
can be broadly divided in three main phases, according to the main effects produced, 
the physical (≤ 10-14 s), the chemical (10-12 – 10-3 s) and the biological (10 s ~ days). Late 
stage effects fall into physiological and epidemiological processes. There are no distinct 
lines to discriminate the different phases, rather they overlap. The physical and chemical 
phases overlap in the physiochemical phase (10-14 – 10-12 s), while the chemical and 
biological phases overlap at 10-3 – 10 s post-irradiation (46). There are a variety of 
mechanisms involved in the radiobiological processes that are discussed below.    
1.2.3.1 Physical damage  
Immediately after exposure to IR, the physical phase begins where distribution of 
ionisation events and energy deposition in the cellular components occurs. The energy 
deposition depends on the radiation dose, the initial beam energy as well as the type of 
the radiation. At this stage, there are two types of effects initiated; direct ionisation in 
the atoms of the DNA molecule and thus direct damage, such as strand breaks and base 
losses (abasic sites); and ionisations and energy deposition in the atoms of other cellular 
components, particularly the water that constitutes about 70 % of the cell mass (47). 
The physical damage at the cellular level is considered a stochastic effect, meaning that 
there is a proportional (linear) dependence on radiation dose. In other words, the higher 
the radiation dose the more the ionisations and DNA breaks (42). However, for a given 
radiation type, higher initial beam energy results in increased penetration, and a peak 
of energy deposition deeper into biological tissue, something that alters the ionisation 
track, particularly for particle beams. Therefore, in each region the amount of physical 
damage depends on the beam’s energy.  
Furthermore, different radiation types have different interactions and effective ranges, 
as discussed in Chapter 1.1.3. X – rays travel through biological tissue losing energy in 
many small steps, resulting in plenty of ionisations in the cellular atoms along their track, 
and fewer direct breaks including single and double strand breaks (SSB and DSB) within 
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the DNA molecule. In contrast, protons have minimal interactions upon entering 
biological tissue, yet at and around their peak, they undergo through few big energy 
transfers in a very small range. This way, protons produce less sparse ionisation along 
their track but denser ionisation as well as an increased number of SSB, DSB and complex 
DNA damage (CDD; containing multiple DSBs in close proximity, within a short DNA 
region of up to 15–20 bp (48)) in depth. In fact, it has been estimated that 1 Gy (radiation 
dose unit) of x-rays and high energy (entrance dose) protons produces ~70,000 
ionisations in the cell nucleus and ~2000 ionisations directly on the DNA molecule that 
yields ~1000 SSB and ~40 DSB (49, 50). However, it has been reported that PBT induces 
more DSBs (which may also vary in complexity) compared to photon RT, particularly at 
the Bragg peak and distal edge, which I have summarised in a recent review (Table 1.1) 
(51). Nevertheless, it is suggested that PBT is biologically more effective than x – rays 
(52-55).  
Table 1. 1 Comparisons of DSBs induced by PBT versus photon RT (taken from (51)).  






MOLT4 leukemia cells 
Immunofluorescence 
γH2AX foci analysis 
200 MeV 10 MV 
x-rays 
1.2-1.5-fold increase in size and 
amount of foci following PBT, 
30 min to 6 h post-irradiation 
HeLa; SQ20B HNSCC Pulse-field gel 
electrophoresis 
76 MeV,  
201 MeV 
0.662 MeV 
𝐶𝑠137   
γ-rays 
1.2-fold increase in DSB. No 
differences between PBT 
energies nor along the SOBP. 
IN528 and T4213 
Glioblastoma stem-like 
cells 
Alkaline and neutral 
comet assay 
- 320 kV 
x-rays 
~1.2–1.6-fold higher 
numbers of DSBs at 20–48 h 
post-irradiation 
TrC1 prostate cancer cells; 
murine embryonic 
fibroblasts 
Histone γH2AX and 








Similar numbers of foci. 
Delayed, bigger and irregular 
in size for bragg peak protons. 






Similar numbers of DSBs at 
0.5–24 h post-irradiation 
Wild type, HR-deficient, 
and NHEJ-deficient 
Chinese hamster ovary cell 
lines 
Histone γH2AX foci by 
Immunofluorescence  
138 MeV 200 kV 
x-rays 
Similar initial induction of 
DSBs, yet reduced survival. 
HeLa; UMSCC74A and 
UMSCC6 HNSCC cells 
Neutral comet assay 58 MeV 
entrance dose 
11 MeV distal 
edge of SOBP 
100 kV 
x-rays 
No significant difference in the 
DSB repair kinetics. Reduced 





1.2.3.2 Chemical damage  
On top of the direct breaks that threaten the cell survival, all the peripheral ionisations 
can lead to chemical changes within the cellular components, during the physiochemical 
phase, that contribute to further damage on the DNA molecule.  Since water constitutes 
~70 % of the cell mass, it is the most affected cellular component. IR-induced water 
radiolysis (equation 1.9) generates reactive oxygen species (ROS), which are unstable 
and highly reactive free radicals with a range of ~10 nm, such as the hydroxyl radical 
(•OH), ionized and radical water (H2O+, H2O*), hydrogen radical (•H) and hydrated 
electrons (𝑒𝑎𝑞
− ). ROS have rapid chemical reactivity and generate additional damaging 
agents and secondary products, including superoxide (𝑂2
∗) and hydrogen peroxide (H2O2) 
that react with the organic and inorganic cellular components, and induce various 
secondary lesions (56). ROS can trigger indirect DNA damage, enzyme and protein 
synthesis inactivation, and damage to cellular constituents, nutrients and other building 
blocks of macromolecules (57). They are considered a major factor contributing to DNA 
damage and there is evidence of elevated levels of ROS particularly following PBT, 
promoting its cell-killing efficacy (58, 59).         
𝐻2𝑂 → 𝑒𝑎𝑞
− +• OH + • H + 𝐻2 + 𝐻2𝑂2  (1.9) 
𝐻2𝑂
∗ → 𝐻 +• 𝑂𝐻 (1.10) 
𝑅𝐻 + • 𝑂𝐻 → 𝑅∗ + 𝐻2𝑂 (1.11)    
𝑅𝐻∗ → 𝑅 + 𝐻 
H2O+ + H2O → H3O+ + •OH 
(1.12) 
(1.13) 
Shown are some typical reactions of ROS following water radiolysis (1.9), includes 
secondary reactions of the reactive water radiolysis products with water molecules 
(1.10), and with organic molecules (RH) (1.11), as well as secondary products of reaction 
of radical organic molecules (46). 
    
 1.2.3.3 Biological damage 
Following physical and chemical phases, a variety of DNA lesions are induced along the 
radiation track (direct DNA damage) and ROS have been generated (Figure 1.9). During 
the biological damage phase, chemical interactions trigger further (indirect) DNA 
damage, including base oxidation, methylation and alkylation, sites of base loss (abasic 
44 
 
sites), and DNA SSBs that are most abundantly generated. Moreover, the formation of 
DNA DSBs, clustered DNA damage containing two or more DNA lesions in close proximity 
(within 1–2 helical turns of the DNA) and CDD containing multiple DSBs within a short 
DNA region of up to 15–20 bp, are less frequent, although these are considered the most 
lethal (36, 48, 60). At this stage, any DNA damage requires immediate processing and 
repair or else it can lead to chromosomal aberrations or collapse, resulting in loss of 
genetic information, gene mutations and cell inactivation, which can ultimately lead to 
human disease development, including cancers. As soon as the damage is recognised, 
there are numerous proteins and enzymes activated to initiate DNA repair. If the repair 
of the DNA damage is not successful or if the damage is beyond repair, in a single or 
group of cells, specific proteins promote cell death to protect the survival of the 
organism (43).     
 
Figure 1. 9. Induction of DNA damage. Direct damage is induced when photons, electrons 
protons or heavy ions directly break the DNA molecule by interrupting the DNA strand 
core, or by removing a DNA base. Indirect damage occurs when the radiation interacts 
with other cellular molecules, particularly the water surrounding the DNA, which 
generates ROS, that in turn chemically damage the DNA molecule.    
 
1.2.4 DNA damages affected by LET and RBE  
A physical unit describing the energy loss and, therefore dose deposition along the path 
of the beam is the linear energy transfer (LET) and is a measure of ionisation density. 
High LET results in denser ionisations, which cause more extensive damage induction 
45 
 
compared to low LET. Photons present a low LET along their track, whereas protons and 
heavier particles present a variable LET. In the entrance of the beam, the LET is relatively 
low and similar to those of photons for high energy entrance dose, yet the LET increases 
as their energy drop further along their track, particularly at and around the Bragg peak 
(61, 62) . The median energy transfer is the absorbed dose and is counted in grays (Gy), 
where 1 Gy = 1 Joule/Kg and describes how much energy is absorbed by 1 kg of matter.   
LET is inextricably linked with another physical unit, the relative biological effectiveness 
(RBE), that is used to correlate the biological response of a given radiation, usually 
photons, with the biological response of other types of radiation. For example, RBE is 
the ratio of the reference radiation (x – rays) dose divided by proton radiation dose 
required to cause the same biological effect.  
𝑅𝐵𝐸 =  
𝐷10 𝑥−𝑟𝑎𝑦𝑠
𝐷10 𝑝𝑟𝑜𝑡𝑜𝑛𝑠
    (1.13) 
D10 refers to the dose required to achieve 10% survival post irradiation. 
RBE is a complicated quantity, it has been reported that its value depends on both 
physical factors, including the radiation dose, the proton beam energy, the dose 
fractionation, and dose rate, as well as biological factors, such as the type of the tissue, 
the cell cycle phase, the oxygenation level, but also the position along the SOBP. The 
RBE will typically increase with decreasing dose (and biological effect), due the linear 
quadratic shape of the reference radiation (63, 64).  LET is one of the parameters mostly 
determining RBE, which is 1 for low LET radiation. For clinical protons RBE will also vary 
on initial energy and size of SOBP and gradually increases as the LET increases across the 
track and reaches its maximum at the peak and distal edge of the curve, before dropping 
down due to the overkilling effect. For high energy protons, a constant value of 1.1 is 
currently used in clinical practice. Nevertheless, in vitro experimental data suggest that 
RBE increases from 1.35 in the centre of the SOBP, to 1.6 in the distal edge and 1.7 at 
the distal fall off of the SOBP (65-67), and there is an ongoing debate about whether the 
use of a constant RBE of 1.1 is the optimal solution or variable RBE values would be more 




1.2.5 DNA repair 
Preservation of the genetic information stored in the DNA, considering the vast variety 
of DNA damage possible, requires not only a high accuracy DNA replication system but 
also advanced and rapid DNA damage response and repair mechanisms. Indeed, there 
are multiple DNA repair pathways activated in response to different kinds of DNA lesion, 
with usually more than one pathway covering a certain type of lesions. The very 
structure of the DNA offers a huge advantage for its own repair, as the information is 
stored in duplicate, once in each of the strands of the double helix. In addition, the 
chemical structure of the bases enables the distinction between damaged and 
undamaged bases. Most of the repair pathways use the complimentary strands as a 
template, however certain mechanisms must repair DNA damage occurring on both 
copies of the DNA strand, these types of damage are rare but most critical. There are six 
major DNA repair pathways in human cells, that are discussed in this section.  
1.2.5.1 Base excision repair (BER)  
One of the most important DNA repair pathways, base excision repair BER, is triggered 
in response to, damaged or altered bases, including deaminated cytosines and adenines, 
alkylated and oxidised bases, opened ring bases, and degraded carbon – carbon single 
bond bases. This is a constitutively active process given the large amount of such DNA 
damage generated per cell per day. As shown in Figure 1.10, DNA glycosylases are a 
family of enzymes (11 present in human cells in total), each of whom recognise a 
different type of DNA base damage, that proofread each base pair largely using a base-
flipping mechanism, recognise and hydrolytically remove any damaged base. Then, AP 
endonuclease enzymes, particularly APE1, detects the abasic nucleotide, called 
apurinic/apyrimidinic site (AP) for a purine or a pyrimidine loss respectively, and breaks 
the sugar-phosphate phosphodiester bonds on the DNA chain, resulting in a single 
nucleotide gap in the sequence.  Next, DNA polymerase enzymes, particularly DNA 
polymerase β (Pol β), catalyse DNA synthesis and fills the gap using the complementary 
strand as a template. There are two routes at this stage, the short-patch pathway 
mediated by Pol β, and the long-patch pathway co-ordinated by DNA polymerases δ/ε 
(pol δ/ε) along with Proliferating Cell Nuclear Antigen (PCNA), in the same manner that 
natural DNA replication is processed. Finally, DNA ligase enzymes, DNA ligase I (for long-
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patch repair) or DNA ligase IIIα-XRCC1 complex (for short-patch repair), seal the nicks in 
the DNA strand. Furthermore, BER is triggered in response to the very frequent SSB and 
DNA damage caused by depurination, a chemical reaction that releases purines (A and 
G) from the DNA helix. BER is also co-ordinated by the SSB binding protein poly (ADP-
ribose) polymerase 1 (PARP1) in response to DNA damage, and multiple PARP1 
inhibitors have been clinically approved for the treatment of specific tumours, including 
breast and ovarian cancers, through BER inhibition (69-74).  
 
Figure 1. 10. Schematic representation of Base excision repair (BER). A) DNA glycosylase 
enzymes scan the DNA sequence and remove misplaced or damaged bases. B) APE1 and 
APE2 locate the abasic sites, break the phosphodiester bond between the nucleotides, 
and create a gap. C) the nucleotide gap is then synthesised and filled by DNA polymerase 
(Pol β and pol λ /pol δ, pol ε and PCNA) and is reconnected to restore the DNA strand by 
DNA ligase (DNA ligase I, DNA ligase IIIα-, XRCC1).  
 
1.2.5.2 Nucleotide excision repair (NER)  
For the repair of larger changes in the DNA sequence, the nucleotide excision repair 
(NER) pathway is activated. NER is the chosen pathway for the repair of bulky DNA 
lesions and adducts, particularly those induced by ultraviolet radiation. There are two 
types of NER in eukaryotic cells; the global genome repair (GG-NER) which slowly 
inspects the entire genome, in a transcription independent manner; and the 
transcription coupled repair (TC-NER). The two sub-pathways differ only in the initial 
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step, as shown in Figure 1.11. In GG-NER, a multienzyme DNA-binding complex 
consisting of DNA-damage binding 1 and 2 (DDB1 and DDB2) along with Xeroderma 
pigmentosum complementation group C (XPC)-Rad23B complex, scan the DNA 
sequence, recognise and bind on distortions.  
In TC-NER, RNA polymerase detects and stalls on the lesion signalling for NER factors to 
process the repair. The damaged bases are then excised by the excision repair complex 
TFIIH (Transcription factor II H), by breaking the nucleotide phosphodiester bonds of the 
DNA strands on both sides of the lesion. Immediately, the DNA helicase enzymes (XPD 
and XPB) separates the two strands and removes the oligonucleotide fragment. DNA 
polymerases then resynthesise the DNA fragment by using the complementary strand 
as a template, and DNA ligase complete the repair by sealing the nick in the DNA strand. 
In human cells, the removed fragments can be more than 24 nucleotides long. This is a 
major mechanism that can repair almost any kind of large DNA damage (75-78).  
 
Figure 1. 11. Schematic representation of Nucleotide excision repair (NER). A) There are 
two types of NER in eukaryotic cells, GG-NER, catalysed by the DDB1, DDB2 and XPC-
Rad23B complexes, and TC-NER, initiated by RNA polymerase damage recognition. B) 
TFIIH complex excises the damaged site, and DNA helicases XPD/XPB separate the two 
strands and remove the fragment. C) DNA polymerase enzymes synthesise the new 




1.2.5.3 Mismatch repair (MMR)  
Mistakes occurring during DNA replication and go undetected by DNA polymerases, are 
resolved by mismatch repair (MMR). This pathway can identify mispaired bases but also 
insertion or deletion of mispairs, where there are up to 10 unpaired nucleotides in one 
of the DNA strands. The heterodimer MutS Homologs (MSH) complex, consisting of 
MSH2-MSH6 and MSH2-MSH3, proofread the DNA strands and bind on the DNA lesion. 
The heterodimeric MutL homologs (MLH) complexes, consisting of MLH1-PMS2 and 
MLH1-MLH3, then identify and cleave the oligonucleotide fragment containing the 
lesion, recruiting DNA helicase II to separate the two strands. Finally, Pol δ and PCNA 
replicate the DNA strand, replacing the appropriate DNA bases, and DNA ligase I 
completes the repair process. MMR is also a key pathway for the detection and repair 
of DNA adducts, caused by chemotherapeutic agents. Deficiency in MMR introduces 
high rate mutations and has been associated with numerous human cancers (79-82).     
1.2.5.4 Translesion synthesis (TLS) repair 
Translesion synthesis repair (TLS) occurs during the S phase of the cell cycle, where there 
is ongoing DNA replication. This process enables DNA synthesis to be carried out past 
certain DNA lesions, ensuring genome replication and cell survival. In fact, TLS initiates 
DNA lesion bypass, preventing DNA damage to cause delays in the DNA synthesis, and 
thus preventing blockage or collapse of the replication forks. This pathway is mediated 
by the post-translational modification of PCNA that upon recognition of a blocked 
replication fork, gets ubiquitinated, and recruits low stringency TLS polymerases. PCNA 
then regulates a switch between the regular synthesis Pol δ/ε, which lead the synthesis 
of the two strands with specific TLS polymerases. There are several TLS polymerases in 
mammalian cells, including pol η, pol ι, pol ζ, pol II, IV and V, that due to their different 
substrate specificities, deal with many different types of DNA damage by surpassing the 
blocked region resuming DNA replication, allowing for later repair of the DNA damage. 
PCNA progressively switches between the required polymerase until the process is 
completed. TLS is a low fidelity repair process and is often error prone leading to further 
DNA damage and/or mutagenesis, therefore other repair mechanisms are required to 
complete the repair process. However, it is important in preventing degradation of 
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simpler DNA damage that could generate chromosomal aberrations or induce cell death, 
early in the cell cycle and therefore allowing time for further DNA repair (83-86).   
1.2.5.5 Non-homologous end joining (NHEJ) 
Simultaneous damage on both sides of the double helix lead to DSBs, highly toxic DNA 
lesions that if not repaired can cause mutations, chromosomal disruption and severe 
loss of genetic information. One of the major mechanisms for DSB repair and 
chromosome restoration, is the non-homologous end joining (NHEJ) repair pathway. It 
is the predominant mechanism throughout the cell cycle in mammalian cells, particularly 
for direct DSBs, in a template independent manner (87). This pathway, shown in Figure 
1.12, is mediated by a complex of the Ku70/80 heterodimer, composed of the Ku70 and 
Ku80 subunits, and the large catalytic subunit of DNA-dependant protein kinase (DNA-
PKcs), that rapidly detect the broken DNA ends. The Ku heterodimer produces a rink-
shaped structure, that binds onto the sugar-phosphate backbone of the DNA strand, yet 
do not bind onto the bases, making it DNA sequence independent, and this then recruits 
DNA-PKcs to form the repair platform. This binding protects the DNA ends from 
nonspecific processing, that could lead to chromosomal aberrations and genomic 
instability, but also attracts other NHEJ factors to promote repair. X-ray cross 
complementing protein 4 (XRCC4), DNA Ligase IV, XRCC4-like factor (XLF) and Aprataxin-
and-PNK-like factor (APLF), are NHEJ repair factors that are recruited to the DSB site. 
There is no particular order in the recruitment process, neither is one factor necessary 
for the recruitment of the other factors, on the contrary this rather depends on the 
complexity of the DNA damage.  
Simple DSBs, after DNA-PK binding may require only XRCC4, Ligase IV, and XLF for their 
repair. In contrast, for repair of more complex DSBs, the process relies on DNA-PKcs 
possibly recruiting ataxia-telangiectasia mutated (ATM) which is a member of 
phosphatidylinositol-3 (PI-3) kinase-like kinase family (PIKK).  Either way, the DNA-PK 
complex produce a stable core at the DSB site (88). Subsequently, the DNA gaps are filled 
and the DNA ends get compatible for ligation, by specific DNA end processing enzymes 
and proteins, recruited by either XRCC4 and DNA-PKcs, including Artemis, aprataxin, 
ligase IV, polynucleotide kinase-phosphatase (PNKP), DNA Polymerases μ and λ, Werner 
protein (WRN), and APLF (88-91). Finally, DNA ligase IV, mediated by XRCC4, XLF, and 
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likely APLF, connects the loose ends without checking for their homology, and despite 
any remaining gaps. The NHEJ complex is then dissolved and the repair is completed. 
NHEJ repair is an error-prone pathway that could join broken DNA ends with little or no 
homology, however there is evidence that it may be acting synergistically with HR to 
maintain genomic integrity (92, 93). Also considering the majority of the DNA sequence 
is non-coding, NHEJ is a good enough mechanism, that can rapidly repair damaged 
chromosomes, crucial for maintenance of the genomic information and cell survival (92).  
 
Figure 1. 12.  Schematic representation of non-homologous end joining repair pathway 
(NHEJ). A) DNA damage induction; B) The Ku-70/80 heterodimer recognises and binds 
onto the broken ends of the DNA strands, and recruits DNA-PKcs to form the DNA-PK 
complex; C) Simple DNA damage is getting processed by DNA-PKcs or XRCC4, while 
Complex DNA damage is assisted by ATM, recruited by DNA-PKcs. (D) Artemis, aprataxin, 
ligase IV, PNKP, DNA Polymerases μ and λ, Werner protein (WRN), APLF and XLF, are 
independently recruited by DNA-PK, interact with each other and form a stable DNA 
repair complex to process the broken DNA ends. E) Processing of the DNA ends marks 
the end of the repair process, and the DNA repair complexes are dissolved.  
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1.2.5.6 Homologous recombination (HR)  
The second key mechanism for DSB repair is the homologous recombination (HR) 
pathway. In addition to DSB repair, HR is the main mechanism for the repair of blocked 
or collapsed replication forks, but also for resolving of DNA gaps and DNA interstrand 
crosslinks (ICL) (94). HR repair is a high-fidelity error free mechanism that is active only 
during late S and G2 phases of the cell cycle, when the sister chromosome is present, 
and used as a template for the repair of the broken DNA helices. In fact, HR prefers using 
the sister chromosome rather than the homolog chromosome as a template to reduce 
the risk of loss of heterozygosity. It is a prominent mechanism for genome preservation, 
in addition to NHEJ for the repair of DSBs and to TLS for DNA damage surpass and 
tolerance (95). 
Particularly for the DSB repair, HR pathway can be separated into three phases as shown 
in Figure 1.13; the pre-synapses, the synapses, and the post-synapses. During the pre-
synapses phase, the broken DNA ends are recognised and are resected in a 5’ to 3’ 
direction. One of the broken strands is processed to a 3′-OH ending single-stranded DNA 
(ssDNA) tail, that along with Rad51 the central protein to HR, forms the Rad51-ssDNA 
presynaptic helical filament. Since this is antagonistic to the ssDNA-binding protein 
replication protein A (RPA), promoter proteins enable Rad51 to surpass the inhibition by 
RPA, and subsequently to replace RPA in the filament.  
In the second phase, synapses, Rad51 firstly catalyses an homology search in the DNA 
strands where recombination proteins locate the matching DNA sequences between the 
sister chromatids, and secondly promotes DNA strand invasion, where the Rad51-ssDNA 
filament generates a D-loop in the homolog chromosome. There are five human Rad51 
paralogs, Rad51B, Rad51C, Rad51D, XRCC2 and XRCC3, and these form complexes 
catalysing the process that have non-overlapping functions. Multiple core factors and 
mediator proteins are also involved in the progress of the repair process including, but 
not limited to, ATM, ATM and Rad3 related (ATR), WRN, Rad52, Rad54, Rad55, Rad57 
and breast cancer associated gene 1 and 2 (BRCA1 and BRCA2). Moreover, for the repair 
of IR-induced DSBs, the Mre11-Rad50-Xrs2 (MRX) complex is specifically required, and 
it has been shown that defects in this complex lead to significant IR sensitivity (95).   
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During the post synapses phase, DNA replication proteins copy the missing genetic 
information to the broken helix, repairing it and restoring the DNA sequence. Following 
the generation of the D-loop, there are (at least) three alternative pathways to complete 
the repair, namely synthesis-dependent strand annealing (SDSA), break-induced 




Figure 1. 13. Schematic representation of Homologous recombination repair pathway 
(HR). HR can be divided into three main phases; The pre-synapses: recognition of DSB 
and formation of the complex Rad51 - ssDNA tail presynaptic filament. The synapses: 
homology search between the sister chromosomes and generation of the D – loops. The 
post-synapses: repair of the broken strand through 1) SDSA (synthesis – dependent 
strand annealing) often in multiple cycles, 2) BIR (the break – induced replication) where 
the D-loop is assembled into a full replication fork or 3) DSBR (the double – strand break 
repair) a) by double independent strand invasion or by second end capture and b) double 
Holliday junction dissolution/resolution. Rad51 is the core HR protein but several  
proteins mediate the repair process across the different stages including ATM, ATR, 




SDSA is the preferred mechanism in mammalian cells. It is performed in successive 
rounds of DNA strand invasion, short DNA synthesis off the template chromatid, D-loop 
disruption, disengagement of the newly synthesised end and annealing with the second 
end of the broken strand. This leads to localized conversion without crossover, and 
therefore a loss of heterozygosity produced by somatic crossovers is avoided. BIR is a 
straightforward non-crossover process where the D-loop is assembled into a full 
replication fork, and the entire distal part of the DNA strand gets synthesised, copying 
the template chromosome. This process may result in loss of heterozygosity in the 
chromosome, as the second strand does not engage in the repair and the genetic 
information of the fragment may be lost. DSBR involves both ends of the DSB being 
engaged in the repair, either by double-independent strand invasion or by second end 
capture through DNA annealing. The latter leads to double Holliday junction formation, 
a four-way branched DNA joint molecule, that is resolved by structure-specific 
endonucleases, such as Mus81–Mms4, Slx1–Slx4, and Yen1, to yield either crossover or 
non-crossover products. Moreover, double Holliday junctions can be dissolved by a 
mechanism involving Bloom Syndrome (BLM) DNA helicase, that migrates the two 
junctions towards each other, and type 1 TOPOIIIα topoisomerase, that topologically 
links the two duplexes, leading exclusively to non-crossover products. Finally, Resolvase 
A, whose specific activity is yet to be determined, has been shown to cleave Holliday 
junctions into crossover and non-crossover products. Once the synthesis and ligation of 
the broken ends is completed and the DNA strand is restored, it is then used as a 
template for the repair of the complementary strand and the repair process is therefore 
finished (95-98).   
 
1.2.6 DNA repair in response to IR-induced DNA damage 
PBT and conventional radiotherapy (RT) present fundamental physical differences. As 
discussed in Chapter 1.1.3, the physical interaction of protons, as particles with mass 
and positive charge, is fundamentally different than that of photons who have neither 
mass nor charge (99). Consequently, the biological response following proton and x – 
ray induced DNA damage differs (100-102). The choice of the appropriate repair 
mechanism depends on many different factors, with the cell cycle stage to be one of the 
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first contributors identified, but also the DNA lesion induction process, the radiation 
type and beam energy, and the DNA repair protein competence all associated with DNA 
repair pathway choice  (103-106). 
1.2.6.1 Types of DNA damage  
PBT is suggested to induce more DSBs and CDD compared to conventional RT (Table 1.1) 
(100, 101, 107, 108). DSBs can be quantified indirectly by measuring the phosphorylated 
histone H2AX (γH2AX) foci formation that are rapidly generated in response to DSBs, 
and  attract other DSB repair proteins (109). Multiple in vitro studies have reported 
increased amounts of DNA repair γH2AX foci formation following proton irradiation, that 
they were also larger in size and persisted for longer, suggesting a more CDD in 
comparison to photon induced foci (100, 101). This indicated not only a greater number 
of DSBs and clustered lesions, but also persistent DNA damage that was trickier to be 
resolved (108). Interestingly, it has also been reported that the initial induction of DSBs 
was similar, following clinically relevant protons and x – rays in vitro. However, PBT 
induced more lethal DNA lesions than x – rays. These results suggested the quality rather 
than the amount of DNA damage induced was the reason for the different effectiveness 
(102).  Finally, high LET radiation, derived from low energy protons, α particles, carbon 
ions and other heavy particles, is considered even more prominent in cell killing than 
low LET and photon radiation. Both in vitro studies and computer simulations reported 
increased CDD induction, with plenty DSB in close proximity that determine its enhanced 
biological effectiveness for the same physical radiation dose, compared with low LET 
and photon radiation (110-114). 
 
1.2.6.2 DNA repair pathway choice 
The pathway choice for DSB repair following different radiation modalities, is a field of 
ongoing research with rather contradicting findings currently available in literature. 
Between the two major DSB repair mechanisms detailed above, there are a number of 
in vitro experimental evidence suggesting that while HR is important, NHEJ repair is the 
major repair pathway in response to both photon and low LET proton radiation. 
Consequently, DNA-PKcs is considered the main protein involved in resolving IR-induced 
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DSBs (115-117). In these studies, wild type, HR-deficient, as well as NHEJ-deficient 
Chinese hamster ovary cell lines presented increased sensitivity to both radiation types, 
with, however, no significant difference in the DNA repair kinetics following either 
proton or x – ray irradiation. These data are summarised in Table 1.2, taken from our 
recent review (51). In contrast, it is also reported that whilst NHEJ repair pathway is the 
major mechanism for DSB repair following x – ray irradiation, there is increased 
dependence on HR for repair of proton induced DSBs in vitro (102, 118, 119). In these 
studies, PBT was more efficient in killing HR-deficient compared to NHEJ-deficient 
Chinese hamster cell lines, but was less effective in DNA-PKcs inhibited human A259 lung 
cancer and glioblastoma cell lines compared to x – rays. In addition, the proportion of 
cells undergoing HR following PBT versus x – rays was reported to be higher in HeLa cells 
(119). Therefore, further investigation is required to resolve the conflicting evidence.  
 
Table 1. 2 DNA double strand break (DSB) repair pathway choice following proton beam 
therapy (PBT) versus photon irradiation (taken from (51)).  
Cell line Irradiation Outcome 
wild type, NHEJ- and HR-
deficient Chinese hamster cell 
lines 
200 MeV protons and   
137Cs γ-rays 
NHEJ is the major pathway, for 
photons and low LET protons. 
wild type and NHEJ-deficient 
Chinese hamster ovary cell lines 
14.4 MeV plateau protons 
and 667 kV 137Cs γ-rays 
NHEJ is the major pathway, for 
photons and low LET protons. 
Wild type, HR-, and NHEJ-
deficient Chinese hamster ovary 
cell lines 
138 MeV protons           
and 200 kv x-rays  
Enhanced dependence on HR 
following proton.  
A549 lung cancer; glioblastoma 
cells 
138 MeV protons           
and 200 kv x-rays 
Enhanced dependence on HR 
following proton. 
HeLa 21 MeV protons High proportion of cells undergo 
HR following protons 
Non-small-cell lung cancer cell 
lines 
235 MeV protons           
and 250 kV x-rays 





1.3 DNA repair regulators  
Radiotherapy is one of the three major cancer treatments, particularly for treatment of 
head and neck cancers, currently used alone or in combination with surgery and/or 
chemotherapy. As discussed above, this involves using ionizing radiation to induce 
significant DNA lesions and lead to tumor cell death. Among the vast variety of DNA 
damage induced, DSBs are the most cytotoxic lesions, and a single unrepaired or mis-
repaired DSB can be lethal. However, the sophisticated DNA damage response (DDR) 
system initiates DNA repair upon recognition of a DNA lesion, to protect the genomic 
stability of the cell. Three protein kinases ataxia telangiectasia mutated (ATM), ataxia–
telangiectasia mutated and Rad3 related (ATR) and the catalytic subunit of DNA-
dependent (DNA-Pkcs), are actively involved in the DDR, and play a key role in the 
detection and repair of DSBs via the NHEJ and HR repair mechanisms (120-122). 
 
1.3.1 The role of ATM in DDR 
ATM is central in signaling DNA damage and repair, particularly in response to DNA DSBs 
and is a key factor for activation of several DNA repair proteins and cell cycle 
checkpoints. Moreover, ATM deficiency has been associated with severe sensitivity to 
IR and other DNA damaging agents, as well as acute apoptotic rates (123). ATM is 
actively involved the two major DSB repair mechanisms, HR and NHEJ with hundreds of 
substrates phosphorylated in an ATM-dependent manner, highlighting the complexity 
of DDR pathways (121). Upon DSB induction, ATM is activated and instantly an 
intermolecular auto-phosphorylation on Serine 1981 (S1981) is initiated. It is then 
recruited by the Mre11-Rad50-Nbs1 (MRN) complex, which is rapidly assembled on DSB 
sites, and acts as a damage sensor that can also form a physical bridge spanning the 
DSBs (124, 125). Recruitment of ATM has also been associated with Nbs1, that also 
enhances ATM kinase activity (126). ATM in turn, activates several proteins associated 
directly with DNA repair, such as histone H2AX, BRCA1, as well as proteins critical for the 
regulation of the cell cycle, at G1, S and G2/M checkpoints, including p53 and Chk2, 
indirectly promoting DSB repair.  
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Phosphorylation of histone H2AX opens up chromatin to allow DNA repair enzymes to 
access the DSBs. ATM is reported to phosphorylate histone H2AX at serine 139 (called 
γH2AX) both in vitro and in vivo, being one of the earliest kinases to be activated in the 
cellular response to DSBs (127). Furthermore, BRCA1 expression is considered critical for 
the appropriate resolution of IR-induced DSBs and colocalizes with the key HR protein 
Rad51, as well as the Nbs1-Mre11-Rad50 complexes involved in both HR and NHEJ. ATM 
phosphorylates CtIP (C-terminal binding protein interacting protein), a BRCA1 
suppressor protein, subsequently driving dissociation of CtIP from BRCA1 and essentially 
upregulating BRCA1 expression, promoting DSB repair (128, 129).  
The tumor suppressor protein p53 regulates cell cycle progression by controlling the 
G1/S checkpoint preventing cell proliferation until the DNA damage is resolved, or the 
cell is led to apoptosis in the case of irreparable damage. ATM promptly phosphorylates 
p53, at serine 15, and upregulates its expression by phosphorylating the E3 ubiquitin 
ligase mouse double minute 2 homolog (MDM2). This stabilizes p53, preventing in 
parallel its rapid degradation (130-132). Similarly, ATM-driven activation of jun kinase 
(JNK), leads to reduced JNK binding on p53 and thus upregulation and decreased 
degradation of p53 (133). Another protein also phosphorylated by ATM in response to 
DNA damage is the checkpoint kinase 2 (Chk2), a kinase that mediates cell cycle 
progression in both S and M phases. Chk2 subsequently phosphorylates the mitosis-
inducing phosphatase, M-phase inducer phosphatase 3 (Cdc25C) on an inhibitory site, 
causing G2/M arrest, preventing entry into mitosis and giving extra time for DNA repair. 
Moreover, Chk2 rapidly phosphorylates p53 on serine 20 and stabilises the protein by 
inhibiting MDM2 binding resulting in G1 arrest (134, 135). Activation of Chk2, also 
mediates and promotes degradation of the S-phase promoter phosphatase, M-phase 
inducer phosphatase 1 (Cdc25A), delaying DNA synthesis (136).    
Finally, ATM has been shown to mediate apoptosis by promoting activation of p73, a 
regulator of DNA damage induced apoptosis. During IR-induced apoptosis, a cascade of 
caspases (cysteine aspartic acid proteases) cleave cellular proteins. ATM is cleaved by 
the caspase-3-like apoptotic protease, generating a truncated protein with limited 
kinase activity, only enough to retain its DNA binding ability, to prevent DNA repair and 
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DNA damage signaling, suggesting a counterproductive DNA repair upon commitment 
to apoptosis (123). The contribution of ATM to the DDR is summarised in Figure 1.14   
 
1.3.2 The role of ATR in DDR 
ATR is a key factor in the HR repair pathway of DSB repair, and promoter of genome 
stability. As indicated by its name (ATM and Rad53 related), ATR is closely linked to ATM. 
Both ATM and ATR are activated in response to IR-induced DNA damage, yet ATR is also 
activated in response to ultraviolet radiation (UV)-induced damage. Interestingly, ATM 
and ATR are in general activated by different types of DNA damage. ATM is associated 
with direct DSB, while ATR is correlated with the repair of single stranded DNA (ssDNA) 
structures that arise from various types of DNA damage, such as stalled DNA replication 
forks and resected DNA DSBs, and it is therefore essential for cell survival even in the 
absence of exogenous genotoxic agents (121).  
Following generation of ssDNA, RPA binds to form an RPA-ssDNA complex. In parallel, 
ATR is activated via an intramolecular auto-phosphorylation on threonine 1989 (T1989). 
This phosphorylation is critical for ATR function and is promptly recognised by DNA 
Topoisomerase II Binding Protein 1 (TopBP1), which in turn attracts the complex ATR-
ATR interacting protein (ATRIP) that directly interact with the RPA-ssDNA complex, 
promoting ATR-driven cell cycle regulation and DNA repair. Moreover, formation of the 
RPA-ssDNA complex recruits the Rad17-RFC complex at ssDNA- dsDNA junctions, which 
engages the Rad9-Hus1-Rad1 heterodimer to bind on to the DNA ends, attracting 
TopBP1 and further promoting ATR phosphorylation and ATR-driven cell cycle regulation 
and DNA repair (121, 137, 138). Phosphorylation of BRCA1 by ATR occurs in distinct sites 
that overlap with ATM phosphorylated sites in response to IR induced DNA damage 
(123).   
The contribution of ATR in the DDR is particularly critical in providing cell cycle control. 
Likewise to ATM, ATR directly activates p53 at serine 15 but also at serine 37, in a way 
that is both overlapping and non-redundant in regulating p53 expression, and thus ATR 
indirectly mediates the G1/S cell cycle checkpoint (139). In addition, ATR phosphorylates 
Checkpoint kinase 1 (Chk1), a serine/threonine-specific protein kinase principal 
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regulator of the cell cycle that impacts progression in three different phases of the cell 
cycle, the S phase, G2/M transition and M phase. Chk1 activation regulates cell cycle 
control on multiple phases, firstly on G1/S phase as it phosphorylates p53 on serine 20, 
upregulating and stabilizing p53 expression, thus delaying entry into the S phase (140). 
Secondly, during the S phase, as it mediates degradation of the S-phase promoter 
phosphatase Cdc25A, prohibiting DNA synthesis (141, 142). Thirdly, Chk1 acts on the 
G2/M cell cycle checkpoint, by the degradation of Cdc25A along with the 
phosphorylation of Cdc25C on serine 216, that reduces its ability to activate nuclear 
Cyclin-dependent kinase 1 (Cdc2), and in turn prevent entry into mitosis allowing further 
time for DNA repair (143-145).  Figure 1.14 summarises the role of ATR in regulation of 
the DDR.  
Overall, ATM and ATR mediate distinct repair pathways, although these partially 
overlap. Together, they regulate over 700 identified possible targets in response to DNA 
damage, many of which are common, such as p53 and BRCA1. Although ATM is mainly 
associated with G1/S phase cell cycle control, and ATR with intra S phase and G2/M 
phase cell cycle regulation, they often switch depending on the DNA damage and the 
cellular context. The two kinases cooperate in mediating damage response, promoting 
genome stability, and they are both required for effective DNA repair. In fact, it is 
suggested that the two pathways may be complimentary to each other and that defects 




Figure 1. 14.  The role of ATM, ATR and DNA-PKcs in the DNA damage response. Protein 
kinases central to DDR, are activated and have multiple interactions to promote DNA 
repair. ATM and ATR are signalling kinases that regulate several factors involved in DNA 
damage repair, as well as cell cycle control. DNA-PKcs, is directly involved in DSB repair 
via the NHEJ pathway. ATR is activated in response to stalled replication forks, while ATM 
and DNA-PKcs are triggered in response to DSBs and are key in mediating cellular 
apoptosis. 
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1.3.3 The role of DNA-PKcs in DDR 
Another member of the PIKK family actively involved in the DDR is DNA-PK, a complex 
of Ku70/80 heterodimer and DNA-PKcs. DNA-PKcs is a major regulator of and directly 
involved in NHEJ repair. Deficiencies in DNA-PKcs has been associated with enhanced 
sensitivity to IR and other DNA damaging agents, while increased resistance to IR has 
been linked to DNA-PKcs overexpression (146-148). Similarly to ATM, DNA-PKcs is 
triggered in response to DSBs, yet the two proteins have separate and distinct functions 
in DSB repair (Figure 1.14). As discussed in Section 1.3.1, ATM acts as a signalling kinase, 
initiating several factors to promote DNA repair, in contrast with DNA-PKcs which 
mediates and contributes directly in the repair of the DSBs (146). Phosphorylation of 
DNA-PKcs promotes the opening of the DNA – DNA-PKcs complex to let other NHEJ 
factors access, process, and ligate the DNA ends. DNA-PK is phosphorylated on at least 
40 amino acid sites but mutation on two of them, the Serine 2056 (S2056) and the 
Threonine 2609 (T2609), have been linked with inability to release the tight DNA – DNA-
PKcs complex, suggesting they mediate the complex opening and thus progression of 
the repair. S2056 is primarily auto-phosphorylated, whilst T2609 is suggested to be 
partly phosphorylated by ATM (146, 147, 149, 150). The two sites have distinct roles in 
DSB repair, S2056 is reported to promote DSB ligation and T2609 to initiate the end 
processing (151, 152).  Interestingly, DNA-PK activation and phosphorylation are not 
necessary for initial recruitment to DNA damage sites yet are required for efficient repair 
of DSBs (146).  
The reasoning on how cells choose the appropriate repair pathway is yet to be 
determined. Interestingly, DNA-PKcs is proposed to be critical in the DSB repair pathway 
choice, between NHEJ and HR. While NHEJ is the predominant mechanism throughout 
the cell cycle, it is suggested that modulation of DNA-PKcs phosphorylation sites can 
promote either NHEJ or HR, by phosphorylating sites with a negative impact on NHEJ, in 
certain types of DNA damage where accurate repair is required. This illustrates that the 
two pathways are not just antagonistic, but also complementary (153, 154).     
On another note, in addition to contribution to DNA repair, DNA-PKcs play a major role 
in promoting signalling of apoptotic pathways, in case of excessive and irreparable DNA 
damage. DNA-PKcs is suggested to mediate p53 expression in response to DNA damage. 
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Actually, it phosphorylates p53 at serines 15 and 37 leading to apoptosis, but also 
phosphorylates MDM2 preventing its inhibitory action on p53, contributing to further 
promotion of apoptosis. Moreover, DNA-PKcs deficiencies have been linked with 
suppressed p53-dependent apoptosis but remarkably not cell cycle arrest (155-157). 
Furthermore, phosphorylation of histone H2AX (γH2AX) that occurs in apoptotic cells, in 
parallel with DNA fragmentation, was shown to be DNA-PKcs initiated and driven. In 
fact, inhibition of DNA-PKcs phosphorylation activity resulted in retention of DSBs, which 
was highlighted by γΗ2ΑΧ persistency. ATM is also linked to Η2ΑΧ phosphorylation 
however this occurs early in response to DSBs and is degraded well before cell 
commitment to apoptosis  (146, 158). During the final steps of apoptosis, DNA-PKcs is 
targeted by caspase 3-like protease (CPP32), cleaved into fragments of 240-, 150-, and 
120-kDa and therefore inactivated further demonstrating that DNA repair is 















1.4 Head and Neck Squamous Cell Carcinoma   
Head and neck squamous cell carcinoma (HNSCC) is a disease comprised of a 
heterogeneous group of cancers originating in the wider area of the head and neck, 
which includes the lip and oral cavity, the paranasal sinuses and nasal cavity, the 
oropharyngeal (pharynx and larynx), laryngeal, nasopharyngeal, and hypopharyngeal 
cavities. About 90 % of head and neck cancers are squamous cell carcinomas (161), also 
called epidermoid carcinomas. They arise from squamous cells, which are flat and thin 
cells, that reside in the epidermis, the outer layer of the skin, and in the mucous 
membranes, the lining of the hollow organs of the body, but also in the lining of the 
respiratory and digestive tracts (162). HNSCCs as a group ranks seventh in the list of the 
most frequent cancer types worldwide, and ninth in the most fatal cancer types 
according to the World Health Organization (WHO) (163). It accounts for approximately 
600,000 new cases diagnosed per year worldwide (164, 165), with the majority being 
locally advanced, often treated locally with surgery and radiotherapy, followed by 
chemotherapy (166). Squamous cell carcinoma (SCC) is considered to display a high 
metastatic rate, especially in cases where the carcinomas are large, deep, or poorly 
differentiated, where they are located on the lip, ear, temple and cheek, or where there 
is perineural invasion.   
Even though it is regarded as a group, the fact that HNSCC originates in multiple regions 
of the head and the neck, with potentially varying molecular mechanisms regulating 
DNA repair, makes it extremely divergent between cases. Thus, it is of great importance 
to understand the origin of the differences in the DNA repair process within the 
individual HNSCC sub-types, and to exploit new treatment pathways that can selectively 
enhance the therapeutic result (167).  
 
1.4.1 Development of HNSCC:  Alcohol and tobacco overconsumption. 
Development of HNSCC has been associated with extensive consumption of alcohol and 
tobacco products, with high frequencies of carcinogenesis particularly in the most 
exposed areas of the upper aero-digestive track in smokers and drinkers (168). In fact, a 
combination of alcohol and the known carcinogens contained in tobacco products have 
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been linked to enhanced genetic disruptions, responsible for HNSCC development. 
Multiple studies have provided evidence for genetic changes including oncogene 
overexpression, muted tumor suppressor genes, chromosomal alterations and 
aberrations, that lead to excess cell proliferation, tumor growth and metastatic invasion. 
It has been suggested that 60 % of HNSCC cell lines displayed deletions in chromosomes 
(3p) coding for multiple tumor suppressor genes, resulting in dysfunctional proteins 
encoded by these genes (169-171). Moreover, up to 50 % of HNSCC cases has been 
reported to display chromosomal amplifications in 11q13, resulting in overexpression of 
Cyclin D1 and cortactin, that may promote tumor progression and are related to poor 
clinical prognosis and increased metastasis (172-176). Finally, HNSCC has also been 
strongly associated with mutation and loss of function of the tumor suppressor protein 
p53 (177).  
 
1.4.2 Development of HNSCC: HPV infection 
Another major risk factor in HNSCC development is infection with Human papilloma 
virus (HPV). The proportion of HNSCC containing HPV DNA is relatively high and is 
estimated to be around 40 – 70 % (178) and approximately 80 % of HPV-positive HNSCCs 
are high-risk type 16 HPV (179).  Interestingly, HPV-positive HNSCCs are clinically and 
molecularly distinct from HPV-negative HNSCCs and have a better prognosis irrespective 
of the treatment (180-185). Multiple studies have reported that survival rates in patients 
with HPV-positive are higher than that of HPV-negative HNSCC (186, 187). Although it is 
not fully understood how the HPV-associated cellular alterations respond to known 
therapies, recent studies have demonstrated that HPV-positive HNSCC cell line cells are 
more sensitive to IR compared to the HPV-negative ones in vitro (188-191). 
HPV is a family of viruses, that consists of at least 200 subtypes, and can be broadly 
divided in two categories; the cutaneous HPV types that infect the basal epithelial cells 
of the hands and feet and the mucosal types that infect the inner lining of tissues, like 
the respiratory tract, the oropharyngeal region, or the anogenital epithelium. HPVs 
contain cyclical, double stranded DNA, coding approximately 8 genes, including the E1, 
E2, E4, E5, E6 and E7 genes. Although all viral genes are necessary for the replication and 
proliferation of the virus, the E6 and E7 are consistently expressed in HPV-positive 
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carcinomas. These oncogenes transcript the respective oncoproteins, E6 and E7, which 
are multifunctional proteins known to regulate cell cycle progression and proliferation, 
and transmembrane signaling. Also due to their transformation properties, E6 and E7 
oncoproteins are known to regulate the transformation of established cell lines, 
immortalization of primary cell lines and chromosomal stability.  
E7 is a small protein consisting of approximately 100 amino acids, that binds on to the 
‘pocket domains’ and consequently downregulates the expression of the 
retinoblastoma protein (pRB), a tumor suppressor protein that represses the activation 
of multiple replication enzymes. E7 forces indirectly, the infected cells into S-phase and 
thus promotes replication. E6, a 158 long amino acid protein, consequently stimulates 
degradation and downregulation of the tumor suppressor protein p53, to prevent 
apoptosis following unscheduled cell cycle progression. This way E6 promotes cell cycle 
progression and tumor growth (179, 192-194). A third less studied oncogene, E5, has 
been recently associated with upregulation of DNA synthesis and cell cycle progression 
in keratinocytes, however it has been suggested that its function is most crucial in the 
initial steps of the viral infection as its expression is often lost following HPV integration 
(179, 195).  
 
1.4.3 HNSCC cell lines for in vitro studies 
Patient-derived cell lines are a tool offering a tumor specific model for scientific 
research. They are commonly used in translational research to investigate basic 
molecular and biochemical mechanisms, as well as genetic and immunological 
properties in various types of mammalian cancers. In addition, they are utilised to assess 
potential treatment responses. These offer significant advantages, such as low cost, high 
sample homogeneity, and most importantly avoidance of legal and ethical issues 
associated with animal experiments (177). The most common technique for HNSCC cell 
line generation is the explant cultured method, during which, fresh tumor tissue is 
surgically removed. The tumor fragments (epithelial cells) grow in culture medium 
supplemented with amino acids and serum, and fibroblasts are removed frequently 
using a cell scraper or differential trypsinization (DF). Next, the cells are cultured and 
maintained under standard conditions of oxygen, CO2, and temperature resembling that 
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of the human body. After a short lag phase where cell growth is minimal, cells pass in 
the log phase and are growing exponentially. During log phases the cells go through 
several passages, which has been reported to affect their resemblance of the original 
tumor, nevertheless in vitro studies in genetic and molecular cytogenetic of HNSCC cells 
suggested that they do closely resemble the primary tumors (177, 196-198).   
It is reported that more than 300 HNSCC immortalized cell lines have been established 
and are commercially available for in vitro studies, with plenty of HPV-negative cell lines, 
particularly from the oral cavity and the larynx, but limited HPV-positive cell lines. It is 
worth noting that generation of HPV-positive HNSCCs primary cell lines has been 
profoundly difficult (177). Indeed, there are only six immortalized HPV-positive HNSCC 
cell lines available. However, only recently a new HPV-positive oropharyngeal SCC cell 
line was established, yet it has been reported to be extremely slow to initiate, with a 
doubling time 3 times slower than those in other HNSCC cell lines, and a success rate for 
establishment of <5% that also required the use of xenografts in nude mice (199). 
Unfortunately, there are major disparities between HPV-negative and the available HPV-
positive cell lines, as the latter largely originate from both the oral and oropharyngeal 
cavities and are derived from heavy smokers and alcohol drinking patients. On top of 
that, both HPV-positive and HPV-negative HNSCC cell lines have proven challenging for 
in vitro culture, with slow doubling times and increased risk of contamination, although 
the reason behind this is yet to be determined. In spite of these drawbacks, these cell 
lines have been fully characterised, have a confirmed HPV status and constitute a 
reasonably reliable model. Also, the fact that these cell lines have gone through 
carcinogenesis in vivo, as they have been derived directly from tumor tissue, offers an 
improved viral model of HPV-positive cancer, in comparison with experimental 
transfection of E6 and E7 into normal squamous cell lines (200).  
 
1.4.4 Targeting DDR in HNSCC cells 
Despite the continuous technological developments, and the ongoing improvement of 
current and novel treatments as well as the advanced delivery techniques, the mortality 
rates of HNSCC have not shown significant improvement over the last few decades. The 
mortality rate for HNSCC patients in the United States have been estimated to be as high 
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as 60 %, with a five - year survival of only 40 % under standard treatment (177). In the 
United Kingdom, according to cancer research UK, there are 12,200 new cases per year, 
2/3 of which are male patients, making HNSCC the 8th most common cancer type. 
Mortality is estimated to be around 33 % and over the last decade, have increased by 
almost 16 % (201). This is due to the great risk of invasive spread and regional metastasis. 
In fact, head and neck cancers are associated with cervical lymph nodes metastasis 
followed by spread to distant sites, mainly the lung and liver. However, HPV-positive 
HNSCCs and particularly oropharyngeal SCCs, display a much lower risk of regional 
recurrences and higher chances of tumor control and increased overall survival (202). In 
addition to the dependence on HPV status and environmental factors such as 
consumption of alcohol and tobacco products, the peculiarity of the region must be 
considered. Head and neck cancers are accounted as a group, yet they consist of 
biologically distinct units that possibly exhibit vast variations in their molecular 
mechanisms underlying development and progression of HNSCC and thus likely result in 
variable therapeutic outcomes (200).   
The improved outcome and survival rates demonstrated in patients with HPV-positive 
HNSCC in comparison to patients with HPV-negative disease, is largely due to increased 
responsiveness of HPV-positive tumours to radiotherapy and chemotherapy (186, 187, 
203, 204). Several studies have reported differences in radiotherapy response between 
HPV-positive and HPV-negative HNSCC in cultured cells derived from patients. It has 
been indicated that the delayed DSB repair  observed via comet assay and DNA repair 
foci analysis, is caused by defects in the signalling and repair of DSBs in HPV-positive 
HNSCC cells (168, 178, 205, 206). However, there are some discrepancies in relation to 
the specific DSB repair defect, as reduced expression of proteins involved in both NHEJ 
(53BP1 and DNA-Pk) and HR (BRCA2 and RAD51) have been observed. In addition, 
upregulated levels of enzymes involved in the base excision repair (BER) pathway, 
including XRCC1 and PARP-1 in HPV-positive HNSCC cells, have been demonstrated 
(207).  
The fact that the improved outcome in HPV-positive HNSCC patients has been 
associated with altered capacity for DNA repair in HNSCC cells in vitro, revealed that 
targeting the DDR, particularly in relatively radioresistant HPV-negative HNSCC, that 
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display proficient DNA repair mechanisms, may be an effective strategy for the 
radiosensitisation of the tumour (208). Specifically, the major protein kinases that co-
ordinate the repair of DNA DSBs through NHEJ and HR, ATM, ATR and DNA-PKcs, are 
increasingly being investigated as targets for inhibitors to increase cellular sensitisation 
to IR, in particular x – ray irradiation. Targeting ATM in HNSCC cells was only examined 
in one study. The ATM inhibitor GSK635416A (2μM) was demonstrated to increase 
radiosensitivity in five HPV-negative HNSCC cell lines, the UTSCC2, UTSCC8, UTSCC24A, 
UTSCC36 and UTSCC40, as suggested by the accumulation and persistence of DNA DSBs 
observed by gel electrophoresis (209).   
A number of studies have also focused on targeting ATR in HNSCC cells. Utilising siRNA 
treatment to knockdown ATR activity significantly increased the radiosensitivity in three 
HPV-negative HNSCC cells, the UPCI-SCC029B, UPCI-SCC040 and UPCI-SCC131. These 
relatively radioresistant cell lines contained loss of chromosome 11q, associated with 
increased radioresistance and poor patient prognosis (210). In addition, treatment with 
ATR inhibitors VE821 (1μM) and AZD6738 (0.25 μM) have demonstrated increased 
radiosensitivity in one HPV-negative HNSCC cell line, SQ20B (211), and four HPV-
negative HNSCC cells in two separate studies, the Cal27 and FaDu (212); HN4 and HN5 
(213) respectively, revealing abrogated HR via γH2AX and Rad51 foci and cell cycle 
progression, with subsequent increased apoptosis. The majority of these studies have 
focused on utilising clonogenic assays as an end point. In addition, targeting ATR in 
combination with radiation was shown to enhance radiosensitivity in HNSCC 3D 
spheroids. Specifically, ATR inhibitor AZD6738 (1 μM) was shown to impede growth of 
HPV-negative FaDu spheroids, which are more representative of the original tumour in 
vivo (214).  
Finally, other studies examined DNA-PKcs as a target for radiosensitisation in HNSCC 
cells included siRNA as well as inhibitor treatments. Specifically, depleting DNA-PK using 
siRNA was demonstrated to significantly radiosensitise two HPV-negative HNSCC cell 
lines, the UTSCC15 and UTSCC45, as shown by the persistent DSBs revealed by the 
increased γH2AX and 53BP1 foci 24 h post irradiation (215). Moreover, the specific DNA-
PKcs inhibitor  KU0060648 (0.25 μM) have been shown to enhance radiosensitivity in 
two HPV-negative HNSCC cell lines, the HN4 and HN5 (213). Similarly, the DNA-PKcs 
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inhibitor IC87361 (3.3 μM) enhanced the radiosensitivity in three HPV-negative HNSCC 
cell lines, the UTSCC54C, UTSCC74B and UTSCC76B, as demonstrated by the reduced 
survival observed via clonogenic assays (216). Lastly, the DNA-PKcs inhibitor NU7441 (1 
and 2.5 μM), effectively radiosensitised HPV-negative, SQD9, SC263 and Cal27, but also 
HPV-positive UMSCC47, UPCISCC104 and UPCI-SCC154 HNSCC cell lines. Following DNA-
PKcs inhibition, persistence of γH2AX foci, and therefore of DSBs, was observed 24 post 
IR in two HNSCC cell lines, the SQD9 and UPCI-SCC154. In addition, in vivo models were 
utilised in the same study, demonstrating that treatment with NU7441 in combination 
with IR led to delayed tumour growth  in SQD9 and UPCISCC154 HNSCC xenografts, but 
also HPV-negative HNSCC patient-derived xenografts HNC019 and HNC021 (217).  
Cumulatively, these data demonstrated to enhance the radiosensitivity of HNSCC cells 
in vitro with some evidence also being generated in xenograft models in vivo, although 
a variability in response was observed that was associated with the specific cell line or 
model utilised. Furthermore, it was unclear whether these discrepancies depended on 
the HPV status and were selective for HPV-positive and/or HPV-negative HNSCC cells. 
Such a dependency could be due to the inherently altered proficiency of DSB repair 
mechanisms of these cells which therefore resulted in their differential radiosensitivity. 
However, the accumulating evidence of targeting strategies in combination with 
radiotherapy suggested that targeting the DSB repair pathway can be an effective 
approach for increasing the radiosensitivity of HNSCC cells in response to x – rays. 
In addition to x – ray radiotherapy, PBT is increasingly being utilised for HNSCC treatment 
(218). This is due to the precise delivery of the radiation dose to the tumour via this 
radiotherapy technique, resulting in sparing of the normal tissues and OARs. However, 
there is still uncertainty about the biological impact of protons versus photons, and the 
use of targeted drugs to optimise tumour cell radiosensitivity, which is important in 
defining potential combinational strategies (51). As discussed in Section 1.2.6, there is 
contrasting literature regarding proton induced DSB repair, with a number of studies  
suggesting that HR is the major pathway for the repair of DNA DSBs, which would 
indicate that targeting ATR would be a successful radiosensitisation strategy (102, 118, 
119). While other studies largely reflect that NHEJ, co-ordinated by ATM and DNA-PKcs, 
is the major DSB repair pathway employed following proton irradiation (105, 115-117). 
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It is most likely that there are tumour specific dependences on the DNA DSB repair 
pathway majorly employed in response to protons, which could also be dependent on 
cell confluency and therefore cell cycle stage at which the cells are irradiated. 
Nevertheless, studies specifically comparing the response of HPV-positive and HPV-
negative HNSCC cells to both photons and protons and the impact of DNA DSB repair 
inhibition have not previously been reported. 
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Chapter 2: Aims 
DSBs are mainly resolved via NHEJ and HR repair, which are driven by ATM, ATR and 
DNA-PKcs protein kinases. These repair mechanisms although important for cell 
proliferation, also contribute to tumor resistance in IR, complicating radiotherapy. This 
includes x – rays (conventional radiotherapy) and proton beam therapy, which is 
increasingly being utilised due to precise delivery of the radiation dose to the tumor, 
although the biological impact of protons versus photons is largely unknown.  
Interestingly, defects in the signaling and repair of DSBs found in HPV infected HNSCC 
patients has been associated with improved survival rates compared to HPV-negative 
associated disease. Indeed, recent studies have shown that HPV-positive HNSCC cells 
are more sensitive to IR. This has revealed that targeting the DNA damage response, 
may be an effective strategy for radiosensitising of the tumour.  
DNA repair inhibitors are widely used in research, as a monotherapy or in combination 
with DNA damaging agents with several studies demonstrating that inhibition of ATM, 
ATR or DNA-PKcs can significantly sensitise tumor cells to x – rays including breast, 
pancreatic, and prostate cancer cells. Few studies have shown radiosensitisation of 
HNSCC cell lines in response to x – rays, although the impact of these inhibitors on HPV-
positive versus HPV-negative HNSCC cells is yet to be determined. Moreover, there are 
currently no published studies investigating the impact DSB repair inhibition in 
combination with PBT in HNSCC.  
With a long-term goal to improve current treatments for HNSCC patients, I aimed to 
explore potent inhibitors for ATM, ATR, or DNA-PKcs in the radiosensitisation of HNSCC 
cells in response to both x – rays and protons. The specific aims of this study were to: 
1. Investigate the impact of DSB repair pathway inhibition, in HNSCC cells in vitro, 
alone or in combination with IR (x – rays and protons). 
2. Exploit potential differences in the DNA damage response, between HPV-
negative and HPV-positive HNSCC cells. 
3. Decrypt differences in cellular responses following exposure to x – ray and 
proton irradiation, and how these regulate the DNA repair pathway choice. 
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Chapter 3: Methodology 
3.1 Materials  
The protein kinase inhibitors KU-55933 (ATM Inhibitor; ATMi), NU7441 (also called KU-
57788, DNA-PKcs Inhibitor; DNA-PKcsi) and VE-821 (ATR Inhibitor; ATRi) were purchased 
by Selleckchem (Munich, Germany) and dissolved in dimethyl sulfoxide (DMSO).  
 Cell culture reagents were obtained from Sigma-Aldrich (St Louis, USA), and general 
laboratory reagents were obtained from Sigma-Aldrich (St Louis, USA), Bio-Rad (Hemel, 
Hempstead, UK), or Fisher Scientific (Loughborough, UK). 
Primary and secondary antibodies were purchased by Cell Signaling Technology, (Leiden, 
The Netherlands), Sigma-Aldrich (Gillingham, UK), Abcam (Cambridge, UK), Thermo 
Fisher Scientific (Massachusetts, USA ), Li-Cor Bioscience (Nebraska, USA), Bethyl 
Laboratories (Montgomery, USA) and BD Bioscience (California, USA) were used to 
probe for specific proteins of interest during immunoblot analysis, and specific foci 
formation during Immunofluorescent staining and DNA repair foci analysis. The 
antibodies used are listed in Tables 3.1 and 3.2, summarising their individual 
characteristic.  
 
3.2 Cell culture 
3.2.1 Cell line Culture 
Tissue culture work was carried out in aseptic conditions. It was performed in class II 
hood cabinets with laminar flow that was cleaned with 70% ethanol both before and 
after use, and was sterilised with 20 min UV light exposure between two uses. Cells were 
maintained and grown in standard conditions equivalent to the human body at 37oC and 
5 % CO2 in a humidified cell culture incubator and were cultured using tissue culture 
grade plastics. All cell culture reagents (obtained from Sigma Aldrich, St Louis, USA) were 
pre-warmed in a water bath at 37oC before use and are listed below. 
• Dulbecco's Modified Eagle's Medium (DMEM) – 25 mM HEPES and sodium 
bicarbonate, 4500 mg/L glucose, sterile filtered. 
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• Minimal Essential Medium (MEM) – 25 mM HEPES, without L- glutamine sterile 
filtered. 
• Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 Ham (adMEM/F12) - With 
15 mM HEPES and sodium bicarbonate, without L-glutamine, liquid, sterile-filtered, 
Medium for Spheroid assays, supplemented with 1 % B27, 1 % L-Glut, 1 % P/S, 0.5 % N2 
and 0.1 % Heparin, as well as 2:10000 EGF and 1:10000 FGF just before use.  
• 0.25% Trypsin-EDTA solution –sterile filtered, 2.5 g porcine trypsin, 0.2 g EDTA, 4Na/L 
Hanks’ Balanced Salt Solution with phenol red. 
• Dulbecco’s Phosphate Buffered Saline (PBS) 
Table 3. 1. Primary antibodies. List of the primary antibodies used throughout this 
research project. Host organism, clonality, dilution and source are displayed. 
Antibody Host organism Clonality Dilution Source 
Anti-phosphoATM S1981 Rabbit monoclonal 1:1000 Cell Signalling 
Anti-phosphoATR S428 Rabbit polyclonal 1:1000 Cell Signalling 
Anti-phopshoATR T1989 Rabbit polyclonal 1:1000 Cell Signalling 
Anti-phosphoDNA-PKcs 
T2609 
Mouse monoclonal 1:1000 Abcam 
Anti-phosphoDNA-PKcs 
S2056 
Rabbit monoclonal 1:5000 Abcam 
Anti-Actin Mouse monoclonal 1:20000 Sigma-Aldrich 
γΗ2ΑΧ Mouse monoclonal 1:5000 Sigma-Aldrich 
53BP1 Rabbit polyclonal 1:4000 Bethyl Labs 
Rad51 Rabbit monoclonal 1:5000 Abcam 







Table 3. 2. Secondary Antibodies. List of the fluorescently tagged secondary antibodies 
used throughout this research project to target the primary antibodies. Host organism, 
target immunoglobulin isotype, dilution and source are displayed. 
Antibody Host organism Dilution Source Exp 
Alexa Fluor 680 Anti-Mouse IgG Goat 1:10000 Invitrogen WB 
Alexa Fluor 680 Anti-Rabbit IgG Goat 1:10000 Invitrogen WB 
IR Dye 800 Anti-Rabbit IgG Goat 1:10000 Li-Cor WB 
IR Dye 800 Anti-Mouse IgG Goat 1:10000 Li-Cor WB 
Alexa Fluor 555 Anti-Mouse  Goat 1:500 Invitrogen IF 
Alexa Fluor 488 Anti-Rabbit Goat 1:500 Invitrogen IF 
 
Human cancer cell lines used in this research study were the HPV-positive UMSCC47 and 
two HPV-negative UMSCC6 and UMSCC74A oropharyngeal squamous cell carcinoma cell 
lines, kindly gifted by Prof T. Carrey, University of Michigan, USA. The HPV-negative A253 
HNSCC cells originated from the submaxillary gland were supplied from ATCC 
(Teddington, UK). All of them were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10 % fetal bovine serum (FBS), 2mM L-glutamine, 1 % 
penicillin – streptomycin and 1 % non-essential amino acids (NEAA). Moreover, the HPV-
positive oropharyngeal squamous cell carcinoma cells UPCI-SCC090 were kindly 
provided by Dr S. Gollin from the University of Pittsburgh; the HPV-negative cells from 
the hypopharynx, FaDu HNSCC, originated from ATCC (Teddington, UK), and the HPV-
positive cells from the oral cavity UPCI-SCC154 HNSCC were cultured in Minimal 
Essential Medium (MEM) supplemented with 10 % fetal bovine serum (FBS), 2mM L-
glutamine, 1 % penicillin – streptomycin and 1 % non-essential amino acids (NEAA). The 
individual characteristics of these cell lines are summarised in Table 3.3. All cells were 
incubated under standard conditions in 5 % CO2 at 37°C and were authenticated in our 
laboratory by STR profiling.   
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Table 3. 3. HNSCC cell lines. List of HNSCC cell lines used in this research project, 
summarising their individual characteristics, region of origin, HPV status, p53 status, age 
& sex of the patient, TNM (Tumour, Node, Metastasis) stage. wt: wild type, mut: mutant 
y.o.: year old, M: male, F: Female, NS: not specified (177, 219, 220).  *Derived from 
metastatic site: tongue 
Cell line Region HPV p53 Age / Sex TNM stage 
UMSCC6 Oropharynx (base of 
the tongue) 
- wt 32y.o./ M T2N0M0 
UMSCC47 Oral cavity (lateral 
tongue) 
+ wt 53y.o./ M T3N1M0 
UMSCC74A Oral cavity (base of 
the tongue) 
- wt 51y.o./ M T3N0M0 
UPCI-SCC090 Oropharynx (base of 
the tongue) * 
+ wt 46y.o./ M T2N0 
UPCI-SCC154 Oral cavity (tongue) + wt 54y.o./ M T4N2 
A253 Oral cavity (salivary 
gland) 
- mut 54y.o./ M NS 
FaDu Hypopharynx - mut 56y.o./ M NS 
 
 
3.2.2 Thawing cells  
Cells, long termed stored in liquid nitrogen (N2), were kept in cryovials containing 90 % 
FBS and 10 % DMSO.  They were defrosted in a water bath at 37oC for 30 sec. As high 
concentration of DMSO can be toxic, 1 ml fresh medium was added dropwise to the 
cells, before complete defrost, and gently mixed via pipetting. The cell suspension was 
then transferred into a sterile 15 ml tube and 8 ml of warm medium was gently added, 
before centrifugation at 1500 rpm for 5 min at room temperature. The DMSO-containing 
supernatant was removed, and the cell pellet was resuspended in 1 ml fresh medium 
and transferred to a T75 culture flask containing 11 ml medium. The flask was then 
incubated in a humidified cell culture incubator under standard conditions at 37o C and 




3.2.3 Passaging Cells   
Cells growing exponentially in tissue culture flasks reach confluency and need to be split 
(passaged) into new flask, in order to have room to grow and nutrients to be fed. When 
cells were 70 – 90 % confluent, the old medium was removed by aspiration, and 7 ml 
warm PBS were added to wash the monolayer of cells and then removed. Then, 1 ml of 
0.25% trypsin-ETDA was added and the cells were incubated for 2 - 10 min in the 
humidified cell culture incubator under standard conditions at 37o C and 5 % CO2, 
allowing time for enzyme activation and cell detachment from the plastic. Following 
that, 9 ml of warm medium were added in order to neutralise the trypsin and cells were 
mixed via pipetting to create a single-celled suspension. Cells were then either used for 
in vitro experimental work, and/or a certain portion of the cells were transferred into a 
new culture flash, and this was topped up with fresh medium to have 12 ml in total. Fast 
growing cells were split in 1:10 ratio twice a week, and slower growing cells were split 
in 1:2 once a week, with the HPV-positive cells were specifically slow growing. In fact, 
during their culture period, splitting ratios varied slightly when cells were undergoing 
more rapid or slower growth than usual. Table 3.4 summarises the individual growing 
characteristics for the cell lines used in this research study. Cells were than stored in the 
humidified cell culture incubator under standard conditions. Cells were cultured for up 
to 20 passages and then were replaced by freshly thawed cells to secure behavioural 
consistency.  
 
3.2.4 Freezing Cells. 
Cells need replacement after approximately 20 passages, and a stock of early passage 
number cells must be stored and replaced in the liquid N2. Therefore, newly thawed cells 
were split into multiple flasks and let to grow. Once the flasks were 70 – 90 % confluent, 
medium was removed, and the cell were washed with PBS as described above. 0.25 % 
Trypsin-EDTA was added for 2 – 10 min, and once the cells detached from the plastic 
surface were mixed with 9 ml of medium. The cell suspension was then transferred to a 
15 ml tube and was centrifugated at 1500 rpm for 5 min in room temperature. The 
medium was removed, and the cell pellet was resuspended in 1 – 2 ml freezing medium 
(90 % FBS with 10% DMSO) and transferred to 1 or 2 cryovials depending on the size of 
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the pellet. Finally, the cryovials were placed in a cell freezing container, (CoolCell 
Freezing Container, Corning, Sigma Aldrich, St Louis, USA) and placed into a -80o C 
freezer for 24 h, for a slow and contained drop in their temperature, before being 
transferred to long-term storage in liquid N2. 
 
Table 3. 4. Passaging of cells. HNSCC cell lines used in this research project along with 
their splitting ratio and frequency as well as the size of the flask used for maintenance 
and culture are displayed.  
Cell line Splitting ratio  Frequency Flask Medium 
UMSCC6 1:3 Twice a week T75 DMEM 
UMSCC47 1:5 Twice a week T75 DMEM 
UMSCC74A 1:10 Twice a week Y75 DMEM 
UPCI-SCC090 1:2 Once a week T25/T75 MEM 
UPCI-SCC154 1:2 Once a week T25 MEM 
A253 1:10 Twice a week T75 DMEM 
FaDu 1:5 Every 5 days T25/T75 MEM 
 
 
3.3 Ionising radiation  
X – ray in vitro irradiations were performed in the lab using the CellRad x – ray irradiator 
(Faxitron Bioptics, Tucson, USA). The radiation dose (1 – 4 Gy) was delivered in a time-
controlled manner with a standard rate of 3 Gy/min, 3 mA and 100 kV with no additional 
filtration on the x – ray beam. 6-well plates and petri dishes (35, 60, or 100 mm) were 
placed in the centre of the irradiation field.  
Proton in vitro irradiations were performed using a horizontal, passive - scattered beam 
line of 60 MeV maximal energy from the Douglas Cyclotron at Clatterbridge Cancer 
centre (221). Cells in 35 mm petri dishes were positioned at the isocentre 70 mm from 
a brass collimator (43 mm diameter) and were irradiated directly by an approximately 1 





3.4 Cell Harvesting following drug and radiation treatment. 
Cells were pre-seeded in petri dishes, usually 60 or 35 mm, and incubated overnight. 
When 80-90 % confluent, the cells were pre-treated for 1 h with the inhibitors dissolved 
in medium, or DMSO dissolved in medium as a control. The concentrations used were 
10μΜ of KU-55933 (ATMi), 1 μΜ of NU7441 (DNA-PKcsi), 1 μΜ of VE-821 (ATRi) or 10μΜ 
of DMSO. Then the dishes were irradiated with 4 Gy x-rays or protons and the medium 
was changed, with fresh medium containing the inhibitor or DMSO at the same 
concentration. Cells were then incubated in a humidified cell culture incubator under 
standard conditions of 5 % CO2 at 37o C for up to 24 h and were removed to be harvested 
at different time points (0, 1 h, 2 h, 4 h, 8 h, 24 h) post irradiation. To harvest the cells, 
the medium was removed and surface of the dishes were washed with ice cold PBS, 
fresh PBS was added and then the cells were carefully scrapped off the plastic and 
transferred into a pre-cooled 15 ml tube, the scraping in fresh PBS was performed twice. 
Then the pellet was collected by centrifugation at 1500 rpm for 5 min at 4°C, the 
supernatant was removed, and the pellet was resuspended in 1 ml of cold PBS and was 
transferred to a pre-cooled 1.5 ml tube, which was then centrifuged at 1500 rpm for 5 
min at 4ºC. Supernatant was removed and the pellet was stored at -80o C. 
 
3.5 Whole cell extracts 
Whole cell extract was produced from a frozen cell pellet. Pellets were left in -80o C for 
at least 1 h, then pellet volume was estimated and resuspended in an equivalent of in 
one volume of Tanaka Buffer 1 [10 mM Tris-HCl (pH 7.8), 200 mM KCl, and 1 μg/ml of 
each protease inhibitor: pepstatin, aprotinin, chymostatin and leupeptin, 1 mM PMSF 
and 1 mM DTT, as well as 10 mg/ml of the phosphatase inhibitor cocktail 3] and two 
volumes of Tanaka Buffer 2 [10 mM Tris-HCl (pH 7.8), 600 mM KCl, 40 % glycerol, 0.1 
mM EDTA, 0.2 % Nonidet P-40, 1 μg/ml of each protease inhibitor: pepstatin, aprotinin, 
chymostatin and leupeptin, 1 mM PMSF and 1 mM DTT, and 10 mg/ml of the 
phosphatase inhibitor cocktail 3, (P0044 , Sigma-Aldrich, St Louis, USA)]. The cell 
suspension was thoroughly mixed for 30 min by rotation at 4° C. Cell debris was pelleted 
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by centrifugation at 40,000 rpm for 20 min at 4°C. Τhe supernatant, containing the whole 
cell protein extracts, was collected and transferred to a pre-cooled 1.5 ml Eppendorf 
tube and kept for long term storage in -80o C, while the solid residues remaining in the 
tube where discarded. 
 
3.6 Bradford Assay  
Protein concentrations in the whole cell extracts were determined via the Bradford 
assay spectroscopic analysis. During this, three different types of solutions were 
prepared in individual 3 ml plastic cuvettes, one blank, one containing a protein standard 
as control, and one for each sample to be measured. The blank was made up with 960 
μl of Bradford reagent (Bio-Rad Laboratories, California, USA), and 40 μl of dH2O, the 
control was composed of 960 μl of Bradford reagent and 40 μl of 0.2 mg/ml BSA (Bovine 
serum albumin; Thermo Fisher Scientific, Massachusetts, USA). Finally, for each sample 
a separate solution was prepared with 960 μl of Bradford reagent, and 40 μl of dH2O 
containing protein extract. The volume of protein extract added varied between 1-4 μl, 
thus the amount of dH2O was changing accordingly between 36-39 μl, in order to have 
40 μl in total, with higher volumes of protein extract required when concentration was 
low (e.g. when protein extract derived from a small cell pellet), and vice versa. The 
solutions were mixed and left to react with Bradford reagent for 5 min at room 
temperature. Using a UV spectrophotometer (Cecil Instruments Limited, Cambridge, UK) 
following zeroing with the blank sample and calibration with the control sample, optical 
density was measured by the absorbance at 595 nm, for each protein extract sample. 







∗ 𝑎 ∗ 𝑥     (3.1) 
C: protein extract concentration; BSA: value of the BSA control sample; α: can be 40, 20, 
or 10 when 1 μl, 2 μl or 4 μl of protein extract were added to the solution; x: value of 




3.7 SDS-PAGE and Western Blot  
The whole cell extracts contain multiple proteins that were then separated according to 
their molecular weight utilising the Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) technique. For higher molecular weight proteins, pre-cast 
10-well gradient gels of 4-12 % Tris-glycine were used (Invitrogen, Thermo Fisher 
Scientific, Loughborough, UK). For lower molecular weight proteins, 10-well 16% Tris-
glycine gels were prepared in the laboratory. To produce these, a separating and a 
stacking gel were prepared and poured into empty 1.5 mm gel cassette (Novex, Thermo 
Fisher Scientific, Loughborough, UK). The separating part of the gel was made up of 377 
mM Tris-HCl pH 8.8, 0.1 % SDS, 2 mM EDTA, 16 % acrylamide/bis solution (30:0.8; Bio-
Rad, Hemel, Hempstead, UK), 0.1 % ammonium persulphate (APS), and 0.1 % 
tetramethylethylenediamine (TEMED) and it was poured up to the ¾ of the cassette. The 
gel solution was then left to set for at least 30 min and topped up with 1 ml of 100% 
ethanol to prevent and remove any bubbles. Once the gel had set, the ethanol was 
removed, and the cassette was washed with dH2O and dried with clean filter paper. The 
stacking part of the gel was a 5 % stacking gel solution consisting of 125 mM Tris-HCl pH 
6.8, 0.1 % SDS, 2 mM EDTA, 5 % acrylamide/bis solution (30:0.8; Bio-Rad, Hemel, 
Hempstead, UK), 0.1 % ammonium persulphate (APS), and 0.1 % 
tetramethylethylenediamine (TEMED) that was poured on the remaining ¼ of the 
cassette, on top of the separating gel. Finally, a 10-well comb was inserted into the gel 
solution within the cassette and the gel was left to set for at least 30 min. The gel was 
then wrapped in wet cloth and kept in 4o C to be used within 2 weeks.  
In each gel well, protein extracts were loaded in the form of SDS-PAGE sample buffer, 
this consisted of 1/3 of 3xSDS dye  (25 mM Tris-HCl pH 6.8, 2.5 % mercaptoethanol, 1 % 
SDS, 10 % glycerol, 0.05 mg/ml bromophenol blue, and 1 mM EDTA) and 2/3 protein 
extract (25 – 40 μg) and dH2O. Due to differences in the initial concentration of the 
whole cell extracts, varying volumes were added in the solution of each sample and 
dH2O was added to top this up to reach the 2/3 of the volume required. Moreover, the 
amount of protein (μg) added could differ between gels yet was the same within an 
individual gel. Once all the components were added, the samples were vortexed, and 
then heated for 5 min in 95o C. Following, the samples were loaded on the gel and 
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electrophoresed in 1x Tris-glycine SDS (TGS) running buffer (25 mM Tris-HCl pH 8.3, 192 
glycine, and 0.1 % SDS; Fisher Scientific, Loughborough, UK) at 125 V for 2 h, in SDS-PAGE 
Mini Gel Tanks (Fisher Scientific, Loughborough, UK). Typically, in the first well of the 
gel, 1μl of the Precision Plus Protein All Blue Prestained Protein Standards (10 kDa – 250 
kDa; Bio-Rad Laboratories, California, USA) were loaded as standard protein marker. 
During electrophoresis, proteins were separated according to their molecular weight 
and after this, proteins were then transferred onto an Immobilon FL polyvinylidene 
diflouride membrane (PVDF) (Millipore, Watford, UK), in order to probe for and visualise 
specific proteins of interest. The transfer was performed utilising a Mini Blot Module 
(Fisher Scientific, Loughborough, UK) that was loaded into the Mini Gel Tank, used in the 
electrophoresis step after this was rinsed off with clear water. The gel cassette was 
opened and the acrylamide gel was removed and placed directly over the PVDF 
membrane that was activated in 100 % methanol for 15 sec, washed in dH2O for 1 min 
and washed in cold transfer buffer [1x Tris-glycine (TG; 25 mM Tris-HCl pH 8.3, 192 mM 
glycine; Fisher Scientific, Loughborough, UK), 20 % methanol] for  at least 1 min. The duo 
was then enclosed within a set of filter papers and a set of sponges, fully covered in cold 
transfer buffer. The so-called sandwich of membrane-gel was then placed inside the 
Mini Blot Module, that was filled with more cold transfer buffer. Finally, the Mini Gel 
Tank was filled with cold water to keep a low temperature during the transfer, which 
was conducted at 25 V for 1 h. 
 Next, the membranes were removed from the Mini blot Module, washed in PBS for 5 
min, and were blocked for non-specific binding using Odyssey blocking buffer (Li-cor 
Biosciences, Cambridge, UK) diluted 1:1 in PBS, for 1 h at room temperature with rocking 
at 27 rpm. The membrane was then incubated with the primary antibody, made up in 
1:1 solution of Odyssey blocking buffer and 1x PBS, containing 0.1 % Tween 20, overnight 
at 4°C rocking at 27 rpm. The next day, membranes were washed three times with PBS 
containing 0.1 % Tween 20 for 5 min with gentle rocking, and were incubated with 
secondary antibodies, made up in 1:1 solution of Odyssey blocking buffer and 1x PBS 
containing 0.1% Tween 20, for 1 h at room temperature with 27 rpm rocking. After that, 
they were treated with three 5 min washes with PBS containing 0.1 % Tween 20 and 1 
time with PBS, at room temperature and gentle rocking. Lastly, the membranes were 
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scanned using the Odyssey image analysis system (Li-cor Biosciences, Cambridge, UK) in 
order to image and quantify the proteins.  
Following the same steps, the primary antibody for Actin (acting as a loading control) 
was added for 1 h in room temperature, washed 3 times, before been incubated with 
secondary antibodies for 1 h at room temperature and further washed three times. It 
was then scanned for the second time using the Odyssey image analysis system in order 
to visualize and quantify actin, to normalise this relative to the protein of interest.  
 
3.8 Immunofluorescent staining and DNA repair foci analysis 
Visualisation and analysis of DNA repair progression was achieved by studying the 
formation, persistence or resolving of DNA repair focus formation, at the sites of DSB. 
For this technique, following the first steps of passaging cells described in Section 3.2.3, 
cells were trypsinised from a 70 – 90 % confluent flask. From a thoroughly mixed cell 
suspension, a sample of 15 μl were taken onto a haemocytometer, and cells were 
counted under a light microscope, in order to estimate the cell concentration of the 
suspension and calculate the volume to obtain the required number of cells. Three cell 
lines were used, two HPV-negative and one HPV-positive, and the number of cells 
seeded per ml for this technique were UMSCC74A 1.5∙104 cells/ml, UMSCC47 2∙104 
cells/ml, and UMSCC6 4∙104 cells/ml. The cells were seeded on round glass coverslips, 
13 mm in diameter (Nunc Thermanox, Fisher Scientific, Loughborough, UK), that were 
pre-sterilised in 100 % ethanol. For x – ray experiments, single coverslips were placed in 
24-well plates (Greiner CELLSTAR® multiwell culture plates, Sigma-Aldrich, St Louis, USA) 
and 0.5 ml of the premade cell suspension was added in each well. There were two 
coverslips per condition. For proton irradiation, 4 coverslips were placed within a 35 mm 
dish, two for each condition, and 2 ml of the premade cell suspension were added, while 
extra care was paid to avoid overlap of the coverslips. After seeding, cells were 
incubated for 48 h in a humidified cell culture incubator under standard conditions at 
37o C and 5 % CO2, to allow cell growth. On the treatment day, the old medium was 
removed from the plates by aspiration and fresh medium containing either of the 
inhibitors or DMSO, as control, was added, 0.5 ml in the individual wells of the 24-well 
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plates, or 1.5 ml in the 35 mm dishes. The concentrations of the drug were 10μΜ of KU-
55933 (ATMi), 1 μΜ of NU7441 (DNA-PKcsi), 1 μΜ of VE-821 (ATRi) or 10μΜ of DMSO 
and cells were further incubated with the drug under standard conditions for 1 h prior 
to irradiation. Following that, the cells received 4 Gy of IR, either x – rays or protons, and 
immediately after irradiation the medium was changed with fresh one, containing the 
same concentration of the inhibitors or DMSO.  Cells were then incubated for up to 24 
h under in 5 % CO2 at 37° C in a humidified cell culture incubator, to allow time for DNA 
repair progression and the foci formation. Then at specific time points the cells were 
fixed, which stopped any biological processes at the stage they were left. Three foci 
markers were investigated, γH2AX, 53BP1, and Rad51, the time points for the first two 
markers were 1 h, 4 h, and 8 h post irradiation, while the time points for Rad51 were 8 
h, 16 h, and 24 h.  
At the appropriate time, plates were taken out of the incubator, medium was removed 
by aspiration and cells were washed with PBS twice (0.5 ml per coverslip), before been 
fixed using 4 % paraformaldehyde (PFA; Sigma-Aldrich, St Louis, USA) for 10 min at room 
temperature (0.1 ml per coverslip). Coverslips were then washed with PBS, and cells 
were permeabilised with 0.2 % Triton X-100 in PBS (Cell Signalling Technology, Leiden, 
The Netherlands) for 10 min (0.2 ml per coverslip), and then washed three times with 
0.1 % Tween-20 (Sigma-Aldrich, St Louis, USA) at room temperature. Coverslips were 
blocked to avoid non-specific staining via incubation with 2 % BSA (bovine serum 
albumin powder, Sigma-Aldrich, St Louis, USA) in PBS for 30 min at room temperature, 
rocking at 27 rpm (0.2 ml per coverslip) and then were further incubated with either 
γH2AX, 53BP1 or RAD51 antibodies (Table 3.1), made in fresh 2 % BSA (1:50 in PBS), 
overnight at 4°C rocking at 27 rpm.  
The following day, the antibodies were removed and following three 5 min washes with 
PBS with gentle rocking at room temperature, coverslips were incubated with either of 
the appropriate fluorescent secondary antibodies (Table 3.2), made in 2% BSA, for 1 h 
at room temperature, rocking at 27 rpm, covered in foil to protect them from exposure 
to light. Finally, the fixed cells were washed with PBS in triplicate for 10 min on a rocking 
platform, in the dark, and were mounted on microscope slides using Fluoroshield 
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containing DAPI (Sigma-Aldrich, St. Louis, USA). The slides and mounting media were left 
to set and were then stored in 4oC, protected from the light. 
Cells were examined using an Olympus BX61 upright fluorescent microscope with a 40x 
Plan Super Apo 0.9NA objective, and a Photometrics CoolSNAP HQ2 CCD camera. 
MicroManager 1.4 software was used to capture images, 5 representative images were 
captured from each coverslip, and there were two coverslips for each condition. The 
images were then analysed using CellProfiler v.2.2.0 running a purpose-written analysis 
pipeline kindly provided by Prof Carlos Rubbi (University of Liverpool). This provided us 
with data that constructed spot frequency curves and ROC curves (Receiver operating 
characteristic) per cell line and treatment, that illustrated the true positive rates (TPR) 
against the false positive rates (FPR) and allowed to discriminate the appropriate 
threshold, Figure 3.1. The number of foci per nucleus were counted and averaged. The 
average number of foci per coverslip of the two replicate coverslips were then averaged 
and that was used as the respective number of foci per cell line per condition from each 
biologically independent experiment. 
     
Figure 3. 1. Threshold discrimination in IF analysis. γH2AX, 53BP1 and Rad51 foci 
formation was counted in HNSCC cell lines in response to inhibitor treatment and 
exposure to IR. Here 53BP1 foci formation in UMSCC47 was calculated above the 
threshold, marked with the red circle, to avoid counting of false positive spots. A) Spot 
frequency versus intensity curve, Negatives: spots in untreated cells, Positives: spots in 
treated cells (inhibitor, IR, or both); B) ROC curve, TP: true positive, FP: false positive; in 



























3.9 Colony Formation Assays 
To assess cell survival and proliferation following treatment with a drug and/or exposure 
to IR, the colony formation (clonogenic) assay was utilised. For this technique, cells from 
a confluent flask were trypsinised and counted as described above (Section 3.2.3 and 
3.8 respectively), and a defined number of single cells were pre-seeded in 6-well plates 
(Greiner CELLSTAR® multiwell culture plates, Sigma-Aldrich, St Louis, USA) for 
experiments involving x – ray irradiation, or 35 mm petri dishes (Falcon, Coning, New 
York, USA) for experiments involving proton irradiations. The plates were left overnight 
in a humidified cell culture incubator, allowing time for the cells to attach. 24 h later, the 
medium was removed by aspiration and 1.5 ml of fresh medium containing either of the 
inhibitors or DMSO, as control, was added 1 h prior to irradiation in each well.  The 
concentrations used were, 10 μM KU-55933 (ATMi), 1 μM NU7441 (DNA-PKcsi), 1 μM 
VE-821 (ATRi) and 10 μM DMSO. After 1 h of incubation with the inhibitor or DMSO 
under standard conditions, cells were irradiated with increasing radiation doses, for x – 
rays 1 – 3 Gy, and for protons 2 – 6 Gy. Immediately after irradiation, the medium was 
replaced by fresh one, containing the same concentration of either of the inhibitors or 
DMSO, and cells were further incubated for 24 h. The next day, the medium was 
replaced again, with fresh medium without any inhibitors or DMSO, and the plates were 
further incubated for 6-10 days in a humidified cell culture incubator allowing time to 
the damaged single cells seeded to be repaired, proliferate, and creating colonies of 
cells.  
Four cell lines were utilised, two HPV-positive and two HPV-negative, the UMSCC6, 
UMSCC47, UMSCC74A and UPCI-SCC090. The seeding densities varied between the cell 
lines and were determined according to their individual characteristics such as doubling 
time, colony morphology and size, as well as their plating efficiency, which is the ratio 
of colonies produced by untreated  cells over the total amount of cells seeded in the 
well (equation 3.1). Increasing number of cells were seeded for increasing doses of IR, 
to secure that enough cells would survive the treatment and grow into colonies. For x – 
ray irradiations, the cells were seeded in two densities per condition in each 6-well plate, 
three replicates of the starting density in the upper row and three replicates of twice 
the starting density in the lower row of the plate. For proton irradiation, the cells were 
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seeded in separate 35 mm dishes and there were 3 dishes per condition. In table 3.5 are 
presented the seeding densities, along with the platting efficiencies for each cell line in 
x – rays (A) and protons (B).  
Table 3. 5. Seeding densities for colony formation assays. The number of cells seeded for 
colony formation assays for each cell line and radiation dose are displayed, along with 
their respective plating efficiencies (PE), in unirradiated conditions. A. Cells seeded in 6-
well plates and expose to x – rays in two densities per condition. B. Cells seeded in 35 mm 
dishes and exposed to proton.  






































Cell line 0 Gy 1 Gy 2 Gy 3 Gy PE 
UMSCC6 1000 2000 4000 8000 8% 
UMSCC47 1000 2000 4000 8000 7 % 
UMSCC74A 500 1000 2000 4000 10 % 




𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑠𝑒𝑒𝑑𝑒𝑑
 (3.1) 
PE was calculated upon non treated and non irradiated cells 
 
After the required incubation period, where distinct colonies of at least 50 cells per 
colony had been formed, the plates were removed from the incubator, the medium was 





with Crystal Violet (6 % glutaraldehyde and 0.5 % crystal violet) for at least 30 min. The 
plates were then washed with clean water, left to air dry, and the colonies were counted 
using the GelCount colony analyser (Oxford Optronics, Oxford, UK). The colonies 
detected on the edges of the wells were excluded from counting, as they were 
underdosed due to shielding effect. The relative surviving fraction (SF), also called 
Colony Formation (CF), were determined from number of colonies over the number of 
cells seeded at individual IR doses (equation 3.2). SF were then compared between 
inhibitor treated versus DMSO treated cells (control) to demonstrate the impact of the 
inhibitor alone or in combination with IR. The 6 wells of the plates (for x – rays) or the 
35 mm dishes (for protons) were averaged for each condition and were normalised to 
the 0 Gy of each treatment, to constitute one biologically independent experiment. 
Moreover, to correlate a given radiation dose (eg D50) with the respective SF, data were 
fitted to the exponential equation 3.3. Then, Dose enhancement ratio (DER), were 
calculated by the ratio of the dose required to achieve 50 % survival in the control cells 
(DMSO treated) divided by the dose required to achieve 50 % survival in the drug treated 
cells (ATMi, ATRi, DNA-PKcsi), equation 3.4 and 3.5. 
𝑆𝐹 =  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑝𝑒𝑟 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑠𝑒𝑒𝑑𝑒𝑑
 (3.2) 
𝑆𝐹 = 𝑒−𝑎𝐷 ⇒ ln(𝑆𝐹) = −𝑎𝐷 (3.3) 




  (3.4) 
𝐷𝐸𝑅 =  
𝐷50𝐷𝑀𝑆𝑂
𝐷50𝑑𝑟𝑢𝑔
   (3.5) 
 
3.10 3D Spheroid growth assay 
Another technique used to investigate the impact of DNA repair inhibitors treatment 
alone or in combination with IR, on cell survival and proliferation in HNSCC cells in vitro 
is the 3D spheroid growth assay, that better represents tumour growth. In this technique 
cells were growing in microscopic spheres (3D) in suspension rather than the previously 
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described techniques where cells were growing as monolayer attached to the culture 
plastic. On Day 1, cells were trypsinised off a 70 – 90 % confluent flask as described in 
Section 3.2.3, the suspension was then transferred in a 15 ml tube and was centrifuged 
for 5 min at 1500 rpm in room temperature. The excess medium was removed, and the 
cell pellet was resuspended in 2 – 5 ml (volume depended on the pellet size) of spheroid 
medium (adMEM/F12, Sigma-Aldrich St Louis, USA), supplemented with 0.02 % EGF and 
0.01% FGF before use. Concentration of the new cell suspension was estimated by 
counting a sample with a haemocytometer, as described in Section 3.8. A seeding stock 
was prepared, but different concentrations were used for each cell line according to the 
physical characteristics of the cells, including their ability to form a spheroid and the 
doubling time of the spheroid. The number of cells seeded per cell lines are summarised 
in Table 3.6. 100 μl/well of the seeding stock was then added on ultra-low attachment 
surface 96-well plates, with rounded well bottom (Costar, Sigma-Aldrich, St Louis, USA), 
in triplicate per condition, using a precise repeater pipette (Gilson Pipettes, France) to 
increase accuracy. Usually not all the 96 wells were filled with cell stock and the 
remaining empty wells were filled with 100 μl/well PBS to boost humidity within the 
plate and prevent medium from drying, over the incubation period. The plates were 
incubated for 48 h in humidified cell culture incubator under standard conditions of 5 % 
CO2 and 37oC. During this time the cells merged, forming microscopic spheroids, 
approximately 200 μm in diameter. 
Table 3. 6. Cell concentration seeding for 3D spheroid growth assays. The number of cells 
seeded for 3D spheroid growth assays for each cell line are displayed. Cells were seeded 
on Day 1 and left to form a sphere before any treatment. 
Cell concentration (cells/ml) 5000 10000 20000 
 FaDu UMSCC6 UPCI-SCC090 
 A253 UMSCC47 UPCI-SCC154 
  UMSCC74A  
 
On Day 3, when spheroids were fully developed, they were individually imaged using a 
light microscope (AMG EVOS, Thermo Fisher Scientific, Massachusetts, USA), with 4x 
magnification. 50 μl out of 100 μl of medium was removed from each well and replaced 
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by 50 μl of spheroid medium containing either of the inhibitors or DMSO as control. 
Since the added medium was half of the total volume, the concentrations of the 
inhibitors and DMSO were doubled, to achieve a final 1x time concentration. Thus, the 
concentrations used were, 20 μM KU-55933 (ATMi), 2 μM NU7441 (DNA-PKcsi), 2μM 
VE-821 (ATRi) and 20 μM DMSO, to have a final concentration of 10 μM, 1 μM, 1μM and 
10 μM respectively. Following 1 h incubation with the drugs in a cell culture incubator, 
the plates were irradiated with 1 Gy, 2 Gy, and 3 Gy of x – rays, or 2 Gy, 4 Gy, and 6 Gy 
of protons. Immediately after exposure, 50 μl of medium was removed from each well, 
and replaced by 50 μl of fresh spheroid medium containing the respective inhibitors at 
1x time concentration (10 μM ATMi, 1 μM DNA-PKcsi, 1μM ATRi and 10 μM DMSO), and 
were further incubated with the drugs for 24 h in a cell culture incubator. On Day 4, 60 
μl of medium was removed from each well and was replaced by 100 μl spheroid medium 
without inhibitors or DMSO, to minimise concentration of the drugs as possible, and the 
plates were incubated for up to 15 days to monitor spheroid growth. On Day 5 and every 
two days, the individual spheroids were imaged using a light microscope and the images 
were then analysed using Image-J software, where the diameter of the growing 
spheroids was measured. The diameter was then converted into radius (r) and using the 





The three replicates of each condition were averaged, the volumes were then 
normalised against the volume on Day 3 (IR day) for each condition which was set to 1, 
and that constituted one independent biological experiment. Growth suppression ratios 
(GSR) were calculated via the ratio of the volume of DMSO treated versus drug treated 
spheroid on a given day and treatment and then was averaged across Day 5 to Day 15, 
equation 3.6.      
𝐺𝑆𝑅 =  
𝑉𝐷𝑀𝑆𝑂
𝑉𝑑𝑟𝑢𝑔




Chapter 4: Results I 
4.1 Introduction 
Three protein kinases directly involved in DNA damage response, ATM, ATR and DNA-
PKcs, are reported to play key role in the repair of DSB via NHEJ and HR pathways. 
Although important for cell proliferation, activity of these proteins contribute to tumour 
resistance in chemotherapy and radiotherapy, thus these proteins are increasingly being 
investigated as targets for inhibitors to increase cellular sensitisation to IR and other 
DNA damaging agents. The impact of three potent and well established inhibitors was 
examined in HNSCC cell lines, as a monotherapy as well as a combination therapy with 
x – ray or proton irradiation. Different end points were evaluated in order to obtain an 
understanding of how these drugs affected the DNA repair process. The inhibitor KU-
55933 targeted ATM (ATMi), VE-821 targeted ATR (ATRi) and NU7441 targeted DNA-
PKcs (DNA-PKcsi).  
First the impact of the drugs on protein level was investigated via immunoblotting. ATM 
is reported to be one of the first proteins initiated in response to DSB induction. It is 
activated through an intermolecular auto-phosphorylation on a single site, Serine 1981, 
and regulates a number of DNA repair proteins, such as H2AX, BRCA1, as well as proteins 
involved in cell cycle control, including p53 and Chk2, therefore indirectly promoting DSB 
repair (124, 125). ATR is reported to be triggered in response to ssDNA and to be 
activated via an autophosphorylation at Serine 428, Serine 435 and Threonine 1898 
(137). S428 is suggested to be associated with UV – induced DNA damage and is 
considered an ATR initiator (222). Similarly, T1989 autophosphorylation is shown to be 
critical for ATR activation, in response to endogenous, UV induced, and IR induced DSBs. 
Following its activation, ATR in turn regulates numerous factors involved in both DNA 
repair and cell cycle control. Finally, DNA-PKcs association with DNA repair progress has 
been linked with phosphorylation on two sites, T2609 and S2056, that are reported to 
regulate the DNA-PK complex dissociation from the site of DSB allowing other NHEJ 
repair factors to access the site and progress repair.  
In this chapter, activation of the proteins via phosphorylation, in response to treatment 
with the respective inhibitors and x – ray or proton irradiation was examined at various 
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time points.  It is worth noting, that direct comparison between the two radiation types 
was not a major goal. This is due to the fundamental differences of x – ray and proton 
irradiation, but more importantly due to the difference in the delivery technique. For x 
– ray irradiations, cells were treated in a laboratory x – ray unit, operating at 100 kV. For 
proton irradiations, cells were exposed to a passive scattered horizontal proton beam 
line of 60 MeV maximal energy and cells were positioned at the entrance dose of a 
pristine (unmodulated) beam (~1 keV/µm). The necessary dosimetry tests were 
regularly performed to confirm the radiation dose delivered via both techniques. That 
been said, the impact of the DNA repair inhibitors alone or in combination with IR is 
investigated, as well as the differences in the inhibitor impact with x – rays versus 
protons. 
4.2 Confirmation of HPV status  
The expression of the tumour suppressor protein p16, also known as CDKN2A (cyclin-
dependent kinase inhibitor 2A), a small protein with a molecular weight of 16 kDa, is 
associated with HPV-positive HNSCC. Naturally, p16 is involved in cell cycle control, 
regulating progression from G1 to the S phase. Mutations or deletions in the p16 gene 
are often found in many types of human cancers, however in HNSCC p16 overexpression 
is observed in HPV-positive tumours. In fact, it was suggested that the E7 HPV 
oncoprotein inactivates pRb, which induces upregulation of p16 (223). The expression 
of p16, as a marker of HPV positivity, was evaluated in 4 oropharyngeal HNSCC cells, the 
HPV-negative UMSCC6 and UMSCC74A cells, as well as the HPV-positive UMSCC47 and 
UPCI-SCC090 cells (Figure 4.1). Exponentially growing cells, without any prior treatment, 
were harvested and protein level were examined for p16 as a confirmation of the HPV 
status. Indeed, there was no expression of p16 in the two HPV-negative UMSCC6 and 
UMSCC74A cells. However, an overexpression of p16 was observed in the two HPV-




Figure 4. 1. p16 expression as a marker of HPV positivity in HNSCC. Exponentially growing 
cells were harvested without any treatment, and protein levels of p16 (16 kDa) were 
imaged via Western blot. 6: UMSCC6, 74A: UMSCC74A, 47: UMSCC47 and 090: UPCI-
SCC090. The p16/actin quantification ratio were normalised against the HPV-positive 
UMSCC47 which was set to 1. 
 
4.3 Inhibitor dose titration  
In order to decide the optimum dose of each drug for our experiments a dose titration 
was performed in two HPV-negative UMSCC74A and UMSCC6 and two HPV-positive 
UMSCC47 and UPCI-SCC090 HNSCC cell lines (Figure 4.2). Dose recommendations were 
available by several studies utilising the ATMi, ATRi and DNA-PKcsi for multiple types of 
human cancers including prostate, pancreatic and colon cancers (120, 121, 224-226). 
However, there were limited data available regarding the impact of these inhibitors in 
HNSCC cancer cells, with only one study utilising DNA-PKcsi and another utilising ATRi, 
yet no published studies examined ATMi (227). Therefore, several concentrations were 
examined, the most commonly used in the literature, which were 10μM ATMi, 1μM 
ATRi, and 1μM DNA-PKcsi, as well as 3 and 10 times higher, and protein levels were 
analysed for ATM phosphorylated (pATM on S1981, 370 kDa), ATR phosphorylated 
(pATR on S428, 300 kDa), and DNA-PKcs phosphorylated (pDNA-PKcs on T2609, 470 
kDa). The cells were treated with the respective drug or DMSO as control for 1 h before 
exposure to 4 Gy x – ray irradiation and for 1 h after, before been harvested. 
In all cell lines ATM phosphorylation on S1981 was maximum in the DMSO treated 
irradiated cells and minimum in the DMSO treated non irradiated cells. Upon treatment 
with the inhibitor at 10 μM and IR, the level of pATM S1981 did not increase 
demonstrating that ATMi suppressed phosphorylation of its target. Treatment with 
increasing concentration of the drug did not majorly affect the degree of suppression of 
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ATM phosphorylation, but have the potential to lead to off target effects. Interestingly, 
the impact of ATMi in suppressing S1981 pATM was equal in HPV-positive and HPV-
negative cell lines, indicating that the drug can be effective in both tumour cell types.  
In contrast to ATMi, the ATRi did not suppress phosphorylation of ATR on S428. The 
protein showed a baseline expression in DMSO treated non irradiated cells, that did not 
increase following exposure to IR. Moreover, the pATR expression did not change after 
a combination treatment with IR and 1x, 3x, and 10x times concentration of ATRi (1 μM) 
and the level of pATR S428 remained fairly the same. These observations suggested that 
neither IR alone nor a combination of IR and ATRi could affect phosphorylation of ATR 
in this site within the time frame of this experiment. Although, this could also be 
associated with low efficiency and/or specificity of the antibody used. That was the case 
in all 4 HNSCC cell lines utilised, irrespective of the HPV status. Considering that ATR is 
involved in HR which occurs later in the cell cycle, the impact of ATRi was then 
investigated in extended time course as well as in different phosphorylation site 
(Sections 4.4.2, Figures 4.4 and 4.5).  
Finally, phosphorylation of DNA-PKcs following inhibitor treatment and IR exposure was 
the most variable between the different cell lines. The level of pDNA-PKcs T2609 in non-
irradiated cells was minimal and increased after exposure to IR. Following combination 
treatment of drug and IR, expression level of DNA-PKcs T2609 was suppressed in one 
cell line, UPCI-SCC090 (HPV-positive), and the decrease was proportional with the 
concentration of the inhibitor, as increasing drug dose resulted in decreasing pDNA-PKcs 
expression. Nevertheless, no major impact was observed in one HPV-negative cell line, 
UMSCC6, where there was only a minimal decrease in phosphorylation at the higher 
drug concentration. In contrast, in two cell lines UMSCC74A and UMSCC47 HPV-negative 
and positive respectively, the phosphorylation increased at the higher concentrations. 
These contradicting findings suggested a cell line dependence regarding the impact of 
DNA-PKcsi in the phosphorylation of T2609 and required further investigation of 
different phosphorylation sites as well as extended time course (Section 4.4.3, Figures 
4.6 and 4.7). In order to decide on the appropriate dose while minimise potential off-
target effects, preliminary 2D cell proliferation studies (clonogenic assays) were 
performed (data not shown) and the lowest efficient concentration was decided to be 
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used, which specifically was 10μM ATMi, 1μM ATRi, and 1μM DNA-PKcsi, although 
different phosphorylation sites and other time points were also investigated. 
 
 
Figure 4. 2. Inhibitor dose titration. 4 HNSCC cell lines were treated for 1 h with the 
respective inhibitor at 1x the recommended concentration (10 μM ATMi, 1 μM ATRi, and 
1 μM DNA-PKcsi), 3x and 10x. Cells were then exposed to 4 Gy x- ray irradiation and were 
further incubated with the inhibitor for 1 h before been harvested. pATM: 
phosphorylated ATM (on S1981), pATR: phosphorylated ATR (on S428) pDNA-PKcs: 
phosphorylated DNA-PKcs (on T2609); NI: Non irradiated DMSO treated cells, IR: 




4.4 Impact of DNA repair inhibitors in combination with x – ray irradiation 
 The dose titrations (discussed in Section 4.3) were performed utilising increasing 
concentrations of each drug and harvesting the cells at a single time point, 1 h post 
exposure to IR. In order to evaluate the impact of the DNA repair inhibitors on 
phosphorylation of their target proteins over a longer period, later time points post 
irradiation were examined. From the previous results, ATMi resulted in a clear 
suppression of pATM in S1981 1 h after exposing cells to 4 Gy x – rays, however data 
were insufficient regarding the effect of ATRi and DNA-PKcsi in phosphorylation of their 
target proteins. This was addressed with further investigation on protein level following 
the same set up, of 1 h pre-treatment with the respective drug, followed by 4 Gy x – ray 
irradiation and by further incubation with the drug until harvesting of the cells. This 
allowed cells time to process the IR induced DNA damage via the required repair 
mechanisms and therefore time for activation and involvement of the targeted proteins 
in the repair process.  
 
4.4.1 The impact of ATMi on ATM phosphorylation. 
4.4.1.1 pATM S1981 expression up to 4h post x – ray irradiation. 
ATM is reported to be one of the first proteins to be activated in response to DNA 
damage. Therefore, phosphorylation of ATM at S1981 was evaluated at 1 h, 2 h, and 4 h 
post x – ray irradiation. Four HNSCC cell lines, UMSCC6, UMSCC74A, UMSCC47 and UPCI-
SCC090 were utilised to evaluate phosphorylation of ATM on S1981. The base line 
expression of pATM was negligible in the non-irradiated cells whether they were 
inhibitor treated or DMSO treated, and it was upregulated (3- to 6.2- fold) within 1 h 
after exposure to IR in the DMSO treated cells. As previously seen in the dose titration 
experiments (Figure 4.2), pATM was again effectively inhibited in the presence of ATMi 
in all four HNSCC cell lines post irradiation, irrespective of their HPV status (Figure 4.3). 
Post irradiation, UMSCC74A DMSO treated cells displayed high levels of pATM S1981, 
increased between 3- to 5- fold above baseline, that was almost completely inhibited in 
ATMi treated cells. In UMSCC6 DMSO treated cells, pATM expression peaked 1 h post 
irradiation by 4.2- fold above baseline, and gradually dropped in the later time points, 
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yet in ATMi treated cells expression of pATM was remarkably reduced throughout the 
time course with the biggest difference observed 1 h post IR where there was an 8- fold 
reduction. Similarly, in the HPV-positive UMSCC47 and UPCI-SCC090, ATM was 
phosphorylated in DMSO treated cells throughout the time course up to 12- and 6.5- 
fold respectively, but this phosphorylation was severely downregulated by 6- and 7- fold 
respectively in the presence of ATMi, compared to DMSO treatment. 
     
Figure 4. 3. Impact of ATMi on pATM S1981. Expression of pATM S1981 (370 kDa) was 
investigated in 4 HNSCC cell lines, two HPV-positive and two HPV-negative. Cells were 
treated with 10 μM of ATMi or 10 μM DMSO as control, for 1 h before exposure to 4 Gy 
x – ray irradiation, and were harvested 1 h, 2 h and 4 h later. Actin (42 kDa) was probed 
as control. NI: non-irradiated cells. NI: non irradiated cells. The pATM/actin 
quantification ratios were normalised against the NI DMSO, which was set to 1. 
 
4.4.2 The impact of ATRi on ATR phosphorylation   
4.4.2.1 pATR S428 expression up to 24h post x-ray irradiation. 
Next, ATR phosphorylation on S428 was examined 1 h, 2 h, and 4 h after treatment with 
a single dose of ATRi (1 μM), or DMSO (1 μM) as control, and 4 Gy x – rays. 4 HNSCC cell 
lines, UMSCC74A, UMSCC6, UMSCC47 and UPCI-SCC090 were utilised, all of which 
exhibited comparable results, irrespective of the HPV status. Interestingly, neither of 
exposure to IR alone, treatment with ATRi alone or combination of ATRI and IR had an 
impact on pATR S428 expression in none of the cell lines.  
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Considering ATR is actively involved in HR that occurs later in the cell cycle, expression 
of pATR S428 was then assessed in the same 4 HNSCC cells, but at later time points, 8 h 
and 24 h post ATRi and IR treatment. These time points were chosen to cover the peak 
period of ATR phosphorylation however, the impact of irradiation and/or ATRi 
treatment was again insignificant in all four cell lines examined and irrespective of the 
HPV status (Figure 4.4). Exposure to IR alone and/or treatment with ATRi did not alter 
ATR phosphorylation at S428 up to 24 h post irradiation. These findings demonstrated 
that IR did not induce ATR phosphorylation at S428 in HNSCC cells, so we could not 
examine the effectiveness of ATRi on this phosphorylation site. Therefore, different 
phosphorylation sites needed to be examined, to investigate how ATRi impact on DSB 
repair.  
    
Figure 4. 4. Impact of ATRi on pATR S428 in extended time course. pATR S428 (300 kDa) 
activation was investigated in 4 HNSCC cell lines, two HPV-positive and two HPV-
negative. Cells were treated with 1 μM ATRi or 1 μM of DMSO for 1 h prior to 4 Gy x- ray 
irradiation and were harvested 8 h and 24 h after. Actin (42 kDa) was probed as control. 
NI: non irradiated cells. The pATM/actin quantification ratios were normalised against 
the NI DMSO, which was set to 1.   
 
4.4.2.2 pATR T1989 expression up to 24 h post x – ray irradiation. 
The phosphorylation site ATR T1989, which is reported to be directly involved in 
activation of ATR in response to single stranded DNA (ssDNA) structures was then 
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investigated. This phosphorylation is critical for ATR function and is promptly recognised 
by TopBP1, promoting ATR driven cell cycle regulation and DNA repair. The same 4 
HNSCC cells were harvested 8 h and 24 h post exposure to IR and following treatment 
with a single dose of ATRi (1 μM) or DMSO (1 μM) as control. These time points were 
chosen to cover the peak period of ATR phosphorylation.  
In all cell lines, expression of pATR T1989 was similar and relatively low in DMSO treated 
cells and ATRi treated cells in the absence of IR, however after exposure to IR, pATR 
T1989 was activated in DMSO treated cells. In contrast, ATRi treatment suppressed 
phosphorylation on T1989 following exposure to IR, although to a different extent in 
each of the HNSCC cell lines examined (Figure 4.5). In UMSCC74A pATR expression had 
a 5- fold peak at 8 h and then dropped at 24 h post irradiation in DMSO treated cells, yet 
remained at baseline expression following combination treatment of ATRi and IR. 
Expression of pATR T1989 in UMSCC6 cells peaked at 24 h post irradiation in DMSO 
treated cells, with a 3.6- fold increase above baseline, but in the ATRi treated cells was 
considerably downregulated, by 1.8- and 3.3- fold at 8 h and 24 h respectively. The same 
trend in pATR T1989 suppression was exhibited in the two HPV-positive HNSCC cell lines, 
UMSCC47 and UPCI-SCC090. Phosphorylation of ATR on T1989 peaked 24 h post 
irradiation in the DMSO treated cells (3.2- to 4- fold increase above baseline), yet in ATRi 
treated cells was downregulated by approximately 2.5- fold 24 h post irradiation. 
Cumulatively, these results highlighted the ATRi potency to delay ATR phosphorylation 




Figure 4. 5. Impact of ATRi on pATR T1989. Expression of pATR T1989 (300 kDa) was 
investigated in 4 HNSCC cell lines, two HPV-positive and two HPV-negative. Cells were 
treated with 1 μM of ATRi or 1 μM DMSO as control, for 1 h before exposure to 4 Gy x – ray 
irradiation and were harvested 8 h and 24 h later. Actin (42 kDa) was probed as control. NI: 
non irradiated cells. The pATR/actin quantification ratios were normalised against the NI 
DMSO, which was set to 1. 
 
4.4.3 The Impact of DNA-PKcsi on DNA-PKcs phosphorylation 
4.4.3.1 pDNA-PKcs T2609 expression up to 4 h post x – ray irradiation. 
The third inhibitor, DNA-PKcsi, and its impact on phosphorylation of DNA-PKcs on T2609 
was then investigated. UMSCC6, UMSCC74A, UMSCC47, UPCI-SCC090 cells were pre-
treated for 1 h with a single dose of DNA-PKcsi (1 μM) or DMSO (1 μM) as control, and 
then were exposed to 4 Gy x – ray irradiation. Cells were further incubated with the 
inhibitor or DMSO and were harvested 1 h, 2 h, and 4 h post irradiation (Figure 4.6). 
Expression of pDNA-PKcs T2609 in the non-irradiated cells, either treated with DMSO or 
with DNA-PKcsi, was baseline and roughly the same between the four cell lines, 
irrespective of the HPV status. However, the response to treatment with the inhibitor in 




Phosphorylation of DNA-PKcs on T2609 peaked 1 h post x – ray irradiation (8.5- fold 
above baseline) and gradually dropped in the later time points in the HPV-negative 
UMSCC74A DMSO treated cells, but it was delayed and peaked 4 h post irradiation in 
DNA-PKcsi treated cells. In the HPV-negative UMSCC6 cells, phosphorylation of DNA-
PKcs T2609 peaked at 1 h post irradiation, with a 10- fold increase in DMSO treated cells. 
Interestingly, in DNA-PKcsi treated cells, pDNA-PKcs T2609 peaked too at 1 h post x - 
rays with a higher increase of 12- fold above baseline. Over the time course the 
activation gradually dropped in DMSO treated UMSCC6 cells, but appeared to persist in 
DNA-PKcsi treated cells.  
In the HPV-positive UMSCC47 cells, phosphorylation of DNA-PKcs T2609 peaked at 2 h 
(4- fold above baseline) and decreased by 4 h post irradiation in the DMSO treated cells, 
yet in the DNA-PKcsi treated cells, the peak was delayed, to 4 h post IR, and upregulated 
6.4- fold above baseline. Remarkably, severe DNA-PKcs protein cleavage was observed 
at ~250 kDa, 1 h and 2 h post exposure to IR in the inhibitor treated cells, indicating 
increased apoptosis occurring shortly after DNA damage induction in this radiosensitive 
cell line. Finally in the HPV-positive UPCI-SCC090 cells, pDNA-PKcs expression peaked 4 
h post x- rays in both DMSO treated and inhibitor treated cells, although it was slightly 
upregulated in the inhibitor treated cells throughout the time course, by 6.2- and 7.2- 
fold above baseline respectively. These finding suggested that phosphorylation of T2609 
is cell line dependent but is not dramatically affected by HPV status. Interestingly, these 
findings demonstrated that, even though DNA-PKcsi delayed phosphorylation on T2609 
in two cell lines, it also moderately enhanced DNA-PKcs activation in all cell lines 
examined, which could be an indication that the drug caused increased persistency of 




Figure 4. 6. Impact of DNA-PKcsi on pDNA-PKcs T2609. Expression of DNA-PKcs T2609 
(470 kDa) was investigated in 4 HNSCC cell lines, two HPV-positive and two HPV-
negative. Cells were treated with 1 μM of DNA-PKcsi or 1 μM DMSO as control, for 1 h 
before exposure to 4 Gy x – ray irradiation, and were harvested 1 h, 2 h and 4 h later. 
Actin (42 kDa) was probed as control. NI: non irradiated cells. The pDNA-PKcs/actin 
quantification ratios were normalised against the NI DMSO, which was set to 1. 
 
4.4.3.2 Impact of DNA-PKcsi on pDNA-PKcs S2056 up to 8 h post irradiation.  
In order to obtain a better understanding of the DNA-PKcsi impact on phosphorylation 
of its target protein, the second phosphorylation site associated with DNA repair 
progression, S2056, was then examined. Auto-phosphorylation of DNA-PKcs on S2056 is 
reported to promote dissolvement of the DNA-PK complex from the DNA ends, allowing 
other DNA repair factors to access the damage site and process the repair. In a 
preliminary experiment, two HNSCC cell lines were utilised, UMSCC74A, and UMSCC47 
to investigate  the phosphorylation of DNA-PKcs on S2056 in response to 1 h pre-
treatment with a single dose of DNA-PKcsi (1 μM) or DMSO (1 μM) as control, 1h, 2h, 
and 4h post 4 Gy x – ray irradiation. Expression of pDNA-PKcs S2056 was low in non 
irradiated cells and increased only after 4 h post exposure to x – ray irradiation in DMSO 
treated cells. However, it was suppressed in the presence of DNA-PKcsi.  
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These findings demonstrated that the phosphorylation site S2056 was impacted by DNA-
PKcsi in response to IR, and subsequently an extended time course up to 8 h post 
irradiation as well as multiple HNSCC cell lines were then examined. Auto-
phosphorylation of DNA-PKcs on S2056 was investigated in four HNSCC cell lines, 
UMSCC6, UMSCC74A, UMSCC47 and UPCI-SCC090, following 1 h pre-treatment with 
DNA-PKcsi (1 μM) or DMSO (1 μM), and 4 Gy x – ray irradiation (Figure 4.7).   
Treatment with the inhibitor alone did not impact phosphorylation of DNA-PKcs on 
S2056 in the absence of IR, which remained low and was approximately the same to the 
protein expressed in DMSO treated cells. Exposure to IR triggered activation on DNA-
PKcs S2056 in both DMSO and DNA-PKcsi treated cells, however, DNA-PKcsi treatment 
resulted in nearly 2- fold downregulations in phosphorylation of DNA-PKcs on S2056 in 
all cell lines. Specifically, in the HPV-negative UMSCC74A cells, phosphorylation on 
S2056 peaked (12- fold above baseline) 8 h post IR in DMSO treated cells yet the increase 
was limited to 6.3- fold in inhibitor treated cells. Likewise, in UMSCC6 cells, S2065 
phosphorylation exhibited a 19- fold increase 8 h post IR, following DMSO treatment but 
only an 8- fold increase above baseline was observed in DNA-PKcsi treated cells 8 h post 
exposure to x – ray irradiation. In the HPV-positive UMSCC47 cells, DNA-PKcs 
phosphorylation on S2056 was delayed compared to the other 3 cell lines, this occurred 
at 4 h post IR, and peaked 4 h later exhibiting a 27- fold increase above baseline in DMSO 
treated cells. However, the activation was less than half in DNA-PKcsi treated cells, 
where an 11- fold increase was observed. Finally, the S2056 phosphorylation in HPV-
positive UPCI-SCC090 cells presented a 10- fold increase above baseline following DMSO 
treatment 8 h post x – rays which was limited to a 6.5- fold increase following DNA-PKcsi 
treatment in the same time point. 
Moreover, DNA-PKcs cleavage was exhibited 4 h and 8 h post irradiation in UMSCC74A 
and UPCI-SCC090 inhibitor treated cells as well as at 8 h post irradiation in UMSCC47 
inhibitor treated cells, while this remained low in the DMSO treated cells. However, 
cleavage of DNA-PKcs, as a potential marker of apoptosis, was not observed in UMSCC6 
cells up to 8 h post exposure to x – rays.  
These findings further demonstrated DNA-PKcsi blocked S2056 auto-phosphorylation, 
which in turn prevented DNA-PK complex dissociation from the DSB sites and therefore 
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suppressed DNA repair. Something that was also highlighted was the increased DNA-
PKcs cleavage, indicating increased apoptosis of cells possibly due to unrepaired DNA 
DSBs. This added to the reports that during the final steps of apoptosis, DNA-PKcs is 
targeted by caspase 3-like protease (CPP32), is cleaved into fragments and therefore 







Figure 4. 7. Impact of DNA-PKcsi on pDNA-PKcs S2056.  Expression of DNA-PKcs S2056 
(460 kDa) was investigated in 4 HNSCC cell lines, two HPV-positive and two HPV-
negative. Cells were treated with 1 μM of DNA-PKcsi or 1 μM DMSO as control, for 1 h 
before exposure to 4 Gy x – ray irradiation, and were harvested 1 h, 4 h and 8 h later. 
Actin (42 kDa) was probed as control. NI: non irradiated cells. The pDNA-PKcs/actin 
quantification ratios were normalised against the NI DMSO, which was set to 1. 
 
4.5 Impact of DNA repair inhibitors in combination with proton irradiation. 
Following investigation of the impact of the DNA repair inhibitors in response to x – rays, 
phosphorylation of the targeted proteins was then investigated in response to protons 
in HNSCC cell lines. Cells were pre-treated with the drugs or DMSO as control for 1 h 
before exposure to 4 Gy proton irradiation and were further incubated with the 
respective drug, and they were allowed time to process the IR induced DNA damage via 
the required repair mechanisms. This allowed time for activation and involvement of the 
targeted proteins in the repair process, before the cells were harvested. 
 
4.5.1 The impact of ATMi on ATM phosphorylation. 
4.5.1.1 pATM S1981 expression post proton irradiation. 
ATMi resulted in a clear suppression of pATM on S1981 in cells exposed to x – rays and 
its impact was then examined in cells exposed to 4 Gy protons. The same HNSCC cell 
lines, UMSCC74A, UMSCC6, UMSCC47 and UPCI-SCC090 were utilised, and expression 
of pATM was investigated in cells that were pre-treated with 10 μM ATMi or 10 μM 
DMSO, for 1 h and were irradiated with 4 Gy protons. Cells were then further incubated 
with the inhibitor or DMSO and were harvested 1 h, 2 h, and 4 h later. Once again, 
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phosphorylation of S1981 was negligible in the non-irradiated inhibitor treated or DMSO 
treated cells, in all 4 cell lines. pATM was upregulated only after exposure to IR in the 
DMSO treated cells. However, it was suppressed in the presence of the inhibitor in all 
four HNSCC cell lines post irradiation, irrespective of their HPV status (Figure 4.8).  
In UMSCC74A, phosphorylation of ATM in S1981 in DMSO treated cells increased across 
the time course and peaked 4 h post irradiation (5- fold above baseline), yet in the ATMi 
treated cells, the increase was delayed and reduced (2.2- fold). In UMSCC6, pATM 
expression peaked 2 h post proton irradiation in DMSO treated cells (4.2- fold above 
baseline) but was downregulated to 1.4- fold above baseline in the ATMi treated cells 
post proton irradiation. The HPV-positive UMSCC47 DMSO treated cells exhibited high 
and sustained pATM expression post irradiation, that was majorly inhibited, by almost 
10- fold, after treatment with ATMi.  Similarly, in UPCI-SCC090 HPV-positive cells, 
phosphorylation of ATM on S1981 remained almost baseline in the presence of ATMi 
and proton irradiation, in contrast to the increased and persistent phosphorylation 
shown in DMSO treated cells post PBT (2.7- to 5.5- fold above baseline). 
 Concluding, the impact of ATMi on phosphorylation of S1981 in combination with 
proton irradiation was irrespective of the HPV status and exhibited an equivalent trend 




Figure 4. 8. Impact of ATMi on pATM S1981.  Expression of pATM S1981 (370 kDa) was 
investigated in 4 HNSCC cell lines, two HPV-positive and two HPV-negative. Cells were 
treated with 10 μM of ATMi or 10 μM DMSO as control, for 1 h before exposure to 4 Gy 
proton irradiation, and were harvested 1 h, 2 h and 4 h later. Actin (42 kDa) was probed 
as control. NI: non irradiated cells. The pATM/actin quantification ratios were 
normalised against the NI DMSO, which was set to 1. 
 
4.5.2 The impact of ATRi on ATR phosphorylation   
4.5.2.1 pATR S428 expression up to 4h post proton irradiation. 
Two targets of ATRi, S428 and T1989, previously investigated in response to x – rays with 
only one been impacted by the drug (Section 4.4.2) were further investigated in 
response to protons. ATR phosphorylation in S428 was examined 1 h, 2 h, and 4 h after 
treatment with a single dose of ATRi (1 μM) or DMSO (1 μM) as control and 4 Gy protons 
in UMSCC74A, UMSCC6, UMSCC47 and UPCI-SCC090 HNSCC cell lines. Similarly with x – 
rays, there was baseline expression of pATR S428 across the time course in all cell lines 
examined. Neither exposure to protons alone, nor in combination with ATRi affected 
ATR phosphorylation at S428 and therefore was not further examined. 
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4.5.2.2 pATR T1989 expression up to 24 h post proton irradiation. 
ATR phosphorylation on T1989, which is directly involved in ATR driven repair, was then 
assessed in the same 4 HNSCC cells, 8 h and 24 h post exposure to proton irradiation 
and following treatment with ATRi (1 μM) or DMSO (1 μM) as a control. In all cell lines, 
baseline expression of pATR T1989 did not majorly vary between the non-irradiated 
DMSO and ATRi treated cells, however in the presence of proton irradiation, ATR T1989 
was phosphorylated in the DMSO treated cells. Nevertheless, ATRi downregulated this 
phosphorylation on T1989 when compared with DMSO, yet to a different extent in each 
HNSCC cell lines examined (Figure 4.9).   
In agreement with the x – ray findings, pATR expression peaked 8 h (1.6- fold above 
baseline) and then dropped 24 h post protons in UMSCC74A DMSO treated cells, 
whereas phosphorylation peaked at 24 h post proton irradiation in DMSO treated cells 
of the other three cell lines. In UMSCC74A ATRi treated cells, pATR was reduced by 2- 
fold compared to DMSO treated cells 8 h post protons.  In UMSCC6 and UMSCC47 ATRi 
treated cells, pATR T1989 remained at or below baseline expression across the time 
course, and ~1.8 - 2- fold lower compared to irradiated DMSO treated cells. Finally, in 
UPCI-SCC090 ATRi treated cells, ATR phosphorylation on T1989 was only downregulated 
24 h post proton irradiation by a factor of ~1.8. 
Summing up, these findings demonstrated the ATRi potency to delay and even inhibit 
DNA repair process, by blocking ATR phosphorylation in T1989 in combination with 
proton irradiation, despite that no impact was observed on S428.  
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Figure 4. 9. Impact of ATRi on pATR T1989. Expression of pATR T1989 (300 kDa) was 
investigated in 4 HNSCC cell lines, two HPV-positive and two HPV-negative. Cells were 
treated with 1 μM of ATRi or 1 μM DMSO as control, for 1 h before exposure to 4 Gy 
proton irradiation, and were harvested 8 h and 24 h later. Actin (42 kDa) was probed as 
control. NI: non irradiated cells. The pATR/actin quantification ratios were normalised 
against the NI DMSO, which was set to 1. 
 
4.5.3 The Impact of DNA-PKcsi on DNA-PKcs phosphorylation 
4.5.3.1 pDNA-PKcs T2609 expression up to 4 h post proton irradiation. 
The impact of DNA-PKcsi on phosphorylation of T2609 and S2056 varied in response to 
x – rays (Section 4.4.3) and was further investigated following proton irradiation. For 
investigation of T2609 phosphorylation, two HNSCC cell lines, UMSCC74A and 
UMSCC47, were treated with DNA-PKcsi (1 μM) or DMSO (1 μM) as control, and 
irradiated with 4 Gy protons. Cells were then harvested 1 h, 2 h, and 4 h post irradiation. 
No difference was observed in expression of pDNA-PKcs T2609 in DMSO and DNA-PKcsi 
treated non irradiated cells. In UMSCC74A cells, phosphorylation on T2609 was induced 
in DMSO treated cells post protons, yet the DNA-PKcsi treatment suppressed this 
phosphorylation but also upregulated DNA-PKcs protein cleavage suggesting increased 
apoptosis at earlier time points. In contrast, UMSCC47 phosphorylation of DNA-PKcs 
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remained low and was not affected by proton irradiation and/or inhibitor treatment. 
Since the results were inconclusive, this site was not examined further.  
4.5.3.2 pDNA-PKcs S2056 expression up to 8 h post proton irradiation. 
DNA-PKcs S2056 phosphorylation was then assessed in response to DNA-PKcsi and 
proton irradiation in four HNSCC cells, UMSCC6, UMSCC74A, UMSCC47 and UPCI-
SCC090. Cells were pre-treated with DNA-PKcsi (1 μM) or DMSO (1 μM) as control for 1 
h, before exposure to 4 Gy protons. Cells were further incubated with the inhibitor or 
DMSO and were harvested 1 h, 4 h, and 8 h post irradiation (Figure 4.10), given that 
these time points covered the peak period of S2056 phosphorylation following x – ray 
irradiation. Phosphorylation of DNA-PKcs in S2056 was relatively minimal in non 
irradiated cells, either inhibitor or DMSO treated, and was only triggered after exposure 
to IR. In agreement with the x – ray findings, phosphorylation of DNA-PKcs S2056 was 
downregulated in all 4 HNSCC cell lines following proton irradiation in presence of the 
inhibitor compared to DMSO, although to a different extent for each cell line. 
DNA-PKcs phosphorylation on S2056 in UMSCC74A DMSO treated irradiated cells, was 
initiated within 1 h and peaked at 8 h post exposure to protons, by 5.2- fold above 
baseline, while it was severely downregulated in DNA-PKcsi treated cells, where it 
generally remained at baseline expression across the time course. Moreover, severe 
DNA-PKcs protein cleavage was observed 8 h post inhibitor treatment and proton 
irradiation, that was much stronger compared to a combination of inhibitor and x – ray 
treatment (Section 4.4.3, Figure 4.7). This indicated increased apoptotic rates in 
response to protons and DNA-PKcsi treatment. 
 In UMSCC6 cells, phosphorylation was triggered within 1 h and peaked at 8 h post 
proton irradiation in DMSO treated cells (7.8- fold above baseline). The same trend was 
exhibited in inhibitor treated cells, yet pDNA-PKcs expression was reduced overall by a 
factor of ~1.4 to ~2.4. Combination of DNA-PKcsi and protons resulted in some DNA-
PKcs protein cleavage 1 h and 4 h post irradiation, indicating increased apoptosis 
following protons irradiation in this radioresistant cell line.  
In HPV-positive UMSCC47 DMSO treated cells, DNA-PKcs phosphorylation on S2056 
peaked 8 h post exposure to protons with a 9.9- fold increase above baseline, but 
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remained low in DNA-PKcsi treated cells, across the time course. In addition, DNA-PKcs 
protein cleavage was observed in DMSO treated cells induced by proton irradiation 
alone, which was enhanced by the inhibitor 4h and 8 h post proton irradiation. This 
cleavage was much stronger compared to a combination of inhibitor and x – ray 
treatment (Section 4.4.3, Figure 4.7) and indicated increased apoptotic rates in response 
to protons and DNA-PKcsi treatment.  
Finally, in UPCI-SCC090 cells, expression of pDNA-PKcs S2056 post irradiation was high 
across the time course in the DMSO treated cells (2.6- to 4.2- fold above baseline) yet 
was noticeably reduced by a factor of ~1.8 – 2.6 in the inhibitor treated cells. Again, 
cleaved DNA-PKcs was introduced due to proton irradiation in DMSO treated cells, but 
this was enhanced in inhibitor treated cells and peaked 8 h post proton irradiation.     
These findings demonstrated delayed or deficient S2056 phosphorylation, due to 
treatment with DNA-PKcsi and protons, that was directly linked to increased DNA-PKcs 
cleavage, indicating increased apoptosis of cells containing unrepaired DNA damage. 
Altogether, it appeared that DNA-PKcsi was effective in suppressing phosphorylation of 
DNA-PKcs in S2056, in combination with protons, with no major differences respective 







Figure 4. 10. Impact of DNA-PKcsi on pDNA-PKcs S2056.  Expression of DNA-PKcs S2056 
(470 kDa) was investigated in 4 HNSCC cell lines, two HPV-positive and two HPV-
negative. Cells were treated with 1 μM of DNA-PKcsi or 1 μM DMSO as control, for 1 h 
before exposure to 4 Gy x – ray irradiation, and were harvested 1 h, 4 h and 8 h later. 
Actin (42 kDa) was probed as control. NI: non-irradiated cells. The pDNA-PKcs/actin 




4.6 Conclusions  
As a starting point of this research, the HPV status of the cell lines involved was 
confirmed through investigation of p16 expression, as a marker of HPV infection. Next, 
technique optimisation included inhibitor dose titration, to decide the correct drug 
concentrations, as well as time titration, to investigate the inhibitor’s impact on 
extended time courses.  Treatment with either of the inhibitor, in the absence of IR did 
not majorly impact on phosphorylation levels on any of the sites investigated within 
ATM, ATR, and DNA-PKcs, and for all HNSCC cell lines examined, irrespective of the HPV 
status. This was an indication that, at least at protein level, the drug alone did not affect 
normal DDR behaviour by inducing or reducing phosphorylation of the critical DSB repair 
protein sites.  
ATMi was found to effectively suppress ATM phosphorylation on S1981, immediately 
and up to 4 h post irradiation, in combination with IR.  The impact of ATMi was similar 
in both HPV-positive and HPV-negative cell lines, indicating that the drug can be 
effective in both tumour cell types. In addition, the impact on pATM S1981 was 
equivalent following x – rays or protons, in the four cell lines examined, demonstrating 
that the drug can be effective in response to either radiation modalities, but also that it 
was the same phosphorylation site that got activated irrespective of the DNA damage 
inducer. 
ATRi was found to have no impact on ATR S428 phosphorylation, either alone or in 
combination with x – rays and protons. In fact, ATR S428 exhibited a standard expression 
across the 4 HNSCC cell lines, which was not affected by exposure to either x – rays or 
proton irradiation, irrespective of the HPV status and up to 24 h post any treatment. This 
made it impossible to study any potential impact induced by ATRi on the 
phosphorylation on S428. In contrast, ATRi in combination with IR was found to delay 
and decrease ATR T1989 phosphorylation, in all 4 HNSCC cell lines. T1989 
phosphorylation, was impacted by the drug in response to x – rays as well as protons, 
with no major differences between the two radiation modalities. These findings 
highlighted the ATRi potency to inhibit ATR activation, irrespective of the HPV status and 
the radiation type.  
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DNA-PKcsi, was shown to delay yet upregulate phosphorylation on DNA-PKcs T2609 in 
combination with x – rays, and irrespective of the HPV status up to 4 h post irradiation. 
However, T2609 was downregulated following inhibitor and proton treatment with 
simultaneous upregulation of DNA-PKcs cleavage, demonstrating increased apoptosis in 
one cell line, while had almost no effect in the other. On the other hand, DNA-PKcsi 
downregulated phosphorylation of DNA-PKcs S2056 in all 4 HNSCC cell lines in response 
to x – ray as well as proton irradiation. Interestingly, DNA-PKcs protein cleavage was 
more readily observed following proton irradiation in DMSO treated cells irrespective of 
the HPV status, suggesting that protons were more effective than x – rays in inducing 
apoptosis. This cleavage was amplified in the presence of DNA-PKcsi indicating that the 
drug suppressed DSB repair, possibly leading to increased cell death.  
Cumulatively, these findings confirm that ATMi, ATRi, and DNA-PKcsi targeted 
phosphorylation of at least one site of the respective proteins, and therefore 
dysregulated the DNA damage response, however more in depth analysis was required. 
In the next chapter, the impact of the three protein kinase inhibitors in the DDR 




Chapter 5: Results II 
Impact of DNA repair inhibitors on the DDR signalling  
5.1 Introduction  
Exposure to IR is known to induce significant amount of DNA damage, and importantly 
DSBs, that immediately initiate the DDR. In Chapter 4, I demonstrated that inhibition of 
the protein kinases ATM, ATR and DNA-PKcs suppressed their phosphorylation on 
critical sites that could lead to delayed or insufficient DNA repair (207). Naturally, and 
upon DSB induction, histone H2AX is phosphorylated on Serine 139 through NHEJ 
pathway and it has been reported that both ATM and DNA-PKcs phosphorylate H2AX in 
response to DSBs in a redundant, overlapping manner, but phosphorylation of H2AX was 
independent of ATR (228). However, other studies reported that ATM is the major kinase 
responsible for H2AX phosphorylation and that DNA-PKcs in unable to phosphorylate 
H2AX in the absence of ATM (120, 225). Phosphorylated H2AX, also called γH2AX, are 
rapidly generated surrounding DSBs to form foci, marking the sites to attract the 
appropriate repair proteins and as the repair process progresses, they disappear. DSBs 
can be quantified indirectly by visualization and counting of the γH2AX foci formation, 
as they appear in a manner of one focus per one DSB (225), as illustrated in example 
images in Figure 5.1.  
Simultaneously, the tumour suppressor p53 binding protein 1 (53BP1) is 
phosphorylated, and forms foci that colocalise with γH2AX. The initial recruitment and 
phosphorylation of 53BP1 depends on the activation of the protein kinases ATM and 
DNA-PKcs (228, 229). Interestingly, γH2AX foci are not involved in the initial recruitment 
of 53BP1, yet are required for the stable formation and retention of 53BP1 foci. 53BP1 
foci are considered markers of DSB repair processing through NHEJ and are diminishing 
accordingly during the repair process (207).   
 Subsequently, HR takes over and the protein Rad51 is recruited. ATM and ATR interact 
with and phosphorylate Rad51, but DNA-PKcs is not directly involved. The formation of 
Rad51 foci highlight the sites where HR is active (230). Rad51 foci are reduced as the 
repair processes progresses, however these foci are delayed compared to γH2AX and 
53BP1 foci as they are only formed once the cells reach the S/G2 phase of their cycle 
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(231). All these foci can be visualized by microscopy and give us an insight of the repair 
process and the role of the three basic protein kinases in the regulation of NHEJ and HR 
repair post irradiation. The impact of ATM, ATR, and DNA-PKcs inhibition in γH2AX, 
53BP1 and Rad51 foci formation and persistence was investigated alone or in 
combination with x – rays and proton irradiation.  
 
Figure 5. 1. DNA repair focus formation in response to IR. Representative images of 
γΗ2ΑΧ (red), 53BP1 (green) and Rad51 (green) foci in UMSCC6 HNSCC cells non irradiated 
(NI) or 1 h, 4 h, 8 h, 16 h and 24 h post exposure to 4 Gy x – rays, and nuclei were stained 
with DAPI (blue). A small number of foci was present in non irradiated cells, marking the 
endogenous DNA damage and repair. Exposure to IR generated high number of each foci 
that peaked and dropped over the incubation period. 
 
5.2 Immunofluorescent staining and foci analysis in response to x – rays.  
In this chapter, the result of DSB repair inhibition was investigated at the molecular level. 
Specifically, the markers of DSB sites and DSB repair, namely γH2AX, 53BP1 and Rad51, 
were examined in response to monotherapy of the DNA repair inhibitors ATMi, ATRi and 
DNA-PKcsi as well as a combination therapy of the inhibitors and IR, in HNSCC cell lines. 
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Two HPV-negative, UMSCC6 and UMSCC74A, and one HPV-negative, UMSCC47, HNSCC 
cell lines were utilised. Due to the morphological characteristics of the HPV-positive 
UPCI-SCC090, where cells grow on top of each other in culture, the use of confocal 
microscopy was investigated, however foci determination in individual z-stacks was still 
extremely difficult. Either high resolution microscopy or possibly sectioning of cells 
following cell embedding would be necessary, in order to distinct and count the 
individual foci and thus it was decided to exclude this cell line for the purpose of this 
experiment. In DMSO treated cells the number foci per nucleus varied in the 3 different 
cell lines between 80-100 of γH2AX foci and 60-85 of 53BP1 foci 1 h post 4 Gy x – rays 
and 30-50 of Rad51 foci 8 h post 4 Gy x – rays.   
5.2.1 Impact of ATMi 
First, the impact of ATMi was assessed on the three foci markers alone, or in 
combination with x – rays. Cells were pre-treated with 10 μM ATMi or 10 μM DMSO as 
control for 1 h and then were exposed to 4 Gy x – rays. The cells were then further 
incubated with the inhibitor up to 24 h to allow for DNA repair progression. Finally, cells 
were fixed and incubated with antibodies for γH2AX, 53BP1 or Rad51, then were imaged 
and analysed.   
5.2.1.1 Impact of ATMi on γH2AX  
Formation of γH2AX designates the sites of DSB and recruits other DNA repair factors to 
process the DNA damage.  Foci formation is reported to occur immediately upon DSB 
induction and to persist until the damage is resolved (232, 233). Therefore, γH2AX foci 
were assessed 1 h, 4 h and 8 h post IR exposure. γH2AX foci were present even in the 
DMSO treated and non irradiated cells, highlighting that DSBs can naturally occur (Figure 
5.1). As shown in Figure 5.2, treatment with ATMi alone, under non irradiated 
conditions, did not have a significant impact on foci formation in any of the three cell 
lines examined. Exposure to IR, severely increased γH2AX foci (by 4- to 7- fold) in the 
DMSO treated cells 1 h after irradiation, but the increase was suppressed in ATMi 
treated cells in all cell lines. In ATMi treated cells, the number of foci was reduced 1 h 
post IR by a factor of ~1.4 - 1.5. This suggested that ATMi inhibited DSB recognition and 




Figure 5. 2.   Impact of ATMi on DSB marker γH2AX. γΗ2ΑΧ foci formation was 
investigated in 3 HNSCC cell lines. Cells were treated for 1 h with 10 μM ATMi or 10 μM 
DMSO, exposed to 4 Gy x – rays and fixed and stained for γH2AX 1 h post irradiation. NI: 
non irradiated. 5 representative images were captured, containing at least 20 cells per 
coverslip. Values were the means of 2 biologically independent experiments, were 
normalised against the non irradiated DMSO treated cells, which was set to 1, and are 
presented with their standard error. 
 
5.2.1.2 Impact of ATMi on 53BP1 
Formation of 53BP1 foci that colocalise with γH2AX, mark the areas of DSB repair via 
NHEJ. Foci formation is reported to occur almost simultaneously with γH2AX 
immediately upon DSB induction and to persist until the damage is resolved (234). 
Therefore, 53BP1 foci were assessed at the same time points, 1 h, 4 h and 8 h post IR 
exposure. 53BP1 foci are too present in the DMSO treated and non irradiated cells, 
highlighting the naturally occurring and repaired DSBs (Figure 5.1). Treatment with ATMi 
alone, in the absence of IR, did not have a major impact on 53BP1 foci formation (Figure 
5.3) in any of the three cell lines. Upon exposure to IR, formation of 53BP1 foci was 
induced in DMSO treated cells with a 2.5- to 4- fold increase. However, this was only 
marginally inhibited in ATMi treated cells where the number of 53BP1 foci was reduced 
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DMSO treated cells, yet this difference was diminished by 8 h. Surprisingly, 53BP1 foci 
persisted up to 8 h post x – rays even in DMSO treated cells, suggesting very little repair 
in all cell lines, which could be related to these specific cell lines or due to overlapping 
of foci masking any progress of the repair. Overall, these findings demonstrated that 
DSB repair as shown by 53BP1 recruitment was slightly delayed by ATMi only at 1 h 
following x – ray irradiation in all cell lines, irrespective of the HPV status. 
 
  
Figure 5. 3. Impact of ATMi on DSB repair marker 53BP1. 53BP1 foci formation was 
investigated in 3 HNSCC cell lines. Cells were treated for 1 h with 10 μM ATMi or 10 μM 
DMSO, exposed to 4 Gy x – rays and fixed and stained for 53BP1 1 h and 8 h post 
irradiation. NI: non irradiated. 5 representative images were captured, containing at 
least 20 cells per coverslip. Values were the means of 2 biologically independent 
experiments, were normalised against the non-irradiated DMSO treated cells, which was 
set to 1, and are presented with their standard error. 
 
5.2.1.3 Impact of ATMi on Rad51 
The third foci formation assessed, Rad51 as a marker of DSB repair via HR, occurs later 
in the cell cycle and thus cells were investigated 8 h, 16 h and 24 h post 4 Gy x – ray 
irradiation. Similarly with the two markers previously addressed, formation of Rad51 



















































and repaired DSBs (Figure 5.1). In the absence of IR, comparable Rad51 foci formation 
was observed in DMSO and ATMi treated cells in two cell lines, but the inhibitor 
moderately upregulated foci formation in UMSCC6 cells, signifying increased HR activity, 
possibly due to increased endogenous DSBs, induced by the drug alone (Figure 5.4).  
Following exposure to x – rays, Rad51 foci formation in DMSO treated cells peaked at 16 
h post irradiation, where it exhibited a 2- to 3- times higher number of foci when 
compared to the DMSO treated non irradiated cells. However, in ATMi treated cells 
Rad51 foci formation was suppressed in all cell lines. The downregulation was ~1.5- fold 
in UMSCC6 and UMSCC47 ATMi treated cells, and ~1.3- fold in UMSCC74A ATMi treated 
cells, compared to the DMSO irradiated cells. These results indicated downregulated 
Rad51 involvement in DSB repair and thus reduced HR activity in all cell lines in response 
to inhibitor treatment and to x – rays, that was not associated with the HPV status.  
 
  
Figure 5. 4. Impact of ATMi on DSB repair marker Rad51. Rad51 foci formation was 
investigated in 3 HNSCC cell lines. Cells were treated for 1 h with 10 μM ATMi or 10 μM 
DMSO, exposed to 4 Gy x – rays and fixed and stained for Rad51 16 h post irradiation. 
NI: non irradiated. 5 representative images were captured, containing at least 20 cells 
per coverslip. Values were the means of 2 biologically independent experiments, were 
normalised against the non irradiated DMSO treated cells, which was set to 1, and are 















































5.2.2 Impact of ATRi  
Next, the impact of ATRi on the DNA repair process was investigated in HNSCC cells. The 
foci formation and persistency were assessed in cells treated with the inhibitor alone, 
or in combination with IR. Cells were pre-treated with 1 μM ATRi or 10 μM DMSO as 
control for 1 h and then were exposed to 4 Gy x – rays. The cells were then further 
incubated with the inhibitor up to 24 h to allow for DNA repair progression. Finally, cells 
were fixed and incubated with antibodies for γH2AX, 53BP1 or Rad51, then were imaged 
and analysed.  
5.2.2.1 Impact of ATRi on γH2AX 
In the absence of IR, there was no impact by ATRi on γH2AX foci in two cell lines, as seen 
in Figure 5.5. However, in UMSCC6 there was an upregulation (1.6- fold above baseline) 
in γH2AX foci formation in non irradiated ATRi treated cells, suggesting increased 
number of endogenous DSBs. In DMSO treated cells γH2AX foci formation peaked within 
1 h post irradiation (by 4- to 7- fold) and the foci were gradually resolved at the later 
time points in all three cell lines. The impact of ATRi on γH2AX foci formation in response 
to x – rays was insignificant in UMSCC74A cells, confirming that ATR does not greatly 
involved in γH2AX foci development. However, formation of γH2AX foci was 
downregulated in ATRi treated UMSCC6 and UMSCC47 cells by a factor of ~1.2 and ~1.4 
respectively following irradiation highlighting a possible ATR involvement in DSB 










Figure 5. 5. Impact of ATRi on DSB marker γH2AX. γΗ2ΑΧ foci formation was investigated 
in 3 HNSCC cell lines. Cells were treated for 1 h with 1 μM ATRi or 10 μM DMSO, exposed 
to 4 Gy x – rays and fixed and stained for γH2AX 1 h post irradiation. NI: non irradiated. 
5 representative images were captured, containing at least 20 cells per coverslip. Values 
were the means of 2 biologically independent experiments, were normalised against the 
non-irradiated DMSO treated cells, which was set to 1, and are presented with their 
standard error. 
 
5.2.2.2 Impact of ATRi on 53BP1 
Treatment with ATRi alone had no significant effect on endogenous NHEJ repair as 
suggested by the minor impact on 53BP1 foci formation in the absence of IR. Formation 
of 53BP1 foci 1 h post exposure to IR was very similar between DMSO and ATRi treated 
HPV-negative cells, UMSCC6 and UMSCC74A (Figure 5.6). Considering that ATR is not 
directly involved in 53BP1 recruitment, these findings were not surprising. A 
downregulation of 53BP1 foci formation (by 1.2- fold) was observed in the HPV-positive 





















































Figure 5. 6. Impact of ATRi on DSB repair marker 53BP1. 53BP1 foci formation was 
investigated in 3 HNSCC cell lines. Cells were treated for 1 h with 1 μM ATRi or 10 μM 
DMSO, exposed to 4 Gy x – rays and fixed and stained for 53BP1 1 h post irradiation. NI: 
non irradiated. 5 representative images were captured, containing at least 20 cells per 
coverslip. Values were the means of 2 biologically independent experiments, were 
normalised against the non irradiated DMSO treated cells, which was set to 1, and are 
presented with their standard error. 
 
5.2.2.3 Impact of ATRi on Rad51 
Rad51 foci formation was investigated in response to ATRi alone and in combination 
with IR. A fluctuation in numbers of Rad51 foci was observed between the DMSO treated 
and ATRi treated non irradiated cells, in the different cell lines, suggesting a possible cell 
line dependant HR regulation by ATRi. Rad51 foci peaked at 16 h post irradiation in 
DMSO treated cells, with a 2- to 3- fold increase. But importantly, in ATRi treated cells 
formation of Rad51 foci was severely downregulated in all cell lines and the amount of 
foci remained almost at baseline. Altogether, these results highlighted the key role of 





















































Figure 5. 7. Impact of ATRi on DSB repair marker Rad51. Rad51 foci formation was 
investigated in 3 HNSCC cell lines. Cells were treated for 1 h with 1 μM ATRi or 10 μM 
DMSO, exposed to 4 Gy x – rays and fixed and stained for Rad51 16 h post irradiation. 
NI: non irradiated. 5 representative images were captured, containing at least 20 cells 
per coverslip. Values were the means of 2 biologically independent experiments, were 
normalised against the non irradiated DMSO treated cells, which was set to 1, and are 
presented with their standard error. 
 
5.2.3 Impact of DNA-PKcsi  
The impact of the third inhibitor, DNA-PKcsi, alone or in combination with IR was then 
examined on the three DSB repair markers. The same three HNSCC cell lines were 
utilised, and cells were pre-treated with 1 μM DNA-PKcsi or 10 μM DMSO as control for 
1 h and then were exposed to 4 Gy x – rays. The cells were then further incubated with 
the inhibitor up to 24 h to allow for DNA repair progression. Finally, cells were fixed, and 
incubated with antibodies for γH2AX, 53BP1 or Rad51, then were imaged and analysed.   
5.2.3.1 Impact of DNA-PKcsi on γH2AX 
No increase was exhibited in the number of γH2AX foci formed in the presence of the 
inhibitor alone, and thus in the amount of endogenous DSB induction and recognition in 















































foci formation reached a 3- to 6- fold increase above baseline at 4 h post irradiation, and 
the foci were gradually were resolved in UMSCC6, but persisted in UMSCC74A (HPV-
negative) and UMSCC47 (HPV-positive) cell lines, suggesting a possible cell line 
deficiency for the resolvent of these foci. However, upregulation and increased 
persistency in γH2AX foci was observed in the presence of DNA-PKcsi 4 h and 8 h post 
irradiation, with ~1.5- fold higher amount of γH2AX foci in inhibitor compared to DMSO 
treated cells. This demonstrated persistent and unrepaired DSB up to 8 h post irradiation 
that suggested insufficient DSB repair due to DNA-PKcsi in combination with x – rays. 
  
Figure 5. 8. Impact of DNA-PKcsi on DSB marker γH2AX. γΗ2ΑΧ foci formation was 
investigated in 3 HNSCC cell lines. Cells were treated for 1 h with 1 μM DNA-PKcsi or 10 
μM DMSO, exposed to 4 Gy x – rays and fixed and stained for γH2AX 4 h and 8 h post 
irradiation. NI: non irradiated. 5 representative images were captured, containing at 
least 20 cells per coverslip. Values were the means of 2 biologically independent 
experiments, were normalised against the non irradiated DMSO treated cells, which was 
set to 1, and are presented with their standard error. 
 
5.2.3.2 Impact of DNA-PKcsi on 53BP1 
Formation and persistence of 53BP1 foci was investigated as a marker of NHEJ repair. A 
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DNA-PKcsi treated cells in the absence of IR, by a factor of ~1.5 and ~1.3 respectively, 
compared to the DMSO treated cells, as seen in Figure 5.9. This suggested that the 
inhibitor alone moderately reduced 53BP1 recruitment and thus involvement in DSB 
repair via NHEJ. 53BP1 was recruited post exposure to IR, displaying a 3- to 5- fold 
increase in the DMSO treated cells at 4 h which was reduced by 8 h in the HPV-negative 
cell lines, but persisted in the HPV-positive UMSCC47 cells, highlighting their increased 
radiosensitivity. But in accordance with the γH2AX foci, 53BP1 foci exhibited increased 
persistency 4 h and 8 h post irradiation in DNA-PKcsi treated cells, by a factor of ~1.2 in 
the HPV-positive UMSCC47, and ~1.4 in the HPV-negative UMSCC6 and UMSCC74A cells. 
These findings showed that combination treatment with DNA-PKcsi and x – rays, 
impacted 53BP1 recruitment leading to persistent unrepaired DSB. Also, this suggested 
that NHEJ is dysregulated through inability of 53BP1 to dissociate from the DSB. 
  
Figure 5. 9. Impact of DNA-PKcsi on DSB repair marker 53BP1. 53BP1 foci formation was 
investigated in 3 HNSCC cell lines. Cells were treated for 1 h with 1 μM DNA-PKcsi or 10 
μM DMSO, exposed to 4 Gy x – rays and fixed and stained for 53BP1 4 h and 8 h post 
irradiation. NI: non irradiated. 5 representative images were captured, containing at 
least 20 cells per coverslip. Values were the means of 2 biologically independent 
experiments, were normalised against the non irradiated DMSO treated cells, which was 



















































5.2.3.3 Impact of DNA-PKcsi on Rad51 
The third marker, Rad51, was investigated in response to DNA-PKcsi alone and in 
combination with x – rays, even though DNA-PKcs is not directly involved in HR. No major 
difference was observed between the number of Rad51 foci in DMSO treated cells and 
DNA-PKcsi treated cells, in the absence of IR, as seen in Figure 5.10. In DMSO treated 
cells, Rad51 peaked at 16 h (1.9- to 3- fold above baseline) and dropped by 24 h post IR. 
Yet foci levels were higher in UMSCC6 and UMSCC74A DNA-PKcsi treated cells by ~1.4 
at 16 h and ~2.3- fold at 24 h post IR. In UMSCC47 cells, Rad51 foci persisted only at 24 
h post IR where they were 1.6- fold higher. This demonstrated increased Rad51 
recruitment that could mean increased DSB repair via HR following DNA-PKcsi 
treatment, possibly because of HR employment as a substitute following an insufficient 
NHEJ repair of DSBs. 
 
 Figure 5. 10.  Impact of DNA-PKcsi on DSB repair marker Rad51. Rad51 foci formation 
was investigated in 3 HNSCC cell lines. Cells were treated for 1 h with 1 μM DNA-PKcsi or 
10 μM DMSO, exposed to 4 Gy x – rays and fixed and stained for Rad51 16 h and 24 h 
post irradiation. NI: non irradiated. 5 representative images were captured, containing 
at least 20 cells per coverslip. Values were the means of 2 biologically independent 
experiments, were normalised against the non irradiated DMSO treated cells, which was 
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5.3 Immunofluorescent staining and foci analysis in response to protons.  
Investigation of the impact of DNA repair inhibition on γH2AX, 53BP1 and Rad51 foci 
formation in combination with x – rays, demonstrated that all three drugs directly or 
indirectly affected DSB repair via NHEJ and HR repair. The outcome of this inhibition in 
combination with proton irradiation was then investigated. As previously described, the 
markers of DSB sites and DSB repair were examined in response to monotherapy of the 
DNA repair inhibitors ATMi, ATRi and DNA-PKcsi as well as in combination with IR, in 
UMSCC6, UMSCC74A and UMSCC47 HNSCC cell lines. In DMSO treated cells the number 
foci per nucleus varied in the 3 different cell lines between 100-150 of γH2AX foci and 
90-110 of 53BP1 foci 1 h post 4 Gy protons and 35-55 of Rad51 foci 8 h post 4 Gy protons.   
 
5.3.1 Impact of ATMi 
First, the impact of ATMi alone, or in combination with proton irradiation was assessed 
in the three markers. Cells were pre-treated with 10 μM ATMi or 10 μM DMSO as control 
for 1 h and then were exposed to 4 Gy protons. The cells were then further incubated 
with the inhibitor for up to 24 h to allow for DNA repair progression. Finally, cells were 
fixed and incubated with antibodies for γH2AX, 53BP1 or Rad51, then were imaged and 
analysed.   
5.3.1.1 Impact of ATMi on γH2AX  
Formation of γH2AX, as a marker of DSB sites, was assessed 1 h, 4 h and 8 h post proton 
irradiation. No major difference was observed in γH2ΑΧ focus formation between DMSO 
treated and ATMi treated cells in the absence of protons (Figures 5.2 and 5.11). 
Following treatment with proton irradiation the amount of foci rapidly increased by 5- 
to 7- fold 1 h post irradiation, in DMSO treated cells in all cell lines examined. However, 
formation of γH2AX foci in ATMi treated cells, was delayed and reduced by 1.45- fold in 
UMSCC6 and UMSCC74A, and by 2.3- fold in UMSCC47, compared to the DMSO treated 
cells, 1 h post proton irradiation. These results suggested that ATMi in combination with 
protons, delayed the DSB recognition through generation of γH2AX foci and therefore 





Figure 5. 11. Impact of ATMi on DSB marker γH2AX. γΗ2ΑΧ foci formation was 
investigated in 3 HNSCC cell lines. Cells were treated for 1 h with 10 μM ATMi or 10 μM 
DMSO, exposed to 4 Gy proton irradiation and fixed and stained for γH2AX 1 h post 
irradiation. NI: non irradiated. 5 representative images were captured, containing at 
least 20 cells per coverslip. Values were the means of 2 biologically independent 
experiments, were normalised against the non irradiated DMSO treated cells, which was 
set to 1, and are presented with their standard error. 
 
5.3.1.2 Impact of ATMi on 53BP1 
As shown in Figure 5.12 (and Figure 5.3), formation of 53BP1 was not affected by 
treatment with ATMi alone, in the absence of proton irradiation. In the DSMO treated 
cells, the number of 53BP1 foci increased by 2.3- to 3.4- fold above baseline at 4 h post 
exposure to protons, and was moderately at 8 h post IR in UMSCC6 cells. However, 
similarly to x – rays, 53BP1 foci persisted up to 8 h post protons in UMSCC74A and 
UMSCC47, which could be related to these specific cell lines or due to overlapping of 
foci masking any progress of the repair. In proton irradiated ATMi treated cells, 53BP1 
foci formation was not delayed 1 h post protons, however it persisted at 8 h indicating 
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time points, could suggest that protons possibly induce more complex DNA damage that 
are more difficult to be repaired. 
 
  
Figure 5. 12. Impact of ATMi on DSB repair marker 53BP1. 53BP1 foci formation was 
investigated in 3 HNSCC cell lines. Cells were treated for 1 h with 10 μM ATMi or 10 μM 
DMSO, exposed to 4 Gy proton irradiation and fixed and stained for 53BP1 1 h and 8 h 
post irradiation. NI: non irradiated. 5 representative images were captured, containing 
at least 20 cells per coverslip. Values were normalised to the non-irradiated DMSO 
treated cells, which was set to 1, and are presented with their standard error. 
 
5.3.1.3 Impact of ATMi on Rad51 
Formation of Rad51 foci was investigated and no impact on Rad51 was observed by 
ATMi alone in two cell lines (Figure 5.13 and Figure 5.4) in the absence of proton 
irradiation, yet the numbers were elevated in UMSCC6, suggesting increased 
dependence on ATM driven DSB repair in this cell line. In DMSO treated irradiated cells, 
Rad51 foci peaked at 16 h post irradiation in all cell lines by 3- to 4.3- fold above baseline. 
ATMi treatment reduced Rad51 foci at 16 h post proton irradiation in all cell lines but to 
a different extent. The HPV-negatives UMSCC74A and UMSCC6 cells exhibited a ~1.2- 
and ~1.4- fold decrease in Rad51 foci respectively compared to DMSO treated cells. The 


















































Rad51 foci, ~2.4 fold lower in inhibitor treated cells compared to DMSO treated cells. 
These findings suggested that ATMi supressed HR repair following proton irradiation. 
 
  
Figure 5. 13. Impact of ATMi on DSB repair marker Rad51. Rad51 foci formation was 
investigated in 3 HNSCC cell lines. Cells were treated for 1 h with 10 μM ATMi or 10 μM 
DMSO, exposed to 4 Gy proton irradiation and fixed and stained for Rad51 16 h post 
irradiation. NI: non irradiated. 5 representative images were captured, containing at 
least 20 cells per coverslip. Values were the means of 2 biologically independent 
experiments, were normalised against the non irradiated DMSO treated cells, which was 
set to 1, and are presented with their standard error. 
 
5.3.2 Impact of ATRi 
Next, the impact of ATRi alone or in combination with proton irradiation was 
investigated on the DSB repair markers γH2AX, 53BP1 and Rad51. Cells were pre-treated 
with 1 μM ATRi or 10 μM DMSO as a control for 1 h and then were exposed to 4 Gy 
protons. The cells were then further incubated with the inhibitor up to 24 h to allow for 
DNA repair progression. Finally, cells were fixed and incubated with antibodies for 


















































5.3.2.1 Impact of ATRi on γH2AX 
γH2AX foci formation was not affected by ATRi alone in UMSCC47 yet was increased 
(1.6- fold above baseline) in UMSCC6 and UMSCC74A (Figure 5.14), suggesting a possible 
increase in baseline DSB levels.  Upon exposure to protons, γH2AX foci formation in 
DMSO treated cells peaked within 1 h post irradiation (5- to 7- fold) in all three cell lines. 
In ATRi treated and proton irradiated cells, 1 h post protons there was an almost 
negligible fluctuation within the standard error, in the number of γH2AX foci in all cell 
lines, whilst foci numbers were slightly down in UMSCC6 and UMSCC47 cells. Altogether, 
the impact of ATRi in γH2AX foci post protons was largely insignificant, confirming that 
ATR is not directly associated with γH2AX foci regulation. Arguably, there is a potential 
involvement for ATR in response to protons, also observed in response to x – rays (Figure 
5.5) in DSB designation by γH2AX in the HPV-positive UMSCC47 cells and HPV-negative 
UMSCC6 cells to a lesser extent. 
 
  
Figure 5. 14. Impact of ATRi on DSB marker γH2AX. γΗ2ΑΧ foci formation was 
investigated in 3 HNSCC cell lines. Cells were treated for 1 h with 1 μM ATRi or 10 μM 
DMSO, exposed to 4 Gy proton irradiation and fixed and stained for γH2AX 1 h post 
irradiation. NI: non irradiated. 5 representative images were captured, containing at 
least 20 cells per coverslip. Values were the means of 2 biologically independent 
experiments, were normalised against the non irradiated DMSO treated cells, which was 
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5.3.2.2 Impact ATRi on 53BP1 
Formation of 53BP1 foci in the presence of ATRi alone was minorly downregulated in 
the three cell lines, suggesting the ATRi alone did not have a significant impact on 
generation of 53BP1 foci and thus on the endogenous NHEJ repair (Figure 5.15), similar 
to Figure 5.6. Following proton irradiation in DMSO treated cells, the foci were formed 
within 1 h post irradiation in all cell lines peaking between 2.3- and 3.4- fold above 
baseline. Following a combination of ATRi treatment and proton irradiation, a minor 
fluctuation within the standard error in the number of 53BP1 foci was exhibited 1 h post 
irradiation in UMSCC6 and UMSCC74A cells. However, in UMSCC47 cells, 53BP1 foci 
formation were upregulated, by a factor of ~1.4, in inhibitor treated cells 1 h post 
protons, demonstrating increased NHEJ repair in this HPV-positive cell line, which was 
not observed following x – rays. This further demonstrated a potentially increased role 
of ATR in DSB designation and therefore repair in UMSCC47 HPV-positive cells, also 
shown with γH2AX (discussed in section 5.3.2.1).   
  
  
Figure 5. 15. Impact of ATRi on DSB repair marker 53BP1. 53BP1 foci formation was 
investigated in 3 HNSCC cell lines. Cells were treated for 1 h with 1 μM ATRi or 10 μM 
DMSO, exposed to 4 Gy proton irradiation and fixed and stained for 53BP1 1 h post 
irradiation. NI: non irradiated. 5 representative images were captured, containing at 
least 20 cells per coverslip. Values were the means of 2 biologically independent 
experiments, were normalised against the non irradiated DMSO treated cells, which was 


















































5.3.2.3 Impact of ATRi on Rad51 
Rad51 foci formation was shown to be increased in ATRi treated non irradiated cells, 
compared to DMSO treated non irradiated cells in UMSCC6 and UMSCC74A (Figure 5.16) 
suggesting increased HR repair possibly due to increased amount of endogenously 
generated DSBs. Exposing DMSO treated cells to protons resulted in Rad51 foci peak at 
16 h, which was 3- to 4.3- fold above baseline, in all cell lines. Following protons and 
ATRi treatment a considerable reduction in the amount of Rad51 foci was observed at 
16 h post irradiation. Specifically, the number of foci was reduced by 1.7-, 4.8-, and 2.1- 
fold in UMSCC6, UMSCC74A, and UMSCC47 respectively. The dysregulation of Rad51 




Figure 5. 16. Impact of ATRi on DSB repair marker Rad51. Rad51 foci formation was 
investigated in 3 HNSCC cell lines. Cells were treated for 1 h with 1 μM ATRi or 10 μM 
DMSO, exposed to 4 Gy proton irradiation and fixed and stained for Rad51 16 h post 
irradiation. NI: non irradiated. 5 representative images were captured, containing at 
least 20 cells per coverslip. Values were the means of 2 biologically independent 
experiments, were normalised against the non irradiated DMSO treated cells, which was 




















































5.3.3 Impact of DNA-PKcsi 
The impact of the third inhibitor, DNA-PKcsi, alone or in combination with protons was 
then examined in the DSB repair markers, in UMSCC6, UMSCC74A and UMSCC47 HNSCC 
cell lines. Cells were pre-treated with 1 μM DNA-PKcsi or 10 μM DMSO as control for 1 
h and then were exposed to 4 Gy protons. The cells were then further incubated with 
the inhibitor up to 24 h to allow for DNA repair progression. Finally, cells were fixed and 
incubated with antibodies for γH2AX, 53BP1 or Rad51, then were imaged and analysed.   
5.3.3.1 Impact of DNA-PKcsi on γH2AX 
Formation of γH2AX foci was not impacted by DNA-PKcsi treatment alone in the absence 
of proton irradiation as shown in Figure 5.17 and Figure 5.8. In DMSO treated cells, 
γH2AX foci formation reached ~4- fold above baseline at 4 h post proton irradiation, and 
the foci were gradually reduced in all three cell lines 4 h later. However, DNA-PKcsi 
treated cells exhibited an upregulation and increased persistency in γH2AX foci 4 h and 
8 h post proton irradiation. Specifically, the numbers of γH2AX foci were higher by ~1.1- 
to 1.3- fold in UMSCC6 cells, ~1.4-to 1.9- fold in IUMSCC74A cells, and ~1.5- to 1.4- fold 
in UMSCC47 cells, at 4h and 8h respectively. This demonstrated the persistency of 
unrepaired DSB up to 8 h post irradiation, indicating insufficient NHEJ repair in response 




Figure 5. 17. Impact of DNA-PKcsi on DSB marker γH2AX. γΗ2ΑΧ foci formation was 
investigated in 3 HNSCC cell lines. Cells were treated for 1 h with 1 μM DNA-PKcsi or 10 
μM DMSO, exposed to 4 Gy proton irradiation and fixed and stained for γH2AX 4 h and 
8 h post irradiation. NI: non irradiated. 5 representative images were captured, 
containing at least 20 cells per coverslip. Values were the means of 2 biologically 
independent experiments, were normalised against the non irradiated DMSO treated 
cells, which was set to 1, and are presented with their standard error. 
 
5.3.3.2 Impact of DNA-PKcsi on 53BP1 
Formation of 53BP1 foci exhibited a marked decrease in DNA-PKcsi treated cells, in the 
absence of proton irradiation, particularly in UMSCC6 and UMSCC74A cells (Figure 5.18) 
which was 1.5- and 1.7- fold below baseline respectively, suggesting that monotherapy 
reduced the sites of 53BP1 recruitment for the repair of endogenous DSB repair via 
NHEJ. Following proton irradiation, in DMSO treated cells the number of 53BP1 foci was 
increased between 2- to 2.7- fold above baseline 4 h and persisted up to 8 h post 
protons, also observed following x – rays. In DNA-PKcsi treated cells, the number of 
53BP1 foci was further increased at 4 h post irradiation, by a factor of ~1.5 in UMSCC6 
cells, ~1.2 in UMSCC74A cells, and ~1.4 in UMSCC47 cells. This matched the γH2AX trend, 
further demonstrating that DNA-PKcsi and protons increased DSB persistence. The 















































remained above baseline in UMSCC6 and UMSCC74A, despite the persistent DSBs 
highlighted by the increased γH2AX foci (Figure 5.17). This suggested reduced 53BP1 
recruitment at later time points following proton irradiation. 
 
  
Figure 5. 18. Impact of DNA-PKcsi on DSB repair marker 53BP1. 53BP1 foci formation 
was investigated in 3 HNSCC cell lines. Cells were treated for 1 h with 1 μM DNA-PKcsi or 
10 μM DMSO, exposed to 4 Gy proton irradiation and fixed and stained for 53BP1 4 h 
and 8 h post irradiation. NI: non irradiated. Values were the means of 2 biologically 
independent experiments, were normalised against the non irradiated DMSO treated 
cells, which was set to 1, and are presented with their standard error. 
 
5.3.3.3 Impact of DNA-PKcsi on Rad51 
The number of Rad51 foci did not differ in DMSO treated cells and DNA-PKcsi treated 
cells in the absence of protons as seen in Figure 5.19 and Figure 5.10. After exposure to 
proton irradiation, Rad51 foci in DMSO treated cells peaked at 16 h (3- to 4.3- fold above 
baseline) in all cell lines, and were considerably reduced by 24 h post irradiation in 
UMSCC6 and UMSCC7A. However, foci appeared to persist for longer in UMSCC47 cells 
indicating increased HR dependence at the 24 h time point, which was not observed 
post x – rays. Combination of DNA-PKcsi and protons considerably reduced Rad51 foci 


















































UMSCC6 cells, and ~2 in UMSCC74A cells. Less of an effect was produced by DNA-PKcsi 
and protons in the HPV-positive UMSCC47 cells, which exhibited a reduction in Rad51 
foci by ~1.2 fold compared to DMSO treated cells. At 24 h post irradiation the difference 
between DMSO and DNA-PKcsi treated cells was diminished. This suggested that DNA-
PKcsi suppressed Rad51 recruitment post proton irradiation at 16 h, although the 




Figure 5. 19.  Impact of DNA-PKcsi on DSB repair marker Rad51. Rad51 foci formation 
was investigated in 3 HNSCC cell lines. Cells were treated for 1 h with 1 μM DNA-PKcsi or 
10 μM DMSO, exposed to 4 Gy proton irradiation and fixed and stained for Rad51 16 h 
and 24 h post irradiation. NI: non irradiated. Values were the means of 2 biologically 
independent experiments, were normalised against the non irradiated DMSO treated 























































5.4 Conclusions  
The DNA repair inhibitors that effectively reduced phosphorylation in crucial sites of 
their target proteins, as observed by Immunoblotting (see Chapter 4), were then utilised 
to investigate the outcome of this inhibition in the signalling of the DNA damage 
response and DSB repair. Particularly, the impact of ATMi, ATRi and DNA-PKcsi on DNA 
repair focus formation was examined in HNSCC cell lines, as a monotherapy but also in 
combination with either x – ray or proton irradiation. In order of appearance, γH2AX foci 
are one of the first to be formed, as a marker of DSB recognition. In response to IR alone, 
they are reported to pick within 30 – 60 minutes post irradiation and then gradually 
drop, although DSB are shown to pick shortly after exposure to IR and then gradually 
drop depending on the repair proficiency of the cells. 53BP1 foci are formed almost 
simultaneously and have very similar kinetics to γH2AX and were studied as a marker of 
DSB repair via the NHEJ pathway (207, 235). Lastly, Rad51 foci were assessed as a marker 
of DSB repair via the HR pathway and they are reported to pick later approximately 12 
h post exposure to IR and then gradually to be resolved (236).  
In the absence of IR, HNSCC cells were incubated with either of the drug for 24 h before 
been fixed and analysed. ATMi had generally no major impact on formation of γH2AX 
and 53BP1 foci, while resulted in only a small increase in Rad51 foci, specifically in 
UMSCC6 cells. This constituted an indication that 24 h treatment with the inhibitor 
alone, in the absence of IR, did not severely affect normal DSB recognition and repair. 
Although the small increase in Rad51 foci in the radioresistant UMSCC6 cells, could 
indicate a respective increase in the amounts of DSBs accumulating later in the cell cycle. 
ATRi, as a monotherapy, had no major effect on the formation of 53BP1 foci, yet had a 
small upregulating effect on γH2AX and Rad51 foci accumulation in HPV-negative 
UMSCC6 cells, as shown in both data sets, and UMSCC74A cells as shown in the proton 
data set. Increased levels of γH2AX could indicate that the drug alone promoted DSB 
recognition or DSB induction something that was also supported by the upregulated 
levels of Rad51 showing increased amounts of DSBs undergoing HR repair. However, the 
apparent lack of impact on 53BP1 recruitment (NHEJ repair marker) was an indicator 
that these endogenous DSBs accumulated later in the cell cycle and were resolved 
mainly by Rad51 recruitment via the HR pathway.  In contrast, treatment with DNA-PKcsi 
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alone, resulted in no difference in γH2AX and Rad51 foci formation, but downregulated 
53BP1 foci in all cell lines. This suggested no impact on DSB induction or recognition by 
DNA-PKcsi alone, but only a reduction in repair of endogenous DSB via NHEJ pathway.  
Combination therapy of ATMi and IR generally resulted in a delay in γH2AX foci 
formation in all cell lines examined (summarised in Table 5.1). The same trend was 
observed in both x – ray irradiated and proton irradiated cells demonstrating that the 
drug was equally effective following both radiation modalities. The delayed DSB 
recognition should therefore predictably lead to delayed DSB repair, which was 
investigated via the 53BP1 and Rad51 foci formation. Indeed, reduced numbers of 
53BP1 foci following x – ray irradiation in all cell lines, suggested reduced NHEJ repair in 
the early time points. Interestingly, however, this was not observed following proton 
irradiation. In fact, NHEJ repair as shown by 53BP1 foci, was not delayed but instead 
exhibited increased foci numbers in the later time points in all cell lines, indicating 
persistent DSB. Therefore, the drug appeared to have an impact on the progression 
rather than the initiation of NHEJ repair, in combination with protons. Next, Rad51 foci 
was examined and found to be downregulated by ATMi, at 16 h post irradiation in all 
cell lines, either exposed to x – rays or protons, demonstrating reduced HR activity. 
Table 5. 1.  Impact of ATMi treatment on γH2AX, 53BP1, and Rad51 foci formation and 
persistence alone (NI), or in combination with x – rays or protons. NI: non irradiated; 24 
h: time of drug treatment alone, 1 h, 8 h, and 16 h: time post irradiation; ↑: upregulated, 
↓: downregulated, -: no impact. 
 γH2AX 53BP1  Rad51  
NI x – rays protons NI x – rays protons NI x – rays protons 
24h 1h 1h 24h 1h 8h 1h 8h 24h 16h 16h 
UMSCC6 ↑ ↓ ↓ - ↓ - - ↑ ↑ ↓ ↓ 
UMSCC74 ↑ ↓ ↓ ↓ ↓ - - ↑ - ↓ ↓ 
UMSCC47 - ↓ ↓ - ↓ - - ↑ - ↓ ↓ 
 
The impact of ATRi in combination with IR, was altogether not important on impacting 
on γH2AX foci formation and therefore in DSB induction or recognition (summarised in 





in most cell lines, could constitute evidence of ATR involvement in the initiation of the 
DDR. Equally, 53BP1 foci formation was not majorly affected in the presence of ATRi and 
x – rays or protons, confirming that ATR is not associated or affecting NHEJ repair. In 
contrast, ATR is directly involved in HR repair, and indeed treatment with ATRi and IR 
had a detrimental effect on Rad51 foci formation, and therefore HR activity in all cell 
lines, particularly at the later time points post irradiation. Overall, inhibition of either 
ATM or ATR was found sufficient to almost completely block Rad51 foci formation 
suggesting that one cannot be adequately substituted by the other and that they work 
synergistically rather than competitively.   Generally, no difference was exhibited in all 
foci measured between x – ray and proton induced DNA damage, indicating that the 
drug affected the DNA repair factors in a similar manner in response to the two radiation 
modalities. 
Table 5. 2. Impact of ATRi treatment on γH2AX, 53BP1, and Rad51 foci formation and 
persistence alone (NI), or in combination with x – rays or protons. NI: non irradiated; 24 
h: time of drug treatment alone, 1 h, 8 h, and 16 h: time post irradiation; ↑: upregulated 
↓: downregulated, -: no impact.  
 γH2AX 53BP1 Rad51 
NI x – rays protons NI x – rays protons NI x – rays protons 
24h 1h 1h 24h 1h 1h 24h 16h 16h 
UMSCC6 ↑ ↓ - ↓ - - ↑ ↓ ↓ 
UMSCC74 ↑ - - - - - ↑ ↓ ↓ 
UMSCC47 - ↓ ↓ - ↓ ↑ - ↓ ↓ 
 
Treatment with DNA-PKcsi in combination with either x – rays or proton irradiation, was 
not found to regulate γH2AX foci in the early time points, yet the increased persistency 
in the later time points indicated persistent unrepaired DSB damage, most likely due to 
inefficient NHEJ repair (summarised in Table 5.3). This was supported by the 53BP1 foci 
formation, which were increased at 4 h and particularly at 8 h post x – ray irradiation, 
highlighting persistent DSBs and ongoing NHEJ. However, the increased persistency of 
53BP1 foci was more important at 4 h post proton irradiation and DNA-PKcsi treatment 
but was almost reduced to baseline at 8 h. This could be further evidence that protons 





suggested that possibly more cells are led to apoptosis in response to DNA-PKcsi and 
protons, as also suggested by the increased apoptosis observed by immunoblotting (see 
Chapter 4). Therefore, less cells are actively being repaired, hence the drop in 53BP1 foci 
at almost baseline levels. Lastly, the increase in Rad51 foci after DNA-PKcsi and x – ray 
treatment suggested that inhibition of NHEJ repair could potentially be substituted by 
increased HR repair of DSBs. Interestingly though, this was not observed following 
proton irradiation, where Rad51 foci were considerably reduced in the later time points 
following protons. This contradicting outcome between x – rays and protons could also 
be correlated to increased apoptosis following protons. 
Table 5. 3. Impact of DNA-PKcsi treatment on γH2AX, 53BP1, and Rad51 foci formation 
and persistence alone (NI), or in combination with x – rays or protons. NI: non irradiated; 
24 h: time of drug treatment alone, 1 h, 8 h, and 16 h: time post irradiation; ↑: 
upregulated, ↓: downregulated, -: no impact.  
 γH2AX  53BP1 Rad51 
NI x – rays protons NI x – rays protons NI x – rays protons 
24h 4h/8h 4h/8h 24h 4h 8h 4h 8h 24h 16h 24h 16h 24h 
UMSCC6 - ↑ ↑ ↓ - ↑ ↑ - - ↑ ↑ ↓ - 
UMSCC74 - ↑ ↑ ↓ - ↑ ↑ - ↓ ↑ ↑ ↓ - 
UMSCC47 - ↑ ↑ - - ↑ ↑ - ↓ - ↑ ↓ - 
 
In conclusion, the three inhibitors were shown to impact the DNA damage response to 
DSB in HNSCC cells, in combination with x – rays as well as protons, constituting evidence 
that the inhibitors are functional and should therefore impact on cell survival. It is worth 
noting that despite some small cell line dependence on the inhibitor effectiveness, there 
was no evidence that this differed based on HPV status. Nevertheless, some scoring 
issues should be noted as this affected the reproducibility of the independent 
experiments. One of the main issues was resolving of overlapping foci that were scored 
as a single focus particularly due to the high IR dose received by the cells, chosen mainly 
for consistency with previous work in the Parsons group. More detailed analysis was 
necessary to estimate the overall impact of the protein kinase inhibitors and to 





Chapter 6: Results III 
Impact of the DNA repair inhibitors on cell survival 
6.1 Introduction 
In the previous Chapters 4 and 5, I demonstrated that inhibition of the three protein 
kinases directly involved in DDR, ATM, ATR and DNA-PKcs, was found to supress their 
phosphorylation on critical sites that regulate DNA repair progression. Moreover, this 
was shown to delay or even restrain DSB repair via NHEJ and HR repair pathways, as 
demonstrated using immunofluorescence staining. In this chapter, the impact on cell 
proliferation and survival of the three potent and well established inhibitors was 
examined in HNSCC cell lines, as a monotherapy as well as a combination therapy with 
x – ray or proton irradiation.  
First, colony formation assays were utilised to investigate the ability of single cells 
treated with the inhibitor alone or in combination with IR, to grow into colonies of at 
least 50 cells in vitro. Clonogenic assays are the gold standard for measuring cell 
sensitivity to DNA damaging agents, particularly IR. Therefore, this is an essential tool to 
examine cell proliferation and subsequently cell death in 2D monolayer cultures. A 
defined number of cells was seeded, treated and allowed to grow in order to calculate 
their surviving fractions (SF), a variable that described the percentage of cell survival 
(237), and thus indicated the efficacy of the treatment when compared against 
untreated cells.  
Second, 3D spheroid growth assays were utilised, which more accurately reflect the 
complex and heterogenous structure as well as the environment of the original tumour, 
including physiological tissue-like morphology and close cell – cell contacts. Spheroids 
constituted of layers of cells with different nutrient and oxygen supplies, that resulted 
in uneven drug penetration and therefore diverse response and resistance to the given 
treatment that better mimic the tumour behaviour, compared to 2D cultures where 
exponential proliferation is dominant (238).  In this technique cells were left to form 
microscopic spheres approximately 200 μm in diameter, that grew in suspension and 
not attached in culture plastic, before treatment with the inhibitor alone or in 
combination with IR. Spheroid volume increase in response to a given treatment 
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compared against the volume increase in the untreated spheroids was determined using 
microscopy and image analysis, to investigate the inhibitors impact on cell growth but 
also on radiosensitisation of HNSCC 3D spheroids. 
6.2 Impact of the DNA repair inhibitors as a monotherapy in 2D 
Given the inhibitors affected the DDR in HNSCC cells in the absence of IR, as illustrated 
by some differences in the number of DNA repair foci observed in Chapter 5, the impact 
of the drug alone on cell survival was firstly assessed via colony formation assays.  
Comparison of cell survival was performed in 4 HNSCC cell lines, the HPV-negative 
UMSCC6 and UMSCC74A, and the HPV-positive UMSCC47 and UPCI-SCC090 in the 
presence of DSB repair inhibitors. Single cells were treated for 24 h with either of the 
drug or DMSO and left to grow colonies before been fixed and counted. It should be 
noted that due to cell dependent growth rate, different variables were introduced for 
each cell lines, including the number of cells seeded, the growing period, and the colony 
size. However, colony counting settings (using the GelCount colony counter) were 
optimised for each cell line and the same settings used across the various treatments 
for consistency.  Plating efficiencies (PE), the ratio of the number of colonies over the 
number of cells seeded, were ~10 % for UMSCC6, UMSCC74A and UMSCC47 and ~2 % 
for UPCI-SCC090. 
Analysis of cell survival, as illustrated in Figure 6.1, showed that ATMi (10 μM) 
significantly reduced survival in 3 HNSCC cell lines, UMSCC6, UMSCC74A and UMSCC47, 
between 25 % to 45 % Interestingly, no difference was observed in the 4th cell line 
examined, UPCI-SCC090. Next, ATRi had the most detrimental effect on cell survival 
among the three drugs. Indeed, ATRi considerably reduced colony formation in all cell 
lines by 40% to 65 %. Finally, DNA-PKcsi significantly downregulated cell survival in only 
one cell line, the HPV-positive UMSCC47 by 60 %, while also reduced survival in the HPV-
negative UMSCC6 by 23 %, although this result was not statistically significant (p>0.05 
as analysed by one sample t-test). Therefore, DNA-PKcsi as a monotherapy appears to 




Figure 6. 1. Impact of DNA repair inhibitors on cell survival as a monotherapy. Clonogenic 
survival assays were utilised in 4 HNSCC cell lines. Cells were treated for 24 h with 10μM 
ATMi, 1μM ATRi, 1 μM DNA-PKcsi or 10 μM DMSO as controls. Survival was analysed 
from six biologically independent experiments and values were normalised against the 
DMSO treated control (blue bar) which was set to 100 %. * p<0.02, **p<0.01, 
***p<0.005, ****p<0.0001 as analysed by a one sample t-test. 
 
6.3 Impact of IR on cell survival in 2D 
It has been previously demonstrated that there is increased radiosensitivity of cells 
derived from HPV-positive HNSCC in comparison to HPV-negative HNSCC, which 
reproduces the effects observed following radiotherapy treatment of the respective 
tumours (168, 206, 207).  Therefore, the comparative radiosensitivity between 4 HNSCC 
cell lines, HPV-negative UMSCC6 and UMSCC74A, and HPV-positive UMSCC47 and UPCI-
SCC090, was investigated in response to increasing dose of x – ray and proton 
irradiation. Single cells were exposed to IR and left to grow in colonies before been fixed 
and counted.  
6.3.1 Comparative radiosensitivity in response to x – rays. 
 Cells were exposed to 0 – 3 Gy x – rays, and survival was observed to be exponentially 
decreasing with increasing radiation dose. However, the intrinsic radiosensitivity of each 
cell line, related to their ability to efficiently repair their DNA damage and survive, 
resulted in varying surviving fractions (SF) (Figure 6.2). Indeed, the by clonogenic assays 
data reproduced the difference in radiosensitivity expected between the two HPV-
positive and the two HPV-negative HNSCC cell lines, in response to x – ray irradiation. 
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Therefore, the HPV-positive UPCI-SCC090 cells were the most radiosensitive, exhibiting 
the lowest survival from 1 Gy x – rays, followed by the second HPV-positive cell line, 
UMSCC47, that exhibited reduced survival from 2 Gy compared to the two HPV-negative 




Figure 6. 2.  Impact of x – ray irradiation on cell survival. A. Clonogenic survival assays in 
response to increasing dose of x – ray irradiation in 4 HNSCC cell lines. Values were 
analysed from three biologically independent experiments and normalised against the 0 
Gy of each cell line, which was set to 1. Statistical analysis using one sample t-test of SF 
rays reveals significant differences of: UMSCC6 vs UPCI-SCC090 p<0.002 at 1 Gy, p<0.03 
at 2 Gy and p<0.004 at 3 Gy x-rays. UMSCC74A vs UPCI-SCC090 p<0.00003 at 1 Gy, 
p<0.005 at 2 Gy and p<0.02 at 3 Gy x-rays. UMSCC6 vs UMSCC47 p<0.01 at 3 Gy x-rays. 
UMSCC74A vs UMSCC47 p<0.03 at 3 Gy x-rays. B. Representative images of colony 
formation in cells treated with 0 Gy (control), 2 Gy and 3 Gy x – rays. The irradiated dishes 
contained 4x and 8x more cells, for 2 Gy and 3 Gy, to account for plating efficiencies. 
 
6.3.2 Comparative radiosensitivity in response to protons. 
Cells were exposed to 0 – 6 Gy protons, and in fact these exhibited a very similar trend 
























dose, confirming that intrinsic radiosensitivity related to ability to repair proton induced 
DNA damage was proportional with radiation dose. This resulted in varying surviving 
fractions, shown in Figure 6.3, highlighting their individual radiosensitivity in response 
to protons.  
 
 
        
Figure 6. 3. Impact of proton irradiation on cell survival. A. Clonogenic survival assays in 
response to increasing dose of proton irradiation in 4 HNSCC cell lines. Values were analysed 
from four biologically independent experiments and were normalised against the 0 Gy of 
each cell line, which was set to 1. Statistical analysis using one sample t-test of SF reveals 
significant differences of: UMSCC6 vs UPCI-SCC090 p<0.002 at 2 Gy and p<0.04 at 4 Gy 
protons. UMSCC6 vs UMSCC47 p<0.01 at 2 Gy. UMSCC74A vs UPCI-SCC090 p<0.01 at 2 Gy 
and p<0.04 at 4 Gy protons. B. Representative images of colony formation in cells treated 
with 0 Gy (control), 2 Gy and 3 Gy x – rays. The irradiated dishes contained 4x and 8x more 
cells, for 4 Gy and 6 Gy respectively, to account for plating efficiencies. 
 
The data reproduced the difference in radiosensitivity expected between the two HPV-
positive and the two HPV-negative HNSCC cell lines, in response to proton irradiation by 
























proton irradiation, exhibiting the lowest survival from 2 Gy protons, followed by the 
second HPV-positive cell line, UMSCC47, that exhibited reduced survival from 4 Gy, 
compared to the two HPV-negative cell lines. Next in radiosensitivity was the UMSCC74A 
cells, closely followed by UMSCC6. No major differences were observed in the relative 
response of cells the various inhibitors with protons compared to the response to x – 
rays. It is worth noting that cells were positioned in the entrance of the pristine beam of 
high energy – low LET protons were dosimetry was performed. 
 
6.4 Impact of DNA repair inhibitors on 2D cell survival in combination with IR. 
Cell survival was then studied via colony formation assays in 4 HNSCC cell lines, UMSCC6, 
UMSSC74A, UMSCC47 and UPCI-SCC090, following combination treatment of DNA 
repair inhibitors and IR. Their variable endogenous radiosensitivity, provided the 
opportunity to study the impact of the drugs in cells with different DDR capabilities, that 
were more representative of the HNSCC group. Cells were pre-treated with 10μM ATMi, 
1μM ATRi, 1 μM DNA-PKcsi or 10 μM DMSO for 1 h before and for 24 h after exposure 
to increasing doses of x – ray or proton irradiation. Cell were then left to grow in 
colonies, fixed and counted. 
6.4.1 X- rays  
Firstly, survival and proliferation were examined in HNSCC cells treated with ATMi, ATRi, 
or DNA-PKcsi following exposure to x – rays. As seen in Figure 6.4, the three DSB repair 
inhibitors had a dramatic impact on reducing cell survival in UMSCC6, UMSCC74A and 
UMSCC47, even from the lowest radiation dose of 1 Gy, compared to the survival 
observed in DMSO treated cells. Survival was further reduced following 2 Gy of radiation 
in all cell lines, where p values of two sample t-test were from <0.04 to <0.001 (Table 
6.1). The difference was limited following 3 Gy irradiation particularly in the radio 
sensitive UMSCC47 cell line, due to the effect of radiation alone (Figure 6.4 C), but also 
a tailing was observed in UMSCC74A and UMSCC47 in the inhibitor treated cells as 
colony formation was already extremely low. In the most radiosensitive cell line, UPCI-
SCC090, two of the drugs, ATMi and DNA-PKcsi, significantly reduced survival, 
particularly following 2 Gy x – rays (Figure 6.4 D). However, ATRi was not suppressing 
149 
 
colony formation in these cells compared to DMSO. Interestingly, whilst ATRi was the 
most effective drug as a monotherapy, in all cell lines, but these findings indicated that 
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Figure 6. 4. Impact of DSB inhibitors in combination with x – rays on cell survival. 
Comparative surviving fraction were analysed following treatment with increasing dose 
of x – rays in 4 HNSCC cell lines, from three biologically independent experiments and are 
presented along with representative images A. UMSCC6; B. UMSCC74A; C. UMSCC47; D. 
UPCI-SCC090. Cells were treated with 10μM ATMi, 1μM ATRi, 1 μM DNA-PKcsi or 10 μM 
DMSO for 1 h before and for 24 h after irradiation with 0 – 3 Gy x – rays. The irradiated 
dishes contained 2x 4x and 8x times more cells, to account for PE with increasing 
radiation dose. Values were normalised against the 0 Gy of each treatment, which was 
set to 1. Statistical analysis using a two sample t-test of surviving fractions at a 2 Gy dose 
of x – rays revealed significant differences between DMSO and each drug summarised in 
Table 6.1. 
 
Table 6. 1.   Inhibition of ATM, ATR and DNA-PKcs decreases HNSCC cell survival in 
response to x - rays irradiation 
Inhibitor UMSCC6 UMSCC74A UMSCC47 UPCI-SCC090 
ATM p<0.03 p<0.003 p<0.03 p<0.02 
ATR p<0.04 p<0.001 p<0.03 p=0.06 
DNA-Pkcs p<0.03 p<0.001 p<0.02 p<0.003 
Statistical analysis performed using a two sample t-test of surviving fractions at 2 Gy 
dose of x-rays 
Dose enhancement ratios (DER) were calculated, to describe the comparative radiation 
dose required to achieve a certain biological damage in DMSO treated cells, versus drug 
treated cells. The values summarised in Table 6.2, were calculated at D50, the dose 
required for 50 % reduction in survival. Higher values were exhibited in HPV-negative 
HNSCC cell lines, UMSCC6 and UMSCC74A, with DER varying between 1.91 and 2.39, in 

















DMSO ATMi ATRi DNA-PKcsi
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Control 2 Gy 
2 Gy+ATMi 2 Gy+ATRi 2 Gy+DNA-PKcsi 
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SCC090 (1.02 – 1.36). This indicates that radiosensitisation was more effective in the 
HPV-negative HNSCC cell lines, which are relatively radioresistant compared to their 
HPV-positive counterparts. 
Among the three inhibitors, DNA-PKcsi appeared to be the most prominent in cell killing 
in response to x – rays, reducing the radiation dose required by 2.39- fold in UMSCC74A, 
1.93- fold in UMSCC6, 1.69- fold in UMSCC47 and 1.36- fold to UPCI-SCC090. Given the 
role of DNA-PKcsi in NHEJ repair, these findings demonstrated the predominant role of 
NHEJ repair in response to DSBs induced by x – ray irradiation, irrespective of the HPV 
status. ATMi and ATRi resulted in comparable DERs, reducing the radiation dose 
required for 50 % survival in DMSO treated cells by approximately 2- fold, in the HPV-
negative cells, by 1.37 fold in UMSCC47, but had minimal impact in UPCI-SCC090. This 
suggested that ATM and ATR might already have a relatively reduced role in regulating 
DSB repair in HPV-positive cell lines resulting in their increased radiosensitivity, and thus 
the drug could not further enhance this response.     
Table 6. 2. Dose enhancement ratios calculated at 50 % cell survival (DER) following ATM, 
ATR and DNA-PKcs inhibition versus DMSO controls in HNSCC cells in response to x- rays.  
Inhibitor UMSCC6 UMSCC74A UMSCC47 UPCI-SCC090 
ATMi 2.06 1.91 1.38 1.15 
ATRi 1.91 2.01 1.36 1.02 
DNA-PKcsi 1.93 2.39 1.69 1.36 
 
6.4.2 Protons  
Similarly, survival and proliferation of HNSCC cells in response to proton irradiation, was 
examined in ATMi, ATRi, or DNA-PKcsi treated cells, and compared against DMSO 
treated cells. Irradiation of up to 6 Gy low LET protons (at entrance dose) was utilised, 
in order to obtain equivalent response to x – rays induced DNA damage. The DSB repair 
inhibitors considerably reduced cell survival in response to protons, but radiosensitised 
each of the four HNSCC cell lines to a different extend, as illustrated in Figure 6.5. The 
drugs, particularly ATMi and DNA-PKcsi, reduced cell survival from 2 Gy of radiation in 
all cell lines. Then the survival was further reduced at 4 Gy, where two sample t-test p 
values indicated significance in three of the four cell lines, UMSCC6, UMSCC74A and 
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UMSCC47, varying between <0.05 and <0.0004, summarised in Table 6.3, except for ATRi 
in UMSCC6 cells which was not significant (p = 0.2). However, the difference in survival 
between DMSO and inhibitor treated cells did not change much at 6 Gy, due to 
significant cell killing by proton irradiation alone, which was observed in all cell lines. In 
UPCI-SCC090 cells, although all inhibitors appeared to radiosensitise the cells compared 
to DMSO, the results were not statistically significant with p values ≥0.4 (Table 6.3). This 
showed, again, that these cells are the most radiosensitive of all those tested. Again, 
some tailing was observed at the higher proton doses, particularly in UMSCC74A and 
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Figure 6. 5. Impact of DSB inhibitors in combination with protons on cell survival. 
Comparative surviving fraction were analysed following treatment with increasing dose 
of protons in 4 HNSCC cell lines, from four biologically independent experiments and are 
presented along with representative images A. UMSCC6; B. UMSCC74A; C. UMSCC47; D. 
UPCI-SCC090. Cells were treated with 10μM ATMi, 1μM ATRi, 1 μM DNA-PKcsi or 10 μM 
DMSO for 1 h before and for 24 h after irradiation with 0 – 6 Gy protons. The irradiated 
dishes contained 2x 4x and 8x times more cells, to account for PE with increasing 
radiation dose. Values were normalised against the 0 Gy of each treatment, which was 
set to 1. Statistical analysis using a two-sample t-test of surviving fractions at a 4 Gy dose 
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Table 6. 3.  Inhibition of ATM, ATR and DNA-PKcs decreases HNSCC cell survival in 
response to proton irradiation. 
Inhibitor UMSCC6 UMSCC74A UMSCC47 UPCI-SCC090 
ATM p<0.05 p<0.02 p<0.0004 p=0.6 
ATR p=0.2 p<0.02 p<0.02 p=0.4 
DNA-PKcs p<0.03 p<0.05 p<0.05 p=0.4 
Statistical analysis performed using a two sample t-test of surviving fractions at 4 Gy dose 
of protons. 
 
Dose enhancement ratios were calculated in response to protons at the D50, the dose 
required for 50 % reduction in survival in DMSO versus inhibitor treated cells, and are 
summarised in Table 6.4. Cumulatively, DER values were reduced in response to protons, 
demonstrating relatively lower impact of the drug in combination with protons in 
comparison to photons possibly due to the smaller difference between the numerator 
and denominator of the ratio following protons. Similarly to x – rays, HPV-negative 
HNSCC cell lines, UMSCC6 and UMSCC74A, exhibited higher DERs than HPV-positive 
cells, UMSCC47 and UPCI-SCC090, yet the difference was not as dramatic following 
protons. This was due to increased cell killing by proton irradiation alone compared to x 
– rays.  
Comparing the three inhibitors, DNA-PKcsi was the most effective in downregulating cell 
survival in response to protons, in all cell lines expect UMSCC47, where it was similar to 
the impact of ATMi. The DERs that expressed the radiation dose required for 50 % 
survival in DNA-PKcsi treated cell was lower than that required in DMSO treated cells by 
2.01- fold in UMSCC6, 1.64- fold in UMSCC74, 1.38- fold in UMSCC47 and 1.32- fold in 
UPCI-SCC090. Next in effectiveness of increasing radiosensitivity was ATMi, where DERs 
were between 1.62 to 1.25. Interestingly, ATRi was the least effective of the three 
inhibitors, with DERs revealing radiation dose reduction by 1.42- to 1.25- fold in ATRi 
compared to DMSO treated cells. These findings, nevertheless, demonstrated that DNA-
PKcsi was the most prominent inhibitor in combination with protons, as was in 
combination with x – rays, indicating that NHEJ repair is the predominant mechanism 




Table 6. 4.  Dose enhancement ratios calculated at 50 % cell survival (DER) following 
ATM, ATR and DNA-Pkcs inhibition versus DMSO controls in HNSCC cells in response to 
protons. 
Inhibitor UMSCC6 UMSCC74A UMSCC47 UPCI-SCC090 
ATM 1.62 1.52 1.49 1.24 
ATR 1.25 1.42 1.28 1.30 
DNA-Pkcs 2.01 1.64 1.38 1.32 
 
 
6.5 3D spheroid growth in HNSCC cell lines  
Growth of 3D spheroids, which better mimic the conditions and environment of the 
original tumour growth, were then analysed in HNSCC cell lines. Two HPV-negative, 
UMSCC6 and UMSCC74A, and two HPV-positive, UMSCC47 and UPCI-SCC090, HNSCC 
cell lines, originating from the oropharynx area, were utilised. Cells were left two days 
post seeding to form spheroids of ~200 μm in diameter and their growth was monitored 
for 15 days. At first, normal spheroid growth was monitored in response to IR without 
any inhibitor treatment, and representative images are shown in Figure 6.6. 
Unfortunately, the HPV-positive UMSCC47 cells, although forming nice symmetrical 
spheroids, these did not grow over the two-week monitoring period. There was also no 
impact in response to x – ray or proton irradiation. Therefore, an additional HPV-positive 
HNSCC cell line, also originating from the oropharynx area, was introduced, UPCI-
SCC154, although spheroids derived from these cells also did not grow majorly over the 
monitoring period neither the controls nor the irradiated spheroids (Figures 6.7 D and 
6.8 D). 
In the other 3 HNSCC lines, spheroid growth was inversely proportional to radiation 
dose, as seen in Figures 6.7 (x – rays) and 6.8 (protons). Specifically, UMSCC74A control 
spheroids exhibited a 7- fold increase in growth that peaked between Day 8 – 10, before 
been reduced by Day 15. X – ray irradiation mildly suppressed spheroid growth at 1 Gy, 
although this was more important following higher dose, 2-3 Gy (Figure 6.7 A). Following 
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proton irradiation, spheroid growth was also suppressed from 2 Gy but higher doses of 
4-6 Gy almost diminished spheroid development (Figure 6.8 A). UMSCC6 control 
spheroids grew into nice symmetric spheres, their volume increased by 5- to 6- fold, 
between Day 8 – 12 and then dropped. However, exposure to IR, x – rays or protons, 
reduced the spheroid growth as well as impacted on their shape, resulting in fuzzy edges 
and loss of integrity (Figure 6.6), particularly later in the monitoring period, indicating 
increased cell death. Spheroid growth was inversely proportional to the x – ray radiation 
dose (Figure 6.7 B) yet was severely decreased following proton doses of 4 – 6 Gy (Figure 
6.8 B). A comparative delay in growth was observed in UPCI-SCC090 control spheroids, 
that gradually increased from Day 5 – 12 and peaked at Day 15, exhibiting an 8- fold 
volume increase in the absence of IR. Exposure to IR had a detrimental effect on 
spheroid growth from the lowest radiation dose of 1 Gy x – rays (Figure 6.7 C) or 2 Gy 
protons (Figure 6.8 C), highlighting the enhanced radiosensitivity of this cell line. Overall, 
in HPV-negative cell lines, a higher radiation dose (2 Gy x – rays, 4 Gy protons) was 
required to achieve growth suppression similar to that observed in the HPV-positive cell 
line in response to 1 Gy x – rays or 2 Gy protons, highlighting their increased endogenous 
radioresistance. Further increase in radiation dose, up to 3 Gy x – rays or 6 Gy protons, 





Figure 6. 6. 3D spheroid formation and growth in HNSCC cell lines. Spheroid growth was 
monitored for 15 days post seeding in 5 HNSCC cell lines, 2 HPV-negative, UMSCC74A 
and UMSCC6, and 3 HPV-positive, UPCI-SCC090, UMSCC47, and UPCI-SCC154. On Day 3, 
spheroids were exposed to 1 - 3 Gy x – rays, 2 - 6 Gy protons while controls were not 
irradiated. Here are displayed representative images of non irradiated, 1 Gy x – ray and 









Figure 6. 7.  3D spheroid growth following x – ray irradiation in HNSCC cell lines. Spheroid 
growth was monitored for 15 days post seeding in HPV-negative UMSCC74A (A) and 
UMSCC6 (B) and HPV-positive UPCI-SCC090 (C), and UPCI-SCC154 (D) HNSCC spheroids. 
On Day 3, spheroids were exposed to 0 - 3 Gy x – rays. Values were analysed from three 
biologically independent experiments and normalised to Day 3 post seeding for each 
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Figure 6. 8.  3D spheroid growth following proton irradiation in HNSCC cell lines. Spheroid 
growth was monitored for 15 days post seeding in HPV-negative, UMSCC74A (A) and 
UMSCC6 (B), and HPV-positive UPCI-SCC090 (C) and UPCI-SCC154 (D) HNSCC spheroids. 
On Day 3, spheroids were exposed to 0 - 6 Gy protons. Values were analysed from three 
biologically independent experiments, were normalised to Day 3 post seeding for each 
condition that was set to 1, and are presented with their standard errors. 
 
Two additional HPV-negative HNSCC cell lines, FaDu and A253 originating from the 
hypopharynx and oral cavity respectively, were introduced, to broaden the 
radioresistant model. These radioresistant cells grew into spheroids, that were 50- fold 
(FaDu) and 20- fold (A253) bigger 15 days post seeding in the absence of IR or inhibitor 
treatment, and representative images are shown in Figure 6.9. Exposure to 1 Gy x – ray 
irradiation only partly suppressed growth in A253 spheroids, yet higher radiation dose, 
2 – 3 Gy sufficiently suppressed growth, Figure 6.10 A. Similarly, low dose of protons (2 
Gy) reduced A253 spheroid growth but it was only after 4 – 6 Gy that this was diminished 






















DMSO 0Gy DMSO 2 Gy























DMSO 0Gy DMSO 2 Gy























DMSO 0Gy DMSO 2 Gy























DMSO 0Gy DMSO 2 Gy




even after exposure to 3 Gy x – rays, and 4 Gy protons, Figure 6.10 B, D. The growth was 
only sufficiently suppressed following 6 Gy protons (Figure 6.10 D), highlighting the 
extreme tolerance of this cell line to IR, and particularly x – rays. 
 
 
Figure 6. 9.  3D spheroid formation and growth in HNSCC cell lines. Spheroid growth was 
monitored for 15 days post seeding in 2 HPV-negative HNSCC cell lines, FaDu and A253. 
On Day 3, spheroids were exposed to 1 - 3 Gy x – ray irradiation or 1 - 6 Gy proton 
irradiation while controls were left unirradiated. Here are displayed representative 
images of non irradiated, 1 Gy x – ray and 2 Gy proton irradiated spheroids on Day 3, 10 
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Figure 6. 10.  3D spheroid growth following x - rays or protons irradiation in HNSCC cells. 
Spheroid growth was monitored for 15 days post seeding in 2 HPV-negative HNSCC cell 
lines, FaDu and A253. On Day 3, spheroids were exposed to A - B) 0 - 3 Gy x- rays and C - 
D) 0-6 Gy protons. Values were analysed from three biologically independent 
experiments and normalised to Day 3 post seeding for each condition that was set to 1, 
and are presented with their standard errors. 
 
6.6 Impact of DNA repair inhibition on non irradiated 3D spheroid growth in 
HNSCC.  
The impact of three DSB repair inhibitors ATMi, ATRi and DNA-PKcsi on spheroid growth 
in HNSCC in the absence of IR, either x – rays or protons, was investigated both in HPV-
negative and HPV-positive cell lines, as a model that better represented in vivo tumour 
growth. Cells were left to form spheroids and on Day 3 post seeding these were treated 
with 10μM ATMi, 1 μM ATRi, 1 μM DNA-PKcsi or 10 μM DMSO for 24 h. Spheroid growth 
was then monitored for an extra 12-day period, equalling a 15-day growth period 
overall. Growth suppression ratio (GSR), a ratio that describes the volume of DMSO 
treated over the volume of drug treated spheroids across the 15- day monitoring period 
were utilised to compare the relative growth suppression by the inhibitors alone. Six 
HNSCC cell lines were utilised, the HPV-negative UMSCC74A, UMSCC6, A253 and FaDu 
cell lines, and the HPV-positive UPCI-SCC090 and UPCI-SCC154 cell lines (Figure 6.11). 
Unfortunately, UPCI-SCC154 spheroids did not grow sufficiently over the two-week 
monitoring period and therefore no significant difference could be observed between 
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In the majority of the HNSCC cell lines examined, treatment with ATMi alone did not 
significantly affect spheroid growth, which were similar in size to the DMSO treated 
spheroids, (Figure 6.11 and Tables 6.5, 6.6). Yet, growth suppression was exhibited in 
two HPV-negative non-irradiated spheroids treated with ATMi. UMSCC74A spheroids 
exhibited an GSR of 1.58, meaning a 1.58- fold growth suppression introduced by the 
drug alone (Figure 6.11 A) and this was statistically significant with a p value < 0.0002. 
This suppression by ATMi alone was equivalent to 2 Gy of x – ray irradiation. In A253, a 
similar 1.63- fold suppression in spheroid growth was induced by ATMi (however this 
was not statistically significant, p=0.49). This was an indication of increased dependence 
on ATM driven repair of endogenous DSBs on these particular cell lines.  
The impact of ATRi as a monotherapy was found to be the most important among the 
three DSB repair inhibitors where it was found to reduce spheroid growth in the 4 out 
of 6 cell lines examined in the absence of IR, Figure 6.11 and Tables 6.5 and 6.6, although 
this was statistically significant in 3 of them. ATRi suppressed growth on UMSCC74A and 
UMSCC6 spheroids, that exhibited GSRs 1.40 (p<0.003) and 1.50 (p<0.002) respectively 
(Figure 6.11 A, B). Moreover, ATRi inhibited and the HPV-positive UPCI-SCC090 by 1.45 
(p<0.006), Figure 6.11 E, and the HPV-negative A253 spheroid growth by 1.73- fold, 
although this was not statistically significant (Figure 6.11 D). The suppression by the drug 
alone was found to be equivalent or even greater than that induced by 1 Gy x – ray 
radiation. In contrast, growth of the radioresistant FaDu spheroids was not impaired by 
ATRi alone. 
DNA-PKcsi was then examined as a monotherapy, in HNSCC spheroids. This was found 
to be the least effective in reducing spheroid growth in the absence of IR, compared to 
ATM and ATR inhibition. As illustrated in Figure 6.11, DNA-PKcsi alone did not impact 
growth on UMSCC74A, UMSCC6, FaDu and UPCI-SCC090 spheroids, in fact these HNSCC 
cell lines exhibited GSR values around 1 which indicates equivalent volume between 
DMSO versus DNA-PKcsi treated spheroids throughout the two week monitoring period. 
Nevertheless, DNA-PKcsi moderately reduced spheroid volume on A253 with a GSR of 







Figure 6. 11. 3D spheroid growth following DSB repair inhibition in HNSCC cells. Spheroid 
growth was monitored for 15 days post seeding in 4 HPV-negative HNSCC cell lines, 
UMSCC74A (A), UMSCC6 (B), FaDu (C) and A253 (D), and 2 HPV-positive cell lines UPCI-
SCC90 (E) and UPCI-SCC154 (F). On Day 3, spheroids were treated with either of 10μM 
ATMi, 1 μM ATRi, 1 μM DNA-PKcsi or 10 μM DMSO for 24 h. Values were analysed from 
six biologically independent experiments and normalised to Day 3 post seeding for each 

































































































































































Table 6. 5.  Impact of targeting of DSB repair as a monotherapy on HNSCC spheroid 
growth. 
Cell line ATMi ATRi DNA-PKcsi 
UMSCC74A p<0.0002 p<0.003 p=0.59 
UMSCC6 p=0.60 p<0.002 p=0.89 
FaDu p=0.69 p=0.89 p=0.82 
A253 p=0.49 p=0.72 p=0.88 
UPCI-SCC090 p=0.34 p<0.006 p=0.44 
UPCI-SCC154 p=0.11 p=0.72 p=0.2 
Statistical analysis was performed across the 15-day growth period using a one-way 
ANOVA, comparing the growth of inhibitor treated spheroids against the appropriate 
DMSO control. 
 
Table 6. 6.  Growth suppression ratio (GSR) calculated over the 15-day growth period 
following ATMi, ATRi or DNA-PKcsi alone. GSR=DMSO spheroid volume/ ATMi spheroid 
volume for each condition. 
Cell line ATMi ATRi DNA-PKcsi 
UMSCC74A 1.58 1.40 1.07 
UMSCC6 1.04 1.50 0.99 
FaDu 1.15 1.03 0.98 
A253 1.63 1.74 1.35 
UPCI-SCC090 1.14 1.45 0.95 




6.7 Impact of DNA repair inhibition in combination with x – rays on 3D spheroid 
growth in HNSCC.  
The impact of the DSB repair inhibitors targeting ATM, ATR and DNA-PKcs in 
sensitisation of HNSCC to IR, both in radiosensitive HPV-positive cell lines and 
radioresistant HPV-negative cell lines, was investigated by spheroid growth, as a model 
that better represented in vivo tumour growth. Five HNSCC cell lines were utilised, 
UMSCC74A, UMSCC6, FaDu, A253 and UPCI-SCC090. Unfortunately, the limited UPCI-
SCC154 control spheroid growth did not allow for reliable results in the distinction 
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between treated and untreated spheroids and therefore analysis of the treatments’ 
impact was not achieved and is not included in this thesis. Cells were left to form 
spheroids and on Day 3 post seeding these were treated with 10μM ATMi, 1 μM ATRi, 1 
μM DNA-PKcsi or 10 μM DMSO for 1 h before and for 24 h after irradiation with a single 
dose (0 - 3 Gy) of x – rays. Spheroid growth was then monitored for a 12-day period post-
irradiation, equalling a 15-day growth period overall. Growth suppression ratio (GSR), a 
ratio that describes the volume of DMSO treated over the volume of drug treated 
spheroids for a given radiation dose across the 15- day monitoring period were utilised 
to compare the relative growth suppression. 
 
6.7.1 ATMi  
Combination treatment of ATMi with x – rays, resulted in reduced spheroid growth in all 
HPV-negative cell lines, to a different extend (Figure 6.12 and Tables 6.7 and 6.8). The 
growth of UMSCC74A and A253 spheroids, that were already reduced by the inhibitor 
alone, were further suppressed in response to ATMi and 1 Gy x – rays with GSR values 
of 1.96 (p< 0.004) and 3.08 (p<0.001) respectively, although there was no further 
decrease following a 2 Gy x – ray dose, even though the suppression was still statistically 
significant (p<0.0004 and p<0.01 respectively), (Figure 6.12 A-B, G-H). In UMSCC6 
spheroids, growth was reduced by 1.34- fold in response to ATMi treatment and 1 Gy x 
– rays, that was further reduced, to 1.7- fold, yet this suppression was statistically 
significant (p<0.02) only following inhibitor treatment and 2 Gy irradiation (Figure 6.12 
C-D). Interestingly, ATMi treated FaDu spheroids exhibited a delay and suppression in 
growth in response to 1 Gy x – rays, but this was more important, with GSR 4.73, and 
statistically significantly (p<0.004) only after 2 Gy x – rays. This demonstrates that FaDu 
is a very radioresistant cell line and that x – ray induced DSB repair in FaDu is only 
moderately ATM dependant. Regarding the HPV-positive cell line, ATMi treatment did 
not further reduce growth in combination with IR in UPCI-SCC090 spheroids, as due to 
their increased endogenous radiosensitivity, radiation alone at 1 Gy x – rays almost 
completely suppressed their growth. Cumulatively, these findings demonstrated the 
ATMi efficacy in enhancing the impact of IR, in radioresistant cell lines, even from low 
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Figure 6. 12. Impact of ATMi on 3D spheroid growth following x - rays in HNSCC cells. 
Spheroid growth was monitored for 15 days in HPV-negative UMSCC74A (A-B), UMSCC6 
(C-D), FaDu (E-F) and A253 (G-H), and HPV-positive, UPCI-SCC090 (I-J), HNSCC cell lines. 
On Day 3, spheroids were treated with 10 μM ATMi or 10 μM DMSO as control, and were 
exposed to 0, 1 or 2 Gy x - rays. Values were normalised to Day 3 post seeding for each 
condition that was set to 1, were the means of 3 biologically independent experiments 
and are presented with their standard errors. Statistical analysis using one way ANOVA 
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Table 6. 7. Targeting of ATM in combination with x – rays decreased HNSCC spheroid 
growth. 
Cell line ATMi + 1 Gy ATMi + 2 Gy 
UMSCC74A p<0.004 p<0.0004 
UMSCC6 p=0.18 p<0.02 
FaDu p=0.09 p<0.004 
A253 p<0.001 p<0.001 
UPCI-SCC090 p=0.76 p=0.45 
Statistical analysis was performed across the 15-day growth period using a one-way 
ANOVA, comparing the growth of inhibitor treated spheroids against the appropriate 
DMSO control. 
 
Table 6. 8.  Growth suppression ratio (GSR) calculated over the 15-day growth period 
following ATM inhibition in combination with x – rays. GSR=DMSO spheroid volume/ 
ATMi spheroid volume for each condition. 
Cell line ATMi + 1 Gy ATMi + 2 Gy 
UMSCC74A 1.96 1.90 
UMSCC6 1.34 1.73 
FaDu 1.98 4.73 
A253 3.08 2.57 





Treatment with ATRi in combination with x – rays reduced volume in the majority of 
HNSCC spheroids examined, further than that obtained by ATRi alone, Figure 6.13 and 
Tables 6.9 and 6.10. In UMSCC74A, UMSCC6, A253, UPCI-SCC090 spheroids, ATRi 
treatment and 1 Gy x – rays sufficiently suppressed their growth by 2.33-, 1.66-,2.79-, 
and 1.32- fold respectively which was also statistically significant as shown in Table 6.7 
(p- values <0.03 to < 0.0004). There was still significant radiosensitisation following 2 Gy 
x – rays which, however, was not further enhanced as shown by the equivalent GSR 
values. Growth in FaDu spheroids treated with ATRi and 1 Gy x – rays was delayed but 
not significantly inhibited. The ATRi treated FaDu spheroids kept growing even after 2 
Gy x – rays, their size was reduced by almost 2- fold, although this was not statistically 
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significant. This suggested that FaDu spheroids were not reliant on ATR driven repair of 
IR-induced DSBs. Overall, ATRi was shown to increase sensitivity to x – rays in HPV-
negative as well as in one HPV-positive, although to a lesser degree, HNSCC spheroids 
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Figure 6. 13. Impact of ATRi on 3D spheroid growth following x - rays in HNSCC cells. 
Spheroid growth was monitored for 15 days in HPV-negative, UMSCC74A (A-B), UMSCC6 
(C-D), FaDu (E-F) and A253 (G-H), and HPV-positive, UPCI-SCC090 (I-J) HNSCC cell lines. 
On Day 3, spheroids were treated with 1 μM ATRi or 10 μM DMSO as control, and were 
exposed to 0 - 2 Gy x - rays. Values were normalised to Day 3 post seeding for each 
condition that was set to 1, were the means of 3 biologically independent experiments 
and are presented with their standard errors. Statistical analysis using one way ANOVA 
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Table 6. 9.  Targeting of ATR in combination with x – rays decreased HNSCC spheroid 
growth. 
Cell line ATRi + 1 Gy ATRi + 2 Gy 
UMSCC74A p<0.0004 p<0.00002 
UMSCC6 p<0.014 p<0.012 
FaDu p=0.28 p=0.09 
A253 p<0.002 p<0.0004 
UPCI-SCC090 p<0.03 p=0.12 
Statistical analysis was performed across the 15-day growth period using a one-way 




Table 6. 10.  Growth suppression ratio (GSR) calculated over the 15- day growth period 
following ATR inhibition in combination with x – rays. GSR=DMSO spheroid volume/ ATRi 
spheroid volume for each condition. 
Cell line ATRi + 1 Gy ATRi + 2 Gy 
UMSCC74A 2.33 2.43 
UMSCC6 1.66 1.64 
FaDu 1.41 1.90 
A253 2.79 2.8 
UPCI-SCC090 1.32 1.28 











The impact of DNA-PKcsi in combination with x – rays was then examined. Following 1 
Gy x – rays, DNA-PKcsi statistically significantly suppressed spheroid growth in all HPV-
negative cell lines, leading to severe radiosensitisation (Figure 6.14, Tables 6.11, 6.12). 
In UMSCC74A and UMSCC6 the GSR values were 1.64 (p<0.17) and 1.40 (p<0.047) 
respectively (Figure 6.14 A, C). Increasing the x – ray dose up to 2 Gy, reduced the impact 
of the inhibitor in UMSCC74A spheroids, where growth was suppressed by 1.32- fold 
and significance was lost (Figure 6.14 B). However, increasing the dose to 2 Gy enhanced 
the DNA-PKcsi impact on UMSCC6 spheroids that were suppressed by 2.24- fold 
(p<0.001) (Figure 6.14 D). Moreover, 1 Gy x – ray irradiation in combination with DNA-
PKcsi was enough to completely suppress growth of A253 spheroids, with GSR of 3.15 
(p<0.001), as well as in the most radioresistant FaDu spheroids, with a GSR of 4.55 
(p<0.003) (Figure 6.14 E, G), while increase of radiation dose further enhanced growth 
suppression in FaDu spheroids (GSR 7.71, p<0.002) (Figure 6.14 F). This highlights the 
increased dependence of HPV-negative cells, including FaDu, to DNA-PKcs and therefore 
NHEJ repair in response to x – ray induced DNA damage.  Regarding the HPV-positive 
spheroids, UPCI-SCC090, these were not statistically significantly impacted by DNA-PKcsi 
in combination with x – rays due to their increased intrinsic radiosensitivity (Figure 6.14 
I-J). Summing up, DNA-PKcsi was effective in sensitising all HPV-negative spheroids to x 
– rays, even from the lowest radiation dose of 1 Gy and representative images are 
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Figure 6. 14.  Impact of DNA-PKcsi on 3D spheroid growth following x - rays in HNSCC 
cells. Spheroid growth was monitored for 15 days in 4 HPV-negative, UMSCC74A (A-B), 
UMSCC6 (C-D), FaDu (E-F) and A253 (G-H), and 1 HPV-positive, UPCI-SCC090 (I-J) HNSCC 
cell lines. On Day 3, spheroids were treated with 1 μM DNA-PKcsi or 10 μM DMSO as 
control, and were exposed to 0 - 2 Gy x - rays. Values were normalised to Day 3 post 
seeding for each condition that was set to 1, were the means of 3 biologically 
independent experiments and are presented with their standard errors. Statistical 
analysis using one way ANOVA revealed significant differences between DMSO and DNA-




Table 6. 11.   Targeting of DNA-PKcs in combination with x – rays decreased HNSCC 
spheroid growth.  
Cell line DNA-PKcsi + 1 Gy DNA-PKcsi + 2 Gy 
UMSCC74A p<0.017 p=0.076 
UMSCC6 p<0.047 p<0.001 
FaDu p<0.003 p<0.002 
A253 p<0.001 p<0.001 
UPCI-SCC090 p=0.08 p=0.61 
Statistical analysis was performed across the 15-day growth period using a one-way 
ANOVA, comparing the growth of inhibitor treated spheroids against the appropriate 
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Table 6. 12.  Growth suppression ratio (GSR) calculated over the 15-day growth period 
following DNA-PKcs inhibition in combination with x – rays. GSR=DMSO spheroid 
volume/ DNA-PKcsi spheroid volume for each condition. 
Cell line DNA-PKcsi + 1 Gy DNA-PKcsi + 2 Gy 
UMSCC74A 1.64 1.32 
UMSCC6 1.4 2.24 
FaDu 4.55 7.71 
A253 3.15 2.41 
UPCI-SCC090 1.05 1.09 
 
 
Figure 6. 15. 3D spheroid formation and growth in HNSCC cell lines. Spheroid 
growth was monitored post treatment with 10μM ATMi, 1μM ATRi, 1 μM DNA-
PKcsi or 10 μM DMSO alone, or in combination with 1 Gy x – rays. 6 HNSCC cell line 
spheroids, 4 HPV-negative (UMSCC74A, UMSCC6, FaDu and A253) and 2 HPV-positive 
(UPCI-SCC090 and UPCI-SCC154), were imaged on Day 3 post seeding prior to any 
treatment and for a 2 week period. UPCI-SCC154 spheroids did not grow over the two-
week monitoring period and therefore no impact of the drugs could be observed and 
were excluded from further analysis. Here are displayed representative images of 




6.8 Impact of DNA repair inhibition in combination with proton irradiation on 3D 
spheroid growth in HNSCC. 
Next, the impact of inhibiting ATM, ATR and DNA-PKcs in combination with proton 
irradiation on spheroid growth was investigated in HNSCC cell lines. Four (relatively 
radioresistant) HPV-negative cell lines, UMSCC6, UMSCC74A, FaDu and A253, and one 
(relatively radiosensitive) HPV-positive cell line, UPCI-SCC090, were examined. Cells 
were left to form spheroids and on Day 3 post seeding these were treated with 10μM 
ATMi, 1μM ATRi, 1 μM DNA-PKcsi or 10 μM DMSO for 1 h before and for 24 h after 
irradiation with 0 – 4 Gy protons. Spheroid growth was then monitored for a 15-day 
period and GSR were calculated.  
6.8.1 ATMi  
Treatment with 2 Gy low LET protons, in combination with ATMi resulted in statistically 
significant suppression of spheroid growth in all HPV-negative HNSCC cell lines, with p 
values varying between <0.05 to <0.005 (Figure 6.16, Tables 6.13 and 6.14). The GSR 
were 1.81-1.99 in UMSCC74 and UMSCC6 and 3.66-3.67 in A253 and FaDu (Table 6.14). 
Notably, growth suppression of the FaDu spheroids was achieved with the lowest proton 
dose of 2 Gy, demonstrating the enhanced impact of ATMi in combination with protons 
in this very radioresistant cell line. An increase in radiation dose to 4 Gy, did not further 
suppress growth in the inhibitor treated spheroids. GSR values were lower and 
significance was lost as the gap between DMSO and ATMi treated spheroids was 
reduced by the excess cell killing by radiation alone, in UMSCC74A and UMSCC6. A253 
spheroids were suppressed to a lesser degree yet the radiosensitisation was significant 
even after 4 Gy protons (p<0.0006). Interestingly, FaDu spheroids were further 
radiosensitised following 4 Gy protons and the GSR rose to 9.05 (p<0.002) (Tables 6.13, 
6.14).  
Regarding the HPV-positive UPCI-SCC090 spheroids, their radiosensitivity was not 
impacted by ATMi, as growth was already diminished by proton irradiation, and thus no 
impact of the drug could be observed. This again highlighted the extreme radiosensitive 
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Figure 6. 16. Impact of ATMi on 3D spheroid growth post proton irradiation in HNSCC 
cells. Spheroid growth was monitored for 15 days post seeding in 4 HPV-negative, 
UMSCC74A (A-B), UMSCC6 (C-D), FaDu (E-F) and A253 (G-H), and HPV-positive, UPCI-
SCC090 (I-J) HNSCC cell lines. On Day 3, spheroids were treated with 10 μM ATMi or 10 
μM DMSO as control, and were exposed to 0-4 Gy protons. Values were normalised to 
Day 3 post seeding for each condition that was set to 1, were the means of 3 biologically 
independent experiments and are presented with their standard errors. Statistical 
analysis using one way ANOVA revealed significant differences between DMSO and 
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Table 6. 13. Targeting of ATM in combination with protons decreased HNSCC spheroid 
growth.  
Cell line ATMi + 2 Gy ATMi + 4 Gy 
UMSCC74A p<0.014 p=0.33 
UMSCC6 p<0.05 p=0.74 
FaDu p<0.024 p<0.002 
A253 p<0.005 p<0.0006 
UPCI-SCC090 p=0.24 p=0.89 
Statistical analysis was performed across the 15-day growth period using a one-way 





 Table 6. 14. Growth suppression ratios (GSR) calculated over the 15-day growth period 
following ATM inhibition in combination with protons. GSR=DMSO spheroid volume/ 
ATMi spheroid volume for each condition. 
Cell line ATMi + 2 Gy ATMi + 4 Gy 
UMSCC74A 1.99 0.86 
UMSCC6 1.81 1.28 
FaDu 3.67 9.05 
A253 3.66 2.29 





6.8.2 ATRi  
The impact of ATRi on cell survival and therefore spheroid growth was found to be the 
most detrimental among the three DSB repair inhibitors, upon exposure to proton 
irradiation. ATRi contributed to suppress spheroid growth in all HPV-negative cell lines, 
as well as in the HPV-positive UPCI-SCC090, as seen in Figure 6.17 and Tables 6.15, 6.16. 
Specifically, ATRi treated UMSCC74A, and UMSCC6 spheroids exhibited statistically 
significant (p<0.003 – <0.0002) growth suppression following 2 Gy proton irradiation, 
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with GSR values of 2.94 and 2.37 respectively. However, no further growth suppression 
was obtained by exposure to higher radiation dose up to 4 Gy protons, due to increased 
cell killing particularly by protons alone (Figure 6.17 B, D, and Tables 6.15 and 6.16). The 
growth of ATRi treated FaDu and A253 spheroids was delayed in response to 2 Gy 
protons (GSR 1.78 and 3.37), although the growth suppression was statistically 
significant (p< 0.004 – <0.0005) only after 4 Gy protons with GSR of 2.18 and 2.55 
respectively. Regarding the HPV-positive HNSCC UPCI-SCC090 spheroids, ATRi treatment 
in combination with 2 Gy protons almost completely suppressed spheroid growth 
(p<0.0008, GSR 1.63), while increase in the radiation dose up to 4 Gy resulted in almost 
equivalent suppression (p<0.01, GSR 1.44). Overall, ATRi was found to be effective in 
suppressing growth in HNSCC spheroids in response to protons by radiosensitising all 
HPV-negative and one HPV-positive spheroids and representative images are 
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Figure 6. 17.  Impact of ATRi on 3D spheroid growth post proton irradiation in HNSCC 
cells. Spheroid growth was monitored for 15 days in 4 HPV-negative, UMSCC6, 
UMSCC74A (A-B), UMSCC6 (C-D), FaDu (E-F) and A253 (G-H), and the HPV-positive UPCI-
SCC090 (I-J) HNSCC cell lines. On Day 3, spheroids were treated with 1 μM ATRi or 10 μM 
DMSO as control, and were exposed to 0-4 Gy protons. Values were normalised to Day 3 
post seeding for each condition that was set to 1, were the means of 3 biologically 
independent experiments and are presented with their standard errors. Statistical 
analysis using one way ANOVA revealed significant differences between DMSO and ATRi, 
summarised in Table 6.13. 
 
Table 6. 15. Targeting of ATR in combination with protons decreased HNSCC spheroid 
growth.  
Cell line ATRi + 2 Gy ATRi + 4 Gy 
UMSCC74A p<0.0002 p=0.36 
UMSCC6 p<0.003 p=0.11 
FaDu p=0.23 p<0.04 
A253 p=0.106 p<0.0005 
UPCI-SCC090 p<0.0008 p<0.01 
Statistical analysis was performed across the 15-day growth period using a one-way 
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Table 6. 16.  Growth suppression ratios (GSR) calculated over the 15-day growth period 
following ATR inhibition in combination with protons. SGR=DMSO spheroid volume/ ATR 
spheroid volume for each condition. 
Cell line ATRi + 2 Gy ATRi + 4 Gy 
UMSCC74A 2.94 1.22 
UMSCC6 2.37 1.54 
FaDu 1.78 2.18 
A253 3.37 2.55 
UPCI-SCC090 1.63 1.44 
 
 
6.8.3 DNA-PKcsi  
Treatment with DNA-PKcsi and 2 Gy protons resulted in severe radiosensitisation in all 
HPV-negative cell lines as illustrated in Figure 6.18 and Tables 6.17, 6.18. The growth 
was statistically significantly reduced by 1.91-1.92- fold in UMSCC74A (p<0.017) and 
UMSCC6 (p<0.047) spheroids, and 3.57- and 7.63- fold in A253 (p<0.003) and FaDu 
(p<0.001) spheroids respectively. Interestingly, the most radioresistant FaDu spheroids, 
were sufficiently suppressed by the lowest proton dose, which supports an increased 
dependence of FaDu to DNA-PKcs and therefore NHEJ repair in response to proton 
induced DNA damage. Exposure of HPV-negative spheroids to DNA-PKcsi and 4 Gy 
protons, further enhance GSR in FaDu spheroids (to 10.59, p<0.002) but this was 
reduced in all the other HPV-negative cell lines, due to excess cell killing by protons 
alone. On the other hand, there was minimal sensitisation of the HPV-positive cell line 
UPCI-SCC090 to protons achieved by DNA-PKcsi, due to their high intrinsic 
radiosensitivity, Figure 6.18 I-J, and Tables 6.17, 6.18. Growth in inhibitor treated UPCI-
SCC090 spheroids was suppressed by 1.21- fold following 2 Gy protons, which was 
increased to 1.31- fold post 4 Gy protons, although these were not statistically 
significant. Altogether, these findings suggested that DNA-PKcsi sufficiently 
radiosensitised HPV-negative HNSCC spheroids to proton irradiation, and that the 
advantage of combination treatment was more eminent in the lowest proton radiation 
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Figure 6. 18.  Impact of DNA-PKcsi on 3D spheroid growth post proton irradiation in 
HNSCC cells. Spheroid growth was monitored for 15 days in 4 HPV-negative, UMSCC74A 
(A-B), UMSCC6 (C-D), FaDu(E-F) and A253 (G-H), and the HPV-positive, UPCI-SCC090 (I-
J) HNSCC cell lines. On Day 3, spheroids were treated with 1 μM DNA-PKcsi or 10 μM 
DMSO as control, and were exposed to 0 - 4 Gy protons. Values were normalised to Day 
3 post seeding for each condition that was set to 1, were the means of 3 biologically 
independent experiments and are presented with their standard errors. Statistical 
analysis using one way ANOVA revealed significant differences between DMSO DNA-
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Table 6. 17. Targeting of DNA-PKcs in combination with protons decreased HNSCC 
spheroid growth.  
Cell line DNA-PKcsi + 2 Gy DNA-PKcsi + 4 Gy 
UMSCC74A p<0.017 p=0.36 
UMSCC6 p<0.047 p<0.05 
FaDu p<0.003 p<0.002 
A253 p<0.001 p<0.004 
UPCI-SCC090 p=0.08 p=0.14 
Statistical analysis was performed across the 15-day growth period using a one-way 




Table 6. 18. Growth suppression ratios (GSR) calculated over the 15-day growth period 
following DNA-PKcsi inhibition in combination with protons. GSR=DMSO spheroid 
volume/ DNA-PKcsi spheroid volume for each condition. 
Cell line DNA-PKcsi + 2 Gy DNA-PKcsi + 4 Gy 
UMSCC74A 1.91 0.85 
UMSCC6 1.92 1.52 
FaDu 7.63 10.59 
A253 3.57 1.94 





        Figure 6. 19. 3D spheroid formation and growth in HNSCC cell lines. Spheroid growth was 
monitored post treatment with 10μM ATMi, 1μM ATRi, 1 μM DNA-PKcsi or 10 μM DMSO 
alone, or in combination with 2 Gy protons. 6 HNSCC cell line spheroids, 4 HPV-negative 
(UMSCC74A, UMSCC6, FaDu and A253) and 2 HPV- positive (UPCI-SCC090 and UPCI-SCC154), 
were imaged on Day 3 post seeding prior to any treatment and for a 2 week period. UPCI-
SCC154 spheroids did not grow over the two-week monitoring period and therefore no impact 
of the drugs could be observed and were excluded from further analysis. Here are displayed 












6.9 Conclusions  
Over Chapters 4 and 5, the three DSB repair inhibitors were shown to regulate 
phosphorylation of their target proteins in crucial sites that promote and mediate DNA 
repair in HNSCC cells. This was correlated with altered DNA damage response, in 
response to x – rays as well as low LET protons, constituting a promising tool for 
radiosensitisation. Therefore, in the last section of this research project, the impact of 
DSB repair inhibition on cell survival was investigated, as the ultimate end-point. This 
was studied both as a result of inhibitor monotherapy, as well as a combination of 
inhibitor with x – rays and low LET protons in HNSCC cells, via two independent 
techniques. First by utilising 2D via colony formation (clonogenic) assays, a gold-
standard technique in cell biology for investigating potential effectiveness of specific 
treatments, and next by assessing 3D spheroid growth assays, a state-of-art technique 
which more accurately reflect the complex and heterogenous structure as well as the 
environment of the original tumour. 
Monotherapy with the inhibitors, particularly ATRi and ATMi, resulted in a reduction in 
cell survival despite the apparent small impact of the inhibitors alone on DNA damage 
response, as discussed in the Chapters 4 and 5. Among the three drugs, ATRi had the 
most dramatic impact, with approximately a 2 fold and statistically significant reduction 
in colony formation in 2 HPV-negative (UMSCC74A, UMSCC6) and 2 HPV-positive 
(UMSCC47, UPCI-SCC090) HNSCC cell lines, which was also reflected in spheroid growth 
that was suppressed in 3 HPV-negative (UMSCC74A, UMSCC6, A253) and 1 HPV-positive 
(UPCI-SCC090) HNSCC spheroids (Table 6.19). Next was ATMi, that resulted in 
statistically significant reduced cell survival, in 2 HPV-negative (UMSCC76A, UMSCC6) 
and 1 HPV positive (UMSCC47) HNSCC cells, but also suppressed growth in 2 HPV-
negative HNSCC spheroids (UMSCC74A, A253) (Table 6.19). Finally, DNA-PKcsi was the 
least impacting inhibitor as a monotherapy, that statistically significantly downregulated 
colony formation in only 1 HPV-positive (UMSCC47) cell line and suppressed growth in 
only 1 HPV-negative (A253) spheroid, although this was not statistically significant (Table 
6.19). Interestingly, a small, but not significant, spheroid growth increase was observed 
in the HPV-positive UPCI-SCC090. This suggested that insufficient NHEJ repair of 
endogenous DSBs in this specific cell line could contribute to increased spheroid growth 
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possibly via upregulated alternative DNA repair routes. Collectively these data indicate 
an increased dependence on ATM and ATR, and less on DNA-PKcsi in controlling survival 
and proliferation of HNSCC cells in the absence of IR, through the repair of endogenous 
DSBs. 
Table 6. 19. Impact of DSB repair inhibitor as a monotherapy on cell survival in 2D 
(clonogenic assay) and 3D (spheroid growth assay). 
Non 
irradiated 
Clonogenic Assay Spheroid Growth Assay 
ATMi ATRi DNA-PKcsi ATMi ATRi DNA-PKcsi 
UMSCC74A ↓ ↓ - ↓ ↓ - 
UMSCC6 ↓ ↓ ↓ - ↓ - 
FaDu * * * - - - 
A253 * * * ↓ ↓ ↓ 
UMSCC47 ↓ ↓ ↓ * * * 
UPCI-SCC090 - ↓ - ↓ ↓ ↑ 
↓: downregulated cell survival, ↑: upregulated cell survival, -: no impact, *: no data 
Treatment with ATMi severely radiosensitised all HNSCC cell lines examined, to x – rays 
and protons even from the lowest radiation dose, as seen via both clonogenic and 
spheroid growth assays. Indeed, a statistically significant reduction in colony formation 
with simultaneously reduced D50 values, was observed in all cell lines in response to x – 
rays and in all but 1 HPV-positive (UPCI-SCC090) cell line in response to protons (Table 
6.20). Similarly, spheroid growth was suppressed in all HPV-negative cell lines, in 
response to the lowest radiation dose, 1 Gy x – rays or 2 Gy protons. The 
radiosensitisation of the HPV-negative cell lines persisted following higher x – ray dose 
(2 Gy), however was limited to only two of them (FaDu, A253) following higher proton 
dose (4 Gy). This was possibly due to increase cell killing by proton radiation alone, that 
did not allow to distinct between the radiation and inhibitors impact. Moreover, in 
spheroid growth assay a potential radiosensitisation by x – rays or low LET protons was 
less evident in the HPV-positive cell line (UPCI-SCC090), irrespective of the radiation 
dose, due to increased intrinsic radiosensitivity. Even though this was achieved in 2D in 






Table 6. 20. Impact of ATMi in combination with x – rays or low LET protons on cell 
survival in 2D (clonogenic assay) D50 and 3D (spheroid growth assay) GSR. 
ATMi 
Clonogenic Spheroid 
X - rays Protons X - rays Protons 
D50 D50 1 Gy 2 Gy 2 Gy 4 Gy 
UMSCC74A ↓ ↓ ↓ ↓ ↓ - 
UMSCC6 ↓ ↓ ↓ ↓ ↓ - 
FaDu * * ↓ ↓ ↓ ↓ 
A253 * * ↓ ↓ ↓ ↓ 
UMSCC47 ↓ ↓ * * * * 
UPCI-SCC090 ↓ - - - - - 
↓: downregulated cell survival, ↑: upregulated cell survival, -: no impact, *: no data 
Next, inhibition of ATR was found to promote cell killing in response to x – rays or low 
LET protons, both in 2D colony formation and 3D spheroid growth. In fact, ATRi, which 
as a monotherapy already impacted cell survival, further reduced colony formation in all 
but 1 HPV-positive (UPCI-SCC090) HNSCC cells, in response to x – rays as well as protons. 
In addition, ATRi considerably suppressed growth in all HPV-negative spheroids, that 
was statistically significant in all except FaDu spheroids, and surprisingly in the HPV-
positive UPCI-SCC090, from the lowest radiation dose, 1 Gy x – rays or 2 Gy protons. 
After exposure to higher radiation dose the impact of ATRi was weaken due to increased 
cell killing by the radiation alone, yet remained significant for UMSCC6 and UMSCC74A 
spheroids following (2 Gy x – rays) and FaDu A253 and UPCI-SCC090 spheroids (4 Gy 
protons) (Table 6.21).  
Table 6. 21.  Impact of ATRi in combination with x – rays or low LET protons on cell 
survival in 2D (clonogenic assay) D50 and 3D (spheroid growth assay) GSR. 
ATRi 
Clonogenic Spheroid 
X - rays Protons X - rays Protons 
D50 D50 1 Gy 2 Gy 2 Gy 4 Gy 
UMSCC74A ↓ ↓ ↓ ↓ ↓ - 
UMSCC6 ↓ ↓ ↓ ↓ ↓ - 
FaDu * * - - - ↓ 
A253 * * ↓ - ↓ ↓ 
UMSCC47 ↓ ↓ * * * * 
UPCI-SCC090 - - ↓ - ↓ ↓ 
↓: downregulated cell survival, ↑: upregulated cell survival, -: no impact, *: no data 
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Lastly, DNA-PKcsi that had the least impact as a monotherapy, showed the most 
promising results in combination with IR, in reducing cell survival in 2D clonogenic assays 
and 3D spheroid growth assays. DNA-PKcsi treatment resulted in statistically significant 
downregulation of colony formation, and therefore D50 values, in all HNSCC cells 
examined in response to x – rays. The impact was similar in response to protons, in 3 
out of four HNSCC cell lines examined, although no impact could be observed in the HPV-
positive UPCI- SCC090 cells, due to excess cell killing by protons in this inherently most 
radiosensitive cell line. Moreover, DNA-PKcsi exhibited the strongest radiosensitisation 
effect among the three drugs. This was also reflected by severe growth suppression in 4 
HPV-negative (UMSCC74A, UMSCC6, FaDu, A253) HNSCC spheroids in response to low 
(1 Gy x – rays, 2 Gy protons) radiation dose. Inhibition of DNA-PKcsi was particularly 
effective in the radioresistant FaDu and A253 cell lines, resulting in severe 
radiosensitisation following either x – rays or low LET protons, which was not as evident 
following ATRi, but also ATMi in combination with x – rays, indicating increased DNA-
PKcs dependence. Increase in the radiation dose up to 2 Gy x – rays or 4 Gy protons, 
minimised the radiosensitisation in all HPV-negative spheroids apart FaDu, although this 
remained statistically significant for UMSCC6, A253 and FaDu spheroids. Unfortunately, 
similarly to ATMi, no impact of the inhibitor could be observed in the radiosensitive 
UPCI-SCC090.  
Table 6. 22.  Impact of DNA-PKcsi in combination with x – rays or low LET protons on cell 
survival in 2D (clonogenic assay) D50 and 3D (spheroid growth assay) GSR. 
DNA-PKcsi 
Clonogenic Spheroid 
X - rays Protons X - rays Protons 
D50 D50 1 Gy 2 Gy 2 Gy 4 Gy 
UMSCC74A ↓ ↓ ↓ - ↓ - 
UMSCC6 ↓ ↓ ↓ ↓ ↓ ↓ 
FaDu * * ↓ ↓ ↓ ↓ 
A253 * * ↓ ↓ ↓ ↓ 
UMSCC47 ↓ ↓ * * * * 
UPCI-SCC090 ↓ - - - - - 
↓: downregulated cell survival, ↑: upregulated cell survival, -: no impact, *: no data 
 
In conclusion, the DSB repair inhibitors ATMi, ATRi and DNA-PKcsi were found to 
enhance the impact of IR in HNSCC cells in vitro, offering the potential to reduce the IR 
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associated toxicity. radiosensitisation with x – rays and low LET protons was observed in 
both HPV-negative as well as HPV-positive HNSCC cell lines, although arguably to a lesser 
extent in the later precisely due to their increased endogenous radiosensitivity. 
Remarkably, no major differences were observed on the impact of any of the drugs in 
response to x – ray versus low LET proton induced DNA damage. This highlights that DNA 
repair inhibition is a promising tool to be used for radiosensitisation in combination with 
either radiation type, as well as suggesting that corresponding DNA repair pathway 
choice occurs in response to x – ray or low LET proton induced DNA damage, which will 








Every day 104 DNA lesions per cell (base damages, single and double strand breaks, DNA 
strand cross-links and other) occur naturally in humans (239). DSBs, even though less 
frequent, are highly toxic and they can lead to a great loss of genetic information, 
mutations, or cell death, with all of these ccontributing to the development of human 
diseases, including premature aging, neurodegeneration and cancer (36). In defense of 
their genomic stability, cells have developed a signaling network, the DDR, which detect 
and repair any DNA lesions with specific repair mechanisms. There are two main repair 
pathways resolving DSBs: NHEJ and HR. Which pathway will be chosen is partly defined 
by the cell cycle stage, NHEJ is the predominant mechanism during G0/G1 and HR is only 
active during late S and G2. Nevertheless, there are contributions of other factors such 
as the cell and tissue type, the DNA repair efficiencies as well as the type and the cause 
of DNA damage, which are not yet understood (240). Three protein kinases, ATM, ATR 
and DNA-PKcs, members of the PIKK, family of serine/threonine protein kinases, are 
actively involved in HR and NHEJ DSB repair (120, 241, 242). These repair mechanisms, 
although important for the cell proliferation, also contribute to tumor resistance in 
response to IR which complicates radiotherapy. 
 Radiotherapy is one of the three major cancer treatments, particularly for HNSCC where 
it is currently used alone or in combination with surgery and/or chemotherapy. This 
involves using IR to induce significant DNA lesions and particularly DSBs that promote 
tumor cell death.  Conventional radiotherapy, using x – rays, is a well-studied end 
established treatment applied worldwide in the last century. In addition, proton beam 
therapy is increasingly being utilised for HNSCC treatment, due to precise delivery of the 
radiation dose to the tumor, resulting in sparing of the normal tissues and organs at risk. 
However, the biological impact of protons versus photons is largely unknown and 




HNSCC are a heterogenous group of cancers in the wider area of the pharynx, larynx, lip, 
oral and nasal cavity. HNSCC has been associated with excessive consumption of alcohol 
and tobacco products, as well as infection with the type 16 high risk HPV. Interestingly, 
HPV-positive HNSCC patients have improved survival rates compared to HPV-negative 
ones irrespective of the treatment (180-187). Although how the HPV associated cellular 
alterations respond to known therapies is not fully understood, recent studies have 
demonstrated that HPV-positive HNSCC cells are more sensitive to IR, mainly because of 
defects in the signaling and repair DSBs (188-191). This has revealed that targeting the 
DNA damage response, particularly in relatively radioresistant HPV-negative HNSCC that 
display proficient DNA repair mechanisms, may be an effective strategy for the 
radiosensitisation of the tumor.  
Indeed, specific and potent inhibitors of the major DNA repair regulators exist and are 
widely used in research, either as monotherapy or in combination with DNA damaging 
agents, such as chemotherapy drugs and IR. Several studies have demonstrated that 
inhibition of ATM, ATR or DNA-PKcs can significantly sensitise and kill tumor cells in 
response to x – rays in various types of cancer cells such as breast, pancreatic, prostate 
and colon (120, 225, 226, 243). Also, this inhibition have been demonstrated to increase 
radiosensitivity of HNSCC cell lines in a few studies largely conducted during the course 
of this research project  (209, 214, 227, 244-247) in response to x – rays. However, there 
is an urgent need to expand our knowledge in regard to the different impact of the DNA 
repair inhibitors on HPV-positive versus HPV-negative HNSCC cells, in order to exploit 
the potential of utilising such drugs in HNSCC therapy.  Moreover, currently published 
studies utilising DNA repair inhibitors in combination with protons, in HNSCC but also in 
other tumours, are extremely limited. Considering the increased demand on proton 
radiotherapy, the implementation of such drugs to improve the therapeutic potential 
whilst minimising radiation associated risks and toxicity is necessary.  
Here, three potent DNA repair inhibitors KU-55933 targeting ATM (ATMi), VE-821 
targeting ATR (ATRi) and NU7441 targeting DNA-PKcs (DNA-PKcsi), directly associated 
with the repair IR (x – rays and protons) induced DSB, were utilised in HNSCC cells in 
vitro as a monotherapy or as a combination therapy with x – rays or low LET protons. 
The impact of the drugs was investigated on multiple end points, from the induction of 
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the DSB and initiation of DDR, to regulation of DSB repair progression and more 
importantly to the impact on HNSCC cell survival in 2D as well as in 3D spheroid models. 
It is worth noting, that direct comparison between the two radiation types was not the 
major target of this research project. Instead, the impact of the DNA repair inhibitors 
alone or in combination with IR, was investigated, as well as the differences in the 
inhibitor’s impact in combination with either x – rays or protons. This was due to the 
fundamental differences of x – ray and proton irradiation, but more importantly due to 
the difference in the delivery technique. For x – ray irradiations, cells were treated in a 
laboratory x – ray unit operating at 100 kV, which is significantly less than e.g. 6MV x – 
rays used clinically, and with no filtration. Therefore, the low energy x – rays dominate, 
and LET is greater than ~2 keV/mm (typically quoted for 200kV x – rays), making x – rays 
potentially more efficient at producing DSB. For proton irradiations, cells were exposed 
to a passive scattered horizontal proton beam line of 60 MeV maximal energy and cells 
were positioned at the entrance dose of a pristine unmodulated beam, with LET of ~1 
keV/µm. This is resulting in an RBE significantly less than 1, hence the difference in the 
radiation doses chosen for proliferation experiments, 2D clonogenic assays and 3D 
spheroid growth assays.  
7.2 DNA repair inhibitors delay or downregulate DDR activation.  
The first end point investigated, was the phosphorylation of the protein kinases on sites 
associated with DSB repair. This was achieved via immunoblot analysis of protein levels 
within oropharyngeal HNSCC cells treated with either of the inhibitors in the absence or 
presence of IR. Phosphorylation was investigated at multiple time points, allowing 
adequate time for the involvement of the respective protein in the DDR. 
Immunoblotting was chosen to visualise the protein modifications as well as quantify 
the relative protein expression related to the specific treatment. This is a tool majorly 
used for semi-quantitative analysis and the detection of multiple proteins 
simultaneously, although is limited by low detection sensitivity (248, 249). As a 
monotherapy neither of the drugs had any significant impact in phosphorylation levels 
of any of the sites investigated and for all HNSCC cell lines examined, irrespective of the 
HPV status. This could suggest that the inhibitors alone did not regulate DDR in protein 
level, but more likely was associated with the low sensitivity of this technique, 
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considering that endogenous DSBs are at a very low level, and therefore significant 
activation of the respective kinases is not necessary (or at least is beyond the limits of 
detection). It was, therefore, further investigated via alternative end points. 
The impact of ATMi was investigated on phosphorylation of ATM in S1981, which is 
reportedly activated through an intermolecular auto-phosphorylation in response to 
DSBs, and regulates a number of DNA repair proteins, such as H2AX, BRCA1, as well as 
proteins involved in cell cycle control, including p53 and Chk2, thus indirectly promoting 
DSB repair (124, 250). ATMi was found to effectively suppress ATM phosphorylation on 
S1981, up to 4 h post irradiation, in response to x – rays and low LET proton irradiation 
in oropharyngeal HNSCC cells. The drug was in fact equally effective in combination with 
either radiation modality. Similarly, ATMi has been reported  to abrogate ATM 
phosphorylation on S1981 in a number of tumour cell models in response  x – rays, 
including in E2 and G7 primary glioblastoma cell lines (251), in H460 lung cancer cells 
(252), and in LNCaP and PC3 prostate cancer cells (120). Such inhibition by ATMi was 
also observed in A549 lung adenocarcinoma cells in response to low LET protons and γ 
– irradiation (253), as well as in human embryonic stem (ES) cells in response to γ – 
irradiation (254). In addition, ATMi was also shown to downregulate S1981 
phosphorylation in response to high LET carbon ion radiation, in AT5BIVA and GM0639 
human fibroblast cells (255). Interestingly, my results demonstrated that the same ATM 
residue (S1981) was phosphorylated in response to damage induced by the two 
different radiation types, having similar activation levels following exposure to x – rays 
(between 4.2- to 12- fold) and low LET protons (between 4.2- to 10- fold). This was in 
contrast with a study utilising A549 lung adenocarcinoma cells, which suggested that 
low LET protons resulted in a massive activation of ATM in S1981 when compared to 
that induced by γ – radiation, that is an x – rays equivalent (253). This could possibly be 
explained by the relatively higher LET used in this study, 4 MeV protons versus 60 MeV 
protons used for the experiments in my thesis. Moreover, the impact of ATMi in 
supressing activation of ATM was comparable between HPV-positive and HPV-negative 
oropharyngeal cell lines, indicating that the drug can be effective in both HNSCC tumour 
cell types.  
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ATR is activated in response to ssDNA structures that arise from stalled DNA replication 
forks and resected DNA DSBs, and in turn regulates numerous factors involved in both 
DNA repair and cell cycle control. Mass spectrometry revealed that activation of ATR is 
mediated through phosphorylation of three amino acids sites, S428, S435 and T1898. 
(137). Here, two of these sites were investigated following treatment with ATRi and/or 
IR exposure. Firstly, S428 phosphorylation was investigated, however exposure to either 
x – rays or protons, did not induce ATR phosphorylation on S428 up to 24 h in all 
oropharyngeal HNSCC cell lines irrespective of the HPV status. Therefore, no impact of 
ATRi in combination with IR could be observed through assessment of this specific site. 
This result could be an indication that phosphorylation of S428 within ATR is constant in 
the cells and that is independent of IR treatment and of ATRi. In fact, it has been 
suggested that phosphorylation of ATR in S428 is not DNA damage-regulated as it was 
not affected by hydroxyurea (HU) treatment in yeast (256) nor by UV treatment in 293E 
cells (137), with both studies suggesting that T1989 is the only critical phosphorylation 
site for ATR activation. Nevertheless, S428 phosphorylation has been reported to be 
upregulated in response to DNA breakage induced by 5,7,3′,4′-tetrahydroxyisoflavone, 
a genistein metabolite (222). Next, T1989 phosphorylation within ATR, was investigated. 
Among the three sites, T1989 autophosphorylation has been identified to be the only 
site to regulate Chk1 and TopBP1 phosphorylation, in response to endogenous, UV 
induced, and IR induced DSBs, making it critical for ATR activation and thus DSB repair 
(137). This agreed with my findings which revealed that IR, x – rays and protons, 
upregulated T1989 phosphorylation in vitro. Treatment with ATRi delayed and 
decreased expression of ATR in T1989 in all 4 oropharyngeal HNSCC cell lines in response 
to x – rays as well as protons and for up to 24 h post IR exposure, with no major 
differences between the two radiation modalities. The impact of ATRi in combination 
with x – rays or protons on T1989 phosphorylation has not been previously reported. 
Although, there are few studies demonstrating similar findings regarding the inhibitors’ 
impact on T1989 in combination with other DNA damaging agents. Indeed, ATRi in 
combination with Camptothecin or LMP-400 (indotecan), chemotherapeutic drugs 
known to produce replication-associated DSBs, supressed T1989 phosphorylation up to 
18 h post treatment, and downregulated the ATR mediated Chk1 S345 activation, in 
HT29 and COLO 205 colon cells, and MDA-MD-231 breast carcinoma cells (257). 
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Moreover, Chk1 S345 activation have also been demonstrated to be inhibited by ATRi, 
in response to γ – radiation (137Cs radiation) and Gemcitabine, a chemotherapeutic DNA 
damaging drug, in pancreatic tumour cells (226). These findings along with those 
presented in this thesis, highlight that T1989 is the main DNA damage-regulator site for 
ATR activation in HNSCC cells, but importantly, that this site is targeted by ATRi 
irrespective of the HPV status and the DNA damage inducer, including photons and low 
LET protons. 
Finally, two phosphorylation sites, T2609 and S2056, associated with DNA-PKcs 
activation and regulation of the DNA repair process, has been reported to promote the 
DNA-PK complex dissociation from the site of DSB allowing other NHEJ repair factors to 
access the site and progress repair (146-148). It was shown in this research project that 
T2609 phosphorylation peaked 1 h post irradiation in the HPV-negative cell lines but was 
delayed in the HPV-positive cell lines following x – rays, without any inhibitor treatment. 
The early peak can be explained considering the role of T2609 phosphorylation on 
initiating and promoting DNA end processing (151, 152). In a study utilising flow 
cytometry, T2609 phosphorylation was observed to peak shortly (within 30 minutes) 
after exposure to γ – radiation in human fibroblasts GM5758, GM16088 and AG07217 
cells and in HCT116 colon cancer cells and A431 epidermoid SCC cells, all of which are 
proficient in DSB repair (258). This supported my data and moreover suggested that the 
inherent DSB repair deficiencies of HPV-positive cell lines are probably causing the delay 
in T2609 initiation in response to IR alone, without inhibitor treatment. Treatment with 
DNA-PKcsi, delayed T2609 phosphorylation post x - rays in one HPV-negative and one 
HPV-positive HNSCC cell line yet upregulated the overall phosphorylation in all HNSCC 
cell lines examined irrespective of the HPV status. Interestingly, the inhibitor also 
promoted DNA-PKcs cleavage in one HPV-positive (UMSCC47) HNSCC cell line. A similar 
delayed phosphorylation on T2609 has also been reported in response to DNA-PKcsi and 
γ – radiation, in a study utilising AG07217 and HCT116 cells, in addition to delayed 
dephosphorylation that was reported in the later time points (258). Moreover, increased 
phosphorylation on T2609, supporting my results, was demonstrated in LNCaP and PC3 
prostate cancer cells following IR and DNA-PKcsi treatment (120). This could be 
associated with persistent unrepaired DSBs that correspondingly contributed to 
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increased apoptosis, shown by the increased DNA-PKcs protein cleavage, in the 
radiosensitive UMSCC47 cells. In contrast to the x – ray data, T2609 phosphorylation was 
downregulated following inhibitor and proton treatment with simultaneous 
upregulation of DNA-PKcs cleavage, indicating increased apoptosis in one (UMSCC74A) 
HNSCC cell line, although no impact could be observed in the second cell HNSCC cell line 
examine (HPV-positive UMSCC47) and therefore it was not feasible to reach safe 
conclusions. In addition, there are currently no published data examining this aspect and 
was not further investigated in this research project.   
Phosphorylation on DNA-PKcs S2056 was assessed and found to peak 8 h post IR, both 
x – rays and protons, in all oropharyngeal HNSCC cells. Considering that S2056 is 
reported to promote DSB ligation which occurs in the final steps of DSB repair (151), the 
later peak in phosphorylation was expected. DNA-PKcsi downregulated phosphorylation 
of DNA-PKcs on S2056 in all 4 HNSCC cell lines in response to x – ray as well as proton 
irradiation. In agreement with this, studies have reported that inhibition of DNA-PKcs 
resulted in reduced S2056 phosphorylation in MCF-7, MDA-MB-231, and T47D breast 
cancer cells  (243), and in LNCaP and PC3 prostate cancer cells (120), following DNA-
PKcsi and IR treatment. In addition, formation of S2056 foci has previously been shown 
to be inhibited by DNA-PKcsi in human epithelial cells in response to γ – radiation ( 137Cs) 
(259). On the other hand, no evidence of the inhibitor’s impact on S2056 in response to 
proton radiation has previously been reported. It is worth noting that following proton 
irradiation, the inhibitor severely upregulated DNA-PKcs protein cleavage in all 
oropharyngeal HNSCC cell lines, in comparison to x – rays, suggesting that protons were 
more effective than x – rays in inducing apoptosis in DNA-PKcsi treated cells, irrespective 
of the HPV status. This may possibly indicate that protons induce marginally more 
complex DNA damage that is trickier to be resolved and which contributes more to cell 
death. Nevertheless, these findings described here suggest that the inhibitor effectively 
suppressed S2056 phosphorylation in response to both x – rays and low LET protons. 
In conclusion, ATMi, ATRi, and DNA-PKcsi were found to target and inhibit 
phosphorylation on the respective protein sites critical to DSB repair, and therefore to 
impede the cellular DDR. The impact of the three protein kinase inhibitors in response 
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to x – ray or proton irradiation was further examined in regards to their role in DDR and 
cell survival. 
 
7.3 DNA repair inhibitors delay and downregulate DDR signalling  
Three DDR signalling markers, γH2AX, 53BP1 and Rad51 associated with DSB repair via 
NHEJ and HR, were investigated. Exposure to IR rapidly phosphorylates the H2AX variant 
and generates γH2AX foci, which is mediated by ATM and DNA-PKcs. These foci surround 
DSBs, in a manner of one focus per DSB, attracting other DNA repair factors (120, 225, 
228). Simultaneously, 53BP1 foci, markers of DSB repair processing through NHEJ, are 
formed and colocalise with γH2AX foci in an ATM, and DNA-PKcs dependent manner. 
γH2AX foci are not involved in the initial recruitment of 53BP1 yet are required for the 
stable formation and retention of 53BP1 foci (207, 228, 229). Later in the cell cycle, 
Rad51 foci regulated by ATM and ATR, highlight the sites where DSB repair are being 
processed via HR (230, 231).  
In the absence of IR there was generally no effect on DNA repair foci formation in 
oropharyngeal HNSCC cells following inhibition of ATM, ATR and DNA-PKcs. γH2AX foci 
were mildly upregulated only following ATRi, suggesting a possible increase in 
endogenous DSB recognition or induction by the drug alone. 53BP1 foci were only 
downregulated in the presence of DNA-PKcsi, demonstrating that the inhibitor reduced 
the endogenous recruitment of 53BP1 in the sites of DSB repair via NHEJ. Finally, Rad51 
foci were marginally upregulated in the HPV-negative UMSCC6 cells only, in response to 
ATMi or ATRi, indicating that both drugs affected Rad51 recruitment, possibly due to 
accumulated DSBs later in the cell cycle. Unfortunately, the amount of foci in non 
irradiated cells is relatively low, implicating the comparison of DMSO versus drug 
treatment, resulting in reduced sensitivity in detection of the drug’s impact. 
Nevertheless, these findings suggested that the inhibitors could regulate DSB repair 
even in the absence of IR.     
In response to IR, formation of γH2AX foci were not majorly impacted by ATRi in any of 
the oropharyngeal HNSCC cell lines examined, which was expected given that 
phosphorylation of H2AX has been demonstrated to be predominantly independent of 
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ATR (228).  ATMi in combination with either x – rays or protons, delayed and decreased 
γH2AX foci 1 h post IR exposure. Similarly to my findings, ATMi in combination with IR 
was shown to decrease γH2AX foci in LNCaP and PC3 prostate cancer cells (120). In 
addition, this study suggested that ATM is the major kinase responsible for H2AX 
phosphorylation and that DNA-PKcs is unable to phosphorylate H2AX in the absence of 
ATM, although they presented increased γH2AX foci in the later time points after 
treatment with DNA-PKcsi. Interestingly, this was in accordance with my results where 
DNA-PKcsi did not delay the foci formation, however it increased the amount of γH2AX 
foci 4h and 8 h post irradiation, indicating increased persistency of DSB in the later time 
points following x – rays as well as protons. The same trend was exhibited in LoVo and 
SW620 human colon cancer cells, where increased γH2AX persistency was reported 
following DNA-PKcsi and x – rays or Etoposide treatment (109).  The DSB accumulation 
in later time points post inhibitor and IR treatment could be corelated to the 
downregulated S2056 phosphorylation, that led to reduced dissociation of the DNA-PK 
complex, prohibiting repair and therefore promoting DSB retention. My findings 
highlighted that the impact of the inhibitors on γH2AX did not differ between x – rays 
and protons, suggesting an equivalent degree of DDR signaling in response to the two 
radiation types which was also not associated with HPV status.   
The initial recruitment and phosphorylation of 53BP1 is dependent on the activation of 
ATM and DNA-PKcs, but not of ATR since this protein kinase is not directly involved in 
NHEJ repair (190, 228, 229). Indeed here, 53BP1 foci formation and retention was not 
majorly impacted by ATRi treatment in combination with x – rays or protons in HNSCC 
cells, confirming that ATR is not directly involved with NHEJ repair. Increase in 53BP1 
foci was only observed in one HNSCC cell line, UMSCC47 which are HPV-positive1 h post 
proton irradiation highlighting a possible cell line dependent on ATR involvement in 
53BP1 recruitment for DSB repair. Interestingly, a similar increase was shown in 
pancreatic tumor cell lines, PSN-1, MiaPaCa-2 and PANC-1, following ATRi treatment and 
exposure to 6 Gy γ – radiation (137Cs) (226). Moreover, I found that ATMi treatment, 
which induced a decrease in γH2AX foci formation 1 h post x – rays or proton irradiation, 
also resulted in reduced 53BP1 foci formation in response to x – rays at the same time 
point (1 h post IR). This has been observed following ATMi treatment and exposure to γ 
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– radiation (137Cs), in bladder cancer cells, T24 and 5637, (260) and in human fibroblast 
cells, GM05757, GM18366 and GM02052 (261), as well as in primary human fibroblasts, 
HLEC1 and WI-38, following ATMi and x - rays (262). However here, there was no 
apparent reduction in 53BP1 foci formation 1 h post proton irradiation in the presence 
of ATMi. In fact, 53BP1 foci exhibited increased persistency 8 h post protons, in all cell 
lines, indicating unrepaired DSB and thus ongoing NHEJ in all oropharyngeal HNSCC cell 
lines examined. This possibly pinpoints to increased complexity of the DNA damage 
induced by protons, which is more difficult to be repaired in the presence of ATMi, 
resulting in DSB persistence. Next, my results demonstrated that DNA-PKcsi induced 
increased amount of 53BP1 foci and increased persistency in the later time points, 
particularly 8 h post exposure to x – rays and 4 h post proton irradiation. This was in 
agreement with other studies that suggested that DNA-PKcsi upregulated the amount 
of 53BP1 foci in primary human fibroblasts, HLEC1 and WI-38, following x – ray 
irradiation (262), and in A549 lung adenocarcinoma cells following treatment with DNA 
damaging agents AMR, CPT-11 and paclitaxel (PTX) (Topoisomerase-I inhibitors) from 1  
h to 24 h post irradiation (263). It is worth noting that in the results shown here, 53BP1 
foci peaked 8 h post treatment with DNA-PKcsi and x – rays, following the same trend 
as γH2AX, and suggesting accumulated DSB levels and thus ongoing NHEJ repair that 
could be associated with the downregulated S2056 phosphorylation, discussed above. 
However, the number of 53BP1 foci peaked at 4 h post DNA-PKcsi and proton treatment, 
demonstrating greater amount of DSB accumulating earlier following protons compared 
to x – rays, possibly due to increased complexity of the DNA damage induced. Then by 8 
h, the number of 53BP1 foci in DNA-PKcsi treated cells dropped to the DMSO levels. This 
could be linked with increased apoptosis, which was also demonstrated by the increased 
cleavage of DNA-PKcs following DNA-PKcsi and proton treatment observed by 
immunoblotting and discussed above. My findings are supported by a study indicating 
that the number of 53BP1 foci was greater and persisted for longer following x – rays 
compared to low LET protons in A549 adenocarcinoma cells treated with the DNA-PKcs 
inhibitor, NU7026 (118). It was also suggested that DNA-PKcs is the major protein kinase 
and NHEJ repair the lead repair pathway following x – rays but not following proton 
irradiation. However, my findings would conflict with this evidence and largely indicate 
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that NHEJ repair is the major DSB repair mechanism following both radiation modalities, 
as inhibition of either ATM or DNA-PKcs resulted in defective DSB repair.  
Later on the time course, phosphorylation of Rad51 highlights the sites where DSBs are 
repaired through HR. Taking into account that HR is driven by ATM and ATR protein 
kinases while DNA-PKcs is not directly involved (120-122), no effect on Rad51 foci 
formation was expected following DNA-PKcs inhibition while a reduction was 
anticipated following ATR and ATM inhibition. Indeed, my results illustrated a relative 
decrease in Rad51 foci in the presence of ATMi 16 h post IR, but that this was 
significantly greater with ATRi at the same time point, 16 h post IR. It should be pointed 
out that no major difference was observed on the ATMi and ATRi impact in combination 
with x – rays versus protons, with the exception of ATMi treated UMSCC47 where Rad51 
foci were considerably more reduced following protons than x – rays. In agreement with 
my findings, ATMi was shown to reduce Rad51 foci in HeLa cells exposed to the DNA 
damaging agent CPT (camptothecin, topoisomerase I inhibitor used in 
chemotherapeutic drugs) (264). Additionally, ATRi was shown to severely downregulate 
Rad51 foci formation 6 h post γ – radiation (137Cs) in pancreatic tumor cell lines, PSN-1 
and MiaPaCa-2, although this study suggested that ATMi had no significant impact on 
Rad51 foci formation or persistence (226). Surprisingly, my results showed that DNA-
PKcsi led to an upregulation of Rad51 foci at 16 h (UMSCC6, UMSCC74A HNSCC cells) 
and 24 h (all 3 cell lines examined) post x – rays but not following proton irradiation. In 
support of that, elevated Rad51 foci (by 3- fold), were reported following DNA-PKcsi and 
IR or doxorubicin treatment in 6 hepatoma cell lines HepG2, Hep3B, Huh7, SNU-182, 
SNU475 and PLC/PRF/5 (265). This unexpected outcome could be explained by a 
possible increased involvement of ATM/ATR when DNA-PKcs is unable to act earlier in 
the cell cycle. Thus, a blocked NHEJ pathway could be substituted by HR or other 
alternative pathways for the resolution of DSBs. In fact, DNA-PKcs is proposed to be 
critical in the DSB repair pathway choice, between NHEJ and HR, and that modulation of 
DNA-PKcs phosphorylation sites can promote either NHEJ or HR, the latter case where 
accurate repair is required (153, 154). In contrast though, DNA-PKcsi treatment in 
combination with proton irradiation from my data resulted in decreased Rad51 foci 
formation, at 16 h post irradiation. One explanation for this contradicting result could 
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be a possible association with increased cell death, i.e. apoptosis, as observed by the 
increased DNA-PKcs protein cleavage specifically following protons when compared to 
x – rays. Therefore, less cells could survive and undergo HR, resulting in reduced Rad51 
foci formation, although this requires further investigation. This highlights the important 
role of DNA-PKcs in DSB repair following protons, as well as a possible role for a more 
complex nature of the DNA damage induced by protons causing the increased apoptosis.  
Altogether, inhibition of ATM, ATR and DNA-PKcs was shown to lead to a defective DNA 
repair process through the analysis of surrogate DSB protein markers. It appears that 
the role of each kinase in DSB repair is overlapping but non-redundant and there must 
be a more complex interaction between them through co-oridnation of NHEJ and HR. 
More detailed studies are necessary in order to fully understand the way the repair 
pathways are affected by the kinase’s inhibition, which was not a major scope of this 
research project.  
 
7.4 DNA repair inhibitors reduce cell survival.  
In the final part of this study, I analysed the effect of ATMi, ATRi and DNA-PKcsi on cell 
growth and proliferation on both monolayer 2D cultures, and 3D spheroid models of 
HPV-positive and HPV-negative HNSCC in combination with x – ray and proton 
irradiation. Particularly in the spheroid assays, multiple HNSCC cell lines (from 
oropharynx, hypopharynx and oral cavity) were examined, displaying different 
endogenous capacities for DNA repair and thus better representing the heterogenous 
HNSCC group. Whilst the major focus was an examination of the impact of the inhibitors 
in combination with IR, treatment with these as a monotherapy revealed reduced colony 
formation and spheroid growth by ATRi in particular, and by ATMi to a lesser degree. 
Nevertheless, DNA-PKcsi was not found to significantly inhibit cell survival and 
proliferation either in 2D nor in 3D.  
Interestingly, I discovered that targeting either ATM, ATR or DNA-PKcs can significantly 
decrease clonogenic survival of oropharyngeal HNSCC cells in response to both x – rays 
and protons. Although a tailing was observed in the higher IR doses in clonogenic assays 
in the inhibitor treated cells, which seemed to be seen across cell types and for both x-
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ray and protons and consistently occurred just above the 1 % survival level. This may be 
related to the limitation of the current assay due to low platting efficiency and the 
respective small colony numbers. This could be tested by scaling up the number of 
dishes irradiated, and therefore surviving colonies, for these data points and may be 
checking for potential false positives, such as small abortive colonies,  in the scoring.  
Between the three drugs, DNA-PKcsi appeared to be particularly effective in 
combination with both of the radiation modalities in all HNSCC cell lines. My findings 
correlated with other studies, particularly in HPV-negative HNSCC cells, which reported 
enhanced radiosensitisation in 2D clonogenic survival assays in vitro, utilising DNA-PKcs 
siRNA in UTSCC15 and UTSCC45 cells (266), as well as the DNA-PKcs inhibitors 
KU0060648 in HN4 and HN5 cells (244), and IC87361 in UTSCC54, UTSCC74B and 
UTSCC76B cells (245). Similarly, a study examining ATM inhibition in HNSCC cells, using 
the ATM inhibitor GSK635416A, reported enhanced radiosensitivity in five HPV-negative 
HNSCC cell lines (UTSCC2, UTSCC8, UTSCC24A, UTSCC36 and UTSCC40) which was in 
agreement with my results (209). In addition, a number of studies have focused on ATR 
as a target. Increased cell killing was reported following x – ray irradiation and ATR siRNA 
treatment in HPV-negative HNSCC cells UPCI-SCC029B, UPCI-SCC040 and UPCI-SCC131 
(210).  Improved radiosensitivity and reduced colony formation was also demonstrated 
following ATRi treatment and exposure to IR in HPV-negative SQ20B cells (246). An 
alternative and more potent ATR inhibitor, AZD6738, showed equivalent 
radiosensitisation in Cal27, FaDu, HN4 and HN5 cells, all of which are HPV-negative (214, 
244). Nevertheless, my data suggested that ATRi was the least effective of the three 
drugs used, in radiosensitising HNSCC cells following both x – rays and proton radiation, 
most likely due to increased cell killing by the drug alone that resulted in reduced overall 
impact when combined with IR. I also observed less of an impact on DNA DSB repair 
inhibition in combination with radiation in HPV-positive oropharyngeal HNSCC cells, 
particularly the UPCI-SCC090 cells, principally as these are the most inherently 
radiosensitive as shown here, and in previous study of the Parsons group (207). This also 
replicates the improved response and outcome of HPV-positive HNSCC patients 
following radiotherapy treatment (188-191). However, how protons impact on survival 
on HNSCC, as well as other cancer, cell lines is largely understudied. On top of that, the 
impact of DSB repair inhibitors in combination with proton radiation on cell survival has 
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not been analysed previously. This highlights the novelty of the results presented in this 
research project, particularly regarding the proton data, as well as the necessity for 
further studies on that direction, considering the increasing demand for proton 
radiotherapy. 
Next, utilising 3D spheroid models that more accurately replicate the structure and 
environment of the original tumour, the effectiveness of DNA repair inhibitors was 
further demonstrated. In support of the clonogenic survival assays, all of the three drugs 
impacted spheroid growth particularly in the relatively more radioresistant HPV-
negative HNSCC models. DNA-PΚcsi in combination with either x – rays or protons was 
the most prominent in inhibiting growth of all four HPV-negative HNSCC spheroids 
analysed, including those from the oropharynx, hypopharynx and oral cavity. Noticeably 
though, inhibition of DNA-PΚcs alone did not appear to have any impact on the growth 
of 3D spheroids of both HPV-positive and HPV-negative HNSCC, and indicates that DNA-
PΚcs is not essential for HNSCC cell growth and survival in the absence of IR-induced 
stress. Likewise, treatment with ATMi significantly suppressed growth in just one out of 
four HPV-negative HNSCC spheroid model in the absence of IR, yet was found to 
significantly suppress spheroid growth in all four HPV-negative HNSCC spheroids 
exposed to either x – rays (2 Gy) or proton (2 Gy) irradiation.  Nevertheless, and similar 
to clonogenic assays results, the combination strategy of DSB repair inhibition, 
particularly ATMi and DNA-PKcsi, did not majorly enhance the effect of x – rays and 
protons on the HPV-positive HNSCC spheroids due to these cells being the most 
radiosensitive. Inhibition of ATR was effectiveness in preventing spheroid growth in 
combination with x – rays or protons. In fact, growth was significantly suppressed in 
three out of four HPV-negative HNSCC spheroid models following 1 Gy or 2 Gy x – rays, 
while growth was significantly suppressed in two out of four HPV-negative HNSCC 
spheroid models following 2 Gy or 4 Gy protons. Interestingly, less of an impact was 
observed on the relatively radioresistant HPV-negative HNSCC spheroid models, FaDu 
and A253, that displayed significant spheroid growth over the time period post 
irradiation and required higher radiation dose to be suppressed. This observation is 
similar to previous data utilising  the ATR inhibitor AZD6738, with x – rays only, which 
demonstrated that this combination did not impede growth of 3D spheroids of FaDu 
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cells (214). It is noteworthy that inhibition of ATR as a monotherapy, in the absence of 
IR, was effective in preventing growth of three out of four HPV-negative as well as the 
one HPV-positive HNSCC spheroids, which was comparable to the impact caused by a 
single dose of radiation alone. Overall, relatively similar results were observed in the 
effectiveness of the drugs when combined with x – rays or protons. However, following 
x – rays the impact of each drug was enhanced when higher radiation dose was applied 
(from 1  Gy to 2 Gy), while following protons the impact was reduced at the higher 
radiation dose (from 2 Gy to 4 Gy) due to excessive cell killing by proton irradiation 
alone. This may further support the hypothesis that even low LET protons induce more 
complex DNA damage comparative to x-rays, which is contributing to enhanced cell 
death.   
Cumulatively, my results suggest that targeting DNA DSB repair via NHEJ (ATM and DNA-
Pkcs) or HR (ATR) can exacerbate the impact of IR in sensitising HNSCC cell models. This 
adds to the growing preclinical evidence (209, 210, 214, 227, 244-247, 266) that 
targeting DSB repair is an effective combination for treatment of HNSCC that should be 
investigated further. Moreover, I propose that DNA-PKcsi was the most effective 
treatment, followed by ATMi, in enhancing the therapeutic potential of IR, x – rays as 
well as low LET protons, in HNSCC cells and especially for HPV-negative cell lines that are 
relatively radioresistant. Finally, ATRi was the most effective drug utilised as 
monotherapy in sensitising both HPV-negative and HPV-positive HNSCC cells, although 
in combination with IR, ATRi was the least effective drug precisely due to suppressed 
cell survival by the drug alone. This finding would contradict some very limited evidence 
suggesting a greater dependence on the HR pathway mediated by ATR for repairing DNA 
DSBs induced by protons, which was conducted using RAD51 siRNA in A549 lung cancer 
cells (118). In fact other studies, largely conducted in Chinese hamster ovary cells, reflect 
that NHEJ, co-ordinated by ATM and DNA-PKcs, is the major DSB repair pathway 
employed following proton irradiation (105, 116), which is in agreement with my 
findings. Consequently, we would advocate that inhibition of NHEJ through DNA-PKcs is 
the most promising strategy in optimizing radiosensitisation of HNSCC cells with either 
x – rays or low LET protons. Nevertheless, it should be noted that since low LET protons 
at the entrance dose of a pristine beam were utilised, different results may be obtained 
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with cells irradiated at or around the Bragg peak where the LET increases. This is due to 
the increased amount of complex DNA damage, where multiple lesions are generated 
in close proximity, which the Parsons Group have demonstrated are important for 
contributing to the cell killing effects of protons with increasing LET (114, 267). 
Therefore, the potential for protons to generate complex DNA DSBs that could have a 
different requirement for either NHEJ or HR, requires further investigation (268).  
 
7.5 Future perspectives  
The findings of this thesis lead to the proposal that inhibition with ATMi, ATRi and DNA-
PKcsi can be used to suppress the repair of x – rays and protons induced DSBs and 
promote cell killing. However, and specifically following DNA-PKcsi treatment, increased 
DNA-PKcs protein cleavage was observed in response to protons compared to x – rays 
in the majority of the cell lines examined. Further investigation of this difference 
between the two radiation modalities in relation to cell death initiating mechanisms is 
required, as it could bear relevance to increased apoptosis which I hypothesise is due to 
increased complexity of DNA damage induced by protons, even at low LET entrance dose 
utilised in this project. Therefore, it would be interesting to examine the importance of  
apoptosis in the various cell lines and whether induction is different following x-rays and 
protons in the presence of the DSB inhibitors, and particularly in response to DNA-PKcsi 
treatment. This could be achieved via several independent techniques. The first one 
would be via investigation of poly(ADP-ribose) polymerase-1 (PARP-1) cleavage which is 
commonly used as a marker of apoptosis, as the 113 kDa nuclear enzyme is cleaved in 
fragments of 89 and 24 kDa by caspases 3 and 7, during apoptosis (269). The second 
technique would be to investigate apoptosis via Fluorescence-activated cell sorting 
analysis. During this, cells treated with the inhibitor and/or IR, as well as control cells, 
are stained with Annexin V and propidium Iodide solution and then are imaged by flow 
cytometry. Cells are hydrophobic in nature and express phosphatidyl-serine in the inner 
membrane, but during apoptosis the inner membrane flips exposing phosphatidyl-
serine residues, which are detected by Annexin V. Moreover, the leaky DNA content 
exhibited in necrotic cells is detected by propidium Iodide and can therefore 
differentiate between apoptotic and necrotic cells (270, 271). Considering the findings 
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of this thesis, I would expect increased PARP-1 cleavage, as well as increased number of 
Annexin V stained apoptotic cells, following DNA-PKcsi and proton irradiation compared 
to DNA-PKcsi treatment and x – rays. 
During this research project, I was able to investigate DDR signaling alterations caused 
by the DSB repair inhibitors in response to IR. Some unexpected findings included 
increased persistency in 53BP1 foci at the later time points following ATMi and protons 
compared to ATMi and x – rays. It is reasonable to suggest that the ongoing 53BP1 
recruitment revealed persistent DSBs that were trickier to be resolved, which I believe 
is an indicator of the increased complexity of proton induced DNA damage. Moreover, 
the impact of DNA-PKcsi on DDR signaling differed in response to x – rays and protons. 
Formation of γH2AX and 53BP1 foci peaked earlier, at 4 h post protons versus 8 h post 
x – rays, while Rad51 foci were decreased in response to protons compared to x – rays.  
The reason for this difference could also be related to the increased complexity of 
proton induced DNA damage. Therefore, it would be necessary to examine complex DNA 
damage (CDD) levels. There are several techniques to achieve that. The Parsons group 
recently suggested using enzyme-modified comet assays, where recombinant DNA 
repair enzymes (APE1, OGG1, and NTH1) were used to incise residual DNA base damage 
and abasic sites to allow for CDD detection (114, 267). Others suggested detection of co-
localisation of OGG1/APE1 with γH2AX by immunofluorescence, as an alternative 
approach (48, 272). Increased CDD levels, may lead to increased apoptosis and therefore 
to less cells being actively repaired. This further demonstrate that it would be 
particularly interesting to examine apoptotic levels following inhibitor treatment and IR 
as described above.  
Clonogenic assays and 3D spheroid growth analysis, which better represents the tumour 
environment, performed in this thesis have proven that all three inhibitors severely 
impacted on the sensitivity of HNSCC cells to both x – rays and protons, and particularly 
to relatively radioresistant HPV-negative cell lines. This constitutes a promising starting 
point for future studies on improving radiotherapeutic results. At this point, it would be 
particularly interesting to investigate the impact of hypoxia within the 3D spheroids 
during IR exposure on the oxygen enhancement ratio (OER) in HNSCC spheroids, 
considering that the central cells are tightly packed and have reduced access to oxygen 
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and other nutrients. This could be achieved by sectioning of spheroids and looking at 
necrosis or mitotic catastrophe levels in the central region of the spheroids. The next 
logical step would be the use of these inhibitors on patient-derived xenograft (PDX) or 
patient-derived organoids (PDO). PDX, are generated when tumour tissue is 
transplanted on immunodeficient mice and is considered advantageous over cancer cell 
lines as they better resemble the biological characteristics of the primary tumours and 
more efficiently predict drug responses, although they are cost ineffective and time- and 
resource-consuming (273). On the other hand, PDOs are 3D cell clusters, growing in 3D 
gel matrixes, that form an organ-like tissue which retain the physiological characteristics 
and function of their source tumour, including histological complexity, and genomic and 
transcriptomic characteristics. This results on PDOs being more consistent with the real 
patient response to drugs than either cancer cell lines or PDX, and they offer a great 
potential for disease modeling for cancer research and anticancer drug screenings (274-
277). That been said, it would be interesting to examine the impact on DSB repair 
inhibition in response to x – rays as well as protons in PDO in particular. 
Furthermore, during this research project low LET proton irradiations were performed. 
Cells were positioned at the entrance dose of a pristine (unmodulated) beam (~1 
keV/µm) and were exposed to a passive scattered horizontal proton beam line of 60 
MeV maximal energy and cells. As discussed above, different results may have been 
obtained if cells were irradiated at or around the Bragg peak where the LET rapidly 
increases due to the increased amount of complex DNA damage, where multiple DSBs 
are generated in close proximity, contributing to increased cell killing effects. Therefore, 
it would be particularly interesting to further examine the potential for high LET protons 
versus low LET protons and x – rays, performed in this research project, as monotherapy 
but more so in combination with DSB repair inhibitors, to radiosensitise HNSCC in vitro. 
This would also offer the opportunity to investigate whether generation of more 
complex DNA DSBs would have a different requirement for either NHEJ or HR  which 
constitutes a conflict in current literature (105, 116, 118, 268) 
Another area for future extension of this research project would be to investigate the 
impact of DSB repair inhibitors in combination with IR on other cancer cells and more 
importantly to explore the response on relevant normal cells, as ideally the treatment 
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should be more biologically effective against cancer cells compared to normal cells. 
Moreover, the use of newer and more potent of DSB repair inhibitors than the ones used 
here, which only recently became available for research purposes, could be investigated. 
Specifically, selective inhibitors targeting ATM (e.g. AZD1390), ATR (e.g. AZD6738) and 
DNA-Pkcs (e.g. AZD7648), would require examination of their potential to radiosensitise 
HNSCC cell models following x – rays and proton irradiation. The way this investigation 
could be performed is through the standard techniques utilised in this research project, 
including clonogenic assays and 3D spheroid growth assays, or with more advanced 
techniques like PDO cultures discussed above. 
Finally, it is also important to note that clinical trials are currently using DSB repair 
inhibitors, aiming to exploit the potential of combination treatments to improve the 
radiotherapeutic outcome and reduce radiation associated toxicities. There is evidence 
of clinical trials utilising either ATM inhibitors (AZD0156) or DNA-PKcs inhibitors 
(NU7441-used in this thesis-, CC-115, C-122, VX-984 and MSC2490484A) in combination 
with conventional radiotherapy or other DNA damaging agents that are currently 
underway in HNSCC, as well as in other advanced solid tumors but also in healthy 
volunteers (208, 278, 279). In addition, ATR inhibitor VE-822 in combination with 
Cisplatin, a chemotherapeutic drug that induce replication fork collapse, is being tested 
in an ongoing phase 1 clinical trial in HPV-negative HNSCC patients. Another ATR 
inhibitor, AZD6738, is tested in clinical trials for multiple cancer types as monotherapy 
or in combination with radiotherapy, chemotherapy or Olaparib (214, 279, 280) and 
there are two clinical trials examining combination of AZD6738 with Olaparib in HNSCC 
(208).  
7.6 Conclusions  
In this research project, the impact of targeting the DSB repair mechanisms in response 
to IR was investigated via inhibition of the protein kinases ATM, ATR and DNA-PKcs that 
co-ordinate DSB repair. X – ray irradiation, a well-established tool in cancer 
radiotherapy, and proton irradiation, a rapidly utilised radiotherapy technique clinically, 
were examined. DSB repair inhibition impacted cell behavior on multiple levels. From 
regulating phosphorylation on critical sites of the targeted protein kinases and DNA 
212 
 
repair signaling, to reducing survival and enhancing sensitivity to IR in 2D and 3D in 
HNSCC cell models. Overall, the main outcomes of this project included: 
• ATMi, ATRi, and particularly DNA-PKcsi, enhanced radiosensitivity of 2D monolayer 
and 3D spheroid models of HNSCC in vitro in response to both radiation modalities, x 
– rays and protons, 
• ATMi, ATRi and DNA-PKcsi were more prominent in increasing radiosensitivity of the 
HPV-negative HNSCC cells, in comparison to HPV-positive HNSCC cells that are 
intrinsically more radiosensitive. 
• NHEJ, driven by ATM and DNA-PKcs, is proposed to be the major DSB repair 
mechanism for responding to both x-ray and low-LET proton irradiation in HNSCC 
cells. 
•  The impact of the three drugs did not majorly differ in IR induced protein activation 
and DDR signaling between HPV-negative and HPV-positive HNSCC cells. 
• Low LET protons may induce more complex DNA damage compared to x – rays, which 
is likely to trigger increased cell death.  
The work described in this research project is important as it has investigated the 
potential of combination therapy of DSB repair inhibitors and IR in HNSCC cells. This 
applied not only to the well-studied x – rays, but also to proton irradiation, whose 
radiobiological impact has been relatively understudied. Therefore, this thesis has 
contributed to widening our knowledge and understanding not only on the impact of 
each radiation type alone, but also on their impact in combination with DSB repair 
inhibition in vitro. A long-term goal is the use of the findings presented in this study, 
showing the potential of DSB repair inhibition to improve the radiotherapeutic outcome 
in HNSCC, while reducing radiation associated toxicities, which can contribute to 
increased effectiveness of IR (x – rays and protons) in the effective treatment of HNSCC 
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Abstract: Proton beam therapy (PBT) offers significant benefit over conventional (photon) 
radiotherapy for the treatment of a number of different human cancers, largely due to the 
physical characteristics. In particular, the low entrance dose and maximum energy deposition 
in depth at a well-defined region, the Bragg peak, can spare irradiation of proximal healthy 
tissues and organs at risk when compared to conventional radiotherapy using high-energy 
photons. However, there are still biological uncertainties reflected in the relative biological 
effectiveness that varies along the track of the proton beam as a consequence of the increases in 
linear energy transfer (LET). Furthermore, the spectrum of DNA damage induced by protons, 
particularly the generation of complex DNA damage (CDD) at high-LET regions of the distal 
edge of the Bragg peak, and the specific DNA repair pathways dependent on their repair are 
not entirely understood. This knowledge is essential in understanding the biological impact of 
protons on tumor cells, and ultimately in devising optimal therapeutic strategies employing PBT 
for greater clinical impact and patient benefit. Here, we provide an up-to-date review on the 
radiobiological effects of PBT versus photon radiotherapy in cells, particularly in the context of 
DNA damage. We also review the DNA repair pathways that are essential in the cellular 
response to PBT, with a specific focus on the signaling and processing of CDD induced by high-
LET protons. 
Keywords: DNA damage; DNA repair; proton beam therapy; radiobiology 
 
1. Introduction 
Since its first application in the 1950s, proton beam therapy (PBT) is gaining ground in 
radiation oncology thanks to its radiobiological and physical advantages over photon 
radiotherapy [1]. Proton beams are characterized by a low entrance dose, whereby the protons 
lose energy along the track and just before they stop, the dose peaks in depth at a narrow and 
well-defined range called the Bragg peak (Figure 1A). The energy deposition drops rapidly 
shortly after the peak at the distal fall-off. This spares the surrounding tissue and organs at risk 
(OARs) in close proximity to the tumor being treated. A combination of beams with different 
initial energies can produce a wider peak, the so-called spread-out Bragg peak (SOBP), allowing 
the irradiation of larger target tumor volumes [2] (Figure 1B). However, as the protons slow down 
and lose energy further, their linear energy transfer (LET) increases and becomes maximal in the 




Figure 1. Depth–dose distribution of protons and relationship to energy and linear energy 
transfer (LET). (A) An unmodulated (pristine) Bragg peak produced by a proton beam. (B) 
Spread-out Bragg peak (SOBP) from several modulated proton beams. 
As of now, there are 70 operative facilities worldwide for PBT and 42 under construction 
according to the Particle Therapy Co-Operative Group (https://www.ptcog.ch), with 150,000 
patients receiving PBT treatment. Despite over 60 years of therapeutic use of protons, there are 
several uncertainties regarding the relative biological effectiveness (RBE) of the proton beam 
along the track, particularly throughout the SOBP where there are differences in proton energy 
and, therefore, LET. There is also a lack of understanding of the DNA damage induced by PBT, 
particularly the complexity and relative levels of clustered/complex DNA damage (CDD) 
induced by protons at the distal edge of the Bragg peak. Consequently, the cellular DNA damage 
response (DDR) and repair pathways that are required for resolving CDD generated by PBT are 
not fully understood. Related to this, individual human cancers will furthermore display inherent 
differences in radiosensitivity to PBT, of which proteins involved in the DDR play such an 
important role. These uncertainties limit our ability to use PBT to its full advantage, by exploiting 
tumor killing while reducing the exposure of healthy tissue [3]. 
In this review, we provide the latest knowledge of the radiobiology of PBT, particularly in 
the context of DNA damage and the repair pathways that are important for the cellular DDR, and 
discuss the areas where ongoing research is necessary, which will have a major impact on the 
effective clinical use of PBT for cancer treatment. 
2. Relative Biological Effectiveness (RBE) and Linear Energy Transfer (LET) 
RBE is used to correlate PBT to photon radiotherapy, as is it the ratio of the reference 
radiation (photon) dose to the dose of protons required to cause the same biological effect. In 
clinical practice, a constant RBE value of 1.1 is utilized throughout the Bragg curve, despite the 
ongoing debate about whether this is the optimal solution or not [3–5]. RBE depends on both 
physical factors such as the proton beam energy, the dose fractionation and dose rate, and 
biological factors including the type of the tissue, cell-cycle stage, the oxygenation level, and the 
position of irradiation along the SOBP [5–7]. Experimental evidence largely derived from in vitro 
clonogenic survival assays using PBT facilities ranging from 65–250 MeV have demonstrated that 
the RBE value is variable and increases with decreasing dose [3,5,8,9]. In spite of the large 
fluctuation derived from in vitro data and the biological uncertainty, a constant RBE of 1.1 is used 
clinically to minimize the potential for risks [3,7,10,11]. One of the parameters mainly determining 
RBE values is the LET, which is the energy loss and deposition along the path of the proton beam 
and is a measure of ionization density [3,5]. Therefore, the higher the LET is, the denser the 
ionization events are, resulting in more extensive damage induction. High-energy PBT is 
considered low-LET irradiation; however, as the proton beam energy decreases throughout the 
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SOBP, the LET increases particularly at the distal edge. Consequently, RBE values have been 
reported to rise from ~1.1 in the entrance, to ~1.2 in the center, ~1.4 at the distal edge, and ~1.7 in 
the distal fall-off the SOBP [11,12]. However, RBE values at the distal fall-off were shown to rise 
to over 3, which is supported by two other studies using clonogenic survival assays indicating 
RBE values of up to 2.3 [13] and 3.5 [14]. Furthermore, a dose shift around the distal edge where 
the biological dose extends beyond the range of the SOBP can threaten proximal healthy tissue, 
potentially causing unexpected side effects [15]. Interestingly a recent in vivo study using rat 
cervical spinal cords irradiated at four different positions of an SOBP demonstrated that RBE 
values varied from 1.1 to 1.3, dependent on LET [16]. The uncertainties and challenges with RBE 
are not covered at length here, and we refer the reader to the literature cited above and more 
recent reviews [17,18]. 
3. Radiobiological Effects of Protons 
3.1. DNA Damage and Repair 
The therapeutic effect of PBT, similar to conventional radiotherapy techniques, relies on 
significant DNA damage within tumorous cells leading to cell death. A variety of DNA lesions 
are induced along the radiation track (Figure 2), which include DNA base damage, sites of base 
loss (abasic sites), and DNA single-strand breaks (SSBs) that are most abundantly generated. On 
the other hand, the formation of DNA double-strand breaks (DSBs) and complex DNA damage 
(CDD) containing two or more DNA lesions in close proximity (within 1–2 helical turns of the 
DNA [19]) are less frequent, although these are considered the most lethal [20–22]. However, 
human cells have developed a sophisticated signaling network, the cellular DDR, which detects 
and repairs these DNA lesions [23]. DSBs are mainly resolved via two repair pathways, non-
homologous end-joining (NHEJ) and homologous recombination (HR) (reviewed in [24,25]). 
Pathway choice is partly dependent on cell-cycle stage, with NHEJ mostly active in G0/G1, 
whereas HR is active in S/G2 phases [26]. NHEJ can be further divided into classical NHEJ, which 
involves the Ku70/80 heterodimer that binds to the DSB ends and recruits the DNA-dependent 
protein kinase catalytic subunit (DNA-Pkcs), and X-ray repair cross-complementing protein 4 
(XRCC4)–DNA ligase IV that promotes the end-joining reaction (Figure 2B). Whereas alternative 
NHEJ involves DNA end resection by the MRE11–RAD50–NBS1 (MRN) complex, poly(ADP-
ribose) polymerase-1 (PARP-1) that binds to the DNA ends, and X-ray repair cross-
complementing protein 1-DNA ligase III (XRCC1-Lig III) or DNA ligase I (Lig I) that seals the 
DSB (Figure 2C). During HR, the DNA undergoes end resection by the MRN complex and the 3′-
single stranded DNA is coated by replication protein A (RPA) and RAD51 that promotes invasion 
into the sister chromatid. DNA synthesis is followed by resolution of Holliday junctions before 
completing repair (Figure 2D). CDD, given that this contains localized damage over short 
distances within the DNA, can include a mixture of DNA base damage, abasic sites, SSBs, and 
DSBs [27]. This, therefore, represents a major barrier to the cellular DDR for efficient repair; 
however, considering the nature of the damage, it is assumed that these CDD sites will require 
the relevant proteins involved in base excision repair (BER), as well as DSB repair. BER is 
generally coordinated through the action of damage-specific DNA glycosylases that excise the 
damaged DNA bases, AP-endonuclease 1 (APE1) that incises the resulting abasic sites and 
generates an SSB for PARP-1 binding, DNA polymerase  (Pol ) that removes the 5′-
deoxyribosephosphate moiety and inserts the correct undamaged nucleotide, and a complex of 




Figure 2. The response to ionising radiation (IR)-induced DNA damage. Proton beam therapy 
(PBT), similar to other radiotherapy techniques, targets DNA and can generate an abundance of 
DNA lesions, where oxidative DNA base damage, abasic sites, and single-strand breaks (SSBs) 
predominate, and which are repaired via (A) the base excision repair (BER) pathway. This 
involves recognition of the damaged base by a damage specific DNA glycosylase, incision of the 
abasic site by AP-endonuclease 1 (APE1) and SSB binding by poly(ADP-ribose) polymerase-1 
(PARP-1), 5’-deoxyribosephosphate (dRP) removal and gap filling by DNA polymerase β (Pol β), 
and finally ligation by X-ray repair cross-complementing protein 1-DNA ligase III (XRCC1–Lig 
III) complex. Double-strand breaks (DSBs) are repaired by different pathways dependent on 
cell-cycle phase. In the G0/G1 phases, DSBs are repaired by either (B) classical non-homologous 
end-joining (NHEJ) involving Ku70/80 that binds to the DNA ends, followed by DNA-dependent 
protein kinase catalytic subunit (DNA-Pkcs) and XRCC4–Lig IV that promote DNA ligation, or 
via (C) alternative NHEJ which involves DSB end resection by the MRE11–RAD50–NBS1 (MRN) 
complex, PARP-1 binding to the DSB ends, and subsequent repair by Lig I or XRCC1–Lig III. In 
the S/G2 phases of the cell cycle, DSB repair is achieved by (D) homologous recombination (HR) 
which uses a sister chromatid for repair. Therefore, following DNA end resection by the MRN 
complex, replication protein A (RPA) and RAD51 bind to the single-stranded DNA overhangs 
that promote strand invasion and subsequent DNA synthesis in the presence of RAD52/RAD54, 
as well as formation and resolving of Holliday junctions. The induction of complex DNA damage 
(CDD), consisting of several DNA lesions in close proximity, particularly by high-LET protons at 
the distal edge of the SOBP, likely require multiple pathways for repair. 
3.2. DNA Damage Induction and Repair Following PBT 
Protons, as particles with mass and positive charge, interact with tissue completely 
differently from photons which have neither mass nor charge, although the specific physical 
aspects (e.g., beam intensity, LET, and secondary particle spectra) depend very much on the 
proton beam delivery system [30]. Consequently, DNA damage induction and the mechanisms 
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of DNA repair employed are reportedly different between PBT and conventional radiotherapy 
[31]. Most of the focus of current studies is on examining the induction of DSBs, given that they 
are one of the major contributors, along with CDD, to cell lethality post-irradiation (Table 1). 
Firstly, a significantly higher level (~1.2–1.6-fold) of DSBs, particularly at 30 min post-irradiation, 
via analysis of phosphorylated histone variant H2AX (H2AX) foci, was shown for a 200 MeV 
PBT source compared to 10 MV photons in two human tumor cell lines, ONS76 medulloblastoma 
cells and MOLT4 leukemia cells [32]. The disparities in foci number diminished after 6 h post-
irradiation, although it was reported that the PBT-induced H2AX foci in the ONS76 cells 
appeared to be ~1.2–1.5-fold larger in size, indicating a possible CDD phenotype. The fact that 
these foci were resolved with similar kinetics would, however, argue that these DSBs are possibly 
not complex in nature, given that CDD sites usually take a longer time to resolve. Similarly, the 
number of DSBs in SQ23B head and neck squamous cell carcinoma (HNSCC) cells measured by 
pulse-field gel electrophoresis was found to be ~1.2-fold higher for both 76 MeV and 201 MeV 
PBT sources than with photons induced by -irradiation [9]. Yet interestingly, DSB numbers were 
not significantly different between the two PBT energies or at different positions (entrance, mid, 
and distal) relative to the SOBP, and any potential differences in kinetics of DSB repair were not 
reported. Numbers of both DSBs and SSBs were also shown to be significantly higher (~1.2–1.6-
fold increases in comet percentage tail DNA) in glioblastoma stem-like cells treated with protons 
in comparison to 320 kV X-rays, particularly at 20–48 h post-irradiation, which was associated 
with a higher level of apoptosis [33]. In contrast to the above studies, the numbers of H2AX and 
53BP1 foci (as DSB markers) induced in TrC1 prostate cancer cells and murine embryonic 
fibroblasts irradiated at the entrance dose of a 187 MeV PBT beam compared to 320 kV photons 
were observed to be the same 30 min post-irradiation [34]. The kinetics of DSB repair, specifically 
the resolving of H2AX and 53BP1 foci, were also shown to be similar in response to the two 
irradiation conditions. This is supported by equal numbers of 53BP1 foci induced in AG01522 
skin fibroblasts 30 min post-irradiation at the entrance dose, and their repair up to 24 h post-
irradiation, of a 60 MeV proton beam compared to 225 kV X-rays [35]. Additionally, it was 
demonstrated that the initial level of induction of DSBs (H2AX foci) was the same in wild-type, 
HR-deficient, and NHEJ-deficient Chinese hamster ovary cell lines following 1 Gy irradiation 
with low-LET 138 MeV PBT and 200 kV X-rays [36]. However PBT resulted in further reduced 
clonogenic survival in wild-type cell lines versus X-ray irradiation, suggesting that the quality of 
DNA damage (e.g., formation of CDD) is what differs between PBT and X-rays and their 
effectiveness in cell killing, although differences in levels of CDD was not proven directly. 
Our recent study, using the neutral comet assay, demonstrated that the kinetics of repair of 
DSBs induced by the entrance dose of a proton beam (58 MeV) versus 100 kV X-rays in HeLa and 
HNSCC cells are not significantly different [37]. This would indicate that the nature and 
complexity of the DSBs following the two irradiation conditions are similar. Likewise, the kinetics 
of SSB/abasic site repair using the alkaline comet assay were comparatively the same. 
Furthermore, we observed that low-energy protons generated at the distal edge of a SOBP (11 
MeV mean energy incident on the cells) had no impact on the repair of DSBs in both HeLa and 
HNSCC cells in comparison to 58 MeV protons and 100 kV X-rays, even though there was a 
significant difference in clonogenic survival between the proton irradiation conditions. However, 
we observed a significant delay in the repair of SSB/abasic sites only following low-energy proton 
irradiation. In fact, levels of SSBs were ~4–7-fold higher 2 h post-irradiation under these 
conditions, in comparison to cells irradiated with 58 MeV protons. This suggested that low-
energy protons can generate CDD that is largely SSB-associated, which persists for several hours 
(>2 h) post-irradiation and contributes to decreased cell survival, although the specific nature and 






Table 1. Comparisons of double-strand breaks (DSBs) induced by proton beam therapy (PBT) 
versus photon irradiation. 
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[37] 
N.S. refers to not specified. HR—homologous recombination; NHEJ—non-homologous end-joining; 
SOBP—spread-out Bragg peak. 
3.3. Generation of Reactive Oxygen Species and Cell-Cycle Progression Following PBT 
Related to DNA damage induction is the generation of reactive oxygen species (ROS). 
Interestingly, a more rapid and prominent increase in ROS following PBT was reported in neural 
precursor cells from rat hippocampus exposed to either 250 MeV protons near the Bragg peak, 
versus 250 kV X-rays [38]. Proton-induced ROS peaked 6 h post-irradiation and was ~1.5-fold 
above the control levels, while photon-induced ROS peaked 12 h post-irradiation and was ~1.3-
fold above the control levels at a 5 Gy dose equivalent. However, less prominent increases and 
time-dependent differences in ROS levels were observed at a 1 Gy dose. Furthermore, it was 
shown that protons were more effective in killing cancer stem-like cells derived from non-small-
cell lung cancer cell lines, and that compared to photons, protons induced higher levels (~1.1–1.7-
fold) of ROS after treating these cells with equivalent doses of radiation [39]. ROS were also 
demonstrated to play an important role in inducing cytotoxicity of glioblastoma stem-like cells 
treated with protons, and ROS levels were ~1.8-fold higher following protons versus 320 kV X-
rays at 20 h post-irradiation, which led to increased cellular apoptosis [33]. Levels of ROS were 
continually and dramatically higher (~6–7-fold) three days following protons in comparison to 
photons.  
Cell-cycle progression is another important factor related to proton-induced DNA damage, 
as DNA damage checkpoints will be activated to allow cells to undergo extensive DNA repair 
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prior to DNA synthesis or replication. This is also important for understanding the repair 
pathway choice (see Section 3.4), given that DSBs can be repaired by either NHEJ or HR in 
different cell-cycle phases. One study conducted using human lung cancer cells suggested that, 
following 62 MeV protons, CRL5876 cells appeared to accumulate (~2-fold increase) in the G1 
phase at 24 h post-irradiation, but that both CRL5876 and HTB177 cells accumulate (~1.5–2-fold 
increase) in G2/M at 48 h post-irradiation, versus unirradiated controls [40]. However, no 
comparisons against photon irradiation were performed. We also recently noted an accumulation 
(~1.5-fold increase) of HeLa cells in G2/M, particularly at 8–24 h post-irradiation with 58 MeV 
PBT, which was not LET-dependent as the same observation was seen with cells irradiated with 
low-energy protons generated at the distal edge of a SOBP (11 MeV mean energy incident on the 
cells) at higher LET [37,41]. This, however, suggests that CDD induced by high-LET protons, at 
least under the conditions analyzed, is not a major contributory factor to the observed cell-cycle 
checkpoint activation. An early study observed G2 arrest of glioblastoma cells at 24–72 h post-
irradiation following 5.7 MeV protons at relatively high-LET, which was more pronounced (~1.5–
2.5-fold) than irradiation of cells using 120 kV X-rays [42], suggesting potential proton-specific 
effects. In contrast, there was no dramatic difference in cell-cycle distribution of Chinese hamster 
ovary cells when comparing the response to low-LET 138 MeV PBT and 200 keV X-rays, where a 
degree of G2/M accumulation (~1.2–2-fold increase) of cells irradiated at 5 Gy dose equivalent, 
particularly at 6–12 h following both irradiation types, was observed [36]. Furthermore, it was 
shown that proton irradiation of glioblastoma stem-like cells actually led to a shortened G2/M 
arrest compared to 320 kV X-ray irradiation, as demonstrated by a ~2-fold accumulation of cells 
in this cell-cycle phase at six days post-irradiation following photon irradiation only [33]. 
However, the baseline levels of cells in G2/M in this study were noticeably different (~10 and 20 
%) in the experiments comparing proton and photon irradiation. Given the variability in the 
observations, more studies to directly compare progression of cells through the cell cycle in 
response to protons versus photons in specific cell models, and the impact of LET need to be 
performed. 
3.4. DSB Repair Pathway Choice Following PBT  
NHEJ is considered the primary mechanism for DSB repair, particularly in response to 
photon irradiation, but there are a few conflicting reports to date suggesting that the DNA repair 
pathway choice specifically following PBT may in fact be different (Table 2). Firstly, by studying 
DNA repair kinetics in wild-type, NHEJ-deficient (XRCC4 and DNA-Pkcs) and HR-deficient 
(XRCC2 and XRCC3) Chinese hamster cell lines exposed to photon (-irradiation) versus low-
LET 200 MeV protons, the same biological effect was observed in each cell line comparing the 
two radiation types [43]. Therefore, a delayed decrease in H2AX foci at 3–12 h post-irradiation, 
as well as significantly reduced clonogenic survival, was observed in DNA-Pkcs-deficient cells in 
comparison to wild-type cells. However, HR-deficient cells also displayed increased sensitivity 
to protons and photons, and significantly higher chromosomal aberrations (~2–4-fold increases) 
were found in both NHEJ- and HR-deficient cells compared to the wild-type cells following both 
radiation types. From this study, it was suggested that NHEJ is the major pathway, and DNA-
Pkcs is the main protein involved in resolving DSBs induced not only by photons but also by low-
LET protons. This is supported by another study demonstrating that there were no significant 
differences in H2AX foci formation and their repair in wild-type and DNA-Pkcs-deficient 
Chinese hamster ovary cell lines in response to γ-irradiation versus low-LET protons [44]. 
Persistent H2AX foci was observed in the DNA-Pkcs-deficient cells 6 h post-irradiation with 
higher doses (2-3 Gy) of photons or protons, correlating with increased radiosensitivity versus 
wild type cells. In contrast using a similar experimental set-up of Chinese hamster ovary cell lines 
deficient in HR (XRCC3) or treated with small interfering RNA (siRNA) targeting RAD51 and 
comparing low-LET 138 MeV proton and 200 kV photons, it was suggested that PBT induced 
more lethal chromosomal aberrations [36]. Moreover, this study reported that PBT was more 
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effective in killing HR-deficient cell lines than NHEJ-deficient cells and, therefore, there was an 
enhanced dependence on HR for repair of proton-induced DSBs. The same conclusion was found 
following an examination of low-LET PBT (138 MeV) versus 200 kV photon irradiation in human 
tumor cells that were treated with siRNA or inhibitors targeting key proteins involved in HR and 
NHEJ [45]. It was found that DNA-Pkcs inhibition significantly radiosensitized A549 lung cancer 
and glioblastoma cells to photon-irradiated cells, but that this was to a lesser degree following 
low-LET PBT. Photon-irradiated cells in the presence of the inhibitor also showed delayed 
resolving of H2AX foci at 6–24 h post-irradiation which were ~1.5–3-fold higher than the 
corresponding cells following proton irradiation. In addition, it was found that HR-deficient cell 
lines (RAD51 siRNA) were more sensitive to proton irradiation and similarly had difficulty 
resolving H2AX foci, again suggesting a dependence of the cells to utilize HR for repairing 
proton-induced lesions. Evidence examining the response of HeLa cells to 21 MeV protons by 
immunostaining and high-resolution microscopy demonstrated an association of RAD51 with 
almost every 53BP1 foci 1 h post-irradiation, also indicating that the proportion of cells 
undergoing HR following PBT may be higher [46]. Interestingly, when examining the 
comparative RBE of 17 non-small-cell lung cancer cell lines in response to 235 MeV protons and 
250 kV X-rays, only five of these displayed increased sensitivity to protons and two had 
confirmed defects in BRCA1 indicative of a deficiency in HR [47]. The unexpected differences in 
RBE between protons and photons was again predicted to be due to differences in the formation 
of CDD. Given these opposing findings, more definitive evidence of the DNA repair pathway 
choice following proton irradiation is necessary. 
Table 2. DNA double strand break (DSB) repair pathway choice following proton beam therapy 
(PBT) versus photon irradiation. 
Cell line Irradiations Outcome Ref 
Wild-type, HR- and NHEJ-
deficient Chinese hamster 
ovary cell lines 
200 MeV protons and 
137Cs -rays 
NHEJ is the major pathway for both 
photons and low-LET protons 
[43] 
Wild-type and NHEJ-deficient 
Chinese hamster ovary cell 
lines 
14.4 MeV plateau protons 
and 667 keV 137Cs -rays 
NHEJ is the major pathway for both 
photons and low-LET protons 
[44] 
Wild-type, HR-, and NHEJ-
deficient Chinese hamster 
ovary cell lines 
138 MeV protons and 
200-kV X-rays 
Dependence on HR following protons [36] 
A549 lung cancer; 
glioblastoma cells 
138 MeV protons and 200 
kV X-rays 
Dependence on HR following protons [45] 
HeLa 21 MeV protons 
Higher proportion of cells undergoing 
HR following protons 
[46] 
Non-small-cell lung cancer 
cells 
235 MeV protons and 250 
kV X-rays 
HR only partly required following 
protons 
[47] 
LET—linear energy transfer; HR—homologous recombination; NHEJ—non-homologous end-joining. 
3.5. CDD Formation Following PBT 
Given the increase in LET toward the distal edge of the SOBP, this is considered to be 
particularly effective in increasing the amount of CDD, which is similar in nature to that observed 
following heavy-ion irradiation [31]. CDD is considered equally as effective as DSBs in cell killing 
due to the difficult nature of its repair leading to its persistence in cells and tissues [27]; therefore, 
it should be considered as a crucial factor in the cellular response to PBT. However, to date, most 
of the evidence relating to CDD formation specifically following proton irradiation is indirect. 
Indeed, through Monte Carlo simulations, and by examining DNA damage clustering with 
increasing PBT energies (500 keV–50 MeV) and, thus, decreasing LET, the amount and size of 
both complex SSBs and complex DSBs were found to decrease [48]. Similarly, the relative 
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frequencies of complex SSBs and DSBs were also shown to increase proportionally with 
increasing LET, which is dependent on proton energy [49,50]. A biophysical model of radiation-
induced cell death and chromosomal aberrations based on the critical role of CDD, and compared 
to experimental data in AG01522 and V79 cells following irradiation with 62 MeV protons 
predicted that these end-points increased along the SOBP and were highest at the distal fall-off 
due to low-energy protons [6]. Cell death at a 2 Gy dose was calculated to increase ~1.5-fold and 
chromosome aberrations (dicentrics per cell) increased ~4-fold at the distal fall-off compared to 
the entrance dose. Additionally, more recently, Monte Carlo simulations were utilized to examine 
unrepaired DSBs 24 h after proton irradiation, which were observed to increase ~1.5-fold (2 Gy) 
and 1.7-fold (5 Gy) toward the distal fall-off of the SOBP at higher LET, predictably through 
increased DSB complexity [51]. 
In relation to experimental evidence, apart from observations of changes in RBE via 
clonogenic survival assays, which are suggestive of CDD formation, direct evidence is lacking, as 
CDD is notoriously difficult to measure and specifically define in terms of the nature of DNA 
damage complexity in vivo [21,52]. However in SQ23B HNSCC cells CDD, specifically complex 
DSBs measured by utilizing the Escherichia coli enzymes Fpg and Nth for excision of residual 
oxidative DNA base damage prior to pulse-field gel electrophoresis, was found to be ~1.2-fold 
higher for PBT at 76 MeV, but not 201 MeV, in comparison to -irradiation [9]. Interestingly, CDD 
formation did not depend on the position of irradiation in the SOBP, which conflicts with other 
reported data. In particular, it was demonstrated in AG01522 skin fibroblasts that persistent 
53BP1 foci, as a marker of DSBs, was evident when cells were irradiated at the distal end of the 
SOBP of a 60 MeV proton beam in comparison to cells irradiated at the entrance dose or at the 
Bragg peak itself [35]. These persistent foci were evident at 24 h post-irradiation with Bragg peak 
protons and were elevated ~2-fold in comparison to the entrance dose and to 225 kV X-ray 
irradiation. This is supported by observations of a delay in resolving H2AX and 53BP1 foci in 
TrC1 prostate cancer cells and murine embryonic fibroblasts irradiated at the Bragg peak (31 
MeV) compared to those irradiated at the entrance dose (187 MeV) [34]. Whilst the initial numbers 
of H2AX and 53BP1 foci under the comparative conditions were observed to be the same, there 
were significantly (~1.1–1.3-fold) higher levels of foci particularly at 1–4 h post-irradiation in cells 
irradiated at the Bragg peak, and these foci were also shown to be on average ~1.3-fold larger in 
size at 0.5 h and 6 h post-irradiation. However, all foci, indicative of DSB levels, were shown to 
be resolved by 24 h irrespective of the irradiation set-up. These two studies are suggestive of the 
formation of complex DSBs, particularly at higher LET, which have a longer lifetime to resolve, 
although direct evidence for this was not presented. More recently, we described utilization of 
different versions of the comet assay to directly demonstrate that CDD is generated in HeLa and 
HNSCC cells by low-energy protons (11 MeV mean energy incident on the cells; relatively high-
LET) at the distal edge of an SOBP, in comparison to the cells irradiated at the entrance of a proton 
beam (58 MeV mean energy; low LET) that do not [37]. In particular, using an alkaline version of 
the comet assay, we showed that low-energy protons caused a reduced rate of repair of cellular 
SSBs and alkali-labile sites, suggesting that CDD was largely SSB/abasic site in nature. Under 
these conditions, we observed that SSB levels in cells were ~4–7-fold higher 2 h post-irradiation 
in comparison to cells irradiated with 58 MeV protons. Interestingly, there was no defect in the 
repair of DSBs visualized using the neutral comet assay. Furthermore, an enzyme-modified 
neutral comet assay employing recombinant DNA repair enzymes to excise any residual 
oxidative DNA base damage and abasic sites in association with DSBs confirmed direct evidence 
that CDD is formed by low-energy protons generated at the distal end of the SOBP. We 
demonstrated that CDD formation in HeLa cells was increased by ~1.3-fold immediately post-
irradiation with low-energy protons versus 58 MeV protons, and that this damage persisted for 
at least 4 h post-irradiation. These findings altogether highlight the ability of PBT to induce 
potentially more lethal CDD at and around the Bragg peak where the highest LET occurs. 
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3.6. Cellular Response to CDD Generated by PBT 
CDD sites are considered lethal, although this very much depends on the degree of 
complexity and the nature of the damage. Indeed, given that, broadly speaking, these are likely 
to consist of either complex SSBs or complex DSBs, the cellular response to these may require 
multiple DNA repair pathways and proteins, including, as indicated above (Figure 2), a 
combination of BER and NHEJ/HR [22,27]. However, despite an appreciation that CDD is a 
critical factor in the radiobiology of PBT, the cellular response to CDD induced by PBT, 
particularly with increasing LET along the SOBP, is surprisingly understudied. Predictably, there 
should be a signaling (DDR) mechanism within cells, similar to H2AX for DSBs, which is 
responsible for promoting the repair of CDD sites. We recently reported for the first time that 
monoubiquitylation of lysine 120 on histone H2B is promoted in HeLa and HNSCC cells in 
response to CDD induced by low-energy (11 MeV mean energy incident on the cells) protons at 
the distal edge of an SOBP, catalyzed by the E3 ubiquitin ligases ring finger 20/40 complex 
(RNF20/40) and male-specific lethal 2 homolog (MSL2) [37]. In fact, levels of histone H2B 
ubiquitylation increased by ~1.3–1.6-fold in HeLa cells and ~1.6–2.2-fold in HNSCC cells at 3–6 h 
post-irradiation. We demonstrated that this mechanism is important for the efficient repair of 
CDD sites, as revealed by delayed repair and significant persistence of CDD induced by low-
energy protons in RNF20/40 and MSL2 siRNA-depleted cells using the enzyme-modified neutral 
comet assay, where CDD levels were ~2.3-fold higher compared to the non-targeting control 
siRNA treated cells at 4 h post-irradiation. Furthermore, RNF20/40 and MSL2 were shown to be 
required for promoting cell survival under these conditions, as revealed by clonogenic assays. 
We, therefore, believe that this is a mechanism for signaling recruitment of DNA repair proteins 
and/or for chromatin remodeling necessary for CDD repair (Figure 3). We also described possible 
evidence that other chromatin changes, particularly through histone trimethylation, are evident 
following irradiation of cells with low-energy protons; however, whether this is directly related 
to CDD repair is currently unknown. As a development of these findings, we also recently 
performed siRNA screening of deubiquitylation enzymes (DUBs) to further identify the specific 
enzymes controlling protein ubiquitylation that are involved in modulating cell survival in 
response to CDD induced by low energy (11 MeV; relatively high LET) protons at the distal edge 
of an SOBP, versus more simple DNA damage generated by both low-LET (58 MeV) protons and 
100 kV X-ray irradiation [41]. This study revealed that ubiquitin-specific protease 6 (USP6) is 
required to promote survival in HeLa and HNSCC cells specifically in response to low-energy 
protons, and that this effect is mediated through stabilization of the SSB repair protein PARP-1 
required for efficient CDD repair. In fact, levels of CDD were ~1.8-fold higher in USP6 siRNA-
depleted cells compared to the non-targeting control siRNA treated cells at 4 h post-irradiation. 
This evidence was strengthened and mimicked using the PARP inhibitor olaparib, or through 
depletion of PARP-1 using siRNA, which was demonstrated to increase the radiosensitivity of 
cells to low-energy protons as a consequence of a significant deficiency in CDD repair. This 
correlates with our previous evidence suggesting that CDD generated under these conditions is 
largely SSB in nature [37], and that PARP-1 plays a critical role in its repair. However, our study  
revealed significant synergy between PARP inhibition and CDD induced by low-energy protons 
in enhancing cancer cell killing. Predictably, there is also dependence on other proteins in the 





Figure 3. Proposed model for the cellular response to complex DNA damage (CDD) induced by 
proton beam therapy (PBT) in chromatin. On induction of CDD, this triggers monoubiquitylation 
of histone H2B on lysine 120 (Ub) by the E3 ubiquitin ligases ring finger 20/40 complex 
(RNF20/40) and male-specific lethal 2 homolog (MSL2). This stimulates recruitment of the 
necessary DNA repair proteins and/or chromatin remodeling factors that promote CDD 
accessibility. Poly(ADP-ribose) polymerase-1 (PARP-1) in particular is essential for efficient CDD 
repair. Our evidence also suggests the involvement of histone trimethylation (Me) and 
predictably a deubiquitylation enzyme (DUB) that is able to regulate access to CDD. Repair then 
proceeds through the respective DNA repair pathway dependent on the nature of the damage, 
although we suggest a particular dependence on the base excision repair (BER) pathway in the 
cellular response to high-LET protons, prior to subsequent chromatin assembly. 
Previous studies of CDD have largely focused on high-LET heavy-ion irradiations. Here, 
these have demonstrated that in irradiated cells, CDD increases with increasing LET, but that 
these are predominantly unrepairable CDD that generate either chromosome aberrations through 
the lack of cell-cycle checkpoint activation or drive cells into senescence [53,54]. Therefore, it is 
important not to draw direct parallels between the unrepairable, highly complex CDD generated 
by heavy ions, and CDD sites generated by PBT which are likely to be less complex in nature and 
indeed repairable. Furthermore, it is thought that CDD may also be prone to generating increases 
in mutation frequency due to abortive or slow repair of CDD sites [55]. Nevertheless, due to 
technical limitations and lack of experimental studies in this area, we do not have a full 
appreciation of the cellular response to CDD specifically generated by PBT at different energies 
along the radiation track, and whether the nature of the damage, particularly toward the distal 
edge, is of sufficient complexity to drive mutagenesis and/or chromosomal aberrations. 
Therefore, more extensive research in this area is necessary. 
4. Conclusions and Outlook 
The utilization of PBT for cancer treatment is increasing worldwide and is appreciated to be 
advantageous over conventional radiotherapy as the maximum energy deposition occurs in a 
well-defined region (the Bragg peak) that can be specifically targeted to the tumor, which 
minimizes unnecessary irradiation of the surrounding normal tissues and OAR. However, there 
are still uncertainties with the radiobiology of PBT along the track of the proton beam and 
particularly the generation of high-LET protons at the distal edge that can have a greater impact 
on the molecular and cellular effects. Therefore, there is an urgent need to further understand the 
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biological effects of PBT, and particularly to understand the impact on DNA and how this varies 
with LET. Indeed, whilst it is widely accepted that CDD is induced at the distal edge of the SOBP, 
there is little information on the nature of the damage (e.g., DSB- or SSB-associated) related to 
proton energy/LET, and how cells are able to process this through cellular DDR pathways. This 
is challenging given that CDD is difficult to measure in vivo; thus, new strategies need to be 
devised to tackle this problem. There is also conflicting evidence that simple DSBs induced by 
PBT are largely repaired by HR, in contrast to NHEJ which is employed in response to photon 
irradiation, and whether this is cell-type-dependent. Furthermore, there are potential differences 
in the levels of ROS and impact of cell-cycle progression between protons and photons, although 
again more experimental data are required to substantiate these findings. These essential studies 
have to be carefully designed, particularly as cancer cell lines frequently have defects in DNA 
repair and in the cellular DDR; furthermore, irradiation of cells in specific cell-cycle phases must 
be taken into account given the dependence of cells to largely utilize HR in S/G2 phases. 
Another consideration is that additional experimental models and techniques need to be 
utilized in PBT research, rather than the conventional in vitro experiments using cultured 
monolayer cell lines mostly used to assess clonogenic survival post-irradiation. Increasingly, 
three-dimensional (3D) models are being employed in translational research, which more 
accurately reflect the structure and environment of the original tumor. Therefore, either 3D 
spheroid models of cancer cell lines, or multicellular spheroids encapsulating the tumor cells 
within the correct cellular microenvironment should be used to examine spheroid growth in 
response to PBT. These models will also allow a further examination of PBT radiobiology in terms 
of the types of DNA damage (e.g., DSBs and CDD) induced throughout the SOBP, the DNA repair 
pathways essential for their repair, and the impact of combinations of targeted drugs or inhibitors 
(e.g., those targeting the DDR [56]) with PBT in effective suppression of 3D spheroid growth. The 
next level would be to employ patient-derived organoids for examining how these respond to 
PBT in vitro, and possibly in the future to use these as predictive models for determining tumor 
response and ultimately patient outcome to PBT. Finally, more in vivo experiments employing 
xenograft models to assess growth of specific tumors following PBT, such as those conducted 
using HNSCC [57], should be conducted. These additional models and experiments bring their 
challenges, such as the availability and use of clinical facilities for performing animal irradiations, 
and technical challenges including the precise positioning and delivery of PBT to animals. In 
addition, a large proportion of PBT facilities worldwide are not usually equipped with on-site 
laboratories to effectively perform biological experiments in vitro and in vivo. 
There is also an added level of complexity in terms of considering biological factors that may 
have a significant impact on the cellular DDR to PBT, particularly on overall efficacy of the 
treatment. For example, tumor hypoxia is well known to represent a barrier to the effectiveness 
of photon radiotherapy, although there is evidence that particle therapy with higher LET, 
particularly carbon ions, has a lower oxygen enhancement ratio and can, therefore, overcome 
radioresistance of the tumors. However, whether PBT, particularly at the Bragg peak and the 
associated distal edge with higher LET, is able to have the same impact on experimental models 
is unclear. Also, the tumor microenvironment is of particular importance given the recent success 
of immune checkpoint inhibitors (e.g., targeting PD-1/PD-L1) and their effective combination 
with radiotherapy for cancer treatment. However, again, there is little evidence available to 
understand the added benefit of immunotherapy strategies in combination with PBT. 
Nevertheless, there should be a drive from the clinical and scientific community to collaborate 
and engage in driving this preclinical and translational research which will ultimately be utilized 
for the optimization and personalization of PBT for patient benefit. 
In summary, future PBT research should focus on the following: 




• Employing additional in vitro models (e.g., 3D spheroids/organoids) in radiobiology 
experiments; 
• Increased utilization of in vivo experiments employing specific tumor models; 
• Consideration of other biological factors (e.g., hypoxia, tumor microenvironment). 
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Abstract: The response of head and neck squamous cell carcinoma (HNSCC) to radiotherapy 
depends on human papillomavirus type 16 (HPV) status, and where improved outcome and 
survival is observed in HPV-positive disease. However, strategies to further radiosensitise the 
tumours, particularly relatively radioresistant HPV-negative HNSCC, are actively being sought. 
The impact of targeting the major protein kinases involved in the signaling of DNA double-
strand break (DSB) repair, namely ataxia telangiectasia-mutated (ATM), ataxia telangiectasia 
and Rad3-related (ATR), and the catalytic subunit of DNA-dependent protein kinase (DNA-
Pkcs), on the radiosensitisation of HNSCC cells was examined. The response to both 
conventional photon radiotherapy, but also proton beam therapy, was analysed by clonogenic 
assays and 3D spheroid growth. We observed that inhibition of ATM, ATR, and particularly 
DNA-Pkcs, caused a significant reduction in HNSCC cell survival post-irradiation with both 
photons and protons, with less of an impact on the most radiosensitive HPV-positive cell line. 
The inhibition of DNA-Pkcs and, to a lesser extent ATM, in combination with radiation was also 
more effective at inhibiting the growth of 3D spheroids derived from relatively radioresistant 
HPV-negative HNSCC. Similar effects of the inhibitors were observed comparing photon and 
proton irradiation, demonstrating the potential for targeting DSB repair as an effective 
combination treatment for HNSCC. 
Keywords: ATM; ATR; DNA-PKcs; DNA repair; ionising radiation; proton beam therapy 
 
1. Introduction 
The incidence of head and neck squamous cell carcinoma (HNSCC) has been reported to be 
~800,000 cases per year, and linked with this is the increased rise in oropharyngeal tumours 
associated with human papillomavirus type 16 (HPV) infection (281-283). It has been clearly 
demonstrated that patients with HPV-positive squamous cell carcinoma of the oropharynx 
display improved outcomes and survival rates in comparison to patients with HPV-negative 
disease (186, 187, 203, 204), which is largely due to the increased responsiveness of HPV-positive 
tumours to radiotherapy and chemotherapy. Indeed, this difference in radiotherapy response 
between HPV-positive and HPV-negative HNSCC has been observed in cultured cells derived 
from patients (168, 178, 206). Several studies have indicated that this is caused by defects in the 
signaling and repair of DNA double-strand breaks (DSBs) in HPV-positive HNSCC cells, largely 
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through the measurement of the DNA damage by neutral comet assays, but also through analysis 
of surrogate markers, including γH2AX, 53BP1 and RAD51 foci (168, 207, 284). However, there 
are some discrepancies in relation to the specific DSB repair defect, as the reduced expression of 
proteins involved in both non-homologous end joining (NHEJ; 53BP1 and DNA-Pkcs) and 
homologous recombination (HR; BRCA2 and RAD51) have been observed. We also recently 
reported that HPV-positive HNSCC cells have upregulated levels of enzymes involved in the 
base excision repair (BER) pathway, including XRCC1 and PARP-1 (207). Furthermore, studies 
conducted at the genomic level have identified significant genome instability in HPV-positive 
HNSCC cells and tissues, including alterations in DNA repair genes (285-287). 
Given that HPV-positive HNSCC cells display an altered capacity for DNA repair, this has 
revealed that targeting the DNA damage response, particularly in relatively radioresistant HPV-
negative HNSCC that display proficient DNA repair mechanisms, may be an effective strategy 
for the radiosensitisation of the tumour (208). Specifically, the major protein kinases that co-
ordinate the repair of DNA DSBs through NHEJ and HR, namely ataxia telangiectasia-mutated 
(ATM), ataxia telangiectasia and Rad3-related (ATR), and the catalytic subunit of DNA-
dependent protein kinase (DNA-Pkcs), are increasingly being investigated as targets for 
inhibitors to increase cellular radiosensitisation, principally in response to conventional (photon) 
radiotherapy. For example, the DNA-Pkcs inhibitors KU0060648 (244) and IC87361 (245), and the 
ATM inhibitor GSK635416A (209) have been demonstrated to increase radiosensitivity of HNSCC 
cell lines. A number of studies have also focused on ATR as a target to radiosensitise HNSCC 
cells, through the inhibitors VE821 (246) and AZD6738 (214, 244). Whilst the majority of these 
studies have focused on utilising clonogenic assays as an end-point, the ATR inhibitor AZD6738 
was shown to impede the growth of 3D spheroids of hypopharyngeal (FaDu) cells in combination 
with radiation, which are more representative of the original tumour in vivo (214). Cumulatively, 
these data would suggest that targeting the DSB repair pathway can be an effective approach for 
increasing the (photon) radiosensitivity of HNSCC cells. 
In addition to conventional (photon) radiotherapy, proton beam therapy is increasingly 
being utilised for HNSCC treatment (218). This is due to precise delivery of the radiation dose to 
the tumour via this radiotherapy technique, resulting in sparing of the normal tissues and organs 
at risk. However, there is still significant uncertainty regarding the biological impact of protons 
versus photons, which is important in defining potential combinatorial strategies using targeted 
drugs to optimise tumour cell radiosensitivity (reviewed in (268)). Specifically, and given that 
DNA DSBs are the major lesion contributing to ionising radiation-induced cell killing, there are 
contrasting studies suggesting a dependence on either NHEJ or HR for DNA DSB repair in 
response to protons. For example, it has been suggested that HR is the major pathway for the 
repair of DNA DSBs induced in response to protons in A549 lung cancer and glioblastoma cell 
lines, which would indicate that targeting ATR may be a successful radiosensitisation strategy 
(118). However, studies analysing the comparative response of HPV-positive and HPV-negative 
HNSCC cells to photons versus protons, and the impact of targeting the major kinases involved 
in DSB repair has not been reported previously. Additionally, utilising HNSCC cells grown as 
monolayers, but also as 3D spheroids that more accurately reflect the structure and environment 
of the original tumour, is necessary. 
Herein, we have characterised the impact of ATM, ATR and DNA-Pkcs inhibition on the 
response of HPV-positive and HPV-negative HNSCC cells from the oropharynx to both photons 
and protons, through the utilisation of clonogenic survival assays and 3D spheroid growth 
assays. Given that the HPV-negative HNSCC cells are relatively radioresistant compared to their 
HPV-positive counterparts, we also expanded the results using cells derived from the 
hypopharynx and oral cavity focusing on 3D spheroid growth, which is more representative of 
the original tumour and its treatment in vivo. We report that the clonogenic survival and growth 
of 3D spheroids of cells derived from HPV-positive and HPV-negative HNSCC can be 
significantly reduced using inhibitors targeting ATM, ATR, and particularly DNA-Pkcs, in 
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combination with both photon and proton irradiation. This suggests that these potential 
therapeutic strategies could be exploited for the effective treatment of HNSCC, and particularly 
for relatively radioresistant HPV-negative tumours. 
 
2. Results 
2.1. HPV-Positive HNSCC Cells Are More Radiosensitive than HPV-Negative HNSCC Cells to Photons 
and Protons 
We, and others, have previously demonstrated that there is increased radiosensitivity of cells 
derived from HPV-positive HNSCC in comparison to HPV-negative HNSCC, which reproduces 
the effects observed following irradiation of the respective tumours (168, 206, 207). To expand on 
these observations, we used two cell lines derived from each tumour type, where the expression 
of E6 and E7 oncogenes was confirmed by p16 expression (Figures 1A and S1). Similar to previous 
data, we were indeed able to reproduce the difference in radiosensitivity of two HPV-positive 
HNSCC cell lines (UMSCC47 and UPCI-SCC090) in comparison to two HPV-negative HNSCC 
cell lines (UMSCC6 and UMSCC74A; Figure 1B,C) in response to photon irradiation by 
clonogenic assays. It should be noted that the colony size was variable between the cell lines, but 
that colony counting settings were optimised for each cell line and the same settings used across 
the various treatments for consistency. We also analysed the survival of the same cells following 
proton irradiation and demonstrated that, similar to results observed following photons, the two 
most radiosensitive were from HPV-positive HNSCC (Figure 1D,E). The radiosensitivity of the 
cell lines was generally in the order UMSCC6 > UMSCC74A > UMSCC47 > UPCI-SCC090, and 
statistical analysis reveals the significantly increased radiosensitivity of UPCI-SCC090 in 





Figure 1. Comparative radiosensitivity of human papillomavirus type 16 (HPV)-negative and 
HPV-positive head and neck squamous cell carcinoma (HNSCC) cells in response to photons and 
protons. (A) Whole cell extracts from HNSCC cells were prepared and analysed by 
immunoblotting with the indicated antibodies. Clonogenic survival of HNSCC cells following 
treatment with increasing doses of (B,C) x-rays or (D,E) protons was analysed from three to four 
biologically independent experiments. (B and D) Shown is the surviving fraction ± S.E. (C and E) 
Representative images of colonies in non-irradiated and irradiated plates (the latter were seeded 
with four times and eight times the number of cells, accordingly). Statistical analysis using a one 
sample t-test of surviving fractions at a 2 Gy dose of x-rays reveals significant differences of p < 
0.03 (UMSCC6 vs. UPCI-SCC090), p < 0.005 (UMSCC74A vs. UPCI-SCC090); and at a 4 Gy dose 
of protons of p < 0.04 (UMSCC6 vs. UPCI-SCC090), p < 0.04 (UMSCC74A vs. UPCI-SCC090). The 
uncropped blots and molecular weight markers of Figure 1 are shown in Figure S1. 
2.2. Survival of HNSCC Cells Following by Photon and Proton Irradiation Can Be Reduced by 
Targeting ATM, ATR and DNA-Pkcs 
Using clonogenic assays, we first analysed the impact of targeting the major protein kinases 
involved in DNA DSB repair using specific and characterised inhibitors (ATMi, KU-55933; ATRi, 
VE-821; DNA-Pkcsi, KU-57788) on the survival of HPV-positive and HPV-negative HNSCC 
incubated with the inhibitors for 24 h in the absence of radiation, versus a vehicle-only control 
(DMSO). This demonstrated a varied response dependent on the cell line utilised (Figure S3), 
although ATRi significantly decreased cell survival by 41–54% in all HNSCC cell lines, ATMi by 
22–44% in three cell lines (UMSCC6, UMSCC74A and UMSCC47), and DNA-Pkcsi had a 
significant impact on survival of only one of the four cell lines (UMSCC47) by ~56%. We then 
analysed the impact of the inhibitors on HNSCC cell survival post-irradiation. As a starting point, 
we demonstrated that the respective inhibitors, following a 1 h pre-incubation of the cells prior 
to irradiation, were functional in suppressing ATM, ATR and DNA-Pk phosphorylation, and 
therefore DSB signaling, in response to photons (Figure S4) and protons (Figure S5). In 
combination with photon irradiation, we demonstrate that there was a significant impact in 
reducing cell survival of HPV-negative HNSCC cells in the presence of either ATMi, ATRi or 
DNA-Pkcsi (1 h pre-incubation, followed by a further treatment for 24 h post-irradiation) versus 
the DMSO control (Figure 2A–D; see also Figure S6A–D for linear scale graphs and data fitting), 
with dose enhancement ratios (DER) of 1.91–2.39 (Table 1). The significantly enhanced 
radiosensitivity of only one HPV-positive HNSCC cell line (UMSCC47) was also seen (Figure 2E–
H), although the DER values of 1.36–1.69 were notably lower than those observed in the HPV-
negative cells (Table 1). The cell survival of the most inherently radiosensitive HPV-positive cell 
line (UPCI-SCC090) only appeared to be dramatically decreased in the presence of DNA-Pkcsi 
(DER of 1.36). These data are supported by statistical analysis (Table S1) and, in general, DNA-




Figure 2. Inhibition of ataxia telangiectasia-mutated (ATM), ataxia telangiectasia and Rad3-
related (ATR) and DNA-dependent protein kinase (DNA-Pkcs) can enhance sensitivity of 
HNSCC cells to photon irradiation. Clonogenic survival of HNSCC cells following treatment with 
increasing doses of x-rays in the presence of DMSO (Control), ATMi (10 µM), ATRi (1 µM) and 
DNA-Pkcsi (1 µM) was analysed from three biologically independent experiments. (A, C, E and 
G) Shown is the surviving fraction ± S.E. (B, D, F and H) representative images of colonies in non-
irradiated and irradiated plates (the latter of which were seeded with four times the number of 
cells). 
Table 1. Dose enhancement ratios calculated at 50% cell survival (DER) following ATM, ATR and 
DNA-Pkcs inhibition versus DMSO controls in HNSCC cells in response to photons. 
Inhibitor UMSCC6 UMSCC74A UMSCC47 
UPCI-
SCC090 
ATM 2.06 1.91 1.38 1.15 
ATR 1.91 2.01 1.36 1.02 
DNA-Pkcs 1.93 2.39 1.69 1.36 
Following proton irradiation, and similar to photons, we again observed that ATMi and 
DNA-Pkcsi significantly enhanced the radiosensitisation of both HPV-negative HNSCC cell lines 
(Figure 3A–D and Table S2; see also Figure S7A–D for linear scale graphs and data fitting) with 
DER values of 1.52–2.01 (Table 2). HPV-positive HNSCC cell lines were also radiosensitised, with 
DER values of 1.24–1.49 (Table 2), following proton irradiation in combination with inhibition of 
ATM and DNA-Pkcs (Figure 3E–H). However, radiosensitisation was only significantly 
enhanced in UMSCC47, and not UPCI-SCC090 cell lines (Table S2). ATRi appeared in general less 





Figure 3. Inhibition of ATM, ATR and DNA-Pkcs can enhance sensitivity of HNSCC cells to 
proton irradiation. Clonogenic survival of HNSCC cells following treatment with increasing 
doses of protons in the presence of DMSO (Control), ATMi (10 µM), ATRi (1 µM) and DNA-Pkcsi 
(1 µM) was analysed from four biologically independent experiments. (A, C, E and G) Shown is 
the surviving fraction ± S.E. (B, D, F and H) representative images of colonies in non-irradiated 
and irradiated plates (the latter of which were seeded with four times the number of cells). 
Table 2. Dose enhancement ratios calculated at 50% cell survival (DER) following ATM, ATR and 
DNA-Pkcs inhibition versus DMSO controls in HNSCC cells in response to protons. 
Inhibitor UMSCC6 UMSCC74A UMSCC47 
UPCI-
SCC090 
ATM 1.62 1.52 1.49 1.24 
ATR 1.25 1.42 1.28 1.30 
DNA-Pkcs 2.01 1.64 1.38 1.32 
2.3. 3D Spheroid Growth of HNSCC Cells Following by Photon and Proton Irradiation Can Be Inhibited 
by Targeting ATM, ATR and DNA-Pkcs 
We subsequently analysed the impact of DNA DSB repair inhibitors on the radiosensitivity 
of HNSCC cells utilising 3D spheroids, which more accurately reflect the structure and 
environment of the original tumour. Of the cells used, unfortunately one HPV-positive cell line 
(UMSCC47) did not form 3D spheroids that grew during the 15-day analysis period. It was also 
noted that spheroids from both HPV-negative HNSCC grew significantly faster (peaking at days 
8–10 post-seeding) than the one remaining HPV-positive HNSCC (the increase in growth largely 
occurred at days 7–15 post-seeding). All spheroids grew ~5–8-fold in volume in the absence of 
any treatments over the analysis period (Figures 4A–I and S8). We demonstrate that ATMi alone 
caused a significant ~1.7-fold delay in the growth of only HPV-negative HNSCC (UMSCC74A) 
253 
 
spheroids, and that the combination of ATMi plus photon irradiation was effective in suppressing 
the growth of these spheroids by ~2.0-fold compared to radiation alone, but not of the other two 
spheroid models (Figure 4A–C and Table 3). In contrast, ATRi alone caused a statistically 
significant ~1.5–1.6-fold growth delay in all spheroid models. The inhibitor significantly 
exacerbated the effects of photon irradiation, by ~1.3-fold (UPCI-SCC090) to 2.3-fold 
(UMSCC74A) (Figure 4D–F and Table 3). DNA-Pkcsi alone was, interestingly, ineffective in 
inhibiting spheroid growth, although the combination of DNA-Pkcsi with photons was effective 
in suppressing the growth of HPV-negative HNSCC spheroids ~1.4-fold (UMSCC6) and ~1.6-fold 
(UMSCC74A) compared to the radiation alone (Figure 4G–I). 
 
Figure 4. Inhibition of ATM, ATR and DNA-Pkcs in combination with photons can decrease 
growth of HNSCC 3D spheroids. Spheroids were allowed to develop for 48 h, pretreated with 
DMSO (Control), ATMi (10 µM), ATRi (1 µM) and DNA-Pkcsi (1 µM), and irradiated with a 
single dose (1 Gy) of x-rays. Spheroid growth of (A, D and G) UMSCC74A, (B, E and H) UMSCC6 
and (C, F, and I) UPCI-SCC090 was measured by microscopy and analysed from three 
biologically independent experiments. Solid blue line is DMSO only, dashed blue lines are DMSO 
plus 1 Gy x-rays, solid red line is inhibitor only, dashed red lines are inhibitors plus 1 Gy x-rays. 
Shown is the spheroid volume ± S.E. 
Table 3. Targeting of ATM, ATR and DNA-Pkcs alone and in combination with photons and 
protons to decrease 3D HPV-positive and HPV-negative HNSCC spheroid growth. 
Inhibitor UMSCC74A UMSCC6 UPCI-SCC090 
ATM p < 0.0002 p = 0.60 p = 0.34 
ATR p < 0.003 p < 0.002 p < 0.006 
DNA-Pkcs p = 0.59 p = 0.89 p = 0.54 
ATM + photons p < 0.004 p = 0.18 p = 0.76 
ATR + photons p < 0.0005 p < 0.02 p < 0.03 
DNA-Pkcs + photons p < 0.02 p < 0.05 p = 0.08 
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ATM + protons p < 0.02 p = 0.06 p = 0.24 
ATR + protons p < 0.0002 p < 0.003 p < 0.0008 
DNA-Pkcs + protons p < 0.03 p < 0.02 p = 0.18 
Statistical analysis was performed on all the dataset across the 15-day growth period using a one-
way ANOVA, comparing the growth of inhibitor treated spheroids against the appropriate 
DMSO control (± radiation). 
We observed very similar results in HPV-negative HNSCC spheroids following proton 
irradiation (Table 3). Here, the combination of protons with ATMi (Figure 5A–C) was 
significantly effective in only one spheroid model (UMSCC74A) as observed by the ~2-fold 
growth inhibition versus the radiation alone, whereas ATRi (Figure 5D–F) and DNA-Pkcsi 
(Figure 5G–I) had a significant impact on delaying the growth of both spheroid models by ~2.5-
fold and ~1.9-fold, respectively (see also Figure S9). HPV-positive HNSCC (UPCI-SCC090) 
spheroids were only significantly radiosensitised, by ~1.6-fold, with protons in the presence of 
ATRi (Figure 5F). Notably, following both photon and proton irradiation of the HPV-positive 
UPCI-SCC090 spheroids, there was a reduced impact of the inhibitors compared to the radiation 
alone, which is consistent with this being the most radiosensitive cell line, as observed by 
clonogenic assays (Figure 1B,D). 
 
Figure 5. Inhibition of ATM, ATR and DNA-Pkcs in combination with protons can decrease 
growth of HNSCC 3D spheroids. Spheroids were allowed to develop for 48 h, pretreated with 
DMSO (Control), ATMi (10 µM), ATRi (1 µM) and DNA-Pkcsi (1 µM), and irradiated with a 
single dose (2 Gy) of protons. Spheroid growth of (A, D and G) UMSCC74A, (B, E and H) 
UMSCC6 and (C, F, and I) UPCI-SCC090 was measured by microscopy and analysed from three 
biologically independent experiments. Solid blue line is DMSO only, dashed blue lines are DMSO 
plus 2 Gy protons, solid red line is inhibitor only, dashed red lines are inhibitors plus 2 Gy 
protons. Shown is the spheroid volume ± S.E. 
We extended our observations of the effectiveness of inhibitors targeting ATM, ATR and 
DNA-Pkcs in radiosensitising oropharyngeal HNSCC cells by utilising additional spheroid 
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models from HPV-negative HNSCC, which are relatively more radioresistant than HPV-positive 
HNSCC. These were designed to gain further evidence that DNA DSB repair inhibition can 
enhance the impact of photons and protons in preventing spheroid growth, which are more 
representative of the original tumour and its treatment in vivo. We therefore used spheroids from 
FaDu and A253 cell lines that originate from the hypopharynx and oral cavity, respectively, of 
which we observed that these increased dramatically in volume (by ~50-fold and ~15-fold, 
respectively) over a period of 15 days post-seeding (Figures 6A–L and S10). FaDu spheroids were 
particularly resistant to ATMi, ATRi and DNA-Pkcsi alone, as observed by the lack of impact on 
spheroid growth. The A253 spheroids appeared to display some delayed growth in the presence 
of the inhibitors alone, particularly at the 12- and 15-day time points, although this was not 
statistically significant across the whole time course (Table 4). The combination of photons with 
either of the inhibitors significantly suppressed the growth of A253 spheroids, which was 
markedly enhanced by ~2.8–3.2-fold versus the radiation alone (Figure 6A–F and Table 4). FaDu 
spheroids were only significantly radiosensitised in the presence of DNA-Pkcsi following photon 
irradiation, through a dramatic ~4.6-fold decrease in spheroid growth. In response to proton 
irradiation, ATRi was not significantly effective at radiosensitising the cells, but the combination 
of ATMi with protons was able to suppress growth of both A253 and FaDu spheroids by ~3.7-
fold. Furthermore, DNA-Pkcsi was particularly effective in combination with protons as 
observed by the ~3.6-fold and ~7.6-fold decrease in the spheroid growth of A253 and FaDu cells, 
respectively, in comparison to radiation alone (Figure 6G–L and Table 4). 
 
Figure 6. Inhibition of ATM, ATR and DNA-Pkcs in combination with photons and protons can 
decrease growth of HPV-negative HNSCC 3D spheroids. Spheroids were allowed to develop for 
48 h, pretreated with DMSO (Control), ATMi (10 µM), ATRi (1 µM) and DNA-Pkcsi (1 µM), and 
irradiated with a single dose of (A–F) x-rays at 1 Gy or (G-L) protons at 2 Gy. Spheroid growth 
of (A, C, E, G, I and K) hypopharynx (FaDu) and (B, D, F, H, J and L) A253 was measured by 
microscopy and analysed from three biologically independent experiments. Solid blue line is 
DMSO only, dashed blue lines (A–F) are DMSO plus 1 Gy x-rays or (G–L) 2 Gy protons, solid red 
lines are inhibitor only, dashed red lines are inhibitor plus (A–F) 1 Gy x-rays or (G–L) 2 Gy 
protons. Shown is the spheroid volume ± S.E. 
256 
 
Table 4. Targeting of ATM, ATR and DNA-Pkcs alone and in combination with photons and 
protons to decrease 3D HPV-negative HNSCC spheroid growth. 
Inhibitor FaDu A253 
ATM p = 0.69 p = 0.49 
ATR p = 0.89 p = 0.72 
DNA-Pkcs p = 0.82 p = 0.88 
ATM + photons p = 0.09 p < 0.002 
ATR + photons p = 0.28 p < 0.003 
DNA-Pkcs + photons p < 0.003 p < 0.002 
ATM + protons p < 0.03 p < 0.006 
ATR + protons p = 0.24 p = 0.11 
DNA-Pkcs + protons p < 0.005 p < 0.002 
Statistical analysis was performed on the dataset across the 15-day growth period using a one-
way ANOVA, comparing the growth of inhibitor treated spheroids against the appropriate 
DMSO control (± radiation). 
3. Discussion 
Accumulating evidence has suggested that the increased response of patients with HPV-
positive versus HPV-negative HNSCC to radiotherapy, and thus the improved survival rates, is 
caused by defects in the repair of DNA DSBs (168, 207, 284). Therefore, targeting key enzymes 
involved in DNA DSB repair, particularly the protein kinases ATM, ATR and DNA-Pkcs, in 
relatively radioresistant HPV-negative HNSCC that are DSB repair-proficient is considered to be 
an approach to sensitise these tumours to radiotherapy. Indeed, there is evidence of at least one 
clinical trial utilising either ATRi or DNA-Pkcsi in combination with conventional radiotherapy 
that is currently underway (208). Additionally, while there is an increasing use of proton beam 
therapy for the treatment of HNSCC, there is no preclinical evidence to date examining the impact 
of DNA DSB repair inhibitors in combination with protons, and whether there is any substantial 
difference compared to that observed following photon irradiation. In this study, we have now 
analysed the effect of ATMi, ATRi and DNA-Pkcsi on both monolayer and 3D spheroid models 
of HPV-positive and HPV-negative HNSCC in combination with photons and protons. 
Interestingly, we discovered that targeting either ATM, ATR or DNA-Pkcs can decrease the 
clonogenic survival of HNSCC cells in response to photons and protons. DNA-Pkcsi appeared 
particularly effective in all cell lines in combination with radiation. This would correlate with 
studies in HPV-negative HNSCC cells describing downregulation of DNA-Pkcs using siRNA in 
UTSCC15 and UTSCC45 cells (266), as well as the DNA-Pkcs inhibitors KU0060648 in HN4 and 
HN5 cells (244), and IC87361 in UTSCC54, UTSCC74B and UTSCC76B cells (245), which were 
shown to enhance radiosensitisation. Only a single study has examined ATM inhibition 
(GSK635416A) in HNSCC cells (209), although this demonstrated increased radiosensitivity in 
five HPV-negative HNSCC cell lines (UTSCC2, UTSCC8, UTSCC24A, UTSCC36 and UTSCC40), 
which is comparable with our data. However, there are a number of studies that have focused on 
ATR as a target, including using siRNA in UPCI-SCC029B, UPCI-SCC040 and UPCI-SCC131 cells 
(210). Additionally, the ATR inhibitor VE821 displayed improved radiosensitivity in SQ20B cells 
(246), and an alternative inhibitor, AZD6738, showed the same phenotype in Cal27, FaDu, HN4 
and HN5 cells (214, 244). In our experiments utilising clonogenic assays, ATRi appeared to be less 
effective at radiosensitising cells following proton irradiation. We also observed less of an impact 
of DNA DSB repair inhibition in combination with radiation in HPV-positive HNSCC cells, 
particularly the UPCI-SCC090 cell line largely as this is the most inherently radiosensitive as 
shown here, and in our previous study (207). 
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Utilising 3D spheroid models that more accurately replicate the structure and environment 
of the original tumour, we further demonstrated the effectiveness of DNA-Pkcsi in combination 
with both photons and protons in inhibiting growth of all the HPV-negative HNSCC spheroids 
analysed. Interestingly though, inhibition of DNA-Pkcs alone did not appear to have any impact 
on the growth of 3D spheroids of both HPV-positive and HPV-negative HNSCC (which was 
largely supported by utilising clonogenic survival assays). This suggests that DNA-Pkcs is not 
essential for HNSCC cell growth and survival in the absence of ionising radiation-induced stress. 
Nevertheless, and similar to clonogenic assay results, the combination strategy of DSB inhibition 
(particularly ATMi and DNA-Pkcsi) did not significantly enhance the effect of radiation on the 
HPV-positive HNSCC spheroids (UPCI-SCC090), due to these cells being the most radiosensitive. 
The inhibition of ATR displayed some effectiveness in combination with photons and protons in 
preventing spheroid growth. However, less of an impact was observed on the relatively 
radioresistant HPV-negative HNSCC spheroid models, FaDu and A253, that displayed 
significant spheroid growth over the time period post-irradiation. This observation is similar to 
previous data utilising the ATR inhibitor AZD6738 with photons only, which demonstrated that 
this combination did not impede growth of 3D spheroids of FaDu cells (214). Noteworthily, as a 
monotherapy, the inhibition of ATR alone in the absence of radiation was effective in inhibiting 
clonogenic survival, but also the growth of HNSCC spheroids (apart from FaDu and A253), which 
was comparable to the impact caused by a single dose of radiation alone. 
Cumulatively, our results suggest that targeting DNA DSB repair via NHEJ (ATM and DNA-
Pkcs) or HR (ATR) can exacerbate the impact of photons in radiosensitising HNSCC cell models, 
and that the combination of DNA-Pkcsi with photons in HPV-negative HNSCC cells that are 
relatively radioresistant was particularly effective. This adds to the growing preclinical evidence 
(209, 210, 214, 244-246, 266) that this is an effective combination for the treatment of HNSCC that 
should be investigated further, particularly using more advanced 3D models (e.g., patient-
derived organoids) and appropriate in vivo experiments. However, we now also demonstrate 
that DSB repair inhibition, particularly DNA-Pkcsi and to a lesser extent ATMi, are efficient in 
reducing the survival and spheroid growth of HNSCC cells in response to protons. In fact in 
general, relatively similar results were observed comparing photons and protons, although the 
DER values derived from clonogenic assay results were much lower with ATRi following protons 
than with photons. This would contradict some very limited evidence suggesting a greater 
dependence on the HR pathway mediated by ATR for repairing DNA DSBs induced by protons, 
which was obtained using RAD51 siRNA in A549 lung cancer cells (118). In fact other studies, 
largely conducted in Chinese hamster ovary cells, reflect that NHEJ, coordinated by ATM and 
DNA-Pkcs, is the major DSB repair pathway employed following proton irradiation (105, 116). 
This is in agreement with our results. Consequently, we would advocate that inhibition of NHEJ 
through DNA-Pkcs is the most promising strategy in optimising the radiosensitisation of HNSCC 
cells with either photons or protons. Nevertheless, it should be noted that our study utilised low 
linear energy transfer (LET) protons at the entrance dose of a pristine beam, and that different 
results may be obtained with cells irradiated at or around the Bragg peak where the LET 
increases. This is due to the increased amount of complex DNA damage, where multiple lesions 
are generated in close proximity, and therefore the potential for the generation of complex DNA 
DSBs that could have a different requirement for either NHEJ or HR (268). We are also acutely 
aware of the availability of more potent and selective inhibitors than the ones used in the current 
study, specifically those targeting ATM (e.g., AZD1390), ATR (e.g., AZD6738) and DNA-Pkcs 
(e.g., AZD7648), which require examination of their potential to radiosensitise HNSCC cell 
models following photon and proton irradiation. These points are consequently the subject of our 





4. Materials and Methods 
4.1. Cell Lines and Culture Conditions  
Oropharyngeal squamous cell carcinoma cells (UMSCC6, UMSCC74 and UMSCC47) were 
kindly provided by Prof T. Carey, University of Michigan, USA. Cells from the hypopharynx 
(FaDu) and submaxillary gland (A253) originated from ATCC (Teddington, UK). HPV-positive 
oropharyngeal squamous cell carcinoma cells (UPCI-SCC090) were kindly provided by Dr S. 
Gollin from the University of Pittsburgh. All cells, apart from UPCI-SCC090 and FaDu (which 
were cultured in Minimal Essential Medium (MEM)), were routinely cultured as monolayers in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM 
L-glutamine, 1× penicillin-streptomycin and 1× non-essential amino acids. All cells were cultured 
under standard conditions in 5% CO2 at 37 °C, and were authenticated in our laboratory by short 
tandem repeat (STR) profiling. 
4.2. Clonogenic Assays  
Cells were harvested and a defined number seeded in triplicate into 6-well plates or 35 mm 
dishes before incubation overnight in 5% CO2 at 37 °C to allow the cells to attach. Plating 
efficiencies for the cells were as followed: UMSCC6 (~10%), UMSCC74A (~10%), UMSCC47 
(~10%) and UPCI-SCC090 (~2%). For inhibition experiments, cells were pretreated with DMSO 
(as a vehicle only control), 10 µM ATM inhibitor (ATMi; KU-55933), 1 µM ATR inhibitor (ATRi; 
VE-821) or 1 µM DNA-Pkcs inhibitor (DNA-Pkcsi; KU-57788; Selleck Chemicals, Munich, 
Germany) for 1 h prior to irradiation. Cells were then irradiated using a CellRad x-ray irradiator 
(Faxitron Bioptics, Tucson, AZ, USA) or with a passive scattered horizontal proton beam line of 
60 MeV maximal energy, as previously described (288, 289). Higher doses of protons were 
comparatively used due to cells being positioned at the entrance dose of a pristine (unmodulated) 
beam (~1 keV/µm). Following irradiation, fresh media containing inhibitors was added to the 
cells for 24 h, which was then replaced with fresh media alone and colonies allowed to grow for 
7–12 days, prior to fixing and staining with 6% glutaraldehyde and 0.5% crystal violet for 30 min. 
Dishes were washed, left to air dry overnight and colonies counted using the GelCount colony 
analyser (Oxford Optronics, Oxford, UK). Colony counting settings were optimised for each cell 
line, based on inclusion of distinct colonies of specific size and intensity, although the same 
settings were used across the various treatments. Relative colony formation (surviving fraction) 
was expressed as colonies per treatment level versus colonies that appeared in the untreated 
control, and data was derived from at least three individual biological replicates. 
4.3. Spheroid Growth Assays 
Cells (500–1000/well) were seeded in triplicate in 100 µL Advanced MEM media (Life 
Technologies, Paisley, UK) containing 1% B27 supplement, 0.5% N-2 supplement, 2 mM L-
glutamine, 1× penicillin-streptomycin, 5 µg/mL heparin, 20 ng/µL epidermal growth factor and 
10 ng/µL fibroblast growth factor into 96-well ultra-low attachment plates (Corning B.V. Life 
Sciences, Amsterdam, The Netherlands) and spheroids of ~200 µm in diameter allowed to form 
for 48 h (Day 3). DMSO, ATMi, ATRi and DNA-Pkcsi were added 1 h prior to irradiation. Post-
irradiation, 50 µL media was removed and replaced with 50 µL fresh media containing DMSO or 
inhibitors for 24 h, and then 50 µL media removed and replaced by 100 µL with fresh media 
alone. Images of spheroids were captured up to 15 days post-seeding using an EVOS M5000 
Imaging System (Life Technologies, Paisley, UK). The diameter of the spheroids was analysed 
using ImageJ, and used to calculate spheroid volume using the formula 4/3 × π × (d/2)3. 
4.4. Statistical Analysis 
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Dose enhancement ratios (DER) were used to assess the significance of the clonogenic assay 
results. DER values are derived from the ratio of the dose (Gy) required for a surviving fraction 
of 0.5 in the vehicle (DMSO) treated cells (D50DMSO), over the dose (Gy) required for the same 
surviving fraction in the inhibitor treated cells (D50inhibitor) [DER = D50DMSO/D50inhibitor]. D50 values 
were calculated using a linear quadratic fitting on each curve. Statistical analysis of spheroid 
growth data was performed on the dataset across the 15-day growth period using a one-way 
ANOVA. For this, the effect of each inhibitor on the spheroid growth was compared against the 
vehicle (DMSO) for a given radiation dose and radiation type. p-values of <0.05 highlight 
statistical significance between DMSO and inhibitor treated spheroids over the growth period.  
5. Conclusions 
We have demonstrated that the inhibition of DNA DSB repair can effectively act in 
combination with both conventional (photon) radiotherapy and proton beam therapy in 
radiosensitising in vitro models of HNSCC. DNA-Pkcsi was shown to be particularly effective in 
preventing clonogenic survival and 3D spheroid growth of HNSCC, and specifically models of 
relatively radioresistant HPV-negative HNSCC. Our data suggest that targeting DNA-Pkcs in 
combination with radiotherapy can be an effective strategy for the treatment of HNSCC. 
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